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Abstract 
 
Exploring the impact and effectiveness of prescribing error feedback in 
an acute hospital setting 
 
Michael Lloyd 
 
Background 
 
Prescribing errors (PEs) are prevalent and a prominent cause of patient 
safety incidents.  Feedback has the potential to improve prescribing with 
pharmacists potential facilitators of PE feedback.  However, evidence 
supporting PE feedback in a hospital setting is limited. 
 
Aims 
 
The aims of this thesis were to explore the effectiveness and impact of 
feedback on prescribing, prescribing behaviour, and the feedback 
participants: prescribers and pharmacists. 
 
Methods 
 
A mixed methodology was adopted.  Focus groups were used to explore 
pharmacist experiences of delivering PE feedback prior to the intervention.  
A pilot study was then undertaken with prescribers on two wards receiving 
constructive PE feedback, and two wards continuing with existing practice.  
Prescribing was audited over a five-day period before delivery of PE 
feedback verbally, and in writing.  Prescribing was re-audited after 3-months.  
A larger controlled study across 16 wards was then repeated.  Change in PE 
rates were compared between groups.   
 
Semi-structured interviews were used to explore prescriber’s and 
pharmacist’s experiences of receiving and delivering feedback and the 
impact on prescribing behaviour. All interviews and focus groups were 
analysed thematically using a framework approach.  
 
Results 
 
Twenty-four pharmacists were recruited to one of four focus groups.  Prior to 
the intervention, PE feedback was delivered inconsistently.  Ward-based 
pharmacists were considered suitable facilitators of PE feedback, but 
expressed concern that the process may adversely affect prescriber-
pharmacist relationships. 
 
Ten and eleven prescribers were included in the pilot intervention and control 
groups.   There was a mean reduction in overall PE rates of 11.5% in the 
intervention group and an increase of 5.9% in the control group, a significant 
change in PE rates of 17.4% (p<0.05) between groups.   
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Thirty-six and forty-one prescribers were included in the intervention, and 
control groups for the larger cohort study. PE rates reduced by 18.3% in the 
intervention group and increased by 5.4% in the control group, a significant 
change in PE rates of 23.7% (p<0.05) between groups. 
 
Eighteen pharmacists and ten prescribers were interviewed to explore their 
experiences of the intervention.  Feedback was valued, considered 
sustainable, and pharmacist’s credible facilitators.  Increased information and 
feedback-seeking behaviours were noted from prescribers with raised 
discretionary efforts and prioritisation of prescribing tasks.  Feedback is an 
educational process benefiting both facilitator and recipient.  Enhanced 
rapport was noted with pharmacists also reporting improved self-worth and 
self-efficacy. 
 
Thirty-eight interviews were conducted with twenty-three prescribers to 
explore the impact of feedback on prescribing behaviour.  Feedback is an 
educational process but benefits extend beyond knowledge-based 
improvements, with a range of adaptive prescribing behaviours reported.  
These included more mindful prescribing and engagement with prescribing 
tasks.  Feedback facilitates reflection, increases self-awareness and informs 
self-regulation of prescribing behaviour. Prescribers reported greater 
situational and error awareness and improvements in their prescribing.  
 
 
Conclusions 
 
PE feedback is valued, considered sustainable and positively influences 
prescribing.  However, it is a complex intervention with potential benefits 
extending beyond PE reduction with pharmacists working less in parallel, 
and more integrated within clinical teams.  Feedback supports prescribing 
practice with changes in prescriber behaviour resonating with non-technical 
prescribing skills.  Feedback can develop the situational-awareness for 
prescribers to reflect-in-action and adapt their behaviour to the clinical 
environment.  Contextualised inter-professional and non-technical skills 
training could enhance prescribing education further. 
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Chapter 1.  Introduction and Background 
 
1.1. Chapter Introduction 
 
This thesis explores the impact and effectiveness of feedback on prescribing.  
Prescribing and feedback both involve people and the impact of feedback on 
prescribers and the facilitators of feedback, pharmacists, will also be 
explored.  In this chapter, the background and motivation for this research 
will be described before exploring key terms and concepts used throughout 
this thesis. The chapter will then progress to provide an overview of 
prescribing error (PE) causation and outlining the scale of prescribing errors 
(PEs) in hospital settings. 
 
1.2. Overview and context of this research 
 
PEs are a prevalent and prominent cause of medication safety incidents in 
the United Kingdom (UK) (Ross et al. 2009) with reductions in these 
incidents a national priority (Vincent et al. 2009).  This research takes place 
in St. Helens and Knowsley Hospitals (STHKH) which is an 800 bed, acute 
hospital in the North West of England.  Patient safety is a key priority of the 
organisation who are fully committed to reducing avoidable harm in line with 
national recommendations (Vincent et al. 2009, Department of Health (DOH 
2000)).  At commencement of this research, the organisation employed 33 
pharmacists, and several hundred prescribers of various grades. 
 
The author has an interest and investment in prescribing and PEs as a 
clinical pharmacist with twelve years’ experience, following involvement in 
large PE studies (Dornan et. al 2009, Seden et al. 2013), and facilitation of 
local PE audits.  An interest in prescribing pedagogy kindled this interest 
further and was supported by a formative role as a specialist medical 
education pharmacist for seven years.  This role informed what PE reduction 
strategies were in place, and that further interventions were necessary to 
improve prescribing. 
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This catalysed the inception of a qualitative study that was undertaken as 
part of a Master of Arts (MA) in clinical education.  The research explored the 
attitudes and opinions of junior doctors to receiving prescribing feedback 
(Lloyd 2014).  Despite local audits suggesting PE rates of 20-42% (Lloyd 
2013), prescribers struggled to recall a PE they had made but acknowledged 
that pharmacists frequently asked them to amend prescriptions.  Prescribers 
reported that they did not receive feedback on their prescribing, but that it 
would be welcomed to support their professional development, and improve 
patient safety. 
 
This preliminary research was followed by a proposal to pursue this line of 
enquiry further with formalized pharmacist-led PE feedback delivered to 
prescribers.  The project received executive level support and funding that 
has allowed the author to undertake the research reported in this thesis. 
 
1.2.1.  Aims and Objectives  
 
The overall aim of the research in this thesis is to explore the effectiveness 
and impact of PE feedback. 
 
Specific research objectives include to explore and investigate: 
 
1. The impact of pharmacist-led feedback on prescribing error rates. 
2.  The views, attitudes and impact on prescribers of receiving 
prescribing error feedback. 
3. The views, attitudes and impact on pharmacists of delivering 
prescribing error feedback. 
4. The impact of feedback on prescriber behaviour. 
 
The overall research hypothesis is that a programme of pharmacist-led PE 
feedback will improve prescribing.   Research questions and hypotheses will 
be revisited in chapter 3 and relevant results chapters. 
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Some of the key definitions and terms used throughout this thesis will now be 
explored. 
 
1.3. Medication errors and prescribing errors 
 
There is a heterogeneity in PE definitions within the literature (Franklin 2005, 
Tully 2012) and so it important that these terms are considered and defined 
from the outset. 
 
1.3.1. Error 
 
Generically, an error can be defined as a ‘mistake’ or ‘the state of being 
wrong in conduct or judgement’, or at the technical level; ‘the degree of 
inaccuracy in calculation’ (Oxford Dictionary 2016).  Other definitions are 
used such as “a failure to complete a planned action as intended, or the use 
of an incorrect plan of action to achieve a given aim” (Kohn et al. 1999).  
Reason (1990) in his seminal work on error causation, described an error as 
‘the failure of a planned sequence of mental or physical activities to achieve 
its intended outcome when failures cannot be attributed to chance.’  
Reason’s definition excludes chance as a causative factor, that is, errors are 
preventable events, an important consideration when discussing errors and 
patient safety. 
 
1.3.2. Medication 
 
There are a multitude of medications used for the prevention and treatment 
of disease.   Healthcare is increasingly complex with patients prescribed 
larger numbers of medications. A recent Scottish study suggested 22% of 
the population are taking five or more medications, and 5.8% are taking ten 
or more medications (Guthrie and Makubate 2012).  A medication has been 
described as ‘a product that contains a compound with proven biological 
effects, plus excipients, or excipients only; it may also contain contaminants; 
the active compound is usually a drug or prodrug, but may be a cellular 
element’ (Aronson and Ferner 2005).  For the purpose of this research, a 
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medication is any prescribed medication in the hospital setting.  Considering 
these two terms now allows us to consider what a medication error (ME) is. 
 
1.3.3. Medication error 
 
The DOH (2001) define a ME as; 
 
“…any preventable event that may cause or lead to inappropriate 
medication use or patient harm while the medication is in the control of a 
health professional, patient or consumer.” 
 
A more recent and simple definition is provided by Aronson (2009a) who 
defines a ME as; 
 
“a failure in the treatment process that leads to, or has the potential to lead 
to, harm to the patient”. 
 
Here, the use of the term ‘failure’ clearly focuses on harm and signifies that 
the process has fallen below some attainable standard (Aronson 2009a), the 
standard being governed by local medicines policies (STHKH 2014) and 
national prescribing guidance stipulated by the General Medical Council 
(GMC) who are the regulatory body for UK doctors.  The ‘treatment process’ 
includes treatment for symptoms, their causes, investigation, prevention of 
disease or physiological changes.  The definition does not specify who 
makes the error – it could be a doctor, a nurse, a pharmacist, a carer or 
another individual involved in the medication use cycle (figure 1).  It should 
also be noted that this definition is more reflective of MEs in general:- not all 
errors reach or indeed harm the patient as they are intercepted before they 
reach the patient with Leape et al. (1995) reporting that pharmacists and 
nurses intercept 70% of all medication errors whilst elsewhere, others report 
that around 10% of errors result in patient harm (Moyen et al. 2008) in one 
setting.  Considering this, ‘near miss’ errors (An error that does not cause 
harm but has the potential to do so) (NPSA 2007) are an important 
consideration and component of PEs through their ‘potential’ to cause harm. 
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Figure 1: The medication use cycle (National Patient Safety Agency 
(NPSA) 2007) 
 
 
1.3.4. Prescription 
 
A prescription is defined as “a written order, which includes detailed 
instructions of what medicine should be given to whom, in what formulation, 
and dose, by what route, when, how frequently and for how long” (Aronson 
2006).  Prescriptions are written by prescribers who are typically doctors but 
can also be non-medical prescribers.  
 
1.3.5. Prescribing  
 
The prescription is the final product of the prescribing process.  Prescribing is 
the first stage of the medication use cycle (figure 1) and is a process 
whereby a doctor or other registered prescriber authorises the use of 
medications for a patient, instructing how and when those medications 
should be used to help optimise their care.  This process consists of two 
distinct phases; an initial decision making process to decide what drug, dose 
and route to prescribe, followed by the technical process of completing the 
prescription with clear and complete instructions (Lesar et al. 1997a).   
Technical errors are easier to identify in practice with some authors 
(Calligaris et al. 2009) focusing on this definition although these studies may 
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under report PEs as a result.  Hence, both stages are capable of introducing 
PEs and should be considered in any PE definition.   
 
1.3.6. Prescribing error 
 
A general definition of a PE has been proposed (Dean et al. 2000) as: 
 
“A clinically meaningful prescribing error occurs when, as a result of a 
prescribing decision or prescription writing process, there is an unintentional 
significant (1) reduction in the probability of treatment being timely and 
effective or (2) increase in the risk of harm when compared with generally 
accepted practice” 
 
This definition covers both the decision making process and technical 
aspects of prescribing and has been widely used in PE studies in the UK 
(Dean and Schater et al. 2002, Tully and Buchan 2009, Franklin and Birch et 
al. 2009, Caruba et al. 2010, Franklin et al. 2011, Ryan et al. 2014).  The 
definition was developed by the Delphi process (Jones and Hunter 1995), a 
consensus process that elicits views of experts that consisted of nurses, 
pharmacists and prescribers.  The expert panel individually agreed or 
disagreed with a series of questionnaire statements that were then 
summarised before repeating the questionnaire following review of the 
group’s responses.  
 
As the process involved prescribers, the authors suggested this makes the 
definition valid and acceptable to prescribers (Dornan et al. 2009).  However, 
this definition focuses on the clinical impact of the PE, ruling out PEs that do 
not result in harm (Aronson 2009a) such as failure to comply with national 
guidelines, trust formularies and product licenses for example (Dean et al. 
2000).  Equally, and perhaps more importantly, it ignores the fact that PEs 
that are not clinically meaningful, can still have considerable impacts on 
those involved with the medication use cycle.  For example, incorrect 
completion of a controlled drug prescription at discharge is unlikely to cause 
harm or delay treatment, but it can delay processing of the prescription.  
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Indirectly, the need to correct and amend the PEs can have cost 
implications, create inefficiencies in the system and distractions that could 
become error inducing conditions themselves.  Equally, non-compliance to 
guidelines could create rule-based errors whilst non-adherence to trust 
formularies could increase the risk of memory failures; all latent error 
inducing conditions that could result in patient harm.  Finally, “generally 
accepted practice” is too vague and prescribing should be compared to local 
and national standards including medicines policies, national guidelines and 
formularies.  Perhaps these confounding issues influence the choice of 
researchers to develop their own definitions, with one systematic review 
(Lewis et al. 2009) reporting 42% of researchers modifying existing, or 
creating their own, definitions of a PE.   
 
As Aronson (2009a) argues, an error “indicates a weakness in the system, 
which might on a future occasion lead to an error of clinical relevance”.  Put 
more simply, a clinically non-meaningful error may become meaningful in a 
different context with a different medication at a different time.  Aronson 
(2009a) attempts to simplify the PE definition by proposing that a PE is; 
 
“a failure in the prescription writing process that results in a wrong instruction 
about one or more of the normal features of a prescription’. 
 
This definition allows scope for pharmacists to record all prescriptions that 
require intervention, irrespective of clinical significance at the decision 
making or technical stage.  
 
In this study, any prescription that does not comply with the standards 
outlined in the hospital medicines policy will be classed as a prescribing 
error.  That is, any prescription that requires a pharmacist intervention to 
make it complete or safe, including both technical and clinically relevant 
interventions, will be included. 
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1.3.7. Prescribers 
 
A prescriber is an appropriately qualified healthcare professional who 
prescribes a medication for a patient.  These are typically doctors although 
non-medical prescribers (NMPs) undertake some prescribing duties.  In the 
hospital setting, independent NMPs could include nurses or pharmacists who 
would prescribe medications for medical conditions that they are familiar 
with. 
 
Doctors in the UK typically study undergraduate medicine for five years 
although there is a shorter four-year degree available to postgraduate 
trainees.  Following completion of their degree, doctors undertake 12 months 
of training as a foundation year one doctor (FY1) after which they can 
register with the General Medical Council (GMC) before completing the 
second year of their foundation training as a foundation year two (FY2) 
trainee.  For those doctors pursuing a career in hospital they can follow a 
Core Training (CT) or specialist training (ST) programme in medicine or 
surgery.  This training involves completion of further assessments and 
typically last for 8-10 years before they qualify as a consultant physician.  
Experience or stage of their training is denoted by a numerical suffix i.e. CT1 
/ ST1 is a first year core or specialist training doctor.  Specialist registrars 
(SpRs) are senior specialist training grade doctors although this term is being 
phased out.  Staff grade doctors or Specialty and Associate Specialist (SAS) 
doctors are typically non-training roles with at least four years of 
postgraduate training, including two years of specialist or core training. 
 
Doctors pursuing a career in general practice (GP) follow a similar pathway 
as a specialist GP (GPST) trainee over a typical 3 year period (GPST1-3) 
before qualifying as a General Practitioner.   
 
Although the literature reports that foundation trainees undertake the majority 
of prescribing (Dornan et al. 2009, Ryan et al. 2013, Ross et al. 2013a), audit 
work by the author suggests that junior CT (CT1-2) grade doctors are equally 
prolific with their prescribing (Lloyd 2013).   
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Table 1: Overview of doctor grades in a hospital setting 
Grade Description 
FY1 1st year foundation trainee.  Not 
yet registered with the GMC. 
FY2 2nd year foundation trainee 
registered with the GMC. 
CT1-2 Core medical training doctor 
ST1-7 Specialty training trainee 
SpR Specialist registrar 
Staff Grade / SAS grade Non-training / Specialty and 
Associate Specialist grade 
doctor 
Consultant Completed postgraduate 
training in hospital 
GPST1-3 Specialist GP trainee 
undertaking clinical placements 
in hospital practice 
 
 
1.3.8. Pharmacists 
 
Pharmacists in the UK typically study pharmacy for four years to gain an 
MPharm degree in a UK University accredited by the General 
Pharmaceutical Council (GPhC). This is proceeded by a 12-month pre-
registration period that is typically completed in either community pharmacy 
or hospital pharmacy.   A small number of trainees undertake 6 months in the 
industrial or community sector and 6 months in hospital.  Following this 
training period, eligible trainees have to pass a registration entrance 
examination to register with the GPhC, the independent regulator of 
pharmacists in the UK.  The majority of the workforce typically work in 
community pharmacy with increasing numbers of pharmacists working within 
Clinical Commissioning Groups (CCGs) in the primary care sector. Within 
hospital, pharmacists are graded (See table 2) according to the agenda for 
change (AfC) system.  A junior or rotational grade pharmacist commences as 
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a band 6 before undertaking a further 2-years of postgraduate training in 
clinical pharmacy.  Band 7 pharmacists have usually completed their 
postgraduate training and are typically specialist pharmacists or have 
extended work-based rotations for further experience.  Band 8a pharmacists 
are advanced pharmacists working within a given specialty, usually with at 
least five years postgraduate experience.  Band 8b-c are highly specialist 
pharmacists with significant managerial responsibilities and usually at least 
ten years of experience.  The head of a hospital pharmacy is typically a band 
8d or 9 with at least ten years’ experience in hospital pharmacy.    
 
Table 2: Overview of Pharmacist grades in a hospital setting 
Grade Description 
Band 6 Newly qualified or junior 
pharmacist typically undertaking 
postgraduate clinical training. 
Registered with the GPhC. 
Band 7 Typically completed or about to 
complete postgraduate clinical 
training.   
Band 8a Specialist pharmacist employed 
to focus on a specific area of 
interest. 
Band 8b Advanced specialist pharmacist 
with managerial commitments 
Band 8c Typically deputy heads of 
department with significant 
managerial commitments 
Band 8d Typically a chief pharmacist 
post 
Band 9 Chief pharmacist / Director of 
pharmacy 
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In this research, all pharmacists are hospital based.  Ward-based 
pharmacists perform medicines reconciliation and supply non-stock items as 
part of their routine responsibilities.  They will also review medication charts 
for clarity, completeness and appropriateness and, where discrepancies or 
errors are identified, resolve them with a prescriber although this may not be 
the original prescriber.  Pharmacists can also participate in ward rounds, 
educational sessions and team meetings with doctors although this is not 
routine practice.  Discharge prescriptions are also checked and authorized 
by pharmacists although this may be completed remotely in dispensary for 
example.   
 
1.4. Error causation 
 
Errors occur at any stage of the medication use cycle from prescription 
initiation through to transcription, ordering, dispensing, administering and 
monitoring processes (Aronson 2009b).  However, prescribing errors (PEs) 
are a substantial problem (Barber et al. 2003) and predominate (70% of all 
ME’s) (Velo et al. 2009).  Equally, PEs are more likely to cause harm (Bates 
1995, Leape et al. 1995) or at the least, create inefficiencies in the care 
system through the need to contact prescribers to clarify or amend 
prescriptions, resulting in unnecessary delays to, or omissions of, treatment. 
 
The healthcare system is a complex working environment and humans are 
prone to making errors, nobody is infallible (Ferner 2012, Leape 1997, 
Reason 1990) with the inevitability of human error argued by psychologists 
(McDowell et al. 2009, Reason 1990).  PE causation is complex and varied 
with multiple points of error possible throughout the prescribing journey.  
Recognition of human error in healthcare industries is well documented.  In 
the seminal institute of medicines (IOM 1999) report “To err is human”, 
complexity of healthcare and use of technologies were highlighted as 
contributing factors to human error.  
 
One of the most widely used taxonomies in the literature for defining error 
causation, including PEs, is James Reason’s “Swiss Cheese” model 
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(Reason 1990).  Within this model (see figure 2), an error is considered to be 
‘a failure to achieve the intended outcome of a planned series of actions, 
when the failure is not due to chance’.   Reason (1990), a British 
Psychologist, devised a now well recognized and established taxonomy of 
human error from observation of other high risk industries such as aviation, 
nuclear power, petro-chemical and military sectors (Flin et al. 2008).  
Analyses of accidents in these sectors revealed that 80% of errors were 
attributable to human factors (Reason 1990).  Reason proposed a “Swiss 
Cheese” model of error causation in complex systems (figure 2) with 
available defensive mechanisms represented by the layers of cheese and 
error causation by the holes. 
 
Figure 2: James Reason’s Swiss Cheese Model of error causation 
(Reason 2000) 
 
 
 
With enough layers, or without superfluous holes in the cheese, the risk of an 
error reaching the patient should be negligible.  However, humans are not 
infallible and the real world is more dynamic than a stationary piece of 
cheese; the size, shape, location and distribution of the holes (or gaps in the 
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defensive process) will be changing fluidly with the working environment and 
the individuals involved in the process.  Where these holes, or errors align, 
an error can occur and patient care compromised.  The risk of PE 
propagation is thus part of a chain of events (See figure 3) of latent 
conditions, error provoking conditions, active failures and inadequate 
defenses where knowledge and understanding of the risks is paramount to 
implementing effective barriers to harm.  
 
Figure 3: Incident analysis framework (from Dornan et al. 2009, 
Coombes et al. 2008 based on Reason 1995) 
 
In order to correct and prevent errors, it is important to understand where 
and why errors are occurring in the prescribing process.  Is it the decision 
making or technical aspects or both?  Fundamentally, psychologists (Reason 
1995) differentiate errors according to broad groups, execution and planning 
failures (see figure 4).   
 
With execution failures, the intentions and plan are correct but are not 
 38
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Incident analysis framework modified from Coombes et al15 
 
In our analysis we grouped errors by the ‘unsafe acts’ or ‘active failures’ that 
doctors discussed. We then explored the error-producing conditions and 
latent conditions associated with each err r, depicting the factors in a diagram. 
This led to the formation of an overall model of the different types of errors, 
according to Reasons framework.  
 
Potential severity. 
As with the prevalence study, a validation panel was set up to assess the 
potential severity of the reported errors using the same technique described 
previously (see section 3.2).  
 
 
 
Latent conditions  
Organisational processes- workload, handwritten 
prescriptions 
Management decisions- staffing levels, culture of 
lack of support for junior staff 
Error-producing conditions   
Environmental – busy ward 
Team- lack of supervision 
Task- poor medication chart design 
Patient- complex, communication difficulties  
Active failures 
Slip, lapse, rule-based mistake, 
knowledge-based mistake  
Defences 
Inadequate, unavailable, 
missing    
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executed correctly, deviating from prescriber intentions for example.  These 
are commonly referred to as ‘slips’ or ‘lapses’ and occur during automatic or 
routine tasks such as prescribing a common medication that the prescriber 
clearly knows and understands.  Given time to review their prescribing, 
prescribers would typically identify such errors (Lewis et al. 2014).   
Conversely, planning failures are considered ‘mistakes’ and may be 
executed correctly but the plan is inadequate with the failure originating from 
a higher process of planning, judging, formulating and solving (Reason 
1995). Hence, such mistakes are less likely to be recognized by prescribers 
and pose greater risks to patient safety (Lewis et al. 2014) where an external 
source is required to highlight the mistake. 
 
Figure 4: Execution and planning failures (from Reason 1995) 
 
Reason (1995) advocates a systems approach to error, considering both 
active failures and latent conditions.  This approach avoids individual blame 
and weakness but rather focuses on the environment and conditions that the 
individual works within to improve system wide defenses (Reason 2000). 
 
1.4.1. Active failures 
 
As discussed, this psychological approach to error causation proposes two 
main types of error, mistakes and failures of skills. These are further divided 
into four distinct classifications; knowledge and rule based errors (planning 
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mistakes), and action and memory based errors (Execution failures) 
respectively (figure 5). 
 
Figure 5: Error classification system based on a psychological 
approach (Aronson 2009b) 
 
 
Active failures are unsafe acts (Moyen et al. 2008, Reason 1990) that can 
present as slips, lapses or mistakes. Examples of such PEs can be seen in 
table 3 below.  Human performance has been described (Rasmussen and 
Jensen 1974, Carayon 2012) according to skill-based, rule-based or 
knowledge-based behaviours and can be considered under two main types 
of error; mistakes and skill-based errors (Figure 5).  This systems approach 
has been widely adopted in the literature to describe, classify and 
understand both PEs and MEs in general (Keers et al. 2015, Lewis et al. 
2014, Ross et al. 2013a, Ajemigbitse et al. 2013, Ferner 2012, Dornan et al. 
2009, Velo and Muniz 2009, Aronson 2009b, Williams 2007).  Slips and 
lapses are considered unintended actions whilst mistakes and violations (see 
later) are considered intentional actions (Reason 1995).   
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Table 3: Example prescribing errors and their error causation using the 
systems approach (Reason 1990) 
 
Error Causation Example of PE 
Knowledge based 
mistake 
1. Prescribing tramadol without controlled drug 
requirements because you are unaware it is a 
controlled drug 
2. Starting a patient on 100mcg/hour fentanyl 
patch because of lack of knowledge of potency of 
fentanyl 
Rule based mistake 1. Prescribing an adult dose to a paediatric patient 
2. Prescribing full dose acyclovir to a patient with 
reduced renal function 
Slip 1. 50mg of morphine prescribed IV instead of 5mg 
2. Selecting three times a day instead of twice a 
day from a   drop down menu on electronic 
prescribing systems 
Lapse 1. Renal function improves but dose reduced 
medications are not increased 
2. Forgetting a patient is penicillin allergic and 
prescribing them a penicillin  
Violation 1. Abbreviating isosorbide mononitrate as ISMN to 
save time 
2. Not checking all prescription charts leading to 
duplication of a medication or drug interaction 
Latent Error  1. e-prescribing system allows selection of drug 
based on no minimum letter combinations resulting 
in LANsoprazole 15mg od prescribed instead of 
oLANzapine 15mg od or AZathioprine 250mg od 
instead of AZithromycin 250mg od  
2. Lack of feedback on prescribing so doctors are 
unaware of their PEs 
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Reason (1990) defines a ‘slip’ as a failure to execute an action correctly due 
to a routine behaviour being misdirected. For example, prescribing the 
incorrect units of a medication, miscalculating a dosage or prescribing a 
medication for the wrong patient. 
 
A lapse is defined as a failure to execute an action due to memory failure 
and a routine behaviour being omitted.  For example, forgetting to restart a 
patient’s withheld medication when their renal function improves, or failing to 
put a review date on a course of antibiotics leading to inappropriately long 
treatment.  Slips and lapses are unintended skill-based errors (see figure 5) 
where routine behaviours are either omitted or performed inappropriately 
(Reason 1990).  
 
A mistake is an intended action or error in the planning process and can be 
either a knowledge based error (KBE) or rule-based error (RBE).   For 
example, an angiotensin converting enzyme (ACE) inhibitor is prescribed to 
a patient with known renal artery stenosis because they either do not know 
the patient has renal artery stenosis or they are unaware of the 
contraindication. A RBE could be the misapplication that all penicillins end in 
“illin”, for example Dornan et al. (2009) report an example where timentin 
[brand name for ticarcillin] is prescribed to a patient who is penicillin allergic.  
Lewis et al. (2014) differentiated the causation between KBEs and RBEs in 
the doctors interviewed in their study, was one of ‘consciously incompetent’ 
and ‘unconsciously incompetent’. 
 
Where prescribers intentionally deviate from best practice, this type of error 
is called a violation and can be a routine violation to save time, a situational 
violation where rules are difficult to follow or an optimizing violation to 
demonstrate skill (Dornan et al. 2009, Parker and Lawton 2006:31-40).  Such 
violations have been reported in the literature (Ajemigbtse et al. 2013, Tully 
et al. 2009, Dornan et al. 2009, Dean et al. 2002) although less frequently 
than slips and lapses for example and include abbreviated drug names, not 
checking a medical student’s transcription or omitting information that they 
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knew should be included. 
 
1.4.2. Latent Conditions 
 
In other industries, 80% of errors have been attributable to human factors 
and active failures (Reason 1990).  However, error causation is not entirely 
due to active failures.  The impact of the system, organization, policies and 
procedures can all create ‘holes’ in the system or layer of cheese and 
influence active failures.  Moyen et al (2008) describe this quite adroitly by 
referring to these latent conditions as ‘pathogens’.  
 
For example, a consultant may prescribe 50mg of morphine intravenously 
instead of 5mg, a clear slip.  They know the standard dose of morphine and 
have prescribed it routinely for a long time, but distractions, and absence of a 
junior doctor on the ward round meant they had to prescribe themselves in 
addition to all of their other responsibilities leading to the PE.  Ross et al.  
(2013a) have recently reported on the causes of PEs in junior doctors with 
time pressures and workload a recurrent work environment theme. 
 
Characteristics of the clinical environment, prescribing culture, workload, 
time, staffing levels and skills mix, available support, hierarchical influences 
and technologies all have an important impact on active failures.  These 
conditions influence prescribing outcomes and equally need to be addressed 
to improve patient safety (Dornan et al. 2009, Tully et al. 2009). 
 
In their systematic review, Tully et al. (2009) reported latent conditions 
influencing PEs including, and most pertinent to this thesis, low self-
awareness of PEs (Dean et al. 2002) and lack of feedback on PEs (Lesar et 
al. 1997a). 
 
Latent failures also include error-provoking conditions (Reason 2000) relating 
to the task and environment.  These have been categorized as the individual 
(prescriber), the work environment, the healthcare team, prescribing task and 
patient factors (Tully et al. 2009).  These factors may not directly cause error 
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but they can strongly influence situations, leading to stress, fatigue and 
confusion that in turn diverts prescriber attention, lowering the threshold for 
active failures. As the term ‘latent’ suggests, these conditions can lie dormant 
for a long period (Reason 2000) until they combine with active failures and 
local factors to create a PE.   Examples of error-provoking conditions are 
provided in table 4 below.   
 
Table 4: Example error provoking conditions 
Condition Example  
Individual prescriber 1. Limited training in prescribing / lack of 
knowledge 
2. Lack of experience (i.e. a junior doctor or new 
rotation) 
Work environment 1. Lack of access to relevant resources 
2. Workload and time pressures (i.e. to process 
prescriptions but also less time to check your 
prescription also) 
Healthcare team 1. Poor communication from senior team members 
on prescribing decisions 
2. Prescribing for an unfamiliar patient increasing 
the risk of knowledge based errors 
Prescribing task 1. Polypharmacy (Multiple medications to 
prescribe) increases the risk of an error 
2. Unfamiliar prescription chart resulting in 
mistakes, omissions or discrepancies 
Patient factors  1. Complex patient with multiple morbidities so 
increased chance of a contraindication or 
inappropriate dose for example 
2. Ward areas for example paediatrics or intensive 
care settings 
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1.5. Prescribing error causation 
 
PE causation is complex and multi-factorial with no single error invoking 
condition. An Australian study (Coombes et al. 2008) reported a median of 
four different error influencing factors per incident.   A 2009 systematic 
review (Tully et al. 2009) reported that knowledge based mistakes (especially 
lack of drug or patient knowledge), slips, and lapses in memory were all 
common causes of PEs and reported on the error provoking conditions and 
latent errors that influenced error causation.   
 
Recently, Ross et al. (2013a) interviewed 40 junior doctors and reported that 
the most common PEs were slips (30%) or mistakes (18%) with multiple 
error provoking conditions reported.  Doctors interviewed also reported 
expecting pharmacists to intercept their PEs and suggested a lower task 
priority was afforded to prescribing, key latent conditions that can influence 
active failures. 
 
More recently, a qualitative study (Lewis et al. 2014) reported that over half 
of errors reported in 30 junior doctor interviews were mistakes.   These were 
compounded by a multitude of error-producing latent conditions including 
time and workload pressures, poor communication and hierarchical barriers.  
  
These studies highlight that whilst slips, lapses and mistakes are common, 
they are influenced by a multitude of conditions that make the error more 
likely to occur.  Reason (2000) analogized this with controlling mosquitoes; 
“active failures are like mosquitoes. They can be swatted one by one, but 
they still keep coming. The best remedies are to create more effective 
defences and to drain the swamps in which they breed. The swamps, in this 
case, are the ever present latent conditions.” 
 
Understanding error causation is important to identify and implement 
effective interventions to reduce PEs.  Increasing awareness of factors and 
conditions that can cause error may increase the threshold of PEs and is a 
theme that will be explored further in this thesis. 
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1.6. Prescribing error prevalence 
 
Precise PE rates are unknown but it is clear from the literature and personal 
experience of the author, that they are common events in the hospital 
setting. Annual audits in STHKH suggest typical PE rates of 20% (Lloyd 
2013).   Single hospital studies in the UK (Fowlie et al. 2000, Gethins 1996) 
have reported PEs in 7.4–18.7% of prescriptions.  Most published reports 
have involved data collection from healthcare professionals, with 
pharmacists the usual medium for collecting data alongside their routine daily 
duties (Lewis et al. 2009). 
 
A systematic review (Lewis et al. 2009) of handwritten prescriptions in 65 
studies, reported that a median 7% (2-14%) of medication orders, 2% of 
patient days and 50% of hospital admissions were affected by a prescription 
error.  Most studies were undertaken in the US or UK as a single site study, 
although 16% of published studies were performed across multiple sites.  
PEs were mostly intercepted before they caused harm.  Wide variations in 
PE rates were reported, an outcome possibly explained by heterogeneity in 
PE definitions and data collection methods (Franklin and Birch et al. 2009). 
For example, using incident reports (Sangtawesin et al. 2003) to collect PE 
information provided lower error rates (0.4 errors per 100 admission) 
compared to triangulated data (Dale et al. 2003) collection methods (323 
errors per 100 admissions).   
 
Considering voluntary incident reporting is acknowledged as underestimating 
the true scale of medication or PEs, (Williams et al. 2013, Franklin and Birch 
2009, Meyer-Massetti et al. 2011, DOH 2004) it is of no surprise that such 
data collection methods have different outcomes and lower PE rates.  
Equally where PE definitions exclude certain types of error or pertain to 
likelihood of harm of delay in treatment, then variations are to be expected.  
These differences and variations also make it difficult to draw valid 
conclusions on the effect of ward areas, environments and specialties for 
example, on PE rates (Lewis et al. 2009, Franklin et al. 2011). 
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Another systematic review (Ross et al. 2009) of 24 studies, predominantly in 
the UK and USA, reported an error rate of 2–514 per 1000 items prescribed 
and 4–82% of prescription charts reviewed although this review was 
concerned with junior doctors only.    
 
In recent multi-site studies, PEs were estimated to affect between 2% and 
15% of prescriptions (Dornan et al. 2009, Franklin et al 2011, Seden et al. 
2013) in the hospital setting.  The large and pivotal EQUIP trial (Dornan et al. 
2009) audited prescribing in 19 hospitals across North West England and 
reported a mean error rate of 8.9 errors per 100 medication orders for 
foundation trainees; rates far greater than consultants (5.9% PE rate) or non-
medical prescribers. Considering the larger volume of prescribing undertaken 
by junior doctors, newly qualified doctors were considered twice as likely to 
make a PE compared to senior doctors.   
 
A three-centre study in London (Franklin et al. 2011) reported a median error 
rate of 14.7%, (95% CI 13.8%-15.6%) and demonstrated variations between 
error rates (13.6%-18.4%) across hospital sites.   
 
In a cross-sectional study of hospitals on Merseyside, Seden et al. (2013) 
reported an observed error rate of 10.9% with only 56.2% of overall 
prescriptions error free.  
 
More recently in Scotland (Ryan et al. 2014) a mean PE rate of 7.5% was 
reported across eight hospitals. These findings are consistent with earlier 
studies (Bates 1995, Dean et al. 1995, Dean 2002, Glavin 2010, Neale et al. 
2001, Vincent 2009, Lewis et al. 2009) and iterate the ongoing prevalence of 
PEs and need for further interventions to tackle the problem.    
 
PEs can include incorrect dosing, frequency, quantity, indication, drug-
interactions and contraindications.  Other confounding factors may include 
illegible prescriptions, inaccurate drug histories, drug name confusion, 
abbreviations and drug calculation errors.  Other errors that may not directly 
affect patient safety at the point of prescribing are use of trade names, 
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forgetting to date or sign the prescription and failure to document course 
durations for example. 
 
It could be argued therefore that PE studies, overestimate PE rates: 
omission and comission errors at point of admission are difficult to categorise 
as ‘errors’ as prescribers may not have all available information for example.  
An omission error is a failure to perform an appropriate action (Pronovost et 
al. 2005), whilst a comission error can be defined as performing an 
inappropriate action (Pronovost et al. 2005).    
 
1.7. Impact of medication errors 
 
Where PEs occur, patients can be harmed, confidence in the medical 
profession undermined, staff time wasted in correcting errors and the 
associated costs a massive burden to the NHS (NPSA 2007). 
 
Reports estimate MEs kill 7000 patients yearly in the United States (US) 
(Phillips 1998) and cause 1 in 20 hospital admissions; figures considered 
commensurate in the UK (Williams 2007).  In the UK, it was reported that 
1100 patients were killed each year because of ME’s or adverse drug events 
(ADE’s) (Audit commission 2001).  More recently, the NPSA (2007) reported 
92 cases of serious harm or death from MEs.  Considering under reporting is 
a concern (Williams et al. 2013), it is likely that this figure is even higher.  
These figures may appear abstract but comparing to other industries can 
contextualize the issue, with Ferner (2012) illustrating that healthcare is one 
of the most dangerous encounters a human can face, akin to bungee 
jumping and mountain climbing; an eerie thought given the raison d’etre of 
healthcare. 
 
Where patients are harmed, their hospital stay can be prolonged and in 
some cases their health permanently affected.  The impact of these errors 
can carry huge financial burdens.  MEs can prolong hospital stay by three 
days at a cost of £265 per day (National Institute for Health and Care 
Excellence (NICE) 2015) whilst 25% of litigation claims in general practice 
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result from MEs (Aronson 2009b).  The NPSA estimated that preventable 
MEs cost the NHS a staggering £750million per year (NPSA 2007): a huge 
financial burden.   
 
It is recognized that the risk of harm from PEs needs to be addressed (Velo 
and Minuz 2009, Dean 2002).  The DOH outlined the need for a 40% 
reduction in serious medication errors (DOH 2000) with good practice 
recommendations published (DOH 2001). Similar recommendations have 
been endorsed elsewhere (DOH 2004) although it should be noted that 
baseline error rates appear irrelevant and error severity is not quantified.  
More recently (DOH 2014), the health secretary has urged NHS institutions 
to reduce serious errors by half with financial incentives for those trusts who 
demonstrate this affect.  However, this is a curious recommendation:  
Considering PEs are largely preventable and avoidable incidents, this figure 
should be non-negotiable at 100% and a target that every organisation 
strives towards. 
 
Recently, the care quality commission (CQC) (CQC 2014) have questioned 
the legibility of prescriptions and signatures at one hospital with implications 
for accountability and risking repeat of the same errors.  It is conceivable that 
prescribing will come under increased scrutiny as part of the wider mandate 
to improve patient safety; to some extent this project could be getting ahead 
of the curve. 
 
The research in this thesis is concerned with exploring the impact and 
effectiveness of pharmacist-led prescribing error feedback.  The intervention 
is described in more detail in chapter 3 but is designed to reflect principles of 
effective feedback, encouraging reflection on prescribing performance and 
negotiating actions to improve practice further.  This process is distinct from 
practice prior to this research where pharmacists would typically inform a 
prescriber of an error and ask them to amend the prescription. 
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1.8. Organization of this thesis 
 
Chapter 2 presents a literature review of the research subject.  Strategies 
that have been employed to reduce PEs are discussed and the need for 
further interventions outlined. The potential for PE feedback is described 
considering available evidence for impact on prescribing performance, and 
principles of effective feedback to inform intervention design.   
 
Chapter 3 describes the research methodologies and methods that underpin 
this research.    Research questions and hypotheses are reviewed and the 
choice of both qualitative and quantitative methods to address research aims 
discussed.  The chapter concludes with consideration of the data collection 
and analysis techniques. 
 
In chapter 4, the attitudes and experiences of pharmacists towards delivering 
PE feedback prior to the intervention are reported using focus groups. 
 
Chapter 5 presents results of a controlled pilot-study exploring the 
effectiveness of PE feedback on PE rates. 
 
In chapter 6, the attitudes and experiences of prescribers towards receiving 
formalized PE feedback are described.  Specifically, their views on the 
process, impact on their prescribing and working relationships, and use of 
pharmacists as facilitators of feedback are explored.  
 
Chapter 7 presents the results of the larger cohort study to determine the 
reproducibility of pilot results.  Quantitative results are presented 
descriptively before the research hypotheses are tested using relevant 
inferential statistics to measure the impact on prescribing, and different error 
types and severities. 
 
In chapter 8, the experiences of pharmacists of delivering the intervention 
are described.  There is particular reference to the value and sustainability of 
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the project as well as an exploration of the perceived impact on prescribing, 
prescribers, pharmacists and pharmacist-prescriber relationships. 
 
Chapter 9 describes the impact of feedback on prescribing behaviour.  
Individual PEs are classified according to James Reasons’ psychological 
approach before exploring the impact of the intervention on prescribing 
behaviour following feedback on these different error types. 
 
Chapter 10 concludes the thesis with a summary of key findings.  
Implications for practice are considered and recommendations for further 
research outlined. 
 
1.9. Chapter Summary 
 
This introductory chapter has described key terms and concepts that will be 
discussed throughout this thesis.  The context and background for the 
intervention has been described and overall aims and objectives presented.   
The prevalence and impact of PEs has been defined and an overview of 
error causation and typology presented to inform further reading in chapters 
3 and 9.  Chapter 2 will now review what interventions have been 
implemented to address PEs and why PE feedback and the research 
proposed in this thesis is needed. 
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Chapter 2. Literature review 
 
2.1. Chapter Introduction 
 
This chapter will explore the literature reporting PE reduction initiatives.  
Firstly, the literature reporting strategies to reduce PEs will be reviewed and 
the need for additional interventions outlined.  The chapter will then progress 
to describe and outline what feedback is, and the principles and processes 
underpinning effective feedback.  This will be followed by a review of the 
empirical literature reporting the impact of feedback on skill-based 
performances.  The literature regarding feedback and PEs and how it informs 
the research in this thesis will then be described. 
 
2.2. Prescribing error reduction initiatives 
 
It is prudent to consider what interventions have been researched previously.  
This will inform the need for the research in this thesis and the contribution 
the author is making to this field of study. 
 
Suggestions to improve prescribing have been proposed previously (Dornan 
et al. 2009) and include changes to the working environment, medical 
education at undergraduate and postgraduate level, and inter-professional 
education.  This focus on education resonates with many of the interventions 
reported in the literature to reduce PEs.  Other interventions include 
equipment or resource redesign such as electronic prescribing or 
standardized medication charts, and greater use of clinical pharmacists.  
These interventions will now be reviewed.  
 
2.2.1 Educational interventions  
 
A variety of educational interventions have been assessed to improve 
prescribing competency and performance.  A systematic review (Ross et al. 
2009) of educational interventions to improve prescribing in medical students 
and junior doctors concluded that the WHO (World Health Organisation) 
good prescribing guide increased prescribing competency in a variety of 
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international settings.  The guide includes a six-step prescribing model to 
choose, prescribe and monitor a medication with a core list of personal drugs 
that prescribers are tacitly familiar with.  Educational interventions based on 
this guide have the greatest body of evidence (Kamarudin et al. 2013) with 
retention of knowledge (Akici et al. 2003, Gordon et al. 2011) and transfer of 
effect to other situations also reported (Akici et al. 2003, Richir et al. 2008). 
However, whilst the studies reported significant outcomes, they reported 
prescribing scores using written scenarios with a limited number of diseases, 
as opposed to practical prescribing stations, limiting conclusions for 
prescribing in practice.  It should also be noted that such interventions 
demonstrate that an individual ‘knows’ as opposed to the highest level of 
competence ‘does’ that reflects real-world prescribing. 
 
Specific teaching using tutorials and workshops have been shown to be 
effective in improving prescribing.  Coombes et al. (2007) reported significant 
improvements for example in a written paper following problem-based 
tutorials for medical students.   Elsewhere Scobie et al. (2003) reported 
improvements in OSCE station scores following pharmacist-led teaching 
sessions.  One educational programme for final year medical students 
reported improvements in prescribing and confidence but errors were still 
present in 30% of prescriptions (Sandilands et al. 2011).  Ross et al. (2009) 
highlight that the validity and generalizability of these interventions is limited 
by their diversity, outcome measures, and single site settings. 
 
Another systematic review (Brennan and Mattick 2013) focused on 
interventions to improve prescribing in junior doctors in the hospital setting 
only.  A wide variety of interventions were reported including use of 
educational materials such as guidelines, workshops and other training 
platforms, audit and feedback, educational outreach, alerts and reminders, 
marketing and patient mediated interventions.  All were reported as effective 
with mixed results for some interventions.  The authors concluded that no 
approach was more effective than others.  Equally, it was acknowledged that 
only 11% of studies investigated single interventions with the majority 
adopting a triangulated approach.  For example, Webbe et al. (2007) 
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reported reductions in PE rates following pharmacist intervention that 
consisted of attending ward rounds, sharing of errors amongst teams, 
provision of prescribing tutorials and distribution of prescribing guidelines.   
 
Another review (Ostini et al. 2009) concluded that educational outreach, 
audit, and feedback dominate the research arena into PE reduction and 
consistently show positive outcomes.    They also conclude that little is 
known as to why certain interventions work whilst others do not.  These 
findings are echoed in a more recent systematic review (Kamarudin et al. 
2013) exploring interventions to improve patient-focused prescribing 
competency.   The use of the WHO guide to good prescribing was again 
outlined as improving competency in a variety of settings, whilst other 
interventions such as academic detailing or personalised feedback also had 
positive effects. 
 
Prescribing is a recognized role of junior doctors (Ross and Maxwell 2012) 
although it is a role that all prescriber grades need to be proficient in.  
Tomorrow’s Doctors (GMC 2009) outline the standards for undergraduate 
medical education in the UK and the knowledge and skills expected of 
medical graduates to “Prescribe drugs safely, effectively and economically.” 
However, undergraduate prescribing education is known to be inconsistent in 
the UK (O’Shaughnessy et al. 2010) with graduates feeling underprepared to 
prescribe (Heaton et al. 2008, Illing et al. 2008) and concerns expressed 
over unsafe prescribing practices (Garbutt et al. 2005).  For practicing 
doctors, the GMC have published standards for prescribing (GMC 2013) 
whilst the foundation programme curriculum (GMC 2012) specifies a list of 
prescribing competencies to ensure that they are safe and effective 
prescribers.  Specifically, the curriculum states that they should: 
 
“Prescribe drugs and treatments appropriately, clearly and unambiguously in 
accordance with “Good Practice in prescribing medicines (GMC, 2008)” 
 
Evidence of such should be assessed as part of any trainee’s portfolio review 
by their supervisor. However, each NHS Trust has autonomy in how these 
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competences are achieved, what evidence is required and what, if any, 
training is delivered.  Equally, variations in foundation doctor training have 
been reported whilst focusing on knowledge and technical aspects of 
prescribing (Kirkham et al. 2015).  Foundation grade doctors have 
demonstrated inadequate prescribing ability previously (Harding et al. 2010), 
and are reported to have the highest PE rates (Dornan et al. 2009), and 
twice as likely as consultant grade prescribers to prescriber erroneously 
(Ashcroft et al. 2015).  At the very least, more could be done to prepare and 
support newly qualified doctors to reflect the standards outlined in the above 
documents.  Such interventions could support the development of junior 
doctors in acquiring a complete skill set for safe and appropriate prescribing.   
 
2.2.2. Academic detailing  
 
Educational outreach, or ‘academic detailing’, describes a visit by a trained 
person to health professionals (i.e. prescribers) in their place of work 
(O’Brien et al.  2007). It has been identified as “an intervention that has the 
potential to change health professional practice, particularly prescribing by 
physicians” (Soumerai 1989; Soumerai 1990).  A systematic review (O’Brien 
et al. 2007) of 69 studies involving more than 15,000 health professionals, 
concluded that educational outreach can be effective in improving practice.  
The effects on prescribing were small (4.8%) but consistent (O’Brien et al. 
2007), and potentially important given the likely multi-targeted approach 
required for improving prescribing practice.  Considering the ease of 
academic detailing as a one-off intervention, it is perhaps no surprise that 
educational outreach predominates as a PE reduction strategy in one 
systematic review (Ostini et al. 2009).  However, educational outreach 
usually focuses on a particular aspect of prescribing such as antibiotics for 
example, or adherence to a particular guideline (Ostini et al. 2009) and not 
prescribing as a whole.   
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2.2.3. Prescribing assessment tools 
 
In the elderly population, assessment tools used in clinical practice to reduce 
inappropriate prescribing include Beers criteria (American Geriatrics Society 
2015) and STOPP/START (Screening Tool of Older People’s 
Prescriptions/Screening Tool to Alert to Right Treatment) (O’Mahony et al. 
2015).  These tools contain criteria that are designed to facilitate review of, or 
to avoid commencing, inappropriate medication.  Application of the 
STOPP/START criteria also reviews the need to commence other 
medications that can reduce mortality in the patient population.  Use of the 
STOPP/START criteria has been shown to reduce medication costs, patient 
falls, number of daily medications and number of potentially inappropriate 
medications (Lavan et al. 2016).  However, such tools are not used widely in 
clinical practice, are often tested in isolated settings and reflect application to 
only one patient cohort (Lavan et al. 2016). 
 
2.2.4. Pharmacists and prescribing errors 
 
Hospital pharmacists perform medicines reconciliation and screen 
prescriptions as part of their clinical duties, intercepting and resolving PEs 
where they are identified. In one report, where pharmacists performed the 
medicines reconciliation before a prescriber in an emergency department, 
the number of errors reduced from 3.3 per patient to 0.04 per patient (Mills 
and McGuffie 2010) and is reported to be cost effective elsewhere (Karnon et 
al. 2009). 
 
Where pharmacists intercept and resolve PEs, the risk of harm is reduced 
with clinical pharmacists reducing PEs in the hospital setting (Tully and 
Buchannan 2009, Abdel-Qader et al. 2010).  The presence of ward-based 
clinical pharmacists has been shown to reduce PEs whilst also reducing 
costs from medications and adverse events (Klopotowska et al. 2010, Ariano 
et al. 1995).  These benefits underscore the recommendation for clinical 
pharmacists to be involved at all points of the medication process (Agrawal 
et al. 2009) where they are an integral part of the medication safety net. 
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Contributions of hospital pharmacists are therefore well regarded in reducing 
error and patient harm (Velo and Minuz 2009) and adverse effects of 
medications (Leape et al. 1999, Holland et al. 2008). Considering this role, it 
is perhaps of no surprise that pharmacists collect the data in many of the PE 
prevalence studies (Velo and Minuz 2009) and are often involved in the 
delivery of tutorials or educational outreach materials to prescribers 
mentioned above.  Pharmacists are also involved in undergraduate 
prescribing education delivering prescribing tutorials for example. Pharmacist 
involvement in prescribing education has been well received at 
undergraduate (McGuire et al. 2015) and postgraduate level (Kennedy et al. 
2016) where they were described as “knowledgeable, accessible and 
important sources of information”.  This suggests that pharmacists are 
credible prescribing educators with the working relationship outlined as an 
important theme (Kennedy et al. 2016). 
 
In a primary care setting, use of pharmacists to analyse PEs and agree 
action plans in General Practitioner (GP) practices, improved primary and 
secondary composite outcomes and was considered a cost-effective 
intervention (Avery et al. 2012).  The intervention in this study consisted of 
pharmacist-led educational outreach and delivery of feedback on specific 
prescribing indicators.  Qualitative analysis reported the intervention was 
valued although team integration and credibility of the pharmacist had 
implications for how the intervention was received.  Where GP’s were 
defensive or refused to act on recommendations, pharmacists reported 
feelings of frustration and isolation. 
 
2.2.5. System redesign 
 
Efforts at the system level to address prescribing standards have focused on 
electronic prescribing with some arguments also proposed for 
standardisation of medication charts.    
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2.2.5.1. Standardised medication charts 
 
The potential for standardised medication charts to reduce PEs is recognised 
and has been proposed for the UK previously (Barber et al. 2003).  In 
Queensland, Australia, a pilot study demonstrated reductions in PE rates 
from 20% to 16% (Coombes et al. 2009).  When piloted across Australia 
(Coombes et al. 2011), the standardised chart reduced PEs by almost one 
third.  Where medication charts are standardised, there is clear potential to 
inform prescribing pedagogy at undergraduate level and for staff moving 
between hospital sites (Coombes et al. 2009).   
 
However, a standardised chart has not been adopted across the UK.  There 
is an all-Wales chart available (Routledge 2012) whilst a standardised chart 
is also being piloted in Scotland, although results for their effectiveness are 
currently unavailable. 
 
2.2.5.2. Electronic prescribing  
 
There are various definitions of electronic prescribing but they all typically 
describe the ordering or prescribing of medication electronically (Ahmed et 
al. 2016).  Such systems show considerable promise in reducing PEs and 
improving patient safety as reported in systematic reviews (Conroy et al. 
2007, Shamliyan et al. 2008, Ahmed et al. 2016).  
 
Electronic prescribing is reported to reduce certain error types (Shamliyan et 
al. 2008) including misinterpretation of illegible handwriting, omissions, 
completeness of prescribed items and patient identification (Ahmed et al. 
2016).  However, these studies were typically in isolated settings, single case 
studies or heterogeneous in design making comparisons and generalizability 
difficult.  Equally, benefits are not consistent (Shamliyan et al. 2008, Ahmed 
et al. 2016) with electronic prescribing introducing new and different PEs 
compared to paper based systems that can compromise patient safety 
(Kannry 2011, Esmaeil Zadeh et al. 2016).  Such errors include incorrect 
entry of dose, patient information or selection of incorrect drug name and 
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frequencies from drop down menus.  One review (Ranji et al. 2014) 
concluded that such concerns limit any benefits introduced by the 
technology.  
 
Electronic prescribing systems are not completely adopted in the UK yet with 
a myriad of platforms used.  In some cases, over half of hospitals have been 
reported to use more than one system and only in limited clinical areas 
(Ahmed et al. 2013).  Nonetheless, NHS hospitals in England are expected 
have paperless prescribing in place by 2020 (National information board 
2014) and so the use and potential impact should become clearer in the 
future with time and motion studies commenced in the UK (Schofield et al. 
2015).  However, given the concerns reported above, it is likely that 
electronic prescribing, will simply be a partial solution to reducing PEs.   
 
2.2.6. Other interventions needed 
 
STHKH is committed to reducing PEs as part of their pledge to optimising 
patient safety and reflecting national recommendations (DOH 2000, DOH 
2004).  An extensive medical education programme is delivered at 
undergraduate and postgraduate level with considerable pharmacist input.  
In addition, all medical graduates undertake the national prescribing safety 
assessment as part of their undergraduate training.  Clinical pharmacists are 
present on most wards and deliver some ward based teaching in the form of 
academic detailing for example.  Whilst full electronic prescribing was not 
used in the hospital during this research, electronic prescribing was available 
for discharge prescriptions.  Additionally, the inpatient medication chart was 
designed to comply with national recommendations (Academy of Medical 
Royal Colleges 2016). 
 
Despite these interventions, there is evidence that PEs are still prevalent 
(Reynolds et al. 2016, Seden et al. 2013).  Prescribing is a complex skill that 
requires more than an adequate knowledge base.  Practical prescribing 
training is perceived to be suboptimal by medical students and junior doctors 
(Heaton et al. 2008) with dissatisfied feedback from recent medical 
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graduates (Nazar et al. 2015).  Equally, what works in other settings may not 
necessarily work in all settings where the intervention is dependent on the 
skill of the facilitator for example.  Further interventions are required to align 
prescribing behaviour with expected competencies and enhance prescribing 
performance; feedback is one possible intervention that can help to achieve 
this.    
 
2.3. Feedback 
 
Feedback is considered central to supporting cognitive, technical and 
professional development of individuals (Archer 2010).  This clearly 
resonates with an educational focus with feedback described as an essential 
component of the educational process to help trainees reach their maximum 
potential (Hesketh and Laidlaw 2002).  Building on this, feedback has been 
described as the “cornerstone of effective clinical teaching” (Cantillon and 
Sargeant 2008, Hesketh and Laidlaw 2002).  
 
2.3.1. What is feedback? 
  
There are various definitions of feedback within the literature.  In medical 
education, feedback has been defined as “information describing students’ or 
house officers’ performance in a given activity that is intended to guide their 
future performance in that same or related activity” (Ende 1983).  In the 
context of this research, the student is the prescriber and the intention is to 
improve their prescribing performance.   However, feedback is not simply a 
descriptive exercise but a complex interaction between the provider and 
recipient of feedback, and the type of interaction and elements of effective 
feedback should be considered when designing any feedback intervention.   
 
2.3.2. Types of feedback 
 
Feedback can be either directive or facilitative (Archer 2010).  Directive 
feedback is simply that, directive.  It informs the learner of what requires 
correction.  This model reflects what happened in STHKH prior to this 
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research with PEs highlighted and amended but rarely discussed, and is 
clearly not a constructive process.  Facilitative feedback uses questions and 
comments to facilitate the learner in understanding and revising their own 
practices.  This approach is consistent with provision of constructive 
feedback.  One study (Kroll et al. 2008) explored doctors’ experiences to 
error, and reported that learning was optimized when error was discussed 
formally, and constructive feedback provided.   
 
It has been proposed that the purpose of feedback is to encourage learner 
reflection on performance and how they can improve (Hesketh and Laidlaw 
2002).  Equally, learners have reported previously that they value and prefer 
feedback that encourages reflection (Cantillon and Sargeant 2008, 
Menachery et al. 2006, Rees et al. 2005), a process that requires facilitative 
feedback.  Sargeant et al. (2009) reported that reflection was an important 
educational focus of feedback to assimilate and accept the feedback.  More 
recently, Archer (2010) concluded that to be truly effective, feedback needs 
to nurture reflection-in-action so that for example, prescribers are fully 
engaged with their prescribing and reflect both on and in the prescribing 
process. 
 
The pedagogical principles of facilitative feedback resonate with the 
experiential learning cycle (Kolb 1984) (Figure 6).  Feedback on prescribing 
raises awareness of a learner’s performance.  This is the “concrete 
experience” yet equally is no more than sensory information.   To make 
sense of that information, reflection is required as is abstraction of ideas to 
improve practice and finally, the learner then commits to testing the new 
ideas and agreed ways of working.  At a biological level, transformation of 
information into knowledge and behavioural change requires involvement of 
the sensory (experience), temporal integrative (reflection), frontal integrative 
(abstraction) and motor (testing) cortexes (Zull 2002).  Therefore, the role of 
facilitative or constructive feedback in completing the learning cycle can be 
seen whereas directive feedback may not progress beyond the concrete 
experience phase.  Building on this, facilitative feedback can encourage 
reflection on the experience, causation and identification of solutions to 
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complete the learning cycle. 
 
Figure 6: Experiential learning cycle (from Lloyd et al. 2016b) 
 
 
Feedback can be either positive or negative where the aim is to reinforce or 
correct behaviour.  Positive feedback can encourage further exemplary 
practices and feedback seeking behaviour (Cantillon and Sargeant 2008, 
Krackov 2009) whilst negative feedback can correct poor performance 
(Ramani and Krackov 2012) and has been shown to particularly encourage 
reflection (Sargeant et al. 2009).  In a systematic review (Ivers et al. 2012), 
feedback designed to reduce certain behaviours was more effective than 
feedback designed to increase certain behaviours.  
 
Additionally, to be effective, feedback needs to be more than simply praise or 
criticism, it needs to be constructive following some key principles as 
described below.  
 
2.3.3. Elements of effective feedback 
 
There are guiding principles that should be considered to enhance the 
efficacy of feedback.  Eight guiding principles are proposed (Cantillon and 
Sargeant 2008) based on educational theory and research: 
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1. Feedback should be part of everyday practice 
2. Assessment criteria should be clear 
3. Feedback should be specific and not vague 
4. Feedback should be on observed practice 
5. Feedback should be timely 
6. Feedback should be limited to one or two items  
7. Feedback should seek learner’s perceptions 
8. Feedback should lead to change in learner thinking, behaviour and 
performance 
 
A more recent review of the literature (Ramani and Krackov 2012) provided 
further practical tips for delivery of feedback in clinical practice.  These 
include: 
 
1. Establish a respectful learning environment. 
2. Communicate goals and objectives for feedback. 
3. Base feedback on direct observation. 
4. Make feedback timely and a regular occurrence. 
5. Begin the session with the learner’s self-assessment. 
6. Reinforce and correct observed behaviours. 
7. Use specific, neutral language to focus on performance. 
8. Confirm the learner’s understanding and facilitate acceptance. 
9. Conclude with an action plan. 
10.  Reflect on your feedback skills. 
11.  Create staff-development opportunities. 
12.  Make feedback part of institutional culture. 
 
Systematic reviews have reported that feedback is most effective when it is 
delivered by a supervisor or colleague, presented frequently, features 
specific goals and action plans, aims to decrease the targeted behaviour and 
is delivered in both verbal and written formats (Jamtvedt et al. 2003, 
Jamtvedt et al. 2006, Ivers et al. 2012, Ivers et al. 2014). 
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Considering these recommendations, a ward-based clinical pharmacist 
should be a respected colleague and suitable facilitator of PE feedback.  
Feedback should be delivered more than once verbally and supported by 
written feedback.  It should also contain specific actions to be implemented 
by the prescriber to reduce their PE rates, as opposed to a team or group of 
prescribers.  
 
The content of the feedback should be clear, understood, specific and 
relevant.  It should also be timely to facilitate memory recall and 
accompanied by an explanation to raise understanding.  Any feedback 
should recognise the recipient perspectives and allow self-assessment and 
development of action plans (Boehler et al. 2006, Hattie and Timperley 2007, 
Richardson 2004).  Therefore, PE feedback should include an explanation of 
potential risks, and encourage reflective practice to identify any potential 
error causation, and strategies to improve practice. 
 
Considering these principles several methods are available to support 
pharmacists in delivering constructive feedback such as BOOST (Clayton 
2012), the sandwich method (Dohrenwend 2002), Pendleton’s model 
(Pendleton et al. 1984) and the reflective conversation (Cantillon and 
Sargeant 2008).  BOOST is an acronym for delivery of feedback that is 
balanced, observed, objective, specific and timely.  The sandwich model 
proposes that any negative feedback is sandwiched between positive 
feedback.  With Pendleton’s rules, the facilitator asks what went well, tells 
the recipient what went well, asks what could be improved and finally tells 
them what can be improved.   
 
It should be noted that no single approach is most effective (Lefroy et al. 
2015). The approach, or approaches, that are adopted is likely to be 
dependent on the facilitator-recipient relationship and the situation, 
emphasising the need for flexibility and a culture of trust and respect.  What 
is important is that the feedback is not directive or passive (Archer 2010) but 
rather a dynamic, interactive conversation that facilitates reflection and 
learning.  
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A Cochrane review (Ivers et al. 2012) of the impact of audit and feedback 
suggests that the impact of feedback depends on how the intervention is 
designed and delivered whilst there are reports of interventions developed 
without consideration of relevant theories (Colquhoun et al. 2013).  This is 
reported more recently (Ivers et al. 2014) with feedback interventions 
continuing to be designed and assessed following a single round of 
feedback.  Therefore, the guiding principles and models of delivering 
feedback described above were used to support design of the written 
feedback tools (Appendices 1 and 2) and learning materials to train 
pharmacists as facilitators of feedback.   
 
2.3.4. Empirical evidence for impact of feedback 
 
Effective feedback is considered to direct and motivate behaviour whilst 
increasing self-awareness, enhancing interpersonal relationships and 
improving service quality (London 2015:21).  It is suggested that when 
feedback highlights suboptimal performance for important and actionable 
targets, individuals are more likely to increase their efforts to improve quality 
of care (Ivers et al. 2012).  
 
In educational settings, the power of feedback as an intervention to improve 
learning outcome and performance has been described (Hattie & Timperley, 
2007).  In healthcare settings, three Cochrane reviews of audit and feedback 
(Jamtvedt et al. 2003, Jamtvedt et al. 2006, Ivers et al. 2012) have reached 
similar conclusions that audit and feedback works with small but potentially 
important improvements on professional practice. 
 
2.3.5. Need for prescribing error feedback  
 
Despite efforts to improve prescribing, errors persist and further targeted 
interventions are required to optimise safe and appropriate prescribing.  In 
their review of educational interventions to improve prescribing behaviour, 
Brennan and Mattick (2013) concluded that there was an urgent need for 
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educational interventions to support the development of desirable behaviours 
in doctors.  The potential for feedback to improve practice and modify 
behaviour (Jamtvedt et al. 2006, Archer 2010, Ivers et al. 2012), including 
prescribing behaviour (Barber et al. 2003, Velo and Minuz 2009), has been 
described.  Doctors have reported valuing and welcoming feedback (Franklin 
et al. 2007, Dornan et al. 2009, Bertels et al. 2013) yet have reported a lack 
of awareness of and feedback on their PEs (Lewis et al. 2014, Bertels et al. 
2013, Dornan et al. 2009, Franklin et al. 2011).  One study exploring PEs at 
discharge reported that 83% of errors were corrected without referral to the 
prescriber (Abdel-Qader et al. 2010). Where errors occur, it is important that 
the individual (Dean 2002) and the team (Department of health 2000) learn 
from the error otherwise it is a missed learning opportunity.  Feedback has 
the potential to facilitate this learning and change prescribing behaviour but 
equally, without it, the status quo may not be challenged and inappropriate 
prescribing will continue. 
  
One review of prescribing education in the UK suggested that prescribers 
should have protected time to reflect on prescribing and any feedback, which 
should be delivered in a blame free environment (Likic and Maxwell 2009). 
The national prescribing competency framework (RPS 2016) outlines that 
prescribers should act upon feedback and use tools such as feedback to 
improve prescribing.  Another published framework (Lum et al. 2013), based 
on the WHO safe prescribing model (de Vries et al. 1994), highlights that 
prescribers should have “the ability and willingness to self-reflect on 
prescribing practice, seeking and acting on constructive feedback”.  The 
need for constructive prescribing feedback is therefore clearly recognized yet 
evidence on its use and application is limited.  
 
2.3.6. Prescribing error feedback evidence 
 
A literature search was undertaken to determine the originality of this thesis 
and its contribution to the research field. 
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The initial literature search for the research in this thesis was undertaken in 
2014 although it has been updated throughout data collection, analysis and 
write up of this thesis (2014-2017). 
 
Key search terms included prescribing (OR prescription), error (OR errors), 
feedback, AND pharmacist (OR pharmacy OR pharmacists).  Search terms 
were combined with and without pharmacist. 
 
The following relevant databases were used to perform the literature search: 
CINAHL (Cumulative Index to Nursing and Allied Health Literature), Medline, 
Pubmed and Scopus.  In addition, a general search of the internet was also 
performed. All searches were limited to English language articles. 
 
2.3.7. Systematic reviews of feedback on performance 
 
A systematic review (Jamtvedt et al. 2006) reported a median 5% absolute 
improvement in professional practice following audit and feedback.  
However, few studies looked specifically at prescribing whilst they were 
limited to single drug classes (e.g. benzodiazepine prescribing in the elderly) 
and the effect varied from very large positive effects to negative effects. 
 
A 2012 review of the literature similarly reported small but potentially 
important effects of feedback on professional practice (Ivers et al. 2012).  
Thirty-nine of the included studies targeted prescribing and the authors 
commented that feedback was likely to be more effective when it targeted a 
dichotomous outcome such as prescribing.  It was suggested that this may 
be because prescribing is important but not complex.  An exploratory 
analysis of the prescribing sub-studies reported a median absolute 
improvement of 13.1% (IQR 3% to 17%) (Ivers et al. 2012).  Again however, 
these studies focused on prescribing of specific drugs or for specific medical 
conditions (e.g. asthma) whilst studies reporting the impact of prescribing 
feedback in the hospital setting were notably absent. 
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An updated review (Ivers et al. 2014) reported similar findings but was 
damning in their report that trials were not contributing to existing evidence 
as the feedback intervention was theoretically flawed.  For example, 
feedback was only delivered once in 47 % of studies, did not include goals or 
action plans in 61 % of studies, whilst the facilitator was unknown or was the 
researcher (as opposed to a respected colleague) in 85% of studies. 
 
2.3.8. General perceptions of prescribing feedback  
 
PE feedback at the speciality level has previously been well received by 
consultants and considered feasible to deliver (Franklin et al. 2007).  
Elsewhere (Bertels et al. 2013), FY1 doctors were positive about receiving 
more individualised feedback and that feedback was likely to improve their 
prescribing.  In a more recent qualitative study (Ferguson et al. 2017), 
feedback was reported to have potential to influence future prescribing 
behaviour, especially if it was timely and allowed benchmarking to a 
reference value. These findings echo results of an earlier study (Dornan et 
al. 2009) where FY1 doctors reported welcoming prescribing error feedback 
as a learning opportunity.   
 
Similarly, pharmacists have reported that they would be willing to provide 
more formal feedback to junior doctors where time is provided (Bertels et al. 
2013) although the views of delivering feedback to more senior prescribing 
grades is unknown. 
 
2.3.9. Prescribing feedback in speciality areas  
 
Various studies have evaluated the impact of feedback in isolated settings.  
These results may therefore be context specific, reflecting the dynamics of 
specific areas or indeed the skill of individual facilitators of feedback in those 
areas. 
 
For example, several studies have reported feedback as a prescribing 
improvement intervention in the paediatric setting. One study (Eisenhut et al. 
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2011) assessed sixteen prescribers’ performance in completing prescribing 
exercises who then received e-mailed feedback from a pharmacist on their 
performance.  Prescribing was audited prior to and two months following this 
intervention and the authors reported an improvement in PEs.  However, the 
study was uncontrolled, the assessment and ensuing supervision of 
prescribers who made errors may have biased results, whilst the feedback 
process does not resonate with principles of effective feedback. 
 
Another pilot study (Gordon and Bose-Haider 2012) reported reductions in 
technical PE rates from 8.8% to 1.8% using a departmental poster and e-
mailed feedback.  Whilst demonstrating clear potential, this study was 
uncontrolled and did not include verbal feedback that could facilitate further 
understanding and contextualisation of the feedback.  Equally, the feedback 
focused on the technical aspects of prescribing so inferences for clinical PEs 
are unknown.   
 
Elsewhere, Booth et al. (2012) introduced daily anonymised feedback on 
previous days’ PEs at team hand over and the start of ward rounds.  
Significant reduction in non-clinical errors was reported with non-significant 
reduction in clinical errors.  Such feedback is clearly timely although lacks 
individualisation and where error causation is not identified or actions 
agreed, behaviour is unlikely to change and may reflect the non-significant 
improvement in clinical errors. 
 
In a neonatal setting (Sullivan et al. 2013), one study reported an 83% 
improvement in days between narcotic PEs although these results did not 
extend to other prescribed medications (e.g. antibiotics) or overall errors.  
However, feedback was only delivered via e-mail and at two-weekly intervals 
and so is likely to be directive in nature and not necessarily timely for any 
prescribing event.   
 
Recently, (Leach et al. 2016) prescribers were taught and assessed on 
prescribing standards in a paediatric setting.  This was followed by feedback 
at weekly intervals to entire ward areas with charts indicating performance 
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and star ward of the week.  Initial improvements were not sustained although 
a control group was not used.  Whilst such feedback is acceptable (Franklin 
et al. 2007) it lacks the specificity of effective feedback, the directive nature is 
not constructive and is unlikely to stimulate prescriber reflection.    
 
For adults, one study (Thomas et al. 2008) reported improvements in 
prescription error rates following audit and written feedback at four weekly 
intervals in an intensive care unit.   However, the study design was 
uncontrolled which limits interpretation.  Additionally, the written feedback 
was provided without discussion and so may not stimulate reflection or 
facilitate identification of error causation, which would influence any further 
action or goal setting.   
 
In another study (Chan et al. 2010), provision of prescriber education and 
“real time” feedback demonstrated a reduction in medicines reconciliation 
discrepancies (mean 2.6 down to 1) in an admissions unit in a New Zealand 
hospital.  However, the study was uncontrolled and so it is unclear what 
intervention had an effect.  More importantly, “real-time” feedback consisted 
of placing a sticker with a list of potential medication discrepancies in the 
medical notes for the prescribing team to review.  Whilst this can raise 
awareness of potential errors and improve communication of medication 
related queries, it lacks specificity, individualisation, targets or actions 
required for effective feedback.   
 
2.3.10. General prescribing feedback 
 
Franklin et al. (2007) reported that feedback delivered at the speciality level 
was well received by consultants and was feasible although impacts on 
prescribing were not reported.  Their later work built on these findings to 
design a feedback intervention study (Reynolds et al. 2016).  In this study, 
the authors introduced name stamps to facilitate prescriber identification, 
with provision of feedback on PEs and fortnightly e-mails describing common 
or serious prescribing errors.  A second hospital was used as a control and 
the authors reported no difference in change in PE rates between 
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intervention and control sites.  It was acknowledged that prescribers were 
only identifiable in 50% of cases and that this may have limited intervention 
impact.  However, equally, the principles and processes of feedback delivery 
were not explicitly described.  For example, it was unclear if feedback was 
verbal, written or both, or whether or not the pharmacists delivering the 
feedback had a working relationship with the prescriber.  A description of the 
process suggested that the feedback may have been directive, for example 
“This dose is incorrect for this patient: it should be……here’s where you find 
the protocol”.  Whilst this is feedback, it does not identify the rationale for the 
error or encourage the recipient to identify solutions themselves.  Finally, the 
intensity of feedback was not reported for each prescriber whilst it was 
unclear if all prescribers who were involved in the intervention site had 
received feedback at all. Therefore, the potential effect of feedback may be 
lost in these design flaws.  
 
In an African study (Ajemigbitse et al. 2016), no improvements in overall PE 
rates were reported following educational outreach and feedback at the 
departmental level.  There were some significant improvements in writing of 
routes of administration and non-ambiguous orders for example and perhaps 
echoes the findings of Gordon and Bose-Haider (2012) described earlier. 
Reported improvements were limited to registrar grade prescribers although 
the feedback content lacked individualisation and was only delivered once, 
potentially limiting any effect of feedback.  
 
2.3.11. Prescribing feedback in General Practice 
 
Feedback intervention studies have shown promising results in primary care 
settings.  In one study (Avery et al. 2012), pharmacists provided feedback, 
educational outreach, and dedicated support on a range of prescribing areas.  
The authors reported significant improvements in unsafe prescribing 
practices following this intervention. The triangulated approach limits 
interpretation of the impact of feedback whilst the control arm also consisted 
of computer-generated feedback and therefore, the effect of the intervention 
may be underestimated. 
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More recently, Winder et al. (2015) reported 36% reductions in prescription 
error rates for prescribers following electronic feedback, educational 
outreach and weekly newsletters.  The actual impact of feedback was 
unclear because of the multiple intervention approach whilst directive, 
electronic feedback was also used. 
 
2.3.12. Prescribing feedback on specific medication groups 
 
Several studies have explored the impact of feedback on specific medication 
classes for example antibiotic (McLellan et al. 2016) or benzodiazepine 
prescribing (Ivers et al. 2012). 
 
Recently, a controlled mixed-methods UK study (McLellan et al. 2016) 
reported a lower mean suboptimal antibiotic prescribing rate in intervention 
groups (0.32+0.36) compared to control groups (0.68+0.36).  For the 
intervention group, feedback workshops were provided at two time points 
with feedback based on theoretical principles. Significant differences 
between groups were limited to suboptimal prescription writing as opposed to 
antibiotic choice.  However, the nature of the workshops may have meant 
that feedback was not timely.  Additionally, the use of a single facilitator for 
the workshops (a hospital pharmacist), as opposed to a ward based 
pharmacist, may have limited any open candour in discussing prescribing.  
Additionally, provision of feedback at two set time points may not be frequent 
enough nor part of routine clinical practice.  Therefore, despite positive 
outcomes, the true effect of feedback may be underestimated. 
 
Elsewhere, Hallsworth et al. (2016) reported small but significant 
improvements in antibiotic prescribing following provision of social norm 
feedback that consisted of written feedback on antibiotic usage.  Whilst the 
effect was small, the low cost and ease of the intervention raises potential to 
utilize such feedback as part of wider prescribing improvement programmes.   
 
In Norway (Hogli et al. 2016), one uncontrolled study combined audit and 
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feedback with distribution of antibiotic prescribing guidelines.  The authors 
reported significant improvements in overall mean prescribing of appropriate 
antibiotics from 61.7% to 83.8 %.   However, it is unclear what intervention 
had the impact whilst feedback was only delivered verbally at one time point 
and was not individualized.   
 
2.4. Chapter discussion 
 
The aim of this chapter was to outline the need for PE feedback as an 
interventional tool and the theoretical principles underpinning effective 
feedback.  Audit and feedback can improve task performance with evidence 
supporting its application to improve prescribing.  There is a scarcity of 
literature reporting the impact of feedback on general prescribing or in the 
hospital setting, supporting pursuance of the research in this thesis.   
 
Feedback is often used in collaboration with other interventions whilst many 
studies are often uncontrolled making inferences for the effect of feedback 
difficult.  Additionally, theoretical flaws in the design of the feedback 
intervention echo the sentiments of Ivers et al. (2014) that current research 
efforts are not contributing further to this field of study.  Such design 
limitations could underestimate the impact of feedback where any small or 
absent effect is less to do with the intervention, and more to do with the 
design of the intervention.  The majority of studies reviewed explored 
feedback in isolated settings, for specific medications or medical conditions 
and so feedback may be context specific or reflect the skill of the facilitator.  
Additionally, the use of hospital pharmacists as credible facilitators of 
feedback has been overlooked despite being both a colleague and observer 
of prescribing practice who has potential to deliver timely feedback.  
Exploring the impact of a feedback intervention that is aligned with the 
principles of effective feedback has independent research merit.   
 
The research in this thesis builds and innovates on previous research to 
explore the impact and effectiveness of pharmacist-led PE feedback.  These 
considerations can allow further inferences to be made as to the true effect 
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of feedback.  Additionally, qualitative reports of the impact of PE feedback on 
key stakeholders (pharmacists and prescribers) are limited.  An 
understanding of pharmacist and prescriber experiences of the process 
could provide a more detailed understanding of quantitative results.  These 
results could be used to inform why the intervention works, or doesn’t work, 
how to improve or refine the innovation further, and the scope for wider 
application across the organisation.   
 
2.5. Chapter Summary 
 
This chapter has presented an overview of the literature reporting PE 
reduction initiatives.  The theory and principles of effective feedback have 
been reviewed and the empirical evidence considering the impact of 
feedback on task performance considered.  The impact of feedback on 
prescribing has been reviewed to highlight the contribution of this research to 
existing knowledge and inform research design.  The following chapter will 
now explore the methodologies and methods used throughout this thesis.   
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Chapter 3. Methodology and Methods 
 
3.1. Introduction 
 
This chapter describes the research methodologies used throughout this 
thesis.  An overview of research methodologies will be presented before 
discussing their application within this thesis.  The choice of research 
methods and data collection will then be explored, covering use of interviews 
and focus groups for qualitative methods, and pre / post-test data collection 
for quantitative methods. The chapter will then describe how both 
quantitative and qualitative data will be analysed.   
 
3.1.1. Research questions and hypotheses 
 
The main objectives of this research are to explore the effectiveness and 
impact of pharmacist-led PE feedback as described in chapter 1. 
 
The research questions to be explored include; 
 
1. What is the impact of feedback on prescribing error rates? 
2. What are the views, attitudes and experiences of pharmacists to delivering 
prescribing error feedback? 
3. What are the views and attitudes of prescribers to receiving feedback? 
4. What is the impact of feedback on prescriber behaviour? 
 
Based on the literature review in chapter 2, the hypotheses are; 
 
H1: “There is a difference in mean change in prescribing error rate between 
the intervention and control group” 
 
With two sub hypotheses; 
 
H2: “There is a difference in the frequency of error severity following the 
intervention period” 
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H3: “There is a difference in the frequency of error type following the 
intervention period” 
 
And finally; 
 
H4: “There is an association between number of feedback sessions and 
change in prescribing error rates” 
 
3.2. Research Methodologies  
 
There are two distinct research paradigms in educational research; positivist 
and interpretivist.  The positivist paradigm is the objective paradigm, often 
generating large numbers of subjects for statistical analysis and 
generalisation (Cohen et al. 2011).  Conversely, the interpretivist, or 
naturalistic paradigm focuses on in-depth analyses of behaviour allowing 
interpretation of participant’s reality. These conceptual frameworks allow 
articulation of our world-views, to inform research design (Basit 2010) and 
actions (Bassey 1999). 
 
These paradigms reflect two distinct research methodologies; quantitative 
(positivist) and qualitative (interpretivist).  Quantitative methodology is 
nomothetic and subscribes to the fact that knowledge is generated through 
testing of hypotheses through collection of data and rigorous statistical 
analyses (Cohen et al. 2011).   Conversely, qualitative methodology is 
idiographic or hermeneutic in nature, with a focus on individual behaviour 
and reality (Cohen et al. 2011). 
 
A third paradigm also exists; mixed methodology or a pragmatist approach 
(Cohen et al. 2011), and warrants further consideration for this thesis.  It is 
argued that polarization of research methodology is non-meaningful and 
unproductive (Ercikan and Roth 2006) with the two approaches compatible.  
This issue is discussed more vociferously elsewhere with Robinson (1995) 
arguing that any paradigmatic dichotomous debate should be declared a 
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draw and all methods of knowledge acquisition equally accepted. 
Considering this, a combination of quantitative and qualitative methodologies 
are increasingly favoured within research with Johnson and Onwuegbuzie 
(2004) proposing that mixed methods research is a ‘research paradigm 
whose time has come’.  Mixed methods research can illuminate perspective 
and corroborate data through triangulation of quantitative data, with 
qualitative insight.  Here, the approach can provide a more complete picture 
whilst overcoming any weaknesses of individual approaches (Denscombe 
2008). 
 
It has also been argued (Onwuegbuzie and Leech 2005) that methodological 
puritanism should give way to pragmatism in addressing research questions.  
A quantitative, qualitative or mixed-methods approach may be appropriate 
(Savanye and Robinson 2004). As Marshall (1996) suggests; methodology 
“…should be determined by the research question, not by the preference of 
the researcher”.   
 
As outlined above, this thesis is concerned with determining the impact of 
feedback on PE rates and the recipients (prescribers) and facilitators 
(pharmacists) of feedback. 
 
The primary research question clearly resonates with quantitative 
methodology.  Quantitative research develops knowledge through cause and 
effect thinking (Basit 2010).  It is an objective approach to quantify reason, 
with valid inferences derived through rigorous statistical analysis.   
Epistemiologically, the hard, objective evidence required is consistent with 
the positivist approach to research as described earlier.  The feedback 
intervention is experimental and the research is concerned with exploring the 
impact, if any, on PE error rates. Therefore, any paradigmatic view-point is 
redundant, a numerical method is required to answer this question and 
hence a quantitative approach is required. 
 
However, where PE rates do change, a quantitative approach will not 
illuminate why they have changed exactly, what the motivators are, or what 
 53 
the impact has been on the individuals involved.  Arguably, questionnaires 
could have been designed and distributed to address the latter research 
questions reporting responses as frequencies and percentages.  However, 
as described in chapter 2, little is known on the subject and considering this, 
such an atomistic and reductionist approach to research would not provide 
the depth and richness required to answer research questions 2-4.  Equally, 
the author did not want pre-determined questions to limit findings of the 
feedback process. The impact of feedback on participants will be subjective 
and variable, people after all are autonomous beings and create their own 
reality.  By describing events through different lenses, individual perspectives 
can be illuminated, facilitating comprehension of an authentic world.  This 
resonates with an interpretivist model requiring qualitative methodologies 
that are more responsive to participants (Basit 2010), who define their own 
reality (Cohen et al. 2011).  As suggested elsewhere (Basit 2010:16), the 
‘devil is in the detail’ and a qualitative approach can provide the richness and 
depth of information to inform the latter research questions.   
 
However, equally, quantitative and qualitative approaches should not be 
used individually but in combination to support each other.  In this thesis, the 
research questions demand a mixed methods approach to the research and 
will be “mutually illuminating” (Bryman 2007) to support and corroborate 
findings. 
 
Therefore, a mixed methods approach is warranted to triangulate both 
numerical outputs and narrative understanding.  A “puritan” quantitative or 
qualitative approach could not be used, and therefore a mixed 
methodological approach is needed. Traditionally, mixed methodologies 
allow triangulation of data, affording greater reliability and inferences for the 
results (Cohen et al. 2011) and are poignantly termed the ‘third research 
paradigm” (Cohen et al. 2011:22). 
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3.3. Research Methods 
 
The ontological view of the author is that personal knowledge and 
understanding is a subjective acclimation of experience.  However, 
epistemological assumptions depend on the question, i.e. the methods must 
be fit-for-purpose and the methods used to answer the research questions 
will be described and justified below.   
 
3.4. Qualitative research methods 
 
Qualitative research allows in-depth review of experiences and attitudes to 
understand subjective meaningful experiences (Basit 2010) and will be used 
in this thesis to address the aims and research questions of chapters 4, 6, 8 
and 9.  A range of methods can be used in qualitative research with 
interviews and focus groups two of the most common employed. 
 
3.5. Semi-structured interviews 
 
Semi-structured interviews are ubiquitous with qualitative research and case 
studies, and are most popular in educational research (Basit 2010).  They 
are popular for exploring an individual’s opinions and experiences of a 
particular topic (Roberts and Priest 2010).  In this thesis, they have been 
used to explore experiences, attitudes and opinions of prescribers (chapter 
6) and pharmacists (chapter 8) of the feedback process.  They are also used 
again in chapter 9 to explore and understand the impact of feedback on 
prescriber behaviour following delivery of feedback on different errors.  Here, 
interviews were chosen for as Kvale (2009:xvii) suggests;  
 
“…if you want to know how people understand their world…why not talk to 
them?” 
 
Interviews allow research and interview-question clarification to minimise any 
misunderstandings.  Pragmatically, it would be easier to negotiate time away 
from the workplace with individual prescribers compared to a focus group, or 
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relying on honest and full completion of questionnaires.  Equally, prescriber 
views in chapter 6 may have been limited if they were interviewed as part of 
a focus group with other grades of prescribers who held different views to 
them for example.  This consideration also informed choice of interviews for 
exploring pharmacist views post-intervention in chapter 8 as senior 
pharmacists may have limited or biased the views of more junior pharmacists 
in a focus group.  Interviews were considered more suitable again in chapter 
9 as prescribers were discussing personal PEs; information disclosure that 
may have caused embarrassment if discussed as part of a focus group for 
example.    
 
A clear advantage of interviews is the depth and richness of data (Basit 
2010).  Use of open-ended questions can allow the spontaneity for 
participants to elaborate and articulate views with greater qualitative 
purpose, than for example with questionnaires (Oppenheim 1992).  It is not 
simply yes / no responses that the researcher is looking to elucidate, but 
rather the rationale behind their judgements and responses.  For example, if 
the feedback process affects working relationships, interviews allow the 
opportunity to elucidate this further by asking how, why and by what means.  
Considering this, interviews, as opposed to questionnaires have a clear 
advantage. 
 
As the term ‘inter-view’ suggests, the process is a two-way, interactive 
conversation between researcher and participant (Cohen et al. 2011).  Kvale 
(1996:14) sees an ‘inter-view as an interchange of views between two or 
more people on a topic of mutual interest’. 
 
To support this ‘interchange’ of views, topic guides were used (Appendices 
3-5) based on pre-determined themes and constructs.  These themes and 
questions were underpinned by the literature review in chapter 2, personal 
insight of the author and the research questions.  Each interviewee was 
asked core questions for consistency.  However, the semi-structured 
approach allowed a more fluid interview, digressing through relevant topics 
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and allowing probing and generation of impromptu, spontaneous questions 
devised during the interview. 
 
These supplementary questions can elaborate responses and ideas to 
gather richer, in-depth information (Basit 2010:104) that structured interviews 
may miss.  As Walford (2001) suggests, interviews become a co-constructed 
event, illuminating otherwise hidden information (Basit 2010).   This requires 
active listening or “listening with the third ear” (Oppenheim 1992:67) for what 
may be unspoken.  To this end, close observation of body language is 
necessary to gauge the need for further clarification of interviewee response.  
Where there is an incongruence between the spoken and unspoken word, 
follow-up questions were used to clarify the message echoing the view that 
“…interpersonal skills of a high order…” are essential for successful 
interviews (Oppenheim 1992:65).  Therefore, face-to-face interviews were 
used in this thesis as opposed to telephone interviews for example.   
 
3.5.1. Interview study setting 
 
All interviews were conducted in a neutral, private environment away from 
clinical areas. Pharmacist interviews in chapter 8 were conducted in a private 
seminar room within the pharmacy department.  Prescriber interviews in 
chapters 6 and 9, were conducted in a location at their discretion.  This was 
typically in private interview rooms at ward level or in pharmacy, or for more 
senior prescribers, in their own offices.  For participating pharmacists, 
protected time off rota was negotiated with the clinical services manager 
beforehand.  For prescribers, ward staff were informed of their participation 
and likely duration of the interview in an attempt to limit distractions.   
 
3.5.2. Interview sampling 
 
The research in this thesis is a case study within one NHS organisation.  
Considering this, participants were recruited from within the organisation 
only.   Qualitative research often uses non-probability, purposive samples 
(Cohen et al. 2011).   A purposive sample is selected to represent the study 
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purposes and any participants recruited must have the experience and 
expertise to answer the research questions (Basit 2010).  This informed 
inclusion and exclusion criteria for participation throughout this thesis.  
Sampling is therefore selective and results cannot be generalised (Cohen et 
al. 2011, Basit 2010) with any other groups finding applicability in the results 
a ‘fortunate bonus’ (Cohen et al. 2011:161). 
 
For chapter 6, prescribers were eligible to participate if they had received 
feedback from a ward based pharmacist.  In chapter 8, pharmacists were 
eligible for participation if they had delivered formalised PE feedback. In 
chapter 9, prescribers were eligible to participate if they had received 
feedback on an individual PE. 
 
It is estimated that a 1-hour interview can take up to 6-hours to transcribe 
(Cohen et al. 2011) whilst the coding and data-analysis can be a similarly 
time-consuming process (Oppenheim 1992).  This however, is in 
countenance of the need to provide rich qualitative data and reach data 
saturation, that is, no new codes, categories, relationships or themes are 
emerging from the data (Cohen et al. 2011). 
 
3.5.3. Interview recruitment   
 
The author presented an overview of the project to all pharmacists and 
relevant directorates (for example at clinical meetings) in the hospital where 
prescribers were receiving feedback as part of this research.  This was to 
raise awareness and understanding of the process and their involvement 
with the project. 
 
All pharmacists involved in delivery of feedback either in chapters 5 or 7 
were invited to participate in an interview.  A standard e-mail was distributed 
(Appendix 6) along with a participant information letter (Appendix 7) and 
consent form (Appendix 8).  Following expression of interest, a follow-on e-
mail was sent to arrange a mutually convenient time.   
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For prescriber interviews in chapters 6 and 9, following delivery of feedback 
ward-based pharmacists provided participant information sheets 
(Appendices 9 and 10) to prescribers.  Where prescribers expressed an 
interest to participate, standard e-mails (Appendices 11 and 12) and consent 
forms (appendix 8) were sent by the author to arrange a mutually convenient 
time for the interview. 
 
Recruitment of pharmacists or prescribers did not pose any great difficulty.  
At times, interviews with prescribers had to be postponed because of 
unforeseen changes in their clinical demands, reflecting the working 
environment of a busy district general hospital.  Where interviews had to be 
rearranged, it was typically within a day. 
 
3.5.4. Interview Schedule  
 
Pilot interviews informed only minor typographical or grammatical changes to 
the topic guide.   
 
Following standard introductions, participant information sheets were 
distributed and then discussed to cover the purpose of the interview and 
likely duration. Consent forms were signed for all pharmacist and prescriber 
interviews. 
 
Pagers and mobiles were turned off to minimise disruptions during the 
interviews.  For prescribers, this was not possible but disruptions were 
limited by advising ward staff of their participation beforehand and likely 
duration of absence.   Where the interview was disrupted, the recording was 
paused and restarted upon return of the prescriber although this only 
occurred on one occasion with an interviewee in chapter 9. 
 
Topic guides were used to limit interviewer bias whilst affording a systematic 
approach to data collection, although it is acknowledged that differences in 
interviewer sequencing of questions may affect responses (Cohen et al. 
2011).  The author was aware of this risk and attempted to maintain 
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sequencing of questions, whilst also repeating questions that the interviewee 
may have addressed earlier in discussion. 
 
All interviews commenced by collecting relevant demographic data.  The 
semi-structured interview questions were exploratory and designed to 
address the relevant research question which, along with the researcher’s 
understanding of the literature (as discussed in chapter 2) informed question 
design and themes.  For example, for the prescriber interviews in chapters 6, 
the interview would open with general questions of the process to engage 
the interviewee and get them discussing their experiences of receiving 
feedback.  This would then lead into other key themes to explore the impact 
on prescribers themselves and their views of receiving feedback from 
pharmacists.  Open-ended questions and further prompting were used to 
allow the spontaneity for participants to elaborate and articulate views with 
greater qualitative purpose (Oppenheim 1992).  The flexibility of this 
approach to engage in discussion was also desirable to encourage rapport 
and facilitate interactive, open conversational exchange from interviewees, 
(Cohen et al. 2011) illuminating what could be hidden by closed questions 
(Basit 2010). 
 
A similar process was adopted for the pharmacist interviews in chapter 8.  
The topic guide (Appendix 4) introduced general questions to understand 
experience and views of delivering feedback, before exploring specific 
process themes such as timeliness of feedback and time constraints, and 
finally, impact of delivering feedback on pharmacists themselves.   
 
In chapter 9, the topic guide (Appendix 5) consisted of two phases.   Here, 
the research was concerned with exploring the impact of feedback on 
prescribing behaviour following feedback on different types of PE. Therefore, 
opening questions were designed to ascertain previous training in 
prescribing, PE details and situational factors to determine the type of PE.  
Interviews in particular, are considered the most effective method to identify 
error causation (Tully 2012) where participants can describe what happened 
and why.  Initial questions in the topic guide were constructed based on 
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principles of critical incident theory (CIT) (Flanagan 1954) and the work of 
other authors who have researched PE causation (e.g. Lewis et al. 2014).  
CIT was a desirable approach to discuss specific aspects of prescribing and 
the intentions, behaviours and actions of the prescriber as it “does not collect 
opinions, hunches and estimates but obtains a record of specific behaviour” 
(Flanagan 1954).  Subsequent open questions based on the researchers 
understanding of the literature and research questions were used to explore 
the impact of feedback on prescribing practice. 
 
Classification of the cause of each PE followed the taxonomy of James 
Reason as described in chapter 1, the most commonly adopted approach to 
investigating error causation (Tully 2012). 
 
3.6. Focus groups 
 
A key research question was to determine pharmacist attitudes and 
experiences of delivering feedback prior to implementing the intervention.  As 
described in chapter 2, little is known on this subject and again, a qualitative 
approach was justified.   Semi-structured interviews were used to explore 
pharmacist views of delivering formal feedback in chapter 8 and arguably 
could have been used at baseline to address the research question.  
However, a second qualitative method was employed; focus groups.    
 
A focus group is an interview conducted with a group of participants (Basit 
2010).  They gather rich qualitative data (Neale 2009) for subjects where little 
is known, generating themes and ideas for further research and 
quantification.    
 
They are not a group interview where the researcher asks questions of 
individual group members, but instead are a dynamic interview with the 
researcher merely facilitating discussion amongst participants (Basit 2010).   
To this end, the group actively interact to discuss the topic and present a 
collective view (Morgan 1988).  The researcher, as with interviews, poses the 
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questions (Neale 2009) and keeps the group interactions in check as 
facilitator.   
 
This requires a clear articulation of the subject matter (delivery of PE 
feedback) by the researcher with skilled moderation also tantamount to 
enable participation of all group members (Krueger and Casey 2000), 
encouraging all to speak without controlling the discussion too much (Cohen 
et al. 2011:437).  The researcher can then tease out all relevant information 
through prompting and stimulating reflection of the subject (Newby 
2010:351).  As Morgan (1997) iterates, the emphasis diverges away from 
establishing what people think but rather how they think and why they think 
that way to generate not simply answers, but the reasoning and rationale 
behind responses.  Example questions in the topic guide included; 
 
 Do you think that prescribers should receive feedback on prescribing errors? 
Why? 
 Do you provide feedback on prescribing errors? How? 
 Why do you think delivery of prescribing error feedback might be 
inconsistent? 
 How do you deliver feedback, if any, on prescribing errors? 
 What factors make you decide whether you feedback or not on a PE? 
 
These open-ended questions are perfectly suited to be explored by focus 
groups as they beg for explanations and descriptions as suggested by 
Krueger and Casey (2000:24), who also suggest that focus groups should be 
used when; 
 
 You are looking for a range of ideas 
 You are looking for differences in perspectives 
 You are looking to uncover factors that influence perspectives 
 You want ideas to emerge 
 You want to pilot test ideas 
 You want to gather information for further quantitative studies 
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 You want to shed light on quantitative data 
 You place high value on the voice of the participants 
 
Considering this, focus groups are useful in early case studies to illuminate 
what is unknown of a subject and participant values, attitudes and opinions 
(Cohen et al. 2011).  They can be used pre-emptively to larger studies, 
clarify results from other methods such as questionnaires or indeed they can 
be used in their own right (Neale 2009).   They allow ‘focus’ on a particular 
topic, provided by the researcher, whilst encouraging interaction and the 
voice of multiple participants to illuminate both a consensus and diversity in 
opinions (Morgan 1997).  Focus groups can be useful for engaging less 
confident individuals who may be inhibited by interviews but are actively 
engaged when a discussion is initiated by others (Kitzinger 1994) or where 
they realise that others share their opinions (Stewart and Shamdasani 1990).  
Indeed, focus groups allow ideas to be explored and clarified within a group 
of like-minded people with a ‘common communicative ground’ (Furber 2010). 
 
For the pharmacists who participated in these focus groups, this ‘common 
communicative ground’ is identification and resolution of PEs which should 
involve some form of feedback and corrective action.  They have a shared 
experience and homogeneity of background in this regard, an important 
consideration for focus group samples (Morgan 1997). 
 
As pharmacist views and experiences in addressing PEs were likely to vary, 
this diversity of opinion was ideally suited to be explored, compared and 
contrasted through use of focus groups (Neale 2009).  That said, focus 
groups were purposely avoided in chapter 8 to explore pharmacist views of 
the formal feedback process.   The author was cognisant that the 
experiences of pharmacists of delivering the formal feedback may well vary 
with senior pharmacists for example, potentially having greater confidence in 
their abilities, which may have inhibited more junior pharmacists to openly 
discuss their own experiences.   
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Focus groups have a further advantage in that they are more economical on 
researcher time and costs (Hyden and Bulow 2003) whilst gathering a large 
amount of data in a small amount of time (Cohen et al. 2011): a clear 
advantage for the lone researcher.  This was an important consideration to 
gather pharmacist views before commencing the pilot study (Chapter 5) that 
may have biased the results or at the least reduced the sample pool 
available to interview. 
     
3.6.1. Focus group study setting   
 
The focus groups were undertaken in a seminar room within the pharmacy 
department. Careful attention must be afforded to the environment with 
Krueger and Casey (2000) suggesting that only 80% of data analysis comes 
from the transcripts with the rest coming from the environment.  To this end, 
the author was cognisant to consider group dynamics, interaction and body 
language to summarise and clarify collective views and opinions. As the 
questions encourage debate, focus groups were typically longer than 
interviews.  
 
3.6.2. Focus group sampling   
 
A purposeful sample was used which, as described above, is selectively 
chosen to meet the purpose of the study (Basit 2010).  Therefore, for 
eligibility for inclusion, pharmacists had to be actively involved in screening 
prescriptions either on wards or in dispensary and therefore having to 
intercept and resolve any PEs.  This ensured they had the experience to 
answer the research question. The sample therefore included every 
pharmacist in the department with the exception of the head of pharmacy 
who does not have a clinical or dispensary role.  This allowed recruitment of 
pharmacists with a range of experience and seniority. 
 
 
 
 64 
3.6.3. Focus group recruitment   
 
The author presented an overview of the project at a pharmacy departmental 
meeting.  This was followed by an invitational e-mail (see appendix 13) and 
participant information sheet (see appendix 14). Where pharmacists 
expressed an interest to participate, the author liaised with the head of 
clinical pharmacy services to co-ordinate the focus groups and allow 
protected time away from the rota to participate. 
 
Recruitment of pharmacists did not pose any great difficulty although 
logistically, it was at times challenging to arrange mutually convenient times 
for the focus group participants owing to annual leave or other professional 
commitments for example.   
 
Morgan (1988) advocate that 4-12 people are recruited for the focus group 
whilst Fowler (2009) advocate between 6 and 8 individuals.  Three to five 
groups should be used to ensure data saturation is attained (Neale 2009). 
This should include an oversubscription of participants to allow for potential 
non-attendance (Morgan 1988).  
 
It has been postulated that focus group participants should be 
heterogeneous; that is, they do not know each other (Rabiee 2004).  Such 
dynamics can allow more honest and spontaneous views to be expressed 
whilst limiting any potential seniority bias that may be introduced from a 
homogenous group.  However, equally, homogenous groups can relate to 
each other and may be more willing to challenge others opinions (Kitzinger 
1994).  The participants in the focus group are used to departmental and 
educational meetings where professional candour and challenge are 
common, and it is the view of the author that using a homogenous group 
would not impact negatively on the results. 
 
At the time of recruitment there were 32 pharmacists within the pharmacy 
department eligible for participation.  All pharmacists expressed an interest to 
participate.  Four focus groups were facilitated with 6 pharmacists in each 
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group having a variety of seniority and experience.  Group characteristics are 
discussed further in chapter 4.  Participants were selected according to their 
availability on arranged dates.   
   
3.6.4. Focus group schedule   
 
A similar process to the interviews was followed with standard introductions, 
focus group overview and signing of consent forms.  Pagers and mobiles 
were turned off to minimise disruptions. 
 
A topic guide (Appendix 15) was used, developed by the author and 
informed by the literature review, the author’s own insight as a clinical 
pharmacist and research objectives. Participants were sat around a table 
with junior pharmacists (see chapter 1 for pharmacist grades) seated 
opposite, and more senior pharmacists nearest to, the author to encourage 
open discourse from junior pharmacists and limit potential seniority bias.  
Focus groups commenced with the collection of relevant demographic data 
and the author making a note of table plans although the author knew the 
pharmacists in a professional capacity to further aid identification from audio 
files.  The author facilitated discussion following the topic guide in sequence 
for each focus group.  The topic guide included introductory, transitional, key 
and ending questions (Krueger and Casey 2000).  These were designed to 
collect relevant demographic data and an understanding of how pharmacists 
intercept and deal with PEs.  The guide then progressed to more specific 
process themes to understand views of delivering more formalised PE 
feedback. 
     
3.6.5. Limitations 
  
As a pharmacist employed by the host organisation, there is potential for the 
author’s position to influence the results where the interviewee seeks to 
avoid, impress or reject the researcher questions, a phenomenon described 
as the Hawthorne effect (Basit 2010). Interviewees may feel compelled to 
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reveal what they think the researcher needs, or wants to hear (Kvale 2009), 
a potential authority bias.  
 
Power asymmetry exists in interviews (Kvale 2009).  The researcher decides 
research questions, hypotheses, methods and analytical approaches and will 
also be asking the relevant questions.  Oppenheim (1992) suggests this can 
create interviewee resentment, generating elements of ‘counter-control’ 
(Kvale 2009:34), impeding the depth and authenticity of the interview. 
 
The author was cognisant of these risks and the need to remain empathetic 
and objective throughout, limiting any potential bias from negative or positive 
emotions and developing rapport with the interviewee.  Rapport can 
encourage greater candour in response (Basit 2010).  More truthful and 
elaborated responses are likely, for as Oppenheim (1992:89) suggests, 
rapport “…keeps the respondent motivated and interested…”  whilst Bogdan 
and Biklen (1992:97) suggest that “Good interviews are those in which the 
subjects are at ease and talk freely about their points of view”.  To this end, 
as an experienced pharmacist with a background in pharmacy and medical 
education, the author considered his position in the hospital as a potential 
strength and not a weakness as interviewer.   
 
Limitations of specific methods will be discussed further in chapters 4, 6, 8 
and 9. 
      
3.7. Quantitative Methods 
 
3.7.1. Section introduction 
 
As outlined at the start of this chapter, the primary research question is 
concerned with exploring the effect on PE rates.  This requires an 
experimental design to demonstrate any relationship between cause and 
effect through statistical scrutiny (Basit 2010).  Quantitative approaches will 
be used to address the research aims of chapters 5 and 7 with the qualitative 
results of chapters 6,8 and 9 used to inform rationale and reason for any 
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change.   A range of methods can be used in quantitative research to 
measure the effect of an intervention using pre- and post-testing.  Such 
experiments can include the use of control and / or interventional groups in 
either true or quasi-experiments and will be reviewed further below. 
      
3.7.2. Study design  
 
Experiments bring an element of objectivity to research where an 
independent variable is changed and the effect on a dependent variable is 
measured (Basit 2010).  In this case, the independent variable is whether 
formalised, constructive feedback is provided on PEs, whilst the dependent 
variable is PE rate. 
 
It has been proposed that there are two distinct types of experiment (Basit 
2010); True and quasi-experimental.  In true experiments the variables are 
isolated, controlled and manipulated with random allocation to either control 
or intervention group (Basit 2010) before pre- and post-testing to measure 
the effects of the intervention.  If an experiment does not possess these 
features then it is considered quasi-experimental (Cohen et al. 2011). 
 
Quasi-experimental designs are often employed in educational research 
where for example the random assignment of schools and classrooms is 
impractical (Cohen et al. 2011:322).  In deciding on prescriber allocation in 
this thesis, random allocation of prescribers and wards was considered 
impractical where prescribers often cover more than one ward as part of a 
clinical rotation.  Therefore, a convenience sample was used with wards 
matched based on comparable patient turnover following discussion with the 
pharmacy clinical services manager.  Whilst prescriber demographics may 
vary between wards, the relevant mix of prescriber grades and experience 
should be comparable.  Considering this, random allocation of prescribers 
may create limited potential for feedback whilst contextual factors such as 
specialty, team dynamics or prescribing culture may influence feedback 
response. There is also the risk of potential diffusion (Basit 2010:33) of effect 
to control group prescribers and pharmacists, where the benefits of feedback 
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are discussed, or the process itself influences control group prescribers who 
work in experimental areas for example. Therefore, unlike randomised 
clinical trials, it has been argued that randomisation in educational research 
cannot truly isolate, control and manipulate all variables (Rowe and Oltmann 
2016).  To this end, a quasi-experimental design is used to address the 
primary research aim in this thesis. 
 
The process steps involved in experiments have been summarised (Gorard 
2003:163) as including; 
 
1. Formulate a hypothesis 
2. Assign cases to groups (feedback or normal practice) 
3. Measure the dependent variable (prescribing error rate) 
4. Introduce the intervention to relevant group (constructive 
feedback on prescribing error rates) 
5. Re-measure the dependent variable (prescribing error rate) 
6. Calculate the difference, significance and effect size of any 
difference 
 
The hypotheses were described at the beginning of this chapter.  
Considering these steps, the first null hypothesis for example would be that 
there is no difference in change in PE rates following the intervention period 
for control and intervention groups.  For example, if the intervention group 
error rate is 20% pre-test and 15% post-test, whilst the control group pre-test 
error rate is 15% and 10% post-test, the net change is 0%. In this study 
however, the hypothesis (H1) is that delivery of feedback on PEs will produce 
a change in PE rates between groups. 
 
In the above example, prescribers in the intervention group receive 
constructive feedback and the control group continue with existing standard 
practice (See figure 7 below).  
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Figure 7: Overview of experimental study design 
 
Group Pre-test Feedback on 
prescribing errors 
Post-test 
Intervention group 
(feedback)  
O √ O 
Control Group (normal 
practice)  
O O O 
 
Whilst a single pre-test, post-test experimental group could have been used 
and would be more economical, an uncontrolled design may invalidate any 
findings (Cohen et al. 2011).  For example, any change in PE rates may be 
due to other influencing factors such as prescribers improving over time, or 
prescribers or pharmacists may work in different ways to others.  
Additionally, there may well be other extraneous, confounding factors that 
the researcher cannot predict, account for or control.  Therefore, an 
intervention and control group pre-test, post-test design is used to address 
the aims of chapters 5 and 7. 
 
The dependent variable, PE rate, is dependent on another factor (Scott and 
Mazhindu 2009) which in this case is the independent variable, PE feedback. 
 
The pre-test, post-test design allows repeat measurement of the dependent 
variable following the intervention.  This then allows calculation of the change 
scores in PE rates and allow statistical inferences to be made as discussed 
in section 3.12.12 below. 
 
3.7.3 Data collection 
 
Data was collected using established methods in this field of research 
(Dornan et al. 2009, Seden et al. 2013) and will be discussed here. 
 
PE data can be collected prospectively or retrospectively from case notes 
and medication charts for example or by other means such as incident 
 70 
reporting systems.  However, the former is more common (Lewis et al. 2009) 
and pragmatically resonates with how prescription errors are typically 
identified and resolved by ward-based pharmacists. 
 
Healthcare professionals such as pharmacists are most commonly used to 
collect PE data (Tully 2012).  Ward-based pharmacists can collect such data 
as part of their routine clinical practice and will clearly have greater 
understanding and context of any prescribing decisions.  However, such data 
collection can be burdensome (Tully 2012), an issue the author is both 
familiar with and cognisant of.  External, trained data collectors have been 
used in some studies yet data collection is equally labour intensive (Tully 
2012) and has associated staff costs that would be beyond the scope of this 
project.  However, it is also important to highlight that pharmacists in the 
hospital are familiar with undertaking various audits, including PE audits, as 
part of routine practice. Considering this, a prospective approach to data 
collection was adopted (See figure 8 below) to determine PE prevalence and 
reflects data collection methods commensurate with most PE studies (Lewis 
et al. 2009) 
 
Figure 8: Overview of quantitative data collection method 
 
 
Pharmacists trained in data collection methods
Pharmacists collect prescribing data using standardised audit form over 5 days
Pharmacists return audit forms to researcher
Researcher independently checks and re-assesses error, severity and type
(Any discordant ratings discussed with a third pharmacist)
Data entered into SPSS for statistical analysis per prescription and per prescriber
Results presented in chapter 5 (feasability study) and chapter 7
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Pharmacists audited prescriptions prospectively for five days (Monday to 
Friday) at the same time for both control and intervention wards.  This was 
undertaken at baseline for pre-test data and three months later for post-test 
data.  All pre-test data were collected prior to any delivery of feedback with 
feedback commencing the following week for the intervention group.  This 
was to limit the effects of any other potential confounding effects on 
prescribing (Cohen et al. 2011). When to re-audit was a practical 
consideration as re-auditing too close to the pre-test data would be 
burdensome for the pharmacists.  Equally, if re-measured too soon, any 
effect of the intervention may not be captured where prescribers need time to 
reflect and amend their prescribing behaviour for example.  Conversely, if 
measured too close to the intervention, it is possible that any effect would be 
temporary, a ‘recency effect’ (Cohen et al. 2011:328) where prescribers 
amend their behaviour in response to any feedback yet may revert to 
previous practice shortly after.  In consideration of this, post-testing was 
undertaken 3 months later before training grade doctors would typically 
rotate to other specialties.  This would allow potential inference into the 
longer-term effects on prescribing whilst allowing sufficient time for 
prescribers to receive constructive and contextualised feedback.   
 
All prescriptions were audited including once only, regular, when required 
medications, and infusion fluids.  Where separate charts were used, for 
example warfarin or vancomycin prescribing charts, these were also audited.  
Prescriptions were included in data collection where they had not previously 
been seen by a pharmacist.  When a pharmacist has reviewed a prescribed 
item for a patient they sign the prescription in the designated area.  If a 
pharmacist had already reviewed the prescription, the prescription was not 
included again unless a new error was identified relevant to that prescription 
(for example, change in renal function, drug interaction or error not identified 
by another pharmacist initially), to prevent duplication of data. 
 
A standard data collection proforma was used to collect data (Appendix 16).  
Pharmacists were familiar with this proforma from annual audits of 
prescribing undertaken in the hospital.  The proforma included information on 
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the ward, prescriber, prescriber grade, number of items and listed errors 
where relevant with a description of any error.  Where an error was listed, the 
potential severity and type of error was coded.  The proforma used in this 
thesis was based on that used in the key PE prevalence study (Dornan et al. 
2009), and modified for error type for ease of categorisation based on a more 
recent study (Seden et al. 2013). 
 
A pilot test was conducted initially with results presented in chapter 5.  This 
design consideration allows the researcher to identify any ‘snags’ or 
unanticipated design flaws in the experiment with Cohen et al. (2011:326) 
iterating that such an approach is of ‘crucial importance’.  However, 
pragmatically, given the resources required to conduct the study, it is also 
sensible to conduct a pilot study to determine the feasibility of the project and 
its potential impact and significance.  Answers to these questions will inform 
the need to conduct a larger study as reported in chapter 7. 
 
3.7.4. Prescribing error severity and type 
 
Whilst the key aim of this research is to determine the impact of feedback on 
PE rates, it was also considered useful to determine the impact on potential 
error severity and type of PE.  Directly, this can illuminate the potential 
impact of feedback on different error types.  Indirectly, it could inform future 
avenues of enquiry where for example dosing errors are reduced but writing 
errors are not, or serious errors are reduced but minor errors are not.  
Collection of such data requires interpretation on behalf of the data collector 
to determine both error severity and type of error intercepted. 
  
The author was aware of the potential for inter-rater variation and bias from 
interpretation of PEs from facilitation of previous PE audits at STHKH, and 
the wider literature (for example Seden et al. 2013). To limit bias, the author 
provided relevant training on PE classification as discussed in section 3.8, 
whilst the error type was simplified as described below and the same 
pharmacists collected PE data at pre- and post-intervention.   
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In addition, the author independently reviewed each recorded PE, assessing 
them for concordance with the agreed definitions of a PE, error severity and 
error type.  Where any potential discrepancies were identified, they were 
discussed with a third, senior pharmacist, with experience in PE audits.  The 
third pharmacist was asked to independently grade the PE.  Where there 
was agreement between the author and pharmacist, the PE was reclassified 
accordingly.  Where there was disagreement, the author and pharmacist 
discussed the PE further for consensus agreement. 
 
There were four categories for PE severity (Appendix 17): 
 
1. Potentially lethal 
2. Serious 
3. Significant and; 
4. Minor 
 
Error severity was based on that outlined elsewhere (Dornan et al. 2009), 
informed by earlier research (Folli et al. 1987, Lesar et al. 1990, Lesar et al. 
1997a, Lesar et al. 1997b, Tully et al. 2006) and represents the potential 
impact if the error was not intercepted by the pharmacist. 
 
For error type, the modified classification system reported by Seden et al. 
(2013) was adopted as this was more simplistic, limiting potential for 
misinterpretation whilst making data collection less burdensome on 
pharmacists.  This system amalgamated twenty-nine categories (Dornan et 
al. 2009) into a simplified list of ten categories (Appendix 18); 
 
1. Dosing errors 
2. Writing errors 
3. Allergy status errors 
4. Duration of treatment wrong / not specified 
5. Drug interactions 
6. Omission of medication 
7. Excessive / unnecessary prescribing 
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8. Clinical safety errors 
9. Lack of clear directions for administration 
10. Miscellaneous (no indication, illegible, abbreviated name, incorrect 
patient etc) 
 
3.7.5. Setting 
 
A description of the hospital used in this case study was provided in chapter 
1.  All wards, involved in the research had ward-based pharmacists who 
reviewed inpatient medication charts (kardexes) on a daily basis (Monday to 
Friday).  All inpatient prescribing for control and intervention wards was 
undertaken on paper charts with electronic systems used for discharge 
prescriptions.  Discharge prescriptions may be processed at ward level by 
the ward pharmacist or in the pharmacy department.  Where any 
discrepancies are identified, a prescriber is typically contacted to amend the 
prescription.  For the research presented in chapter 5, wards were chosen to 
provide a comparable mix of pharmacy service, prescriber grades and 
turnover of patients.  For the research presented in chapter 7, a wider range 
of wards were used including medical, surgical and admissions wards to 
represent the hospital and variety of specialties, prescribing demands and 
patient turnover that prescribers are exposed to.   
      
3.7.6. Control group vs. Intervention group 
 
Training grade doctors typically spend four months in a specialty before 
rotating to another area with registrars typically spending longer and 
consultants usually, but not exclusively, attached to one ward area.  For 
example, prescribers may work across several different wards depending on 
their specialty.  Therefore, prescribers were allocated to control or 
intervention groups depending on their ward areas.  Allocation of wards as 
intervention or control was negotiated with the clinical pharmacy services 
manager beforehand.  Wards were matched for size, comparable number of 
prescribers and prescriber grade and turnover of patients.  This is discussed 
further in chapters 5 and 7.  Following collection of pre-test data, pharmacists 
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delivered constructive feedback (as described in section 3.9 below) to 
prescribers on intervention wards, whilst pharmacists on control wards 
continued with normal practice.   
      
3.7.7. Sample size 
 
Consideration of required sample size is an important part of research design 
to ensure that any statistical test can measure difference.  A type 1 error, or 
a false positive, can be made when the level of significance (the p value) is 
too high.  Equally, if the sample size is too small, significant effects may not 
be detected and this is a false negative result (Cohen et al. 2011).  Based on 
the initial research hypothesis, a priori, assuming the error rate in the 
intervention group improves by 5% with a standard deviation (measure of 
dispersal of a result) of 2.5, and the control group remains the same over 
time, a sample size of less than six prescribers per group would be needed 
with a significance of 5% and a power of 80% (calculated via 
http://biomath.info/power/ttest.htm).  This was considered feasible for the 
pilot and larger study in chapter 7. 
 
In addition, considering the results and effect size (d=1.6) from pilot data in 
chapter 5, the sample size calculated to demonstrate reproducible results in 
chapter 7 using the same alpha (0.05) and beta (0.2) values, was less than 
six prescribers in each group, although larger samples were used. 
 
3.7.8. Limitations 
 
The main weakness of the methods described in this section is the non-
randomisation of prescribers to either control or intervention groups.  This 
can raise potential questions over the internal validity of the study design 
through allocation bias as other variables may be confounding the pre-test 
data that influences post-test scores.  For example, some wards may have 
more supportive senior prescribers, or the ward based pharmacists may 
interact with the clinical teams differently that may influence prescribing, for 
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example attending ward rounds.  Any variable not accounted for may be the 
cause of any change and not the feedback.   
 
However, as described earlier, wards are matched for turnover and number 
of prescribers and pharmacy service.  Equally, randomisation may have 
equally biased results through diffusion and influenced the decision to adopt 
a quasi-experimental design.  Any variation in practice at ward level is 
beyond the control of the author, as is response of prescribers to the 
feedback itself and non-randomisation was considered justified by the 
author. 
 
The burden of collecting audit data alongside routine practice could limit the 
total number of prescriptions that are audited.  However, as mentioned, 
pharmacists are used to conducting audits on a regular basis alongside 
routine clinical practice, whilst it would not be feasible to recruit and train a 
supernumerary data collector for example.   
 
As pharmacists are collecting and grading errors, there is potential for 
subjectivity and variance in grading error severity and type.  However, as it is 
a single case study with the same group of pharmacists collecting pre- and 
post-test data, one would expect any variance to be consistent between pre 
and post-tests data collection.  Equally, pharmacists are familiar with the 
data collection proforma as part of annual PE audits.  Pharmacists were also 
trained in data collection as described in section 3.8 below with the author 
also reading and assessing each PE for consistency.  
 
It should be noted that this is only a single case study and the results or 
model of feedback may not reflect practice in other hospitals or settings.  
However, equally it should be noted that 84% of PE prevalence and 
intervention studies are reported as single cases (Lewis et al. 2009) whilst 
STHKH is a typical, large acute hospital in the UK. 
 
Finally, the author is not collecting data on individual drug types or classes.  
Whilst this would be useful to illuminate if for example there are any 
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differences in prescribing behaviour for higher risk medications (for example 
insulin, anticoagulants or opioids), as opposed to other lower risk 
medications, the author considered this outside the scope of this thesis.  The 
results of this research however could be used to inform further 
investigations on the effects of feedback on prescribing particular 
medications or in certain patient populations for example renal patients, 
paediatrics or care of the elderly settings. 
 
3.8. Pharmacist training  
 
All pharmacists involved in data collection for both control and intervention 
groups received a ninety-minute training session facilitated by the author.  
This included review and completion of the data collection tool, and 
classification of error severity and type.  This was supported by scenario 
based training to contextualise information with appropriate discussion and 
feedback.  All pharmacists were provided with an inter-rater assessment 
consisting of a range of prescribing scenarios (Appendix 19), pre-rated by 
the author, for which they had to identify any PE and subsequently grade 
them for severity and error type. This was assessed by the author and 
feedback provided to the pharmacist. 
 
For pharmacists involved with the intervention group, a further 2-hour training 
session was provided to prepare them to deliver constructive feedback.  This 
consisted of discussing the relevant theory, impact and principles of 
feedback, as described in chapter 2.  Tools to support delivery of feedback 
were also discussed including Pendleton’s rules (Lloyd et al. 2016b) for 
example, what constitutes good and poor feedback and use of critical 
incident theory (CIT) to identify error causation.  This was contextualised with 
simulated videos prepared by the author and education team, demonstrating 
examples of good and poor feedback.  The session concluded with 
pharmacists participating in a workshop that allowed practice of peer-to-peer 
feedback on PEs using relevant proformas, and was moderated by the 
author.  Feedback proformas were designed to reflect principles of feedback 
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described in chapter 2.  An overview of guiding principles for each feedback 
session is presented in figure 9 below.  
 
Figure 9: Overview of a standard prescribing error feedback session 
 Prescribing error data collected / identified and resolved by pharmacist 
 Pharmacist identifies need to deliver feedback 
 Pharmacist initiates written feedback form 
 Pharmacist communicates need for feedback with prescriber and 
negotiates time and location to deliver feedback 
 Purpose of feedback outlined (for professional development, reduce 
prescribing error rates) 
 Prescribing error described by pharmacist 
 Understanding of risk of prescribing error checked with prescriber  
 Pharmacist uses open reflective questions (based on principles of critical 
incident theory) to identify cause of error 
 Pharmacist facilitates identification of solutions to prevent error 
recurrence 
 Prescriber summarises lessons learned 
 Pharmacist completes feedback proforma to reflect above 
 Pharmacist and prescriber sign feedback proforma 
 Prescriber provided with signed copy of proforma and advised to 
complete reflective entry in training portfolio 
 Pharmacist scans and files electronic copy of feedback intervention in 
secure pharmacy groups folder 
 
3.9. Prescribing error feedback 
 
Following pre-test data collection, pharmacists would prepare feedback 
reports for their prescribers (Appendix 1).  This would include total number of 
prescriptions reviewed, prescription error rate, total number of items, 
individual item error rate and breakdown of error by severity and stage of 
prescription i.e. inpatient or discharge.  The report would be delivered 
verbally and in writing and include good areas of prescribing to build on as 
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well as areas for improvement, consistent with principles of constructive 
feedback described in chapter 2.  These reports were typically the week 
following data collection at a mutually convenient time arranged between the 
pharmacist and prescriber.  The prescriber was informed of the purpose of 
the feedback in advance and that any discussion was confidential.   
 
Following initial feedback, ongoing feedback was delivered, again in writing 
(Appendix 2) and verbally, for any error classified as significant or above.  
Feedback on single errors was chosen for logistical reasons; repeated audit 
and feedback would be labour intensive and unlikely to be timely.  Feedback 
closer to the time of an incident has a greater impact on individuals (Hysong 
et al. 2006) and it has been proposed that feedback be delivered within one 
month (Ivers et al. 2012). 
 
Equally, the severity threshold was chosen for pragmatic reasons.  Minor 
PEs are the most prevalent in epidemiological studies (Tully 2012), and 
delivery of feedback on every single error would be unfeasible in clinical 
practice.  Equally, it is possible that prescribers may not value feedback on 
minor errors such as forgetting to date or sign a prescription, risking dilution 
of any further messages.  Considering this, it was decided that efforts of 
ward pharmacists should be focused on addressing more significant errors.  
Where relevant PEs were identified, pharmacists were advised that 
resolution of the error was the priority with timely feedback following at a 
later, convenient time, that was typically the same or following day. 
 
Feedback forms were signed by the facilitating pharmacist and prescriber.  
Once complete, a copy of the feedback form was provided to the prescriber 
for inclusion in their foundation portfolio. 
    
3.10. Research Ethics  
 
Participants should not be harmed as a result of the research and ethical 
issues including access, consent, beneficence, non-maleficence, human 
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dignity and confidentiality need to be considered (Cohen et al. 2011; Basit 
2010). 
 
Informed consent recognises and respects the rights of individuals (Cohen et 
al.  2011) and details the purpose, benefits and risks of the study (Kvale 
2009).  Consent was obtained in writing prior to commencing interviews as 
described above, allowing informed decision for participation (Basit 2010), 
whilst acknowledging the right for ‘informed refusal’. 
 
Outlining benefits of research underpins the principles of beneficence.  
Where participants are aware of potential benefits they are more likely to 
want to take part (Cohen et al. 2011, Oliver 2003).  Participant information 
sheets detailing the purpose and benefits of the research were provided as 
described above.   
 
Non-maleficence or ‘primum non nocere’ is a cornerstone of ethical 
principles (Cohen et al. 2011).  No harm was wished upon participants in this 
study and if any participant in the interviews or focus groups became upset 
the interview would have been terminated and participants referred to 
relevant departments.  Robust systems are integrated within the hospital to 
respond to MEs with pastoral support also available through medical 
supervisors, health work and wellbeing and doctors in difficulty procedures.  
However, equally, it should be noted that the process of feedback should be 
no different to that followed in practice where prescribers discuss errors with 
pharmacists or where referred, the responsible officer. 
 
Prescribers were informed prior to interviewing that confidentiality would be 
ensured with the sole exception being the disclosure of intentional 
malpractice or unsafe practice.  This was also covered in writing in the 
participation information sheets (Appendices 9 and 10) although the situation 
did not arise. 
 
The author was cognisant of the need to conduct all interviews with respect 
and professional decorum.  There is a risk of maleficence where the 
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researcher appears judgemental or in disagreement.  Interviews must be 
conducted with sensitivity and finesse (Basit 2010) in a non-threatening 
manner to avoid causing stress (Cohen et al.  2011).  Equally, human dignity 
was respected with each participant treated equally as individuals.  This 
involved avoiding labelling them as ‘subjects’ or stigmatizing them (Cohen et 
al. 2011) for example as less-safe prescribers or less-able pharmacists. 
 
As the research was likely to have impacts on the prescriber and pharmacy 
workforce, the project was discussed with the medical director, head of 
pharmacy and head of clinical pharmacy services in advance.  For all 
intervention wards, the author liaised with each relevant clinical director in 
advance to inform them of the purpose and logistics of the project at ward 
level and expectations of prescriber participation. 
 
To this end, prescriber and pharmacist participation in the feedback process 
was compulsory although further participation in any interviews was 
voluntary.     
 
Relevant hospital and University of Liverpool ethics committees approved 
each phase of this thesis prior to data collection. The study was logged with 
the integrated research application system (IRAS) although ethical approval 
was not required as there was no patient involvement.  This dual ethical and 
research approval also provides added scrutiny and validity to the study 
design and analysis reported in this chapter.  Copies of approval letters can 
be viewed in appendices 20 and 21. 
       
3.11. Data Protection and archiving  
 
Interviews were audiotaped and stored on the author’s personal home drive 
in the hospital, secured by NHS firewalls, and accessed only by the author. 
All interviews were transcribed verbatim with the exception of person and 
place names that were anonymised.  The supervisory team had access to 
anonymised transcripts. 
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All audit forms were stored in a locked filing cabinet at the author’s desk in 
the pharmacy department of the hospital.   
 
All interviews and audit data will be destroyed upon completion of this PhD 
by the author.  
    
3.12. Data Analysis 
 
In the following section, the methods used for analysis of qualitative and 
quantitative data analysis will be described and explored. 
 
3.12.1. Qualitative data analysis 
 
Qualitative data analysis is not a simple task. It can be daunting for the lone 
or neophyte researcher when faced with volumes of transcripts, making data 
analysis a complex and arduous process (Basit 2010). Kvale (2009) 
emphasises the importance of contextualising data with transcriptions likely 
to capture a messy tome of data requiring refinement (Ritchie and Lewis 
2003) before they become meaningful (Bell 2005).  Considering this, 
qualitative analysis requires a systematic and rigorous approach, an 
approach that is equally labour intensive and time-consuming (Pope et al.  
2000). 
 
All interviews and focus groups were transcribed verbatim with the exception 
of anonymising person and place names.  Where participants paused, 
laughed or appeared defensive for example, this was recorded in the 
transcript to capture relevant non-verbal behaviour. 
 
All coding was undertaken manually.  Whilst software tools (i.e. Ethnograph / 
NVivo) are available to facilitate coding of qualitative data (Ritchie and Lewis 
2003), their application is in organising and retrieving data (Gale et al. 2013); 
they do not analyse data as argued elsewhere (Weitzman and Miles 1995:3), 
“…Computer’s don’t analyse data; people do”.  Considering this, manual 
coding was employed with pen and paper to develop the requisite coding 
 83 
skills.   Importantly this also allowed complete focus on the data analysis and 
not familiarisation with new software, for as Saldana (2013) suggests, the 
complexity of computer software programmes can become overwhelming. 
 
There are various approaches to qualitative data analysis including those 
that develop theory from generated data (grounded theory), study of 
language and interaction (discourse analysis), study of experience and 
meaning (phenomenology) and thematic or content analysis for example 
(Cohen et al. 2011, Basit 2010).  Here, analysis can be employed using 
either inductive (derived from data) or deductive (known before or emerges 
part way through analysis) approaches to analysis (Pope 2000).  However, 
most researchers use a combination of approaches (Rabiee et al. 2004). 
Topic guides, researcher insight or knowledge of the literature will inform 
some themes and outcomes but not all, meaning that some analytical 
themes can be predicted a priori but that others will emerge and be refined a 
posteriori.  This echoes the approach adopted in this thesis with a framework 
method applied to thematic analysis to analyse interview and focus groups 
transcripts. 
 
The framework method is a widely-used approach to qualitative analysis 
(Furber 2010) in healthcare and sits within a broad family of thematic or 
qualitative content analysis (Gale et al. 2013). It is a flexible tool, used for 
many approaches but is used most commonly for the thematic analysis of 
semi-structured interviews (Gale et al. 2013) or focus groups (Rabiee et al. 
2004). 
 
The framework method follows a structured and systematic approach to data 
analysis that is conducive to handling what can be a large, complex and 
unyielding amount of data (Rabiee 2004). 
 
This approach involves five key stages as outlined by Ritchie and Spencer 
(1994): 
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1. Familiarisation 
2. Identifying a thematic framework 
3. Indexing 
4. Charting and mapping 
5. Interpretation 
 
Gale et al. (2013) propose a preliminary stage of the analytical process being 
‘transcription’ as it is an early opportunity to become immersed in the data.   
 
The author transcribed all interviews and focus groups personally and 
attempted to transcribe any preceding interview prior to the next to inform 
further facilitation, and understanding of the research subject.   Timely 
transcription minimises the potential of post-hoc abstraction (Kvale 
2009:178) although this was not always possible. 
 
Familiarisation involves fully immersing yourself in the data.  This was 
achieved through listening and re-listening and reading and re-reading the 
transcripts to systematically identify and understand emergent major themes 
(Furber 2010).  Following familiarisation, the author began the coding 
process, reading each transcript line by line, annotating descriptive codes 
and themes in the margins of transcripts whilst constantly comparing each 
interview or focus group transcript.  This abstraction and conceptualisation 
allows appreciation of the data as a ‘whole’. 
 
As pertinent themes emerged, the second stage involved sifting and sorting 
of the data into similar contextual themes.  This produced categories and 
sub-categories for an initial thematic framework, developed through constant 
comparison of transcripts. Initial themes were largely descriptive, informed a 
priori both from the literature, and the research aims and objectives and topic 
guide.  Further themes and codes emerged a posteriori from participant 
views and recurrent themes (Pope et al. 2000) that the researcher could not 
predict (Gale et al. 2013).  Initial frameworks were discussed with the 
research supervisors who independently analysed transcripts to ensure no 
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themes were invisible to the researcher.  Any discrepancies were resolved 
for an analytical consensus through discussion. 
 
For the third stage, the emergent thematic framework was applied to 
transcripts to ‘measure the fit’ (Ritchie and Lewis et al. 2003), annotating 
transcript margins with the relevant code and theme.  This indexing allowed 
further immersion in the data and illuminated further inferences through 
refinement and conceptualisation of meanings and relationships between 
coding units.  This is a more inductive and interpretive approach requiring 
logic and intuition.   This refinement identified further codes whilst others 
were merged and allowed encapsulation of the data as a whole.  This non-
linear process is typical of the framework approach with each stage 
overlapping and merging with the next (Ritchie and Spencer 1994) whilst 
allowing themes to develop from both the research questions and participant 
narrative (Rabiee et al. 2004).  Repeat rounds of coding were applied until 
theoretical data saturation was achieved, that is, no further emergent themes 
were identified. 
 
The fourth stage involves charting and mapping the framework against 
relevant extracts with text lifted (copied and pasted) from the original 
transcript and placed into the conceptualised framework.  This process 
reduced the data into manageable volumes to allow progression to the final 
stage.  Relevant thematic frameworks are presented in chapters 4, 6, 8 and 
9.  Data was finally analysed, interpreting, comparing and contrasting themes 
and codes within and across participants in relation to the research 
objectives for meaning and explanation.  
 
3.12.2. Quantitative Data Analysis  
 
The author inputted all data per prescriber and per prescription into a 
database in statistical package for the social sciences (SPSS) v22.  SPSS is 
a widely used (Basit 2010) and accessible software application for applied 
statistical analysis and contains relevant functions for the statistical analyses 
described below.  Columns of data included ward number, prescriber 
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number, prescriber grade, pre/post-test, intervention or control group, 
number of items, number of errors and calculated error rate.  For each 
prescription, further data were input to determine if the prescription was error 
free or not, the error severity and finally, error type.  Data were checked for 
inaccuracies manually with cross reference to compare number of errors with 
reported severity and error type for each prescription line. 
 
Both descriptive and inferential statics are important to describe and make 
inferences from available data.  In the following sections the statistical 
techniques used throughout this thesis will be presented and described.   
 
3.12.3. Descriptive Statistics  
 
Descriptive statistics are exactly that: they describe, present and summarize 
data, reducing it for the reader to understand (Cohen et al. 2011, Scott and 
Mazhindu 2009).  No inferences are implied or predictions made, they simply 
present the data which can be displayed in various ways, typically divided 
into two broad types; measures of central tendency and measures of 
variability (Scott and Mazhindu 2009). 
 
Error free prescriptions were calculated as a percentage by dividing those 
prescriptions that were error free, by the total number of prescriptions. A 
complete prescription could include one or more prescribed items for each 
patient per prescriber and is considered useful to indicate the number of 
patients at risk from a PE (Seden et al. 2013).  Similarly, PE rates were 
calculated as a percentage by dividing number of identified errors, by 
number of items prescribed.  The central tendency will therefore be reported 
as error frequency and percentage at the prescription level.  This will be 
repeated at an individual prescriber level.  Relevant statistics will be 
supported with the use of bar charts, histograms, scatterplots, boxplots and 
tables to visually present the data.  Measures of dispersion provide insight as 
to the level of variability within a data set and can be reported as standard 
deviations (degree to which values differ from mean) and confidence 
intervals and will be used to describe relevant quantitative data in this thesis.   
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3.12.4. Inferential statistics 
 
In contrast to descriptive statistics, inferential statistics are concerned with 
making predictions and testing for significance of any results to determine 
what the descriptive statistics actually mean (Cohen et al. 2011), and their 
applicability to a wider population.  A p-value provides evidence of statistical 
significance for an experiment to reject the null hypothesis.    The most 
common value is <0.05 (<5%) which indicates there is less than a 5% 
chance that the result has occurred by chance.  A two-sided significance of 
5% (p<0.05) was used for the research in this thesis as is standard practice 
in most statistical tests (Cohen et al. 2011). 
 
Selection of appropriate tests is vital yet one that can be daunting and 
difficult, especially for first time researchers (Scott and Mazhindu 2009).  
There are decision trees and flow charts that can help guide researchers in 
the correct choice of statistical tests (for example see Scott and Mazhindu 
2009 or Cohen et al. 2011) with the premise and filtering questions 
understandably consistent.  These questions include: 
 
1. Is the data parametric or non-parametric? 
2. How many groups are there? 
3. Are the groups independent or not? 
4. Are you looking for differences between groups or associations 
between variables? 
 
Parametric data assumes normality of data, that is, data follows a normal or 
Gaussian distribution (Cohen et al. 2011).  Parametric data is therefore 
continuous, interval or ratio data, and informs use of parametric tests that are 
considered more robust and powerful (Basit 2010).  Examples of parametric 
tests include t-tests, analysis of variance (ANOVA), analysis of co-variance 
(ANCOVA) and Pearson correlation tests. Conversely non-parametric data is 
typically ordinal (such as a numerical scale 1-10) or nominal data 
(categorical data) requiring the use of non-parametric tests such as Mann-
Whitney, Kruskal-Wallis, chi-squared, and Spearman rank tests (Cohen et al. 
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2011, Basit 2009, Scott and Mazhindu 2009). 
 
For number of groups, statistical tests are usually divided into those that 
measure differences between two groups (for example t-tests) and those that 
measure differences between more than two groups (for example ANOVAs).  
For the third question, the treatment and control groups used in this thesis 
are independent of each other.  The author is exploring difference in change 
scores for PE rates and the groups will either receive feedback, or not, they 
cannot be in both groups.  If for example, the test design was one group with 
pre and post testing, they would then become dependent. 
 
For the final question, the research questions and hypotheses inform choice 
of statistical test and typically state differences or associations between 
variables. 
 
Considering these questions, test design and hypotheses, independent t-
tests, chi-squared tests and Pearson correlations were the most appropriate 
tests for the quantitative data and will be described further below. 
 
3.12.4.1. Independent t-tests 
 
It is possible that both control and intervention groups may improve over 
time.  Therefore, it is the difference in change in PE rates that the author is 
interested in.    Statistical tests that could be used to measure this effect 
include independent t-tests on change scores (post-test error rates minus 
pre-test error rates), analysis of covariance (ANCOVA) and repeated 
measure analysis of variance (ANOVA).  These should be considered further 
as it is reported that gain score analysis and ANCOVA for example, can 
produce conflicting results, an outcome known as Lord’s paradox (Knapp 
and Schafer 2009, Lord 1967). 
 
It has been argued that ANCOVA is the test of choice for pre-test post-test 
analyses. Post-intervention PE rate would be the dependent variable, the 
intervention the independent variable, and the pre-test PE rate the covariate.  
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Here, the ANCOVA controls for pre-test differences (Dimitrov and Rumrill 
2003) to control variance, an obvious advantage of this approach. 
 
Assumptions to performing ANCOVA include those of the t-test (see below) 
in addition to a linear relationship between pre-test and post-test scores, 
homogeneity of regression slopes and homoscedasticity of variance between 
and within groups.  Where these assumptions are violated, the reliability of 
the results becomes questionable whilst creating difficulties in interpretation 
of any result.  As described above, a non-randomized sample is used for 
control and intervention groups in this thesis. It is argued that ANCOVA 
treatment effects can be seriously biased in non-randomized designs with 
erroneous conclusions made (Blance et al. 2007) where the relationship 
between baseline and post-test error rates is unknown for example.  In this 
study, where the baseline PE rates and any subsequent change is due to an 
interaction with the environment, Lord’s paradox may be invoked leading to 
difficulties in causal inferences. 
 
Additionally, when comparing a treatment and control group, it is likely that 
there will be heterogeneity in regression slopes (Brogan and Kutner 1980) 
violating a further ANCOVA assumption.   
 
For a repeated measures ANOVA, it is argued that results can be misleading 
where the F test for the treatment effect is conservative, as pre-test scores 
are not affected by treatment (Dimitrov and Rumrill 2003).  Additionally, in 
comparison to ANCOVAs, ANOVAs require more assumptions to be met in 
comparison to t-tests.  That said, where the F statistic is correctly reported 
for time/intervention, it is mathematically equivalent to the square of the t-
value (Knapp and Schafer 2009) suggesting that the simpler t-test could be 
used. 
 
Finally, it is argued that use of change scores is less reliable than the likes of 
ANCOVA which has greater power to report significant results (Vickers 
2001).  In addition, change scores may be negatively correlated with pre-test 
values (Knapp and Schafer 2009) where reductions in error rates are 
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observed for example.  However, there are also sensible arguments for use 
of independent t-tests on change scores.  Chiefly, t-tests are relatively simple 
with fewer assumptions (Brogan and Kutner 1980) and they are ubiquitous, 
influencing their widespread use (Knapp and Schafer 2009).  It is also 
suggested that change score analysis is acceptable when ANCOVA 
assumptions are violated or the baseline variable, PE rate, is comparable 
between groups (Vickers 2001).  Whilst it has been shown that ANCOVA has 
greatest power to detect differences (Dimitrov and Rumrill 2003), it should be 
noted that it is with large sample sizes (Blance et al. 2007).  In this study, 
sample sizes were less than 40 and so the statistical power of ANCOVA 
would therefore be reduced (Blance et al. 2007), whilst t-tests have the 
advantage of application to small groups (De Winter 2013).  Most 
importantly, t-tests address the research hypothesis in this thesis whereas 
ANCOVA would more accurately address a different research hypothesis; 
“There is a change in post-test PE rates not predictable from pre-test PE 
rates”. It is also worth highlighting that having a percentage change score is 
a value that is easily interpreted by any target audience for this research.  
Therefore, considering this, independent t-tests on change scores were used 
in this thesis. 
 
The author hypothesizes that; 
 
H1 “There is a difference in mean change in PE rate between the intervention 
and control group” 
 
The test design and hypothesis supports use of an independent t-test to 
determine if there is a difference between the mean change of the two 
independent groups (Cohen et al. 2011:642).  In this study, the author uses 
the independent t-test to determine the effect of feedback on PE rates and 
percentage of prescriptions error free per prescriber.  
 
For the t-test, the null hypothesis, H0, is; 
 
“There is no difference in mean PE rate change between intervention and 
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control groups” 
 
The null hypothesis, H0, will be accepted where the resultant p-value is >0.05 
and the alternate hypothesis, H1, accepted if the p-value is <0.05. 
 
To be able to perform the independent t-test, various assumptions need to 
satisfied including; 
 
 There is one dependent variable measured on a continuous scale (PE rate) 
 There is one independent, categorical variable consisting of two groups 
(intervention, control) 
 There is independence of observations within and between groups 
 There is an approximated normal distribution 
 There are no significant outliers 
 There is homogeneity of variance 
 
For the latter three assumptions, normality can be determined by inspection 
of histograms and probability plots, assessing for normal distribution or 
skewness.  In addition, the Shapiro-Wilk test provides a measure of normality 
and its value can be determined in SPSS and, where the p-value is > 0.05, 
normality can be assumed. 
 
Outliers will affect distribution and variance and inspection of box and 
probability plots can reveal if any significant outliers are present.   Finally, 
homogeneity of variances can be determined by examining the Levene test 
with a p-value >0.05 indicative of equal variances. 
 
Where these assumptions are violated, a non-parametric equivalent test (e.g. 
Mann-Whitney U test) could be used (Scott and Mazhindu 2009:151).  
However equally, t-tests are robust to deviations of non-normality (Posten 
1978), especially with sample sizes greater than thirty (Pagano 2004:339).  
In addition, where non-normality is identified, the researcher can attempt to 
transform data depending on its skewness although it should be 
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acknowledged that an approximated normality is only necessary, and the 
independent t-test is relatively insensitive to deviations from normality.  
  
Similarly, outliers can be removed or modified and data re-tested with and 
without the modification to determine if the t-test procedures produce 
significant results for both datasets. 
   
Finally, where equal variances are not assumed and the Levene test is 
<0.05, it is recommended that Welch’s t-test is reported.  However, again the 
t-test is robust to unequal variances where the sample sizes of each group 
are similar (Posten et al. 1982), as in this study, with uneven sizes defined as 
a greater than 1.5 fold difference (Morgan et al. 2004). 
 
3.12.4.2. Calculating effect size 
 
It is increasingly common to report effect sizes within the literature to quantify 
the difference between groups and, in this regard, it is more useful than a p-
value.  One test that is commonly used for this purpose is Cohen’s d (Cohen 
et al. 2011:617) where; 
 
 
Here, the mean difference between groups 1 and 2 is divided by the pooled 
standard deviation where; 
 
For Spooled, S1 is the standard deviation for group 1 and S2 the standard 
deviation for group 2.  Similarly, n1 is the sample size for group 1 and n2 the 
sample size for group 2. 
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Once d is calculated, the reported value allows inference into the size of the 
effect with a d of 0.2 to 0.5 a small effect, 0.5 to 0.8 a medium effect and > 
0.8 a large effect. 
 
3.12.4.3. Chi squared tests 
 
Chi square (χ2) tests are commonly used in univariate analysis (one 
variable) to compare frequencies (items and errors) and to investigate 
difference between groups (Cohen et al. 2011:651).  χ2 is used to measure 
the difference between an observed and expected result based on the null 
hypothesis; 
 
H0: “There is no difference in distribution/frequency of prescribing error / type 
/ severity of error between groups”   
 
Where a statistically significant difference is identified, p<0.05, the alternate 
hypothesis will be accepted; 
 
Ha: “There is a difference in distribution/frequency of prescribing error / type / 
severity of error between groups”   
 
Chi squared (χ2) test of homogeneity were used in this study to measure 
frequency of error type and severity within groups for pre- and post-test data.  
Chi squared test of independence, also called chi squared test of 
association, were used to determine frequency of PEs both within and 
between groups.  The latter can support and validate the use of t-tests where 
baseline error frequencies are similar.    
 
A two-tailed p<0.05 was considered statistically significant.  
 
Assumptions of the chi-square test include 80% of cells having cell counts of 
at least 5.  Otherwise the exact test statistic should be reported (Cohen et al. 
2011:654).   
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As with the t-test, effect size can be reported as phi (φ) where; 
 
Where χ2 is the chi-squared value and n is the number of observations. A 
result of 0.1 indicates a small effect, 0.3 a medium effect, and 0.5 a large 
effect (Cohen et al. 2011:654) 
 
3.12.4.4. Pearson correlation coefficient 
 
In addition, the author was looking to determine if there was any association 
between change in PE rate (continuous data) and number of feedback 
sessions.  This was described as; 
 
H4: “There is an association between number of feedback sessions and 
change in prescribing error rates” 
 
Pearson correlation coefficient, represented as r, is a commonly used to test 
for associations with continuous or interval data (Cohen et al. 2011:631). In 
this thesis, it is used to determine the strength and direction of the 
relationship between two variables (error rate and number of errors received 
feedback on).  Here, if PE rate reduces with number of feedback sessions, r 
will be negative, if it increases it will be positive and if it is zero, there will be 
no relationship. 
 
Assumptions of Pearson’s correlation coefficient include paired data, a linear 
relationship, no significant outliers and bivariate normality.  Where these 
assumptions are violated an alternative non-parametric test such as 
Spearman’s rank order correlation test can be used. 
 
3.12.4.5. Spearman rank coefficient  
 
This test is the non-parametric equivalent to the Pearson correlation 
coefficient (Cohen et al. 2011:631), determining how two variables can 
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predict each other, with correlation reported from -1 to 1 (Neideen and Brasel 
2007). 
 
3.13. Chapter summary 
 
This chapter has explored the research methods and methodologies used 
throughout this thesis.  These include the use of interviews and focus groups 
for qualitative methods to explore the views and opinions of participants in 
the studies.  Quantitative approaches were also described using prescribing 
audits for control and intervention groups to determine impact of feedback on 
PE rates.  Finally, data analysis methods were described including thematic 
analyses using the framework approach for qualitative data, and relevant 
descriptive and inferential statistics for quantitative data.  Subsequent 
chapters will now focus on the results of this thesis with chapter 4 exploring 
the attitudes and opinions of pharmacists to delivering feedback prior to 
formalising the process and introducing the feedback intervention.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 96 
Chapter 4. Pharmacist focus groups 
 
4.1. Chapter Introduction 
 
This chapter describes the attitudes and opinions of twenty-four hospital 
pharmacists of intercepting and delivering feedback on PEs.  As reported in 
chapter 2, little is reported in the literature to help understand these views.   
 
The primary research aim of this chapter was to: 
 
Explore and determine pharmacists’ experiences of delivering 
prescribing error feedback 
 
Focus groups are used to collect the in-depth qualitative data required to 
address the research aim.  Eight key themes are used to highlight PE 
feedback practices prior to implementing the intervention and pharmacist 
attitudes towards delivering more formalised PE feedback.   
 
4.2. The focus groups 
 
Pharmacists were recruited as described in chapter 3.  All eligible 
pharmacists (33) expressed an interest to participate although not all could 
commit to the arranged dates of the focus group interviews.  All focus groups 
were conducted in a seminar room within the pharmacy department 
throughout August 2014.  All pagers / mobile phones were turned off to 
prevent interruption.  Additionally, a notice was placed on the room door to 
prevent interruption. 
 
Prior to commencing the interview, the purpose of the study was covered 
again and both verbal and written consent obtained.  A topic guide (Appendix 
15) was used to explore key themes whilst ensuring consistent issues were 
discussed.  All focus groups were digitally recorded and lasted between 1 
hour 6 mins and 1 hour 12 mins. 
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4.3. Data analysis  
 
All focus groups were transcribed verbatim by the author, the sole exception 
being to anonymise person and place names.  Transcriptions took an 
average of six to eight hours per focus group, a timeframe consistent within 
the literature (Rabiee 2004).   
 
The author listened, re-listened, read and re-read the transcripts to correct 
any typographical errors and for early immersion in the data.  Both 
supervisors (SDW and SVOB) independently read each transcript.  
Transcripts were discussed between focus groups by the research team to 
consider similarities and variations of findings. 
 
Focus group transcripts were coded manually line-by-line and analysed 
thematically using the framework approach as described in chapter 3.    
Emergent codes were informed by the topic guide, research aim and the 
author’s knowledge of the literature.  Codes were sorted into similar 
contextual themes.  Initial themes and codes were discussed at regular 
meetings with SDW and SVOB.   Discrepancies were resolved through 
discussion for an analytical consensus.  The resultant initial thematic 
framework (Appendix 22) was then applied to the transcripts with further 
revisions as new meanings emerged from the data.  The final thematic 
framework was then applied and relevant transcript extracts copied and 
pasted under the codes for analysis and meaning.   
 
4.4. Results 
 
Twenty-four pharmacists were recruited (16 female and 8 male) with six 
pharmacists in one of four focus groups.  A range of pharmacist grades (6 to 
8) and experiences were recruited (see table 5) reflecting the skill mix within 
the department.  More junior pharmacists were seated opposite, and more 
senior pharmacists nearest to, the author to encourage open discourse from 
junior pharmacists (Shenton 2004). 
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Table 5: focus group participants  
Focus 
Group 
(duration) 
Pharmacist 
Number 
AfC Band a Years 
Qualified 
Gender 
1 
(1hr 6 
mins) 
1 7  2 Female 
2 8c  25 Male 
3 8a  6 Female 
4 7  3 Female 
5 8a  8 Female 
6 8a 20 Male 
2 
(1hr 12 
mins) 
7 6  2 Female 
8 8a  33 Female 
9 7  2  Female 
10 6  1  Male 
11 8a  15 Female 
12 8a  15 Male 
3 
(1hr 7 
mins) 
13 7  2 Male 
14 7  3 Female 
15 8a  9 Female 
16 7  10 Male 
17 6  1 Female 
18 6  1 Female 
4 
(1hour 8 
mins) 
19 8b   20 Female 
20 6  1 Female 
21 7  40 Female 
22 8b  28 Male 
23 7  8 Female 
24 8b  23  Male 
a See chapter 1 for an overview of pharmacist grades 
 
The final thematic framework included eight major themes with additional 
secondary codes determined from the focus groups (see table 6).  The 
results will be summarised under the eight key themes below. Example 
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quotations to illustrate the results were chosen by the author and agreed with 
the supervisory team (SDW and SVOB) beforehand. 
 
Table 6: Thematic framework for pharmacist focus groups   
Theme Code 
Delivery of feedback Inconsistent 
 Formal vs. informal 
 Communication of error 
 Incident reporting 
 Correction vs. feedback 
  
Impact of feedback  Patient safety 
 Time saving 
 Information seeking behaviour 
 Feedback seeking behaviour 
  
Prescription error  Error severity 
 Error repetition 
 Timely feedback 
  
Work environment Time pressures 
 Location  
 Contacting prescriber 
 Blame vs. no-blame culture 
 Pharmacy service 
 Out of hours 
  
Feedback facilitator Staff group 
 Job satisfaction 
 Expert knowledge 
 Emotional intelligence 
 Interpretation of error 
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 Pharmacist training 
  
Working relationships Rapport 
 Team integration 
 Hierarchy 
 Anxiety / reticence  
  
Education and training Independent learning 
 Constructive feedback 
 Reflective practice  
 Positive vs. negative 
  
System improvements Electronic prescribing 
 Prescriber training 
 Clinical governance  
 Ward based 
 Shared vs. individual learning 
 Facilitator training 
 
 
The results will now be discussed under the following key themes: 
 
1. Delivery of feedback 
2. Impact of feedback 
3. Prescription error 
4. Work environment 
5. Feedback facilitator 
6. Working relationships 
7. Education and training 
8. System improvements 
 
In general, all pharmacists participated openly and engaged with the topics 
of discussion.  Limited follow up questions were required by the author.   
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Three groups appeared to be mostly positive about the need for formalised 
feedback although one focus group (focus group 4) expressed greater 
reticence and apprehension towards the process. 
 
Pharmacists consistently agreed that PE feedback was essential with various 
benefits of the process proposed. There were inconsistencies in how 
feedback was delivered between and across focus groups with various 
reasons for these inconsistencies reported.   
 
Pharmacists agreed that they would be credible PE feedback facilitators 
although focus group 4 questioned why it should be them and not another 
doctor for example.  Anxieties surrounding the process were reported with 
concerns surrounding any potential negative impact on prescriber working 
relationships expressed. 
 
All groups advocated that PE feedback should be educational, supporting 
prescriber development. 
 
The results will now be presented for each theme using relevant quotes. 
 
4.4.1. Delivery of Feedback 
 
Five key codes were included in this category: Inconsistent practice, Formal 
vs. informal, communication of error, incident reporting, and error correction 
vs. feedback. 
 
a. Inconsistent practice 
 
Pharmacists acknowledged that the current processes of PE feedback were 
opportunistic and inconsistent, whilst feedback may not be delivered at all.   
 
P6: “It’s ad hoc there is no formal system and so there will be 
inconsistencies.” 
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Reasons for inconsistent approaches included lack of formality of any 
feedback process and differences in pharmacist practice or pharmacy 
service, for example attendance on ward rounds, or departmental meetings. 
 
P5: “You know, you’re not told how to do it and so a lot will depend on the 
individual to feedback so that will be variable as well, we’ll all feedback 
differently.” 
 
It was also reported across groups, that response to PEs depended on the 
perceived severity of the error. 
 
P5: “It depends on the severity; if it was serious I would probably challenge 
them and say why have you done that, is there a reason why you thought to 
do this? But then if it was something quite minor then I would probably just 
write it on the list (jobs list) and ask them to change it.” 
 
b. Formal vs. informal 
 
It was unanimously acknowledged that PE feedback was essential and 
should be formalised for consistent practice.  Two pharmacists (P6 and P14) 
advanced this recommendation by arguing that they had a professional 
obligation to provide PE feedback otherwise they may be complicit in future 
PEs. 
 
P14: “If they are making the error consistently and someone comes to harm 
from it and you have been clocking the error for six months and you never 
told them about that error then are you complicit in that error?  Are you part 
of that error because you have picked it up for six months and not told them 
and that one time you let it slip the patient is harmed?  Whereas if you had 
told them six months ago could you not then argue that … not that you’ve 
done your bit but that you have tried to make a difference.” 
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Pharmacists additionally suggested that formalisation of the process would 
not only ensure consistent delivery of PE feedback, but raise expectation that 
feedback will be delivered. 
 
P14: “If it was a formalised approach then it wouldn’t be maybe your 
pharmacist is going to approach you it will be they are going to approach you 
to discuss an error.” 
 
c. Communication of feedback 
 
Pharmacists acknowledged that face-to-face feedback was the preferred 
format to support individualisation of feedback and interactive dialogue.  
Equally, how the feedback is delivered is important with rapport clearly 
influencing communication.   
 
P4: “I think it’s easier to deliver feedback also when you are standing face to 
face with someone than when you’re on the phone.” 
 
Pharmacists reported that other methods of feedback such as e-mail or 
telephone were less desirable. It was suggested that the asynchrony of e-
mail communication and potential misinterpretation of messages could limit 
the impact of feedback that was not delivered face-to-face.   
 
P11: “I do mine sometimes over the phone and I don’t know, maybe it’s my 
mannerisms, but sometimes I’ll go oooo you’ve really just taken that the 
wrong way from me. I didn’t mean that, so I’ve obviously gone in guns 
blazing because I’m busy, and they’re busy, and becomes a bit like… they 
can’t see me, they don’t know me and they possibly hear the aggression.” 
 
d. Documentation of error 
 
Pharmacists agreed that PEs should be documented for communication and 
governance purposes.  However, there were inconsistencies with what was 
documented, if at all, and by what medium.  Pharmacists advocated that PEs 
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should be documented in the clinical notes but described variations in 
practice such as writing on medical charts, leaving post-it notes or writing in 
doctors’ jobs books.  Some pharmacists suggested they rarely, if at all, 
reported PEs in the notes. 
 
P22: “I have to be honest I don’t know the last time that I documented 
anything in the notes.  I’ll annotate drug charts or I’ll leave notes stapled to 
them to say you need to do this.” 
 
Some pharmacists reported that their practice varied depending on the ward 
they were covering and the relationship they had with prescribing staff. 
 
P13: “If I’m on an unfamiliar ward I’m more likely to document things in the 
notes whereas on my ward I have no problem with going up to someone and 
feeding back directly.” 
 
Several pharmacists across focus groups challenged these inconsistencies 
and suggested that feedback should be communicated face-to-face and 
documented in the clinical notes to ensure prescribing jobs were acted on. 
 
P12: “Yeah, well some people just write on the kardex too and I don’t agree 
with writing on the kardex.  It’s got to be in the notes otherwise they may not 
read it or just ignore it.” 
 
e. Incident reporting 
 
Pharmacists expressed that a PE that caused or has the potential to cause 
harm should be reported to support trending of data.   
 
P14: “In an ideal world you would datix all of these near misses and then 
look for the issues.” 
 
However, it was acknowledged that this rarely occurred as the system was 
cumbersome and the volume of PEs too great.    
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P1: “I’ll hold my hand up and say that I don’t fill in as many as I should 
Ermmm… they take time and they’re complicated forms and they’re lengthy, 
not user friendly.” 
 
Additionally, it was considered that incident reporting systems were punitive 
or that the message never reached the prescriber, outcomes that were 
considered countermeasures to what should be an educational process. 
Pharmacists also reported a sense of apathy and futility in reporting errors 
because they are unsure what happens or if the individual involved receives 
any feedback.   
 
P10: “Well I don’t know, does a datix [incident reporting system] ever get 
back to the doctor or is it designed to look for trends to see if there is 
common error or a system failure?  But does anybody actually feedback to 
the doctor.” 
 
f. Error correction vs. Feedback 
 
A prominent theme throughout all focus groups was what constituted 
feedback and whether pharmacists delivered feedback or simply got errors 
corrected.  Some pharmacists thought the two processes were the same: 
 
P11: “It really depends on your definition of feedback.  Is it just going and 
getting it changed, corrected?” 
 
However, other pharmacists astutely recognised that the two are not 
synonymous but different processes altogether where the focus is on 
identifying what happened and what they can do to prevent error recurrence. 
 
P15: “I think feedback also includes some sort of thought process for the 
doctor to help them think about how they’re going to prevent that error 
happen again.” 
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Pharmacists reported that correction of errors occurred more often reflecting 
the immediacy of workload pressures.  Equally, where the prescriber is 
unavailable or unidentifiable, then another prescriber would be asked to 
amend the prescription.  Advancing on this, some pharmacists questioned 
the need to provide feedback if the PE has already been corrected: 
 
P19: “If you are feeding back to a consultant and they have written Tazocin 
[penicillin antibiotic] eight hourly and they have an eGFR [estimated 
Glomerular Filtration Rate] of ten and I go and say change the dose then I’m 
not going to go and make an appointment with their secretary and say right, 
do you remember that Tazocin that you wrote last week! It’s just nonsense it 
doesn’t make any sense it just seems to be hammering home a point that 
you have already addressed.” 
 
Pharmacists reported routinely amending prescriptions for minor PEs to save 
time where the prescriber was unavailable or to avoid disrupting the doctor 
where the prescribing intention was clear.   
 
P12: “Well you know, if it’s a TTO [To take out discharge prescription] or 
requisition coming down to pharmacy then you probably wouldn’t ring the 
ward and you’d probably just annotate it yourself and if you’re on a surgical 
ward where the juniors float on and off then it’s going to be harder to contact 
them isn’t it.” 
 
Equally however, pharmacists acknowledged that they should not be doing 
this and it was unlikely to alter prescriber practice and could increase 
pharmacy workload. 
 
4.4.2. Impact of Feedback 
 
Four key codes were included in this category: Patient safety, time saving, 
information-seeking behaviour, feedback-seeking behaviour. 
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a. Patient Safety 
 
Pharmacists agreed that feedback could reduce PEs and improve patient 
safety.  Some pharmacists advanced on this by suggesting that by not 
delivering PE feedback, patient care is compromised. 
 
P4: “firstly you have to get the prescription right and without feeding back to 
them you can’t get it right.” 
 
b. Time saving 
 
Pharmacist proposed potential indirect benefits of feedback including more 
efficient practice and time savings, outcomes that could allow them to focus 
on other patient-centered activities.  However, some pharmacists advanced 
on this and proposed that their workload required a focus on short term goals 
and priorities such as processing prescriptions.     
 
P4: “It saves time in the long run but not in the short run and we all sort of 
work in the short run because we work to a deadline all try and get through 
the day and complete our jobs by 5 o’clock, and we don’t have the time to do 
the formal feedback.” 
 
c. Information-seeking behaviour 
 
Several pharmacists suggested that feedback could encourage prescribers 
to ask them more questions to inform prescribing either during any feedback 
or prescribing process itself.  
 
P3: “Or if you give them feedback on a particular area then before they 
prescribe that again they will be like oh can I just ask you … so I find then 
that they will question before they prescribe.” 
 
Some pharmacists suggested that this was because they could demonstrate 
their knowledge and raise awareness of their roles at ward level. 
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P10: “I think that’s important because that’s when they really start asking you 
stuff when they know that you actually know something.” 
 
d. Feedback-seeking behaviour 
 
It was suggested by several pharmacists that prescribers are receptive to 
feedback and seek feedback as part of their training requirements. This was 
in contract to the reported pharmacist apprehensions of the process.  One 
pharmacist suggested that prescribers are trained differently to pharmacists 
and received feedback on their practice throughout their formative careers. 
 
P12: “They are used to having feedback and used to meeting with people in 
an educational setting and having face to face discussions about problems.” 
 
4.4.3. Prescription error 
 
Three key codes were included within this category: Error severity, Error 
repetition and timely feedback. 
 
a. Error severity 
 
Pharmacists advocated that feedback would be more appropriate for more 
serious PEs.  However, the importance of minor errors was recognised 
especially where the cumulative effect on pharmacist time could be 
considerable.  Equally, pharmacists suggested that any impact of feedback 
could be diluted if it was delivered for every single PE, a process that could 
be detrimental to prescriber perceptions of pharmacists. 
 
P5: “I think that you should just be feeding back on serious errors; otherwise, 
they are just going to think oh here’s (pharmacist) with her green pen again 
[colour ink that pharmacists use in the organization] and so we need to make 
that distinction between what’s serious and what’s not.” 
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Supporting the inconsistent practice reported, pharmacists described 
individual and subjective thresholds for responding to PEs.  Severe errors 
are generally corrected immediately, with minor errors resolved by other 
means.  
 
P3: “Depending on error severity then on ward round something like renal 
dose or IV (intravenous) change I would ask them to do it on ward round but 
if it was a matter of just writing up meds (medications) I would ask them in 
the afternoon after the ward round and say go to bed this, this, and this and 
they need their regular meds prescribed but I just feel it’s not done unless its 
documented.” 
 
b. Error repetition 
 
Pharmacists in all groups agreed PE feedback should reduce error repetition.  
Equally, they proposed that repetitive PEs, irrespective of severity, should be 
fed back to the prescriber.  Advancing on this, pharmacists suggested that 
processes should be in place to escalate poor performance that was not 
improving.  
 
c. Timely feedback 
 
The need for timely feedback was considered critical to highlight the 
importance of safe and appropriate prescribing practice.  Additionally, 
pharmacists suggested that timely feedback was essential to facilitate 
memory recall, not only of the prescription, but the situation and potential 
contributing factors.   
 
P24: “Being able to remember any mitigating factor on that day is absolutely 
valid you know, there may be contributing factors that you may forget about 
so you need to know as soon as possible.” 
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4.4.4. Work environment 
 
Six key codes were included within this category: Time pressures, location, 
contacting prescriber, blame vs. no-blame culture, pharmacy service, out of 
hours. 
 
a. Time pressures 
 
Increasing demands and time pressures were cited as key drivers for any 
task completion and were proposed as barriers to delivery of PE feedback. 
 
P3: “It’s not always feedback; sometimes it’s just can you change this, like 
you know time issues.” 
 
Despite outlining the need for PE feedback, some pharmacists suggested 
that other tasks would take priority over any feedback. 
 
P18: “Do you want to sit and document that error or do you want to sit and 
check everything else that that doctor has prescribed and make sure they 
haven’t given any piptaz [piperacillin/tazobatam] to a penicillin allergic 
patient.  Because if they’ve missed that even though it’s on the allergy status 
do you not want to check everything else?”  
 
Advancing on this, one pharmacist questioned whether the resource 
implications of feedback would be less efficient than continuing with the 
status quo to simply correct PEs.   
 
P19: “If you’re talking about a trade-off between doing this and correcting 
errors, would that be realised?” 
 
These views were not shared by the majority of pharmacists who suggested 
that they would find the time for such an intervention and that PE feedback 
should be a key responsibility. 
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P13: “Even if it means that you don’t see a kardex or two or some other 
things that are further down your priority list so that that can get jumped right 
to the top.” 
 
b. Location 
 
The ward environment was considered most appropriate to deliver PE 
feedback.  Pharmacists suggested that this would facilitate face-to-face 
delivery of feedback and negotiation of convenient times to feedback.     
Additionally, ward-based PE feedback would have the advantage of being 
delivered by a pharmacist who should know the prescriber involved and have 
established rapport. 
 
P18: “If you’re on the ward and it’s your ward doctor…they’re immediately 
available to you in person so it’s not a telephone conversation and you get 
much better communication between the two of you and it’s a much better 
process then.” 
  
Other locations such as the pharmacy dispensary were considered less 
appropriate due to greater time pressures, limited communication and 
potential lack of rapport with the prescriber.  
 
c. Contacting prescriber 
 
A prominent theme described was difficulties in identifying and contacting 
prescribers: barriers that would limit any potential PE feedback.   
 
P15: “If you can’t identify the signature then you might be wasting a lot of 
time.”  
 
Pharmacists described taking reasonable efforts to contact prescribers but 
where they were unable to identify or contact the prescriber, they would often 
get another to amend the prescription or amend it themselves as reported 
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earlier.  Pharmacists acknowledged that this would not be an issue for their 
own prescribers whose signatures they would recognise.   
 
d. Blame vs. No-blame culture 
 
Pharmacists expressed that a “no-blame” culture was paramount for any PE 
feedback.  This supported the earlier suggestion that incident-report forms 
were inappropriate for PE feedback.  In part this was because pharmacists 
felt it should be a clear educational process. There appeared to be some 
apprehension in delivering feedback that could have punitive measures for a 
prescriber. 
 
P13: “I’d certainly be less inclined to because I don’t want to get the person 
in trouble.” 
 
e. Pharmacy service 
 
Across groups, pharmacists considered that PE feedback could be a 
reasonable extension of their roles and that they would be appropriate 
facilitators.  However, some pharmacists outlined that it was not their 
responsibility to deliver PE feedback: 
 
P4: “there is nothing in our job description that talks about giving feedback 
and I don’t think that is anywhere near the top priorities of what you need to 
do on the ward.” 
 
Three other pharmacists (P4, P18 and P19) advanced this by suggesting 
other, more senior prescribers should be delivering the feedback.   
 
P18: “Their consultant is responsible for their prescribing so should they not 
be involved in their feedback because if they don’t know that’s such and such 
is making the mistake consistently in their name so the consultant is 
accepting responsibility for what that F1 does so the consultant should know 
what the F1 is doing.” 
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It was suggested that limited time on wards can influence rapport with 
prescribers, and limit potential for delivery and receipt of timely feedback.  
Where wards have no pharmacist cover, pharmacists reported limited 
potential for PE feedback.  Equally, for ward-based pharmacists, these 
factors were considered less of a concern underlining the suggestion that a 
ward-based pharmacist is the most appropriate facilitator as reported below. 
 
P2: “If you’re not there all the time it makes rapport more difficult.  The 
medics, nurses and physio staff are on there all day and if you’re just 
popping onto the ward for half an hour at a time it makes it difficult for you to 
be viewed as part of team and you’re just a visitor.  It’s very difficult to 
establish any sort of rapport with a doctor that you may only see for 5 
minutes or so.  If you’re seeing the same guys day in day in out it’s a bit 
different than if you see them for example every third day.” 
 
Pharmacists recognised that despite potential time savings, there would be 
resource implications and that protected time would be desirable to deliver 
feedback.  
 
f. Out of hours 
 
The work environment presented further barriers to feedback out of hours 
where it is more difficult to contact a prescriber, there are limited pharmacists 
working and the priority focuses on processing prescriptions. 
 
4.4.5. Feedback facilitator 
 
Six codes were included within this category: Staff group, job satisfaction, 
expert knowledge, emotional intelligence, interpretation of error and 
pharmacist training. 
 
 
 
 114 
a. Staff group 
 
All pharmacists agreed that anyone who identifies a PE could deliver PE 
feedback. Some pharmacists questioned why more senior prescribers should 
not deliver PE feedback although others countered that feedback could 
become punitive where a senior prescriber or line manager for example 
delivers feedback.  
 
All pharmacists agreed that they were probably best placed to deliver 
feedback.  It was suggested that this was because prescribers would be 
more open to feedback from pharmacists who may be perceived as experts 
in medicines use, whilst it was also their perceived role to intercept and 
correct PEs.   
 
P13: “Because at the end of the day we are experts on medicines.  We are 
the ones identifying medication errors so we are best placed to feedback why 
that is significant or insignificant because we have a thorough understanding 
of the error.” 
 
Pharmacists were unanimous in advocating that ward-based, as opposed to 
dispensary based, pharmacists were best placed to deliver PE feedback.  
This was because they will understand the patient and situational context 
and have established working relationships with the prescriber, which they 
considered important for any feedback process.  It was also suggested that 
having a single ward-based facilitator would allow monitoring of trends and 
responses to feedback for individual prescribers whilst mitigating any 
potential anxiety surrounding the process.   
 
P22: “The other thing is you have a limited number of people feeding back to 
an individual then you are more likely to pick up if there is a problem with that 
in individual because potentially if one prescriber is being contacted once a 
week by every pharmacist with an error then that’s thirty errors a week.  But 
for us, it’s one error a week which doesn’t flag up anything at all.” 
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b. Job satisfaction  
 
Pharmacists reported that feedback could improve their job satisfaction 
where it was received positively and considered useful. In contrast, feedback 
that was poorly received could be destructive to further facilitation of PE 
feedback. Some pharmacists (P1, P4, P23) reported frustration and 
indignation where their efforts to deliver feedback have been dismissed. 
 
P4: “It depends on the response that you get when you give it.  If you give it 
to a doctor who is receptive and thankful then actually I’ll think I’ll do that 
again but if you come up against a barrier and someone just goes oh its 
wrong and crosses it off and dismisses you although the error isn’t there 
anymore you sort of feel like you’ve inconvenienced them and haven’t 
provided constructive feedback at all because they’ve just literally brushed 
you aside.” 
 
c. Expert knowledge  
 
Pharmacists suggested that they have expert drug knowledge and that this 
provides them with a credibility to deliver PE feedback.  Some junior 
pharmacists advanced this discussion, describing how certain pharmacists 
were perceived as more credible and utilised more because of their expert 
knowledge.  
 
P10: “Like I know there are some pharmacists that doctors will just go up to 
them because they know their stuff so they’re perceived in a better light.” 
 
Some pharmacists also expressed apprehension about delivering feedback 
on a medication that they were unfamiliar with.  Some suggested that they 
would be happy for others to deliver the feedback in these situations and that 
poorly delivered feedback could adversely affect the feedback process.  
 
P14: “If it’s your ward or your clinical area or you know a lot about that drug 
in particular then yeah.  If it’s something that you are a bit questioning of 
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yourself in the first hand, then if you sort of approach it in this oh maybe it’s 
this or this and you don’t have this authority then maybe they might not take 
it that seriously.” 
 
d. Emotional intelligence  
 
Pharmacists reported that feedback should be individualised to support the 
process.  There is potential to upset prescribers and this requires an 
emotional intelligence and facilitator flexibility to change approach depending 
on the prescriber response. 
 
P19: “You can judge it face to face can’t you?  If you are upsetting somebody 
then you can change tact.” 
 
e. Interpretation of error 
 
Pharmacists reported that there are likely to be variations in interpretation of 
errors between pharmacists and prescribers that could lead to 
inconsistencies in what feedback is delivered.   
 
P6: “I also think that there is a perception that we as pharmacists see errors 
more seriously than doctors do.  You know, if you were to sit the two 
professions down, because bare in mind they don’t just make errors in 
prescribing they are making errors in diagnosing, surgical procedures… and 
so in the bigger scheme of things making prescribing errors aren’t taken that 
seriously even though they may be making a serious prescribing error.” 
 
f. Pharmacist training 
 
Pharmacists reported variations in willingness to both communicate with and 
feedback to prescribers depending on undergraduate and professional 
training.  Several experienced pharmacists (P2, P8, P11, P22) 
acknowledged that they trained in an era when it would be unusual to 
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challenge a prescriber, write in the clinical notes or provide feedback on 
prescribing but that expectations have changed in more recent times. 
   
P8: “When I first qualified as a pharmacist it was before pharmacy was out 
there about the wards.  It took a lot of confidence to phone a consultant up 
and tell them they had done something wrong.” 
 
Advancing this point, pharmacists reported that they have received little or no 
training on communication skills or communicating with prescribers 
specifically, either as an undergraduate or qualified pharmacist.  This was 
despite reporting greater expectations of hospital pharmacists.  Pharmacists 
were unanimous in the need for training to support any feedback process.   
 
P5: “I think it may be expected but we’re not trained at any point to feedback 
on errors either at undergrad or even through your diploma as a professional 
to feedback on errors.  You know, you’re not told how to do it and so a lot will 
depend on the individual to feedback so that will be variable as well, we’ll all 
feedback differently.” 
 
4.4.6. Working relationships 
 
Four key codes were included within this category: Rapport, team 
integration, hierarchy and anxiety / reticence 
 
a. Rapport 
 
Pharmacists unanimously agreed that rapport, through established working 
relationships, enhanced communication with prescribers and was integral for 
both delivery and receipt of PE feedback.  Without rapport, pharmacists 
suggest they may be less confident and more apprehensive about the 
process, re-iterating the suggestion that the feedback facilitator should be 
ward-based. 
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P11: you need that rapport don’t you to be integrated into the team and have 
the confidence to go up to them and say you have made a mistake and it 
should be this. 
 
b. Team integration 
 
Pharmacists reported that feedback has the potential to enhance team 
integration through improved communication.  Such outcomes were 
suggested to support further rapport building and could raise the profile of 
pharmacists further by raising their profile and role awareness.  
 
P23: “Well the more that we are doing on the wards will raise our profile on 
the wards.  Like if I find an alendronate once daily and then speak to the 
patient to find out what day they take it and cross out the days.  If I discussed 
this with the doctor every time then they wouldn’t think oh they didn’t just 
graffiting all over the kardex in that green pen and they are actually doing 
something.”   
 
c. Hierarchy 
 
Hierarchical issues were reported by pharmacists with a notable 
apprehension at approaching consultants with feedback on their prescribing, 
particularly for more junior pharmacists.  This in part, was secondary to a 
consultant’s status as head of the team and subject experts. When 
consultants make a PE, some pharmacists reported getting a more junior 
prescriber to amend the prescription for this reason. 
 
P11: “I think also, maybe, I don’t know but the grade of the pharmacist.  You 
know, I wouldn’t mind so much but there are consultants where I would be 
like oh here we go.  But I would do it… but I don’t know how that would be for 
a new band 6.” 
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Some pharmacists described situations where consultants dismissed their 
concerns, although experiences appeared to vary depending on the grade of 
the pharmacist.   
 
P14: “There is a consultant who I wouldn’t walk up to in a million years 
because I don’t want to get shouted at and I would speak to anyone but that 
person.” 
 
Senior pharmacists reported having more favourable and positive 
interactions with consultants with one pharmacist suggesting this is because 
they have trained alongside them as junior grades supporting the value of 
rapport as reported earlier.  
 
Several pharmacists reported that prescribers would be more receptive to 
feedback from pharmacists because they are not part of their hierarchy and 
hence the feedback is not considered punitive.   
 
P2: “We’re not part of their team so we can feedback into any part of that 
without it being viewed as top down.” 
 
d. Anxiety / reticence  
 
There was a notable apprehension and hesitancy towards delivering PE 
feedback by pharmacists.  Pharmacists were concerned that feedback may 
be perceived negatively or punitively, or they may be viewed as pedantic, 
outcomes they considered could damage working relationships.   
 
P18: “You know I don’t want them thinking every time I go up to them what 
have I done. Just make it so that it’s not the only interaction I have with them 
is telling them they have done something wrong” 
 
Previous negative experiences of delivering any feedback were also telling 
with defensive prescribers leaving lasting impressions on pharmacists.   
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P4: “Whereas you get other people who really don’t care what they’ve 
prescribed or what error they’ve made they just don’t care and so it doesn’t 
matter what feedback you’ve given them.  To be honest you’re probably 
going to give them less feedback because it isn’t having any impact at all 
because of how they have received feedback so poorly previously.  I think 
there is a lack of respect in some instances and I just think well I’m not going 
to approach you.  There are instances where there is a lack of respect for our 
profession where we’re seen as the green pen people who just annoy them.  
It’s a minority of people who have the perception but when you come across 
those individuals it has an impact on how you deliver feedback as a whole.”   
 
4.4.7. Education and Training 
 
Four key codes were included within this category: Independent learning, 
constructive feedback, reflective practice and positive vs. negative 
 
a. Independent Learning 
 
Pharmacists were consistent in reporting that feedback should be an 
educational process to support development of safe and appropriate 
prescribing. 
 
P12: “The only way they can learn is to have stuff fed back to them, it’s the 
current way that they are educated and it’s the way that they learn.” 
 
b. Constructive feedback 
 
Pharmacists reported that constructive feedback was required to identify 
solutions to problems and create a more meaningful learning experience. 
 
P12: “They don’t want to be told to do something they want to be told to do 
something and why.” 
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c. Reflective Practice 
 
Pharmacists reported that PE feedback could facilitate reflective practice and 
identify why PEs are occurring.  It was reported that reflection allows change 
in behaviour where the error causation is more than a simple knowledge 
deficit. 
 
P20: “Well with education it might be a knowledge error whereas with 
reflection it might be you have made an error because you are too busy or 
you have been stressed out or something like that.” 
 
d. Positive vs. Negative 
 
Some pharmacists considered the need for positive feedback essential to 
limit the process becoming a negative experience.  Other pharmacists 
countered that negative feedback can be constructive if delivered correctly, 
and that positive feedback could be condescending with limited value.   
Additionally, it was suggested by some pharmacists that absence of 
feedback could be positive itself where there is an expectation that 
prescribers received feedback on PEs. 
 
P12: “But feedback doesn’t have the word negative in it does it? Feedback is 
feedback.” 
 
4.4.8. System improvements  
 
Five codes were included within this category: Electronic prescribing, 
prescriber training, clinical governance, shared vs. individual learning and 
facilitator training 
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a. Electronic prescribing 
 
Some pharmacists reported that electronic prescribing could facilitate 
feedback on PEs through seamless data collection and prescriber 
identification. 
 
P7: “I just remember in our old place that we would document all of the errors 
on a different tab on the electronic system, and every month the senior 
pharmacist would feedback to all of the doctors, you know they’d get an e-
mail and get a percentage of all of the errors that they have made.” 
 
b. Prescriber training 
 
It was felt that prescribers needed further training on medication errors with 
foundation training, journal clubs or ward based teaching suggested as 
potential platforms.   
 
P17: “They could get a whole presentation on errors; you know get a 
presentation on the most common errors” 
 
Feedback was considered a reactive process with some pharmacists 
suggesting local ward-based inductions could inform prescribers of context 
specific PEs before they make them.  
 
P16: “That is definitely a good idea.  Because there are common patterns of 
mistakes that are common on every ward.  We can have a go and prevent 
them from happening.” 
 
c. Clinical governance  
 
Pharmacists proposed that regular prescribing audits were required to 
support the feedback process.  However the logistics of this was questioned 
with suggestions that a more robust and seamless process, distinct from the 
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incident reporting system, was required.  This would allow trending of errors 
and seamless capture of data per prescriber.   
 
P4: “like if we had a pharmacy only database, not a datix, but pharmacy only 
for prescribing errors that took a maximum of 2 minutes to complete so you 
put in one, what the error was, who made it and we had to put in who made 
it...  If we could identify the prescriber and we could do this, it would allow the 
feedback to be a lot more simple.”    
 
d. Shared vs. individual learning 
 
Some pharmacists suggested that group feedback at a specialty or even 
hospital-wide level could facilitate shared learning.  Some junior pharmacists 
felt this approach could reduce any anxiety around delivering or receiving 
individual feedback.   
 
P10: “Yeah, not necessarily speaking to them, maybe just a poster that you 
stick up you know and feedback on these have been the common errors this 
month” 
 
Others suggested that this approach may not be effective and that individual 
feedback was essential.  
 
P8: “I think that if you feed it back every time then they’d be more aware and 
actually think more when they are prescribing.  They won’t just think well if I 
do it wrong then pharmacy will just pick it up.” 
 
e. Facilitator training 
 
The need for training on delivery of PE feedback was recommended.  
Pharmacists advocated that such training would support the process and a 
consistency in approach whilst mitigating potential anxieties.   
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P15: “I think as well because there is not guidance out for us and if there is 
no guidance for us then we are all free to do whatever we wish with our 
feedback.” 
 
Scenario based teaching was proposed to demonstrate exemplary feedback 
on a range of errors allowing pharmacists to model their behaviour 
accordingly. 
 
P12: “What you should have, probably, is some face to face scenarios, 
workshops where you deal with different errors, different prescriber 
responses to being fed back so that you know you have to feedback the 
errors and that there in a timely way you have to deal with them.” 
 
4.5. Chapter discussion 
 
The aim of this chapter was to explore the PE feedback practices and 
attitudes of pharmacists towards delivering formalised PE feedback.  The 
focus group interviews have provided the rich qualitative data needed to 
address this aim.  The need for individualisation of PE feedback was 
outlined, that it should be constructive and timely and delivered by ward-
based pharmacists.   
 
Before delivery of the intervention described in chapter 3, PE feedback 
practices were inconsistent, opportunistic and informal.  Additionally, it was 
reported that prescriptions were frequently amended by pharmacists, 
findings consistent with results elsewhere (Abdel-Qader et al. 2010, Franklin 
et al. 2011, Bertels et al. 2013). These issues highlight missed learning 
opportunities for prescribers to learn from their errors. 
 
PE correction was more commonly occurring than any PE feedback.  Whilst 
such error correction could be considered directed feedback (Archer 2010), it 
does not resonate with the principles of effective feedback described in 
chapter 2.  Where constructive feedback is not provided, error correction 
may be received mindlessly and limit its learning potential (Bangert-Drowns 
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et al. 1991).  Mismatches between prescriber confidence and competence 
have been reported previously (Ryan et al. 2014) and low self-awareness of 
prescribing issues (Sullivan et al. 2013), from lack of constructive feedback 
may exacerbate such gaps in performance.  Where constructive feedback is 
provided, junior doctors have reported previously that their response to and 
learning from error was optimised (Kroll et al. 2008). 
 
The need for formalized PE feedback was recognized by pharmacists to 
ensure consistent approaches to PEs.  Formalization of the process as part 
of routine pharmacist practice could raise expectations of staff to deliver and 
receive feedback where the priority of feedback is raised to equal that of 
resolving any error.   
 
However, apprehensions were reported from pharmacists towards delivering 
feedback.  This was understandably influenced by time pressures and 
workload but equally, previous studies involving feedback have reported 
limited impact on pharmacist’s time (Sullivan et al. 2013, Gordon and Bose-
Haider 2012), suggesting feedback could be non-intrusive and feasible.  
Additionally, where feedback improves prescribing practice, the potential to 
reduce prospective errors can be seen.  One study suggests PEs can take 
15 minutes to resolve with significant operational costs (Sullivan et al. 2013).  
Where the time saved correcting PEs is greater than the time spent 
delivering feedback, there may well be net time savings for prescribers and 
pharmacists. 
 
The potential for reporting of errors to tarnish working relationships with 
prescribers has been reported previously (Ross et al. 2013a).  Pharmacists 
did not want their only prescriber discussions to be about PEs with 
thresholds for delivering PE feedback proposed. These are sensible 
recommendations and reflect the design of the feedback intervention 
described in chapter 3. 
 
Additionally, apprehensions reported by some pharmacists may have been 
grounded in previous experiences of prescribers dismissing their comments 
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or feedback.  Similar outcomes have been reported previously in primary 
care settings (Avery et al. 2012) with feelings of frustration and isolation 
reported by pharmacists, where their input was dismissed or received 
defensively by GPs.   
 
Pharmacists considered themselves credible facilitators of PE feedback 
echoing reports elsewhere (Bertels et al. 2013).  Effective feedback is 
influenced by whether the facilitator is a colleague (Ivers et al. 2012), has 
observed practice and if it is delivered as part of everyday practice (Cantillon 
and Sargeant 2008).  This can increase motivational behaviour (Gordon and 
Bose-Haider 2012) and supports the results reported in this chapter that 
ward-based pharmacists in particular are best suited to deliver PE feedback, 
where they review and intercept PEs at ward level.  Pharmacists have been 
highlighted as a ‘main defence’ in intercepting PEs (Franklin et al. 2011), 
whilst junior doctors have reported anticipating pharmacists would intercept 
their PEs (Ross et al. 2012).  Pharmacists reported similar views in this study 
and if interception of PEs is accepted practice of a pharmacist, then PE 
feedback could be a logical extension of their practice. 
 
There were wide variations in how PEs were communicated with prescribers 
with the prescriber not always made aware of their error. These are missed 
learning opportunities and it could be argued that there is an element of wilful 
neglect where the error recurs and a patient is harmed.  Poor communication 
between health care professionals is considered a contributing factor 
towards MEs (Dean et al. 2002).    
 
In this chapter, pharmacists reported some apprehensions in approaching 
prescribers, a “communication apprehension” described in the literature as 
“… fear or anxiety associated with either real or anticipated communication 
with another person or persons.” (McCroskey 1984)”.  An earlier study 
(Baldwin, McCroskey and Knutson 1979) suggested that 30% of pharmacists 
seek to avoid communication whenever possible.  More recently, 
pharmacists have been described as aloof (Elvey et al. 2013) or perceived 
as having poor social skills (Hean et al. 2006).  Such perceptions may be 
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less to do with pharmacist communication skills, and more to do with role-
awareness, with pharmacists suggested as anonymous characters 
elsewhere (Elvey et al. 2013).  Where pharmacists are communicating via 
post-it notes, the medication chart or even primarily in the clinical notes, 
there is a risk of them being perceived as anonymous.  Equally, if PE 
feedback can change pharmacist-prescriber interactions, then perceptions of 
pharmacists may change. 
 
Delivery of constructive feedback is a skill and one that requires training.  In 
this chapter, pharmacists have expressed unpreparedness to deliver 
feedback despite, in some cases, being in educational and management 
roles.  These views may have been influenced by the limited training 
reported in communicating with prescribers.  Pharmacy is a science-based 
discipline with pharmacy graduates typically not engaging with doctors until 
their pre-registration year (See chapter 1).  The need for enhanced 
communication skills training for pharmacy students has been outlined 
previously (Smith and Darracott 2011). 
 
The NHS is about people, and people are prone to human error.  
Interpersonal communication is an essential skill for pharmacists 
(Wiedenmayer et al. 2006, Mackellar et al. 2007) to correct and resolve PEs, 
with one report outlining that pharmacists “must be knowledgeable and 
confident while interacting with other health professionals.” (WHO 1997). 
 
Good communication is a prerequisite for safe prescribing (Routledge 2012) 
and if pharmacists are to be used as PE feedback facilitators, training should 
be provided to improve the quality of feedback and enhance pharmacist– 
prescriber interactions. Bangert-Drowns et al. (1991) suggest that feedback 
can ‘promote learning if it is received mindfully, but it can inhibit learning if it 
encourages mindlessness’, iterating the importance facilitator skills.  
 
Facilitator training for the research in this thesis is described in chapter 3.  
The training was designed to provide pharmacists with the skills, confidence 
and self-efficacy to communicate clear and objective PE feedback: skills that 
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can drive further feedback-seeking behaviour (Bok et al. 2013). 
 
Feedback should be timely for accurate memory recall and reflection, with 
feedback closer to the time of the incident having a greater impact on 
individuals (Hysong et al. 2006).  Ivers et al. (2012) suggest that feedback 
should be within one month for performance feedback.  However, given the 
daily volume and frequency of prescriptions, it would seem logical that more 
timely feedback would be prudent with pharmacists suggesting less than a 
week for feedback to be effective.  This supports recommendations in the 
literature that feedback closer to the time of the incident has a greater impact 
on the individual (Schramm et al. 2011, Jacques et al. 2011) and should be a 
gold standard for successful feedback (Hysong et al. 2006).  
 
Individualized feedback, delivered face-to-face can allow clarification of any 
feedback points, creating a more social interaction and “a full circle of shared 
responsibility” (Sullivan et al. 2013).   Furthermore, feedback that is specific 
and targeted is considered more effective (Ivers et al. 2012), supporting the 
need for individualization of feedback as reported in this chapter.  
 
Constructive feedback is an educational process, a clear non-punitive 
approach endorsed in the literature (Hysong et al. 2006) to make feedback 
actionable.  In this chapter, incident reporting was considered punitive and 
inappropriate for feedback with potential to create tensions between 
professionals. Comparable inter-professional tensions from reporting of 
errors via formal systems has been reported previously (Williams et al. 
2013), with pharmacists preferring to speak to a doctor as opposed to 
completing an incident form, views shared by participants in this chapter. 
 
Pharmacists were divided on the need for positive feedback.  The need for 
positive feedback is likely influenced by whether individuals have a 
performance-oriented behaviour or learning- oriented behaviour (Hysong et 
al. 2006, Kluger and DeNisi 1996),  underscoring the need for a flexible 
approach to feedback delivery.  Equally, systematic reviews (Ivers et al. 
2012) suggest that feedback aimed at reducing behaviours (i.e. prescribing 
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errors) are more effective than those aimed at improving a behaviour. 
 
4.6. Implications for this research 
 
The focus groups have showed that there are inconsistencies in what, if any, 
feedback was provided on PEs supporting the need for a more formalised, 
constructive and consistent approach to feedback as described in this thesis. 
  
Pharmacists believe that they are credible facilitators of PE feedback and 
would value a more formal approach to PE feedback in STHKH.  Importantly, 
pharmacists expressed a willingness to deliver more feedback to prescribers. 
 
Pharmacists proposed that PE feedback should be individualised, timely and 
delivered by a ward-based pharmacist who works with the prescriber who 
has made any error. These recommendations are consistent with empirical 
evidence as described in chapter 2. 
 
Positive feedback is desirable and has informed the feedback intervention 
with opportunity for positive feedback when delivered for overall prescribing 
as described in chapter 3. 
 
There were some anxieties reported over delivering formalised feedback. 
This supports the need for training of pharmacists in delivery of feedback to 
mitigate apprehensions and raising awareness of prescribers to the initiative.  
An overview of facilitator training is described in chapter 3.  The results of the 
pilot study and prescriber views will be presented to the pharmacists as early 
as possible to further raise the awareness of any benefits and value of the 
process. 
 
4.7. Strengths and Limitations 
 
This qualitative study has presented the in-depth views of pharmacist 
practices for providing feedback PEs. It is the first known research drawing 
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exclusively on this methodology to contribute to what little is known on the 
subject. 
 
This is a case study involving the opinions of individual pharmacists in a 
single setting.  Therefore, results cannot be generalised although as 
described in chapter 1, STHKH is a typical large acute hospital with a 
standard hospital pharmacy service and so the findings will be of relevance 
and most likely applicable to similar organisations.   Equally, the purpose of 
the study was to determine the views of pharmacists in STHKH prior to 
implementing formal feedback, and this has been achieved. 
 
Participant numbers could be considered small although they are consistent 
with recommendations in the literature (Fowler 2009 and Neale 2009) for 
data saturation.  
 
The author knew the pharmacists involved in a professional capacity and it is 
possible that this may have influenced their responses.  The author was 
aware of these risks and maintained objectivity throughout and encouraged 
all participants to express their views.  Additionally, follow-on questions from 
the author allowed clarification of pharmacist responses although such 
‘member checking’ (Shenton 2004) was used reservedly to limit disruption of 
the group discussion. 
 
The range of pharmacist grade and experience in each group was 
considered a strength, although it is possible that more junior pharmacists 
were unwilling to challenge more senior pharmacist views.  Such ‘social 
desirability’ bias may adversely influence the trustworthiness of data 
(Shenton 2004), a limitation the author was aware of.  To mitigate this, more 
junior staff were sat facing and less experienced staff sat to the side of the 
author to allow more direct engagement of junior staff. 
 
Finally, coding is a subjective and interpretive experience and it is possible 
that the author has not identified or interpreted inferences from the data 
accurately or completely.  However, this risk was mitigated by the author 
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having previous experience of qualitative research and second coding by the 
research team (SDW and SVOB).   
 
4.8.  Chapter Summary 
 
A key aim of these focus groups was to understand the experiences of 
hospital pharmacists of delivering feedback on PEs.  This chapter has 
presented participant details, qualitative data collection, and analysis 
methods and results. 
 
The results reported in this chapter suggest that feedback practices are 
currently inconsistent and informal.  Pharmacists would value and welcome a 
more formalised approach and outlined potential benefits for patient safety 
and working practices.  Potential barriers to the process were outlined 
including workload and time pressures, prescriber response and lack of 
training. 
 
Notable apprehensions concerning the process included potential adverse 
effects on prescriber relationships.  The need for facilitator training was 
outlined and could help to mitigate these apprehensions. 
 
Chapter 5 will now explore the impact of PE feedback on PE rates in a pilot 
study. 
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Chapter 5. Feasibility study 
 
5.1. Introduction 
 
This chapter reports the impact of feedback on PEs to provide insight into the 
primary research question: 
 
What is the impact of feedback on prescribing error rates? 
 
Where the hypothesis described in chapter 3 was: 
 
H1: “There is a difference in mean change in prescribing error rate 
between the intervention and control group” 
 
Whilst this is an initial pilot study over four hospital wards, it explores the 
potential impact of feedback to inform if the intervention can be effective and 
support the need for larger studies.  It will also contribute to what little is 
known on the subject in hospital settings as described in chapter 2.  An 
overview of data collection and analysis will be described followed by 
presentation of the results.  A combination of descriptive and inferential 
statistics are used to determine if there is a statistically significant difference 
in change in PE rates between groups following delivery of feedback.  The 
chapter will then conclude with a discussion of findings and a chapter 
summary. 
 
5.1.1. Sample size 
 
Four wards were audited, two with doctors receiving feedback (intervention 
wards) and two wards with existing practice (control wards).  Choice of wards 
were negotiated with the clinical pharmacy services manager in advance as 
data collection and delivery of feedback would impact on pharmacy service.  
All wards were medical and similar sized, with comparable prescriber 
numbers and grades (Table 7), and patient turnover (See table 8).   
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Table 7: Number of each prescriber grade included in intervention and 
control group analysis 
Prescriber 
grade a 
Number 
Intervention Control 
FY1 4 4 
FY2 1 2 
CT/ST 3 4 
Consultant 2 2 
Total 10 12 
a See chapter 1 for an overview of prescriber grades  
 
Table 8: Ward characteristics for control and intervention groups 
Ward Ward type Number 
of beds 
Approximate patient 
turnover 
(patients per week) 
Intervention Control 
1 Medical Medical 32 40-50 
2 Medical Medical 32 60-80 
3 Medical Medical 32 50-60 
4 Medical Medical 32 40-50 
 
A total of 22 prescribers were included, with 10 in the intervention group and 
12 in the control group.  Prescribers were included in data analysis if they 
had prescribing data at both baseline and post-intervention.  In addition, 
prescribers on the intervention ward had to have received feedback at least 
once from a ward-based pharmacist to be included.  This was confirmed by 
checking for evidence of a completed feedback form in the secure electronic 
folder in pharmacy.  Prescriber details are presented in table 9. 
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Table 9: Prescriber and ward characteristics for intervention (feedback) 
and control (normal practice) groups 
 
Prescriber Grade Gender Intervention 
or control 
group 
Ward Ward 
type 
Number 
of 
feedback 
sessions 
(including 
overall) 
1 FY1 Female Intervention 2 Medical 11 
2 FY1 Female Intervention 2 Medical 10 
3 FY1 Female Intervention 1 Medical 5 
4 FY1 Female Intervention 1 Medical 8 
5 FY2 Female  Intervention 2  Medical 4 
6 CT2 Female  Intervention 1 Medical 12 
7 CT1 Female  Intervention 2 Medical 9 
8 ST3 Male Intervention 1 Medical 3 
9 Consultant Male Intervention 1 Medical 2 
10 Consultant Male Intervention 2 Medical 2 
11 ST7 Male Intervention 2 Medical 0 
12 FY1 Male Control 3 Medical  0 
13 FY1 Female Control 3 Medical 0 
14 FY2 Female Control 3 Medical 0 
15 CT1 Male Control 3 Medical 0 
16 CT4 Male Control 3 Medical 0 
17 Consultant Male Control 3 Medical 0 
18 Consultant Male Control 3 Medical 0 
19 FY1 Female Control 4 Medical  0 
20 FY1 Male Control 4 Medical 0 
21 FY2 Female Control 4 Medical 0 
22 CT1 Female Control 4 Medical 0 
23 CT2 Female Control 4 Medical 0 
 
5.1.2.  Data collection 
 
Pharmacists were trained in data collection methods beforehand as 
described in chapter 3.  Additionally, pharmacists on the intervention wards 
were trained in delivery of constructive feedback as described in chapter 3. 
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Pre-intervention data was collected over five consecutive days in September 
2014.  Pharmacists collected prescribing data prospectively recording: ward 
area, prescriber name, number of items prescribed and, where identified, the 
number, type and severity of PEs.   Prescribing data was collected using the 
proforma in appendix 16.  
 
Following data collection, ward pharmacists prepared prescribing feedback 
reports to deliver feedback on overall prescribing to prescribers based on 
their wards.  This was followed by further feedback on any PE where the 
severity was classified as significant or greater (See appendix 17).  This 
process continued for a period of 3 months before re-auditing over a further 
five consecutive days in December 2014. 
 
One doctor, prescriber number 11, was excluded from data analysis as they 
had not prescribed any medications in the post-intervention period for 
comparison of PE data.   
 
5.1.3. Data analysis  
 
All data from pre-test and post-test audit periods was inputted into SPSS 
v.22 for data analysis.  PE rate was calculated by dividing total errors by total 
number of items. Error free prescription and prescribing error rates were 
calculated as described in chapter 3. 
 
Results were calculated for the mean PE rate with standard deviation and 
95% confidence intervals reported.  As discussed in chapter 3, chi-squared 
tests were used to compare error frequencies at the prescription level 
between and within groups.  Independent t-tests were used to determine the 
impact on PE rates (continuous data) at the prescriber level between groups. 
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5.2. Results 
 
5.2.1. Impact of feedback on overall prescription error rates 
 
A summary of overall prescribing data for control and intervention groups is 
summarized in table 10 and figures 10-12 below.   
 
5.2.1.1 Pre-test prescribing data 
 
A total of 303 prescriptions were audited, 170 of which were error free 
(56.1%), with 1292 items prescribed and 244 PEs identified, an overall PE 
rate of 18.9%. 
 
There were 149 prescriptions in the intervention group, with 81 error free 
(54.4%).  There were 641 prescribed items with 123 PEs (figure 10), an 
overall PE rate of 19.2%. 
 
There were 154 prescriptions in the control group, with 89 error free (57.8%). 
There were 651 prescribed items with 121 PEs (figure 11), an overall 
prescribing error rate of 18.6%. 
 
5.2.1.2 Post-test prescribing data 
 
A total of 376 prescriptions were audited, with 204 error free (54.3%).  There 
were 2664 prescribed items and 329 prescribing errors identified, an overall 
prescribing error rate of 12.4%. 
 
There were 211 prescriptions in the intervention group, with 141 error free 
(66.8%).  There were 1677 prescribed items with 90 PEs (figure 10), an 
overall PE rate of 5.4%. 
 
There were 165 prescriptions in the control group, with 63 error free (38.2%).  
There were 987 prescribed items and 239 PEs (figure 11), an overall PE rate 
of 24.2%.  
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Table 10:  Overview of prescribing error data for overall prescribing in 
intervention and control groups  
Group Pre-
items 
Pre-
errors 
Pre-
error 
rate % 
Post-
items 
Post 
errors 
Post-
error 
rate 
(%) 
Difference 
in error 
rate 
Pre - post 
Chi-
square 
and p-
value 
Intervention  641 123 19.2% 1677 90 5.4% -13.8% χ2(1) = 
83.8, 
<0.005, 
φ = 
0.182 
Control 651 121 18.6% 987 239 24.2% 5.6% χ2(1) = 
4.7, 
p=0.03, 
φ = -
0.048 
Total 1292 244 18.9% 2664 329 12.3% -6.6%  
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Figure 10: Bar chart illustrating prescribed items and errors for the 
intervention group before and after the intervention period 
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Figure 11: Bar chart illustrating prescribed items and prescribing errors 
for the control group before and after the intervention period 
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Figure 12: Bar chart illustrating prescribed items and prescribing errors 
for the intervention and control groups pre-intervention 
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Figure 13: Bar chart illustrating prescribed items and errors for the 
intervention and control groups post-intervention 
 
 
5.2.2. Impact on overall prescription error rate 
 
Descriptive statistics indicate that the PE rate changed between pre- and 
post-intervention with a mean reduction in the intervention group and a mean 
increase in the control group.  Frequency of errors pre- and post-intervention 
were compared using the chi squared test.  Here the null hypothesis is; 
 
H0: There is no difference in the frequency of prescribing errors 
within/between groups 
 
Assumptions of the chi-squared test include independence of observations, 
categorical data (i.e. group and error occurrence) and that all expected cell 
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counts are greater than five as described in chapter 3.  In this chapter, all 
reported chi-squared tests had cell counts greater than five.  
 
At baseline (figure 12), there was no statistically significant association 
between error frequency and group (intervention or control), χ2(1) = 0.052, p 
= 0.819, φ = 0.06.  Therefore, the null hypothesis is accepted, error 
frequency did not differ between groups at baseline.  
 
Post intervention (figure 13), there was a statistically significant association 
between group and frequency of prescribing errors, χ2(1) = 153.4, p = 
<0.005, φ = -0.226.  Therefore, the null hypothesis is rejected, error 
frequency did differ between groups post-intervention. 
 
Within group analysis suggested there was a statistically significant 
association between error frequency and pre-post testing for both 
intervention (χ2(1) = 83.8, p = <0.005, φ =0.182) and control groups (χ2(1) = 
4.7, p = 0.030, φ =-0.048).  Therefore, the null hypothesis is rejected, error 
frequency did differ within groups following the intervention period. 
 
Whilst these results indicate that there is a difference between the two 
groups following delivery of feedback, the primary research question is 
concerned with determining if there is a difference in the mean change in PE 
rates between the two groups.  Independent t-tests were used to determine 
this as outlined below.   
 
5.2.3. Impact on error free prescriptions 
 
Similar results were reported for error free prescriptions.  There was no 
significant difference between groups at baseline (χ2(1) =0.102, p=0.75, φ =-
0.015) with a significant difference reported post-intervention (χ2(1) =9.37, 
p=0.0022, φ =0.127).   
 
Within group analysis suggested a significant difference in error free 
prescriptions post intervention for the control group (χ2(1) =4.353, p=0.037, φ 
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=0.096), although there was a non-significant difference in the intervention 
group (χ2(1) =1.381, p=0.240, φ = -0.049). 
 
5.2.4. Impact on overall prescriber error rate 
 
A summary of overall prescribing data with the prescriber as the unit of 
analysis for both control and intervention groups at baseline and post-test is 
summarized in table 11 below.   
 
Change scores were calculated by determining the difference between post-
intervention PE rates and pre-intervention PE rates. This allowed comparison 
of the mean change in PE rates. 
 
An independent t-test can be used to test the null hypothesis: 
 
H0: There is no difference in the mean change in prescribing error 
rates between the intervention and control groups following delivery of 
feedback to the intervention group 
 
Population sample 
 
Ten prescribers were included in the intervention group, one prescriber 
(number 11) was excluded as post-intervention prescribing data was not 
available for comparison.  
 
Mean baseline PE rates were 23.1% (SD 18.0%, 95% CI 10.3 to 36.0) and 
11.6% (SD 15.6, 95% CI 0.4 to 22.8) post intervention.  
 
There was a mean reduction in PE rate in the intervention group of 11.5% 
(SD 13.0, 95% CI -20.8 to –2.3).   
 
Eleven prescribers were included in the control group (one excluded as an 
extreme outlier).   Mean baseline PE rates were 17.7% (SD 9.2%, 95% CI 
11.5 to 23.8) and 23.5 % (SD 6.2, 95% CI 19.4 to 27.7) post intervention.  
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There was a mean increase in PE rate in the control group of 5.9% (SD 8.4, 
95% CI 0.27 to 11.5).  
 
Table 11: Overall prescribing data per prescriber for control and 
intervention groups 
Prescriber Pre-
items 
Pre-
errors 
Pre-
error 
rate% 
Post-
items 
Post 
errors 
Post-
error 
rate 
(%) 
Change 
score 
(%) 
1 82 7 8.5 568 27 4.8 -3.7 
2 188 39 20.7 279 12 4.30 -16.4 
3 4 1 25 193 7 3.63 -21.4 
4 126 23 18.3 121 7 5.8 -12.5 
5 34 4 11.8 210 7 3.3 -8.5 
6 143 32 22.4 161 12 7.5 -14.9 
7 57 14 24.6 119 7 5.9 -18.7 
8 1 0 0 1 0 0 0 
9 3 2 66.7 6 2 33.3 -33.4 
10 3 1 33.3 19 9 47.4 14.1 
11 17 9 52.9 n/a n/a n/a n/a 
12 60 6 10 36 3 8.3 -1.7 
13 69 11 15.9 194 43 22.2 6.3 
14 151 35 23.2 91 21 23.1 -0.1 
15 85 15 17.7 131 26 19.6 2.1 
16 49 5 10.2 50 15 30 19.8 
17 * 2 0 0 3 3 100 100 
18 1 0 0 5 1 20 20 
19 50 15 30 95 26 27.4 -2.6 
20 83 15 18.1 55 14 25.5 7.4 
21 19 6 31.6 117 32 27.4 -4.2 
22 13 3 23.1 46 14 30.4 7.4 
23 69 10 14.5 164 41 25 10.5 
Total 1292 244  2664 329   
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* Prescriber 17 was excluded from analysis as they were an extreme outlier 
affecting distribution of data as discussed below. 
 
5.2.4.1.  Independent t-test assumption testing 
 
As described in chapter 3, various assumptions must be met to determine if 
the data is suitable for performing independent t-tests.  These assumptions 
are normality of distribution, absence of outliers and homogeneity of 
variance. 
 
Shapiro-Wilk tests suggest normality of distribution with a p-value >0.05 for 
the intervention group (p=0.946) and non-normality for the control group 
(p=0.000081).  However, inspection of the histogram (Figure 14) suggests an 
approximated normality for the control group. Inspection of the normality 
plots (Figures 15 and 16) also suggested an approximated normality with 
one severe residual departing below the normal line influencing non-
normality. This was further supported by inspection of the box plot (Figure 
17) suggesting one extreme outlier (prescriber 17) in the control group. 
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Figure 14:  Histogram of distribution of change scores for overall 
prescribing in control and intervention groups 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 147 
Figure 15: Probability plot for change in overall prescribing error rates 
for the intervention group 
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Figure 16: Probability plot for change in overall prescribing error rates 
for the control group 
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Figure 17: Boxplot for change in prescribing error rates for overall 
prescribing 
 
Whilst t-tests are robust to deviations in normality and outliers as discussed 
in chapter 3, the analysis was performed without the outlier (prescriber 17) 
before attempting further data manipulation such as data transformation for 
skewed data. 
 
Eleven prescribers were therefore included in the control group.   The 
adjusted mean change in PE rate in the control group without the outlier was 
an increase of 5.9% (SD +/-8.4, 95% CI 0.3 to 11.5).   
 
Removal of prescriber 17 (data point 16) revealed a normal distribution with 
Shapiro-Wilk values of 0.946 for the intervention and 0.221 for the control 
groups. 
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This was supported by inspection of the histogram (Figure 18) below whilst 
the probability plot (see figure 19) revealed a normal distribution with a few 
residuals above and below the normality line.  No outliers were identified 
from inspection of the revised box plot (see figure 20 below). 
 
Therefore, initial assumption testing was satisfied and the t-test performed.  
A sensitivity test can be performed to compare outcomes with and without 
the outlier.   
 
Figure 18:  Histogram of distribution of change scores for overall 
prescribing in control and intervention groups without the identified 
outlier 
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Figure 19: Probability plot for change in overall prescribing error rates 
for the control group without identified outlier 
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Figure 20: Boxplot for change in prescribing error rates for overall 
prescribing without identified outlier 
 
 
Homogeneity of variance 
 
Homogeneity of variances was demonstrated by Levene’s tests (p>0.05 at 
0.3) and this assumption was met.   
 
5.2.4.2. Independent t-test results for prescribing error rates 
 
PE rates were statistically significantly lower in the intervention group 
compared to the control group.  Mean difference of 17.4% (SD 4.7, 95% CI, -
27.3 to –7.6), t(19) = -3.694, p<0.05 (0.00154), effect size (d) = 1.60 (large).  
Therefore, the null hypothesis is rejected, mean change in PE rates do differ 
following delivery of PE feedback.  
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Removal of outliers for overall prescribing  
 
The t-test was also performed with the outlier (prescriber number 17). 
 
There was homogeneity of variances as demonstrated by Levene’s score 
>0.05 (0.374).  Mean difference as determined by the independent t-test was 
statistically significant favouring the intervention group with a mean 
difference of -25.28% (SD 9.73, 95% CI = -45.58 to -4.97)  t(20) = -2.597, 
p<0.05 (0.017242).  Results were still significant justifying exclusion of the 
outlier. 
 
5.3. Summary of results  
 
PE rates have been reported for intervention and control groups pre- and 
post-intervention.  Baseline PE frequencies were similar between groups 
(p=0.819) with significant differences post-intervention within and between 
groups.  Prescribing error frequencies were significantly lower for the 
intervention, and significantly higher for the control group following the 
intervention period.  Comparing mean change in PE rates between groups, 
PE rates were statistically, significantly lower, in the intervention group 
compared to the control group with a mean difference of 17.4% (p<0.05). 
 
 
5.4. Chapter discussion 
 
As this is a pilot study, it is not the intention of the author to discuss the 
results of this chapter in detail as this area will be revisited and discussed 
further in chapter 7.  Instead, a brief overview will be presented followed by 
consideration of potential limitations of the research presented in this 
chapter.   
 
The results of this chapter suggest that PE feedback can positively influence 
prescribing. Whilst this is a pilot study with relatively small numbers of 
prescribers, the results are promising. 
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PE rates are comparable to those published elsewhere (Franklin et al. 2011, 
Reynolds et al. 2016) although they are higher than the average reported in 
the seminal EQUIP study (Dornan et al. 2009).  The PE rate increased in the 
control group, increasing the size of change in PE rates between groups.  
This could be explained by a lack of feedback and awareness of PEs, whilst 
it is possible that local prescribing etiquette could lead to suboptimal 
prescribing becoming routine or acceptable practice (Charani et al. 2013, 
Mattick et al. 2014, McLellan et al. 2016). 
 
Empirically, feedback is suggested to have small to moderate effects on 
practice (Ivers et al. 2014).  In this chapter, the effect size was reported as 
large.  This could be related to the higher than average (Dornan et al. 2009) 
PE rates with Ivers et al. (2012) suggesting that feedback is most effective 
when “the health professionals are not performing well to start out with”.  
Indeed, if this is a tenet of feedback outcomes, then one might expect 
greater reductions from prescribers who are performing below average than 
those who are performing above average. 
 
Lack of feedback on PEs could be considered a latent error with prescribers 
reporting minimal feedback on their prescribing previously (Dornan et al. 
2009, Dean et al. 2002, Mattick et al. 2014).  Feedback has been identified 
as a priority in clinical settings for developing appropriate diagnostic decision 
making (Elstein 2009).  Given prescribing is a clinical skill, such outcomes 
could translate to prescribing (Mattick et al. 2014).  The need for delivery, or 
active seeking of constructive feedback to inform and educate prescribing 
competency is advocated in best prescribing principles (Lum et al. 2013, 
Likic and Maxwell 2009) and the results of this chapter support this 
recommendation. 
 
The results from this chapter suggest that a feedback intervention, designed 
to reflect the principles of effective feedback, can improve prescribing 
practice.  These results can be used to motivate pharmacists to deliver 
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further feedback, demonstrating the impact of their efforts and endeavours, 
whilst supporting the wider application of the intervention across STHKH. 
 
Whilst the results suggest the intervention can reduce PE rates, it is 
unknown if the results are reproducible.  Unintended consequences may 
have influenced prescribing.  Prescribers were not aware of the audit 
periods, although the intervention group were aware that they would receive 
feedback, potentially creating a ‘Hawthorne effect’ where participants 
perform better as a result of change or being singled out, and so not 
necessarily as a result of the intervention (Franke and Kaul 1978).  A 
feedback avoidance (Bok et al. 2013, Teunissen et al. 2009) has also been 
reported elsewhere with prescribers more engaged with prescribing to avoid 
any negative judgements.  Considering this, it is unknown if it is the feedback 
or another outcome of the feedback process, that has influenced prescribing 
practice.  This theme will be revisited in chapters 7 and 8. 
 
Error causation is complex and it is unknown if the potential for harm is 
reduced from latent conditions or error provoking factors, or from sterilisation 
of the prescribing process where these conditions are managed.  The impact 
on the facilitators and recipients of feedback is also unknown and these 
themes will be explored in later chapters.  In the previous chapter, 
pharmacists expressed anxieties over the process pre-intervention and 
questioned the value of the feedback, and it is unknown if these concerns 
have manifested with the service delivery.  To this end, further qualitative 
studies will explore the impact on prescribers, pharmacists and prescriber 
behaviour in chapters 6, 8 and 9 respectively. 
 
5.5. Limitations  
 
The study presented in this chapter is not without limitations.  The ward 
characteristics do not reflect the mixed ecology of a large district general 
hospital.  The pilot wards were homogeneous and did not include surgical, 
admissions, acute areas or care of the elderly wards for example.  
Considering this, it is unknown if the same effect can be reproduced or 
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replicated elsewhere although the ward areas used in this chapter represent 
a range of pharmacists, prescribers and prescribing situations encountered 
on any typical ward.  Equally, it is unknown if pharmacists could deliver 
feedback to a larger cohort of prescribers across the entire organization.  
However, given clinical pharmacy ward services are comparable across the 
hospital; this should not be a significant barrier. 
 
Participants were non-randomized.  This study design and the reported 
outcomes may therefore be influenced by other unknown factors such as 
local induction, education, working practices or prescribing culture affecting 
internal validity.  That said, wards were matched for size, number of doctors 
with comparable grade distribution and expected turnover of patients to limit 
such bias, although the potential impact of social or environmental 
differences cannot be discounted.  Equally, the possibility of a ‘Hawthorne 
effect’ influencing the intervention group cannot be discounted, and makes 
interpretation of the true effect of the feedback intervention uncertain. 
 
Despite wards having similar activity for patient turnover, there was a 
disparency between prescribed items reviewed post-intervention for 
intervention (1677) and control (987) groups.  The number of items was also 
greater than that collected at baseline, and it could be that pharmacists 
collecting data were more motivated in the intervention group because of 
delivering feedback.  Equally, there may have been variances in patient 
turnover between audit periods although wards were matched for size and 
turnover.  Whilst this could potentially influence results, it should also be 
acknowledged that the control group still had over twice as many errors 
whilst the combined descriptive and inferential statistics demonstrated 
statistically significant reduction in PEs.   
 
Additionally, the results of this chapter have not specifically reviewed the 
impact of feedback on different prescriber grades, stage of prescription (for 
example inpatient or discharge prescribing) error severity or error type.  
Equally however, this was not the true raison d’etre of this chapter: the 
purpose was exploratory to determine if feedback was effective.  The results 
 157 
have answered this question and informed the need for a larger cohort study 
that will be presented in chapter 7 with further in-depth analyses. 
 
Finally, feedback should be a social exercise, co-constructed between 
facilitator and recipient.  Results in this chapter indicate PE feedback can be 
effective but the impact on prescribers and pharmacists, and the reasons for 
changes in prescribing behaviour have not been illuminated and will be 
explored in later chapters.   
 
5.6. Chapter Summary 
 
This chapter has presented the results of a pilot study exploring the impact of 
a feedback intervention on prescribing, and contributes to what little is known 
in this subject field.  Statistically significant reductions in PE rates were 
reported following the intervention period, although further research is 
necessary to explore why these changes occurred and if they are 
reproducible.  There is promise for wider application in STHKH and similar 
settings in the NHS. The following chapter will return to qualitative 
methodology to explore prescriber views of receiving feedback to understand 
the impact of the process at the individual prescriber level. 
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Chapter 6.  Prescriber experiences of, and attitudes towards receiving 
prescribing error feedback 
 
6.1. Chapter introduction 
 
This chapter describes the experiences, opinions and views of ten doctors 
towards receiving formalised PE feedback.  Little is known on this subject as 
described in chapter 2.  Semi-structured interviews are used to explore these 
views in-depth in this chapter.   
 
The primary research aim of this chapter was to: 
 
Explore and determine prescribers’ experiences of receiving 
formalised prescribing error feedback 
 
An overview of the interview process will first be described followed by 
analysis of the data with relevant comments to illustrate the results.  Six key 
themes are reported from analysis of the interviews and are used to present 
prescribers’ experiences of the feedback intervention.  This will be followed 
by a discussion and summary of the findings. 
 
6.2. Semi-structured interviews 
 
Semi-structured interviews were used to elicit the in-depth views of 
participants as described in chapter 3.  Prescribers were recruited as 
described in chapter 3 with pharmacists providing participant information 
sheets to prescribers (Appendix 9).  Where prescribers expressed an interest 
to participate, a follow up e-mail (Appendix 11) was sent by the author.  
Eleven prescribers were eligible to participate where they had received 
formalised feedback from a pharmacist at least once during the pilot study in 
chapter 5.  Interviews took place between October and December 2014.   
 
Prescriber interviews were undertaken in a private location either in an 
interview room on their ward, in their office, or an interview room in pharmacy 
at a time to suit them.  All pagers / mobile phones were turned off to prevent 
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interruption where possible.  For junior staff, consultants and ward managers 
were informed of the interview time to limit potential disruptions.   
 
The purpose of the interview was covered prior to commencing the interview 
and both verbal and written consent obtained.  A topic guide (Appendix 3) 
was used to explore key themes whilst ensuring consistent issues were 
discussed.  The semi-structured interview approach allowed further follow-up 
questions to clarify and expand on prescriber responses as described in 
chapter 3.   Interview duration ranged from 18 minutes to 34 minutes (Table 
12). 
 
6.3. Data analysis  
 
All interviews were digitally recorded and transcribed verbatim by the author, 
except to anonymise person and place names. Interviews took an average of 
2 hours to transcribe. 
  
The author listened, re-listened, read and re-read the transcripts to correct 
any typographical errors and for early immersion in the data.  Electronic 
copies of the transcripts were forwarded to the research supervisors (SW 
and SOB) for independent analysis.  Transcripts were discussed with the 
research supervisors and emergent codes and themes compared and 
contrasted.  Data saturation (See chapter 3) was considered achieved by 
interview 7. 
 
Interviews were coded manually line-by-line and analysed thematically using 
the framework approach as described in chapter 3.    Emergent codes were 
informed by the topic guide and the author’s understanding of the literature.  
Further codes emerged from the participant interviews that were not 
predicted including ‘raised discretionary effort’, ‘patient context’, ‘hierarchy’ 
and ‘information seeking behaviour’.  Codes were sorted into similar 
contextual themes and discussed at regular meetings with the PhD 
supervisors.   Any discrepancies were resolved through discussion for an 
analytical consensus.  The initial framework (Appendix 23) was applied to the 
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transcripts and refined with each interview and successive rounds of coding 
to produce a final thematic framework (Table 13).  Relevant quotes were 
then copied and pasted into the framework for analysis and interpretation.   
 
6.4. Results 
 
Ten prescribers (seven female, three male) were recruited with a range of 
prescriber grades.  Prescriber grade ranged from FY1 to consultant, 
reflecting the distribution of personnel on the ward.  For anonymity, each 
prescriber is identified by a unique code, R1-R10 (Table 12).  All training 
grade prescribers, who prescribe most prescriptions, were interviewed 
except for one who was unavailable during the recruitment phase.  
 
Table 12: Participant information recruited for interview a 
Prescriber 
number 
Participant 
code 
Gender Prescriber 
grade 
Interview 
duration  
1 R1 Male ST  24 mins 
2 R2 Female FY1  31 mins 
3 R3 Female FY1  24 mins 
4 R4 Female FY2  21 mins 
5 R5 Female FY1  34 mins 
6 R6 Male Consultant  20 mins 
7 R7 Female CT  24 mins 
8 R8 Male Consultant  17 mins 
9 R9 Female CT  29 mins  
10 R10 Female FY1  19 mins  
a see chapter 1 for an overview of each grade 
 
The final thematic framework included six major themes and secondary 
codes (see table 13).  The results are summarised under these key themes 
below. Example quotations to illustrate the results were chosen by the author 
and agreed with the supervisory team (SDW and SVOB) beforehand. 
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Table 13: Thematic framework for prescriber interviews  
Theme Code 
1. Feedback process Impact of feedback 
Formal vs. informal 
Non-intrusive process 
Proforma 
Error severity 
Timely feedback 
Prescriber grade 
Correction vs. feedback 
Prescription stage 
 
2. Work environment Time pressures 
Location 
Pharmacy service 
No-blame culture 
Prescriber identification 
Out of hours 
 
3. Feedback facilitator  Recognised role 
Expert knowledge 
Rapport 
Patient context 
Error interpretation 
Hierarchy 
Communication of error 
Teamwork 
 
4. Education and learning Educational process 
Positive vs. negative 
Constructive feedback 
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Theme Code 
Personal development 
Reflective practice 
Portfolio 
 
5. Prescriber impact Error awareness 
Error reduction 
Discretionary effort 
Information seeking behaviour 
Feedback seeking behaviour 
Emotional Impact 
Time Saving 
 
6. System improvement Trust-wide process 
Protected time 
Evidence of error 
Electronic feedback 
Shared Learning  
Learning Aids 
Induction 
 
The results will now be discussed under the following key themes; 
 
1. Feedback process 
2. Work environment 
3. Feedback facilitator 
4. Education and learning 
5. Prescriber impact 
6. System improvement 
 
In general, all prescribers engaged openly, discussing the feedback process 
and the impact on themselves.  Further probing or question clarification was 
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required compared to focus groups interviews but this reflects the one-to-one 
nature of interviews. 
 
All prescribers were effusive about the feedback process, proposing only one 
limitation: whether the process was sustainable for the pharmacists involved.  
All prescribers agreed that everyone should receive feedback on their 
prescribing although the consultants felt that it was more relevant for junior 
grades who were in training posts. 
 
6.4.1. Feedback process 
 
Nine codes were identified within this category:  impact of feedback, formal 
vs. informal, non-intrusive, proforma, error severity, timely feedback, 
prescriber grade, correction vs. feedback and prescription stage.   
 
a. Impact of feedback 
 
All prescribers welcomed and valued the feedback process.  Benefits of PE 
feedback for patient safety were reported as a priority although prescribers 
acknowledge the process supported their professional development to learn 
from prescribing mistakes. Other potential benefits from enhanced teamwork, 
efficiency gains and reduced litigation were also reported. 
 
R9: “As a team I feel like that if I don’t put the duration, then the nursing staff 
don’t want to give it, the pharmacist asks the nursing staff and ask us and it 
makes the patient not get their medication in an appropriate time.”  
 
b. Formal vs. Informal 
 
Prescribers reported that formalising feedback was an improvement to the 
current system of informal feedback.  The process ensured feedback was 
consistent 
 
 164 
R4: “I think having the formalisation has meant that we are actually receiving 
consistent feedback, in my previous year we didn’t really have any formal 
feedback or informal feedback.” 
 
Trainee grade prescribers outlined that they were now expecting feedback 
on a routine basis and that this created a culture where feedback was 
accepted openly. 
 
R4: “The fact that it becomes a normality means then people are much more 
open to receiving and delivering feedback as opposed to people closing up 
because they don’t like it and are not used to it.” 
 
Prescribers consistently advocated that receiving feedback away from 
routine clinical duties increased the impact of the intervention, making it more 
memorable.  Equally, some trainees suggested that receiving PE feedback in 
general was memorable as it was not part of routine practice. 
 
R9: “It’s formal.  It’s more impact because verbal I get that every day you 
know like (Pharmacist) or (Pharmacist) I get verbal feedback from them 
everyday and it’s beneficial.  Obviously, that’s not formal and I can’t quite 
remember what was discussed so I like formal feedback.” 
 
However, prescribers reported that pharmacists incorporated the process 
into their daily routine activities and that this reduced the formality of and 
apprehension towards any feedback, whilst helping to establish rapport 
between them.  Such an informal approach was also considered more 
conducive to the busy nature of their working environments.  
 
R4: “Well what I think is good and has worked well is formal but also 
informal.  It’s almost like a friendly basis and you created a relationship with 
the pharmacists in that way instead of making it a formal feedback teaching 
session every week.  You never know how the ward goes you know 
someone gets sick and you miss that session so that’s the session for the 
week gone.  But having it whenever you can get the chance and sit down in 
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that way would probably work better for the way that ward is and the way that 
everything is a bit chaotic.” 
 
c. Non-intrusive process 
 
Prescribers reported that work pressures could be potential barriers to 
receiving feedback.  However, feedback was considered brief, an important 
aspect of the process as it was not disruptive to their workload. 
 
R4: “The message was the same and if anything it just meant that in my 
mind I wasn’t thinking oh this is going to drag on for 15 minutes.  You know I 
can give that 5 minutes of my time so now let’s do it now.” 
 
Advancing on this, prescribers felt that feedback was a high impact 
intervention that demanded investment of their time. 
 
R7: “I think it is a very useful intervention with little impact on our workload… 
it’s a high impact intervention for us that I haven’t had before.” 
 
d. Proforma 
 
Prescribers reported that use of proformas (Appendices 1 and 2) to record 
and deliver the feedback provided a structure to the feedback and allowed 
benchmarking to peers. The proforma appeared to contribute to the formality 
of the process with one prescriber reporting that they were expecting the 
‘sheet’ after a PE was corrected. The proforma was also suggested to 
encourage reflection and made the process more memorable. 
 
R5: “Having the paper copies helps to reinforce things so I think that helped. 
The percentages were good and gave you an overview and allowed you to 
compare yourself to others.” 
 
Some doctors reported including a copy of the proforma in their own learning 
portfolios. 
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R7: “It has actually been useful for the portfolio, so you have evidence for 
your portfolio… everything that is documented like that is quite useful I think.” 
 
e. Error severity 
 
It was acknowledged that all PEs are important but that the focus of 
feedback should be on more serious PEs.  This appeared to be a practical 
recommendation given the potential volume of minor errors but equally 
because minor errors may not be memorable if the immediate risk cannot be 
perceived. 
 
R10: “I think only when they are significant errors that I would pick up on the 
risk because then I would be more careful the next time that I am prescribing 
something then I need to think about this.” 
 
It was accepted however that raising these initially as part of the overall 
feedback, was reasonable and appropriate.  
 
R4: “Well I was receiving feedback on errors from minor all the way up to 
significant I think and the minor ones could have been put in the overall 
thing. The significant ones definitely should have a one-on-one feedback 
session.  Although the minor ones did highlight to me how often you can 
make minor mistakes, so it is good to know about that and I think that should 
only be done up to an extent.” 
 
f. Timely feedback 
 
Prescribers reported that feedback was delivered in a timely manner.  This 
was considered essential for reflection, memory recall of the patient and 
situation, and to limit the potential from harm from PE repetition. 
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Whilst prescribers acknowledged that immediate feedback is not always 
practical, it was suggested that feedback should be delivered within a few 
days to a week otherwise the learning potential might be limited.   
 
R8: “If you have done a prescription and there is an error in the prescription 
process and it is fed back in a timely manner maybe a day or the next day or 
something like that then it is still fresh in your mind whereas if you get it a 
week later then it loses its relevance and also from the patient’s point of view 
it hasn’t been corrected and is still going on which is dangerous in terms of 
treatment.  From my point of view, it’s easier to pick up earlier on when the 
prescription is still fresh in your mind.” 
 
g. Prescriber grade 
 
It was acknowledged that all prescribers require PE feedback although it was 
suggested that more junior grades would benefit most.  This was because 
they were in training grade positions and were involved in most prescribing.  
This underscores the educational focus of feedback reported later.  
 
R8: “The level of benefit may vary between the trainees and the consultant.  
It will vary depending on the role that you are in, but in my opinion the 
greatest benefit will be for the juniors but it will be beneficial for the 
consultants.” 
 
In contrast, one prescriber suggested that more senior prescribers would 
perhaps benefit as much as trainees, as they prescribe less and so are more 
likely to make errors.  
 
R5: “It should be all grades too, junior right up to consultant. I think as you 
become more senior then you are prescribing less so you are more likely to 
make mistakes and so having that highlighted to you might make you think a 
bit differently too rather than not being informed about your mistake and just 
continuing to prescribe in that way because bad habits can creep in.” 
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h. Correction vs. feedback 
 
Prescribers reported key differences between the intervention and previous 
PE feedback practice. Previous practice often involved pharmacists getting a 
prescription amended which is received mindlessly or changing it themselves 
without contacting the prescriber.   
 
R9: “Because it’s so easy when people just say can we change it to this 
because it’s actually bd [twice daily] instead of od [once daily] and I’ll say 
yeah instead of going into why [the error occurred].” 
 
Prescribers reported that the feedback intervention now followed usual 
practice and allowed consolidation of learning and focused discussion on the 
PE.  This facilitated memory recall and was more likely to prevent error 
repetition, with some prescribers suggesting that an understanding of the 
error makes it more memorable than being aware of the error.   
 
R1: “The more complex it is the more you are likely to understand and 
remember it.  For example, prescribing that PPI with clopidogrel [an 
antiplatelet medication] or you know remembering the meaning puts it into 
context as opposed to just changing it.” 
 
i. Prescription stage 
 
Prescribers appeared to refer more to discharge prescribing when 
considering improvements in their practice.   They acknowledged that PEs 
were probably more likely to occur at discharge because multiple items were 
being prescribed, or they had many discharge prescriptions to complete. 
 
R5: “I think that (Pharmacist) has said most of my mistakes were on TTO’s.  
At the start I was really rushed doing TTO’s when on the ward round. So I 
have tried to do them the day before or I’ll come in early so that I can pre-
empt who is going to go over the next couple of days and you can sit down 
and go through them then.” 
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Additionally, it was suggested that errors were more likely to occur when they 
were prescribing for a patient they were unfamiliar with and that there was a 
tendency to rush prescriptions.  Feedback appeared to change this 
behaviour with more time dedicated to completing and checking discharge 
prescriptions. 
 
R3: “It’s definitely helped with my TTO’s because I’m quite dyslexic I often 
just click on the first one but then sometimes I click on the wrong one so I 
know that I have to double check my kardex [medication chart] quite closely 
before submitting [to pharmacy].” 
 
6.4.2.  Work Environment 
 
Six codes were included in this category:  Time pressures, location, 
pharmacy service, no-blame culture, prescriber identification and out of 
hours. 
 
a. Time pressures 
 
Time pressures were a cited barrier to receiving feedback.  Pressures of 
clinical commitments created difficulties in finding a convenient time to 
receive feedback.  However, as reported earlier, prescribers recognised the 
benefits of feedback to both patient safety and their own workload and 
outlined that the process was a worthwhile investment of their time. As 
reported earlier, an ‘informal’ approach seemed to be adopted by 
pharmacists to accommodate the dynamic nature of the ward environment, 
whilst the sessions were also brief to limit impact on workload demands. 
  
R4: “Sometimes it is very busy on the ward so for the pharmacist to try and 
grab us for a minute has been quite tricky I know the pharmacist who has 
been giving me the feedback she would try and come and give me feedback 
but it was so chaotic they said oh I’ll come back later… now I don’t know if 
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you can give a protected time slot to that it would be difficult….we did 
manage to get around it and we made the sessions quick.” 
 
b. Location 
 
Prescribers reported that they may not receive feedback if they made a PE 
out of hours for example on another ward, although they acknowledge that 
these would be captured if the process was consistent across the hospital.   
 
R1: “I do most of my prescribing on-call, in A&E or (admissions wards) with 
the acute admissions but that will be caught when it is rolled out.” 
 
Prescribers were happy to receive feedback on their wards as part of routine 
practice.  However, most felt that feedback should be delivered in private to 
limit any potential embarrassment, whilst also allowing them to focus entirely 
on the feedback. 
 
R9: “In a room like this is fine so long as it is away from the work base so 
people can’t listen to what is happening and you are discussing your 40% 
error rate!” 
 
In contrast, one consultant suggested that their feedback could be delivered 
on the ward round for the benefit of all.   
 
R6: “Also, if it’s a consultant or registrar or the consultant gets feedback on 
the ward rounds when he is going around with juniors then you are 
explaining it to the juniors and the entire team would benefit from it. So, it’s a 
generic feedback when everyone learns.” 
 
c. Pharmacy Service 
 
Prescribers questioned if the process was sustainable for pharmacists, 
especially where there is limited pharmacy ward services. 
 
 171 
R6: “It boils down to whether the pharmacist has the time to be there to 
identify the errors and provide the feedback after the ward rounds.” 
 
Several prescribers suggested the process is influencing how pharmacists 
were more proactive with prescribing issues and communicating these more 
effectively. 
 
R4: “You often find that pharmacists have had some input and no one has 
read it and its a few days later.”   
 
d. No-blame culture 
 
Prescribers reported that feedback was delivered objectively and without 
judgement with a clear developmental purpose.  This was considered 
important to reduce apprehensions about the process and avoid it being 
perceived punitively.  The informal approach that pharmacists adopted to 
feedback delivery appeared to support this further. 
 
R1: “You know that people are not out to get you as opposed to being out to 
get you if they were behind a desk.” 
 
e. Prescriber identification 
 
Some prescribers highlighted that you cannot always identify a prescriber’s 
signature which would limit potential for feedback to be delivered consistently 
across the hospital. 
 
R7: “Most people don’t even write their name, it’s just a signature and you 
cannot read it and I wouldn’t know who it was to be honest.  I think the 
signature thing … I think that you should just write your name to be honest 
because it is needed for identifying people.” 
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f. Out of hours 
 
Trainee grade prescribers reported that they were more likely to make a PE 
outside of normal working hours where workload and time pressures were 
greater, and that this risk would persist despite PE feedback. 
 
R5: “Of a weekend it all goes out of the window because you are so busy.  
You are getting bleeped every 30 seconds to prescribe this or re-write this 
kardex and normally when a nurse asks me to prescribe something I’d just 
like to sit down and think do they actually need it?  Look it up in the BNF but 
sometimes of a weekend you can’t and you probably make more mistakes 
really.” 
 
6.4.3. Feedback facilitator 
 
Eight codes were included in this category:  Recognised role, expert 
knowledge, rapport, patient context, error interpretation, hierarchy, 
communication of error and teamwork. 
 
a. Recognised role 
 
Pharmacists were unanimously considered credible facilitators of PE 
feedback and that the ward pharmacist in particular, should deliver PE 
feedback.  This was influenced by their perceived expert knowledge whilst 
others considered PE feedback to be part of a pharmacist’s role. 
 
R2: “If you have gone out of your way to find me I might think it was more 
serious whereas with your ward pharmacists, it doesn’t feel like they have 
gone out of their way, it’s just what they do, it’s part of their job.” 
 
Other healthcare professionals were acknowledged as being able to deliver 
feedback but that pharmacists were best placed to do so as they objectively 
review prescriptions. 
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R2: “If it was from other prescribers I think I would feel like well you’re just as 
bad!  I would probably take it really seriously if it was from a consultant but 
take it on the chin from another junior.” 
 
b. Expert knowledge 
 
Facilitator credibility appeared to be related to expert knowledge or 
respected opinion leader.  Prescribers were effusive that pharmacists have 
expert drug knowledge which provides an objectivity to the feedback.  
Additionally, prescribers reported that a pharmacist’s knowledge facilitated 
greater explanation and clarification of prescribing points, outcomes 
considered critical for later memory recall as reported earlier.  
 
R9: “With pharmacists it’s not just feedback on this should be bd it’s more 
complex its feedback on many different things I suppose it’s more things to 
do with our prescribing as opposed to one prescription.  You know the 
nurses will say this should be given at a certain time whereas pharmacists 
will be focusing on the safety.”  
 
However, in contrast two prescribers suggested that a lack of immediate 
knowledge from the pharmacist could affect their potential credibility, and 
working relationships. 
 
R5: “Where has (other pharmacist) gone now? We have (new pharmacist) 
now who looks everything up so I just phone (other pharmacist) still!” 
 
c. Rapport 
 
Rapport was a prominent theme with prescribers outlining the importance of 
good working relationships to both receive and deliver PE feedback.  Whilst it 
was suggested that any pharmacist could deliver PE feedback, prescribers 
were unanimous in outlining that it should be from their own ward pharmacist 
for consistency, and whom they know and work with.   
 
 174 
R4: “I think that if had been several different pharmacists giving the feedback 
it might have felt different because you feel that you are being bombarded 
with all of these different people.  Having the same pharmacist give the 
consistent feedback made it positive.  Whereas if it was different people, it 
could have easily become negative because at one point it was quite a lot.” 
 
Ward based facilitation of PE feedback was reported to reduce anxieties of 
the process whilst indirectly, encouraging greater rapport and communication 
with their ward based pharmacists. 
 
R4: “It’s almost like a friendly basis and you created a relationship with the 
pharmacists in that way instead of making it a formal feedback teaching 
session every week.” 
 
d. Patient context 
 
Prescribers advocated that an understanding of the patient context was 
important for delivery of feedback.  It was suggested that this would support 
facilitation of feedback by being part of the team, having observed practice 
and understanding relevant situational context.  This supports the proposal 
that whilst anyone can deliver feedback, it should be from the ward 
pharmacist. 
 
R10: “I think the best position would still be the ward pharmacist because 
they are the ones who know our patients.  Especially with (Pharmacist) and 
(Pharmacist) working with them as part of a team, they are very good they 
make sure that everyone’s medication is reviewed and I feel that they have 
such a good background on that patient’s medications because they are the 
ones who will call up the GP’s and look into the system and flag it up oh this 
person has a previous adverse reaction. And this patient used to be on these 
medications do you need to review it do you need to restart it.” 
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e. Error interpretation 
 
Inter-professional differences in definition and interpretation of prescribing 
were reported.  Whilst this had potential to cause conflict, the facilitative 
approach to feedback allowed clarification and explanation of prescribing 
issues.  
 
R2: “It’s opinion, like what’s a contraindication, what shouldn’t be used 
together or what’s in the BNF or the patient could have tried all of these 
different things and that’s the only thing that works for them so like 
specifically using different opioids and stuff.” 
 
f. Hierarchy 
 
Hierarchy was a prominent theme when considering PE feedback.  
Pharmacists were considered outside of a prescriber’s hierarchy which 
reduced the potential for feedback to be received punitively.  Prescribers 
acknowledged that receiving feedback from a consultant could be more fear 
provoking whilst nurse-led feedback may not be as authoritative and 
supports earlier recommendations that pharmacists are best placed to 
deliver PE feedback. 
 
R1: “If it is coming top down from a consultant to a junior doctor then it is 
more fear provoking.  Pharmacist – junior doctor basically are on the same 
level.  Coming from a nurse it still feels like it is coming upwards but then you 
learn from day one as a junior doctor to always listen to the nurses and show 
them respect.  I think pharmacy is definitely on the same level as junior 
doctors so I don’t think there is any problem there.” 
 
g. Communication of error  
 
Face-to-face delivery of feedback, supported by the written proforma, was 
considered the most appropriate platform for delivery of feedback as it allows 
social interaction and questioning and explanation of the feedback.  
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R9: “Face to face would be best.  I can then ask questions straight away.  I 
find face-to-face much easier with supportive evidence of the error as well.” 
 
Where this was not possible, it was suggested that other means of 
communicating, such as e-mail or by telephone, could be used, but were 
more likely to be ignored or misinterpreted.   
 
R1: “Face-to-face is by far the best.  You can’t ignore it.  E-mails you just 
delete.  These days we get so much spam that it’s just delete, delete, so 
face-to-face is so much better.  It’s much harder to ignore if someone is 
talking to you, especially with rapport, we are social animals and respond 
much better if it’s face-to-face.” 
 
h. Teamwork 
 
Prescribers consistently reported that pharmacist-led PE feedback was 
enhancing prescriber-pharmacist communication and interaction. 
 
R7: “I think that you feel like you are more part of team when you get that 
because we actually work quite closely.” 
 
Supporting earlier reports that feedback was raising awareness of 
pharmacists, it was suggested that pharmacists are engaging more with the 
prescribing with greater verbal communication noted. 
 
R10: “I think so because we then communicate a lot because having 
discussions, apart from writing in the clinical notes and leaving notes on 
kardexes, so you tend to speak a lot more in terms of their medications.” 
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6.4.4.  Education and Learning 
 
Six key codes were included in this category:  Educational process, positive 
vs. negative feedback, constructive feedback, personal development, 
reflective practice and portfolio. 
 
a. Educational process 
 
Doctors were unanimous in advocating that PE feedback was an educational 
process to facilitate reflection and learn from their mistakes, and as essential 
for their professional development.   
 
R10: “Feedback was good because I need to learn. For example, the first 
time I had feedback, I didn’t know that ciprofloxacin reduces your threshold 
for seizures and that was in a patient with known epilepsy and that was up to 
me.” 
 
In some cases, feedback was suggested to bridge the gap from 
undergraduate studies to professional practice.  Some prescribers iterated 
that they were trainees and in a learning post with feedback required to 
identify training needs and drive their learning.    
 
R8: “They are training and … when they are training and going from area to 
area and there are certain medicines that are used in certain specialties so 
there will be more interactions and they need to be aware.  That is where 
knowledge gaps are when you are training.” 
 
Pharmacists were reported to provide teaching during feedback sessions.  
Additionally, some prescribers reported that one of the pharmacists provided 
further teaching sessions on specific subjects as a by-product of the 
feedback. 
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R4: “She [pharmacist] has provided teaching for us on warfarin, steroids, and 
inhalers because through the feedback we were telling her that we don’t 
really understand which inhalers to use when or which one.” 
 
As reported earlier, the educational outcome of feedback helps differentiate it 
from error correction. 
 
b. Positive vs. negative feedback 
 
Doctors were divided on the need for positive feedback.  Some suggested 
that it was as valid as negative feedback:  
 
R1: “Positive is just as good… as valid as negative you need that balance 
because you want to know what you are doing right as well as wrong and 
that will gain you more confidence in prescribing and that you are a safe 
clinician.” 
 
Others suggested that negative feedback, delivered constructively, was all 
that was required with absence of feedback perceived as positive itself.  
Quantification of error rates appeared to be valued for benchmarking their 
practice to others and providing targets for improvement. 
 
R7: “It reassures you if you’re not getting loads of stuff brought back to you, 
so you are prescribing safely and clearly.  I mean I know it sounds silly but 
you know…. you know that you are doing it in a sensible way.” 
 
c. Constructive feedback 
 
Prescribers consistently reported that feedback was delivered constructively.  
Advancing on the previous code, some prescribers reported that it was the 
constructive element of feedback that was more important for the educational 
process, to encourage reflection and change future practice.  
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R6: “It has to be constructive feedback on errors but if its constructive 
feedback you are not only correcting that error but preventing future errors as 
well.” 
 
d. Personal development 
 
Supporting the educational outcomes of feedback, prescribers reported that 
feedback was important to drive their personal growth and professional 
practice. Training grade doctors advanced this by iterating that they are ‘in 
training’, and that feedback was necessary to support their development.   
 
R9: “Yes absolutely after all I am still a junior doctor so I think that this is 
excellent for junior doctors so that you know what you are doing wrong and 
can improve it.” 
 
e. Reflective practice 
 
Some prescribers reported that feedback facilitated reflection by providing 
opportunities to do so away from the demands of their clinical duties. 
 
R8: “It certainly makes you reflect on the situation when you prescribed and 
just reflect on whether you had all of the information available.  It makes you 
reflect on whether you could have done the prescription differently or next 
time if you don’t have all of the information may be delegated that task to 
someone with the appropriate information to do that prescription.” 
 
f. Portfolio  
 
Evidence of the feedback was welcomed by prescribers for inclusion in their 
training portfolios, supporting earlier themes that feedback should be 
educational, encourages reflection and supports professional development. 
 
R9: “I was going to include the example of lansoprazole [a stomach acid 
suppressing medication] and lamotrigine [an anti-convulsant] as one of my 
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reflections and it’s going to be part of our e-portfolio as well because as well 
as reflecting on it we reflect on it as part of the portfolio.” 
 
6.4.5.  Prescriber impact 
 
Seven key codes were included in this category: Error awareness, error 
reduction, raised prescriber discretionary effort, information seeking 
behaviour, feedback seeking behaviour, emotional impact and time saving. 
 
a. Error awareness  
 
Prescribers were consistent in acknowledging that feedback raised their 
awareness of their own errors, and of the impact on other team members.  In 
some cases, prescribers were surprised by how it easy it to make a PE and 
outlined that feedback was important to reduce the risk of them making 
similar PEs. 
 
R4: “I didn’t realise before this feedback how easy it is to make at least the 
minor errors on a daily basis and not know about it, because no one has told 
you about.  Even with the more significant errors, you wouldn’t necessarily 
have been told about it.  So, I don’t know over the past year how many 
significant errors I’ve been making because not until this project have I ever 
been fed-back about any errors, so I think that it was really important for my 
own awareness of prescribing to have the feedback.” 
 
Prescribers reported an increased awareness of why they were making PEs: 
 
R8: “It gives you an insight into why you wrote the prescription the way you 
did.” 
 
b. Error reduction   
 
It was unanimously considered that PE feedback could reduce PEs through 
education and raised awareness of PEs.   
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R8: “Having the feedback will certainly help you to not make the same 
mistake again, or not do the same error in your life.” 
 
Errors that were considered as significant or above were considered less 
likely to recur although it was acknowledged that errors were always likely to 
occur because of human error. 
 
R2: “I missed off someone’s valproate from their TTO which I could do that 
again, and I wouldn’t know and that’s an accident I haven’t omitted that item 
on purpose that’s an accident.” 
 
c. Raised prescriber discretionary effort 
 
Prescribers consistently reported increasing their effort whilst prescribing 
following their feedback.  This appeared to be motivated by personal 
development to improve, the desire to avoid any risk of embarrassment from 
the PE, an awareness that their prescribing was being monitored, and 
benchmarking to their peers. 
 
R1: “Knowing that someone is going to look at it and provide you with 
feedback means that you take those extra seconds to check through and 
make sure it is right.” 
 
Some prescribers reported double checking their prescribing in addition to 
taking more time with any prescribing task. 
 
R9: “I’m very much aware that I need to look at prescriptions properly and 
not just look at it quickly because with it being computerised it is so easy to 
just type in LAM or any then it just comes out and I then look at it and think 
well the dose looks the same.”   
 
Others reported making more of a conscious effort and taking pride in their 
prescribing as opposed to the prescribing process being a routine task. 
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R2: “Like today, I prescribed rifampicin and really thought about what I was 
going to do with the warfarin whereas before I think that I would have just 
prescribed it and that’s because I remember having a discussion with 
(Pharmacist) about inducers and inhibitors and stuff so we went through 
them all and decided what we could do with them in the future and that’s as a 
result of feedback.” 
 
d. Information seeking behaviour 
 
Prescribers reported actively seeking prescribing information more frequently 
as a result of feedback.  This supports the earlier reports of greater 
teamwork, enhanced communication and established rapport.   
 
R3: “I ask loads of questions now… I mean poor (Pharmacist on ward) now!” 
 
e. Feedback seeking behaviour 
 
Prescribers reported that they would like feedback to continue for their 
ongoing development.   
 
R3: “I would want to receive feedback in my next rotation in surgery 
definitely.” 
 
It appeared that the process was discussed amongst prescribing peers with 
prescribers on other wards enquiring when they would receive their 
feedback. 
 
R2: “I spoke to some of my colleagues on [other ward] and they want to 
know what they are doing wrong.” 
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f. Emotional impact 
 
Trainee grade doctors reported an initial sense of anxiety towards the 
process, especially if their PE rate was going to be high. 
 
R2: “I mean sometimes you worry like if your error rate is going to be really 
high.” 
 
One prescriber reporting feeling “awful” after making a PE, but that the 
constructive and informal delivery mitigated these worries.  Another 
prescriber expressed a sense of fear of making a serious PE.   
 
R3: “I’m constantly in terror of making a really bad prescribing error.” 
 
However, prescribers consistently advocated that the process provided 
reassurance that there was a safety net to intercept PEs, whilst some 
suggested absence of feedback itself was reassuring. 
 
R7: “It reassures you if you’re not getting loads of stuff brought back to you, 
so you are prescribing safely and clearly.  I mean I know it sounds silly but 
you know…. you know that you are doing it in a sensible way.” 
 
One consultant suggested they were happy that the process was improving 
the safe and appropriate prescribing of medications on their ward. 
 
R9: “As a clinician then I am happy that the prescribing and administration of 
medicines on the ward is much better.” 
 
g. Time saving 
 
Prescribers consistently advocated that they were being contacted less to 
amend PEs, which may have been as a result of feedback.   
 
 184 
R4: “It makes a big difference to my workload and the amount of questions 
that I am having.” 
 
As reported above, less feedback provided a reassurance that their 
prescribing was safe and appropriate.  Prescribers recognised that this can 
reduce their workload considerably allowing time to be focused on other 
tasks instead of correcting PEs. 
 
R7: “It saves time and makes you far more efficient and proficient.” 
 
6.4.6. System improvement 
 
Seven key codes were included in this category: Trust-wide process, 
protected time, evidence of error, electronic feedback, shared learning, 
learning aids and induction. 
 
a. Trust-wide process 
 
Prescribers were unanimous in recommending that formalised PE feedback 
continues.  The need to develop as a prescriber with each rotation, patient 
and clinical speciality was reported with feedback essential to support this 
process. 
 
R4: “It’s important because on different wards there will be different themes 
of medication errors for medications that you are prescribing more regularly 
and so if I now went to a cardiology ward I might not be as confident in my 
prescribing of drugs again and so I think that it is important in that respect.” 
 
Regular audits to demonstrate change in prescribing and reflect clinical 
rotations was proposed if the process was sustainable for pharmacists. 
 
R10: “I think that an audit would be good on a regular basis sometime mid-
placement because foundation doctors you have three different placements 
so mid-placement would be good because then you know that in the last two 
 185 
months on a new ward and I have done this and this and this and then I have 
to next two months to improve before being reviewed again.” 
 
b. Protected time 
 
Prescribers suggested that protected time would be useful but equally 
questioned the practicalities of arranging ‘appointments’ between demanding 
work schedules.  
 
R9: “Well, at the moment, it’s not fitted into a daily schedule like ward jobs.  
It’s not formalized like teaching you know the nursing staff doesn’t know that 
we have feedback or the consultant doesn’t know that we have a feedback 
session.  So, I guess that it would be quite nice if there was a specific 
session.” 
 
c. Evidence of error 
 
Three prescribers reported that supporting evidence of the PE would support 
reflection on the situation. This appeared to be for PEs identified out of hours 
or at discharge by another pharmacist in dispensary, as any PE at ward level 
would be available for viewing. 
 
R2: “I think that actually seeing or looking at the error would be useful and 
allow you to reflect more as opposed to just being told about it.” 
 
d. Electronic feedback 
 
An electronic system of PE feedback was proposed by two prescribers to 
allow remote access as they rotate around areas.  It was also suggested that 
an electronic form would be easier to upload to their portfolios.   
 
R1: “Maybe you need something to follow you through where you have a log 
in and it follows you around that you can log in.” 
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e. Shared learning 
 
The potential for shared learning was described across interviews, 
particularly for more serious errors.  Some prescribers reported sharing their 
PE feedback with others, whilst other prescribers suggested feedback should 
also occur at a ward or specialty level for example. 
 
R3: “I’ve shared amongst other doctors on this ward but not outside, you 
don’t go around comparing serious errors!” 
 
R8: “There are team training days or teaching days like what we had this 
afternoon and it may be that once every few months or once in a quarter you 
could put together a presentation of what the common errors are.” 
 
f. Learning aids 
 
One prescriber suggested that for PE themes, educational sessions or 
prescribing support aids would be useful for quick reference.  These 
suggestions resonate with some of the teaching sessions provided by one 
pharmacist as an outcome of delivering feedback.  
 
R3: “Drug Interactions, like with clarithromycin…..it would be quite useful to 
have like a stepped list … of drug interactions that would be really useful for 
the nurse’s station.  Would that be possible?” 
 
g. Induction 
 
Building on the previous code, it was reported that certain PEs are likely to 
be unique or prevalent in each ward area.  Local ward inductions were 
proposed to raise awareness of these issues and prepare training grade 
doctors as they rotate between each area, a proactive approach that would 
complement any PE feedback. 
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R8: “Integrating it into their induction programme.  You are drawing their 
attention to say please look out for theophylline interactions, please look out 
for warfarin interactions so that junior doctors look at their prescriptions and 
make necessary amendments themselves before waiting for the feedback.” 
 
6.5 Chapter discussion 
 
The aim of this chapter was to explore the experiences of prescribers of 
receiving pharmacist-led PE feedback. The semi-structured interviews have 
provided the rich qualitative data needed to address this aim whilst informing 
the need for the larger study in chapter 7.  All prescriber grades interviewed 
in this chapter both valued and welcomed feedback on their prescribing.  
This echoes reports elsewhere (Franklin et al. 2007, Bertels et al. 2013) and 
is an important acknowledgment for transferability of the intervention to other 
areas of STHK and elsewhere. 
 
Reported benefits included improved prescribing and patient safety, whilst 
time saved not correcting errors was a welcome outcome.  Real-time audit 
and feedback has been suggested to foster a blame-free ‘culture of safety’ 
(Ursprung et al. 2005) elsewhere and here, prescribers expressed a 
reassurance that both their prescribing was improving, and that they would 
receive feedback to support their professional development.  This 
reassurance extended to an understanding of the role of a pharmacist as a 
safety net, and supports the findings of Bertels et al. (2013) where 
prescribers reported concerns over repeating errors because they were not 
informed of them.    
 
Prescribers recognised the differences between previous and current 
feedback practices from being one of directive, to facilitative feedback 
(Archer 2010) that was more memorable and they were likely to learn from, 
where there was a clear focus on learning from error, a solution focused 
approach consistent within the feedback literature (Kluger and DeNisi 1996, 
Hysong 2009). 
 
 188 
This contrasts with the findings of Sullivan et al. (2013) where prescribers 
posed the question “Why do we need this summary information every 2 
weeks when pharmacists already call us for each error?” following e-mailed 
feedback.   Bangert-Drowns et al. (1991) reported that “feedback can 
promote learning if it is received mindfully”.  If directed feedback is merely 
corrective, evokes an automatic prescriber response and does not facilitate 
reflection, then it may be received mindlessly and supports design of the 
feedback intervention used throughout this thesis. 
 
Feedback was considered memorable as it was not routine. If feedback was 
delivered for every single PE, its effectiveness may be limited with feedback 
becoming cognitively or motivationally inhibiting (Bangert-Drowns et al. 
1991), underscoring the importance of a threshold for feedback on 
prescribing performance, for example a significant error or prescribing event, 
as used in this thesis.    
 
Inaccuracies in self-assessment (Colthart et al. 2008) have been reported, 
with external involvement required for more accurate evaluation of 
prescribing performance (Davis et al. 2006).  In this chapter, ward-
pharmacists were considered credible facilitators of PE feedback where they 
have the advantage of established rapport and observing prescribing 
practice, key tenets of effective feedback (Archer 2010, Ivers et al. 2012, Bok 
et al. 2013).  
 
Advancing on this, prescribers reported a raised awareness of the role of 
pharmacists, and increased communication and teamwork to inform 
prescribing decisions. Prescribers also reported greater information and 
feedback-seeking behaviour, outcomes of feedback described elsewhere 
(Velo and Minuz 2009, Bertels et al. 2013), whilst good teamwork alone is 
considered to improve quality of care and patient safety (Firth-Cozens and 
Moss 1998, Baker et al. 2006). 
 
Therefore, the anxieties and apprehensions reported by pharmacists in 
chapter 4 would appear unfounded.  Additionally, the intervention appears to 
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have positive influences on inter-professional relationships with pharmacists’ 
views of the process explored in chapter 8. 
 
One prescriber shared their feedback with others, whilst the potential for 
shared learning was also voiced.  This potential has been reported 
elsewhere (Franklin et al. 2007, Gordon and Bose-Haider 2012, Booth et al. 
2012), although empirical evidence (Ivers et al. 2012) suggests individualised 
feedback is more effective.  Therefore, any shared learning should ideally 
supplement, and not replace personalised feedback, as argued previously 
(Shaw et al. 2003). 
 
The impact of feedback on prescribing suggested that prescribers were more 
motivated and engaged to prescribe correctly.  Whilst this motivation may 
have been to simply improve, it was also clear that the potential for feedback 
or embarrassment from making a PE, were driving influences too, sentiments 
reported elsewhere (Ferguson et al. 2017). 
 
Feedback was perceived as informal and appeared to mitigate potential 
anxieties around the process.  This endorses the need for a no-blame culture 
or ‘safe learning climate’ as reported by Bok et al. (2013) where a non-
punitive process is less likely to be resisted by the recipient (Kluger and 
DeNisi 1996), making the process more useful and actionable as argued by 
Hysong (2009).  The clinical workplace can be an unpredictable and difficult 
environment for both facilitator and recipient, to deliver and receive feedback 
(Bok et al. 2012).  An informal approach may have therefore been adopted 
out of necessity, where pharmacists could not arrange a set time to deliver 
feedback because of clinical commitments.   
 
The “healthcare sterile cockpit” model (Hohenhaus and Powell 2008) iterates 
that non-essential tasks are prohibited during clinical tasks.  Therefore, a 
flexible approach to feedback is critical to ensure that PE feedback does not 
interrupt clinical tasks.  Additionally, feedback should be delivered away from 
the clinical area for an environment that is free from distraction, to facilitate 
effective feedback (Kroll et al. 2008).  In this chapter, the prescribers 
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interviewed reported that errors would often be corrected, with constructive 
feedback following at a later convenient time. 
 
Feedback has potential to enhance knowledge and technical performance 
(Archer 2010) but it also appears to influence other processes.  The 
outcomes reported in this chapter suggest that feedback is not a simple 
intervention, but resonates with a complex intervention (Craig et al. 2008).  
Here, feedback could be considered a complex intervention as it includes: 
 
 A number of interacting components (pharmacist, error, cause of 
error, prescriber, feedback, social context, negotiated outcomes, local 
context). 
 A number and difficulty of required behaviours for both feedback 
recipient and facilitator (delivery and receipt of feedback, negotiation 
of solutions and behavioural change). 
 A variety of prescriber grades and specialty areas requiring the 
intervention (Different learning needs, hierarchy, local culture). 
 A degree of flexibility / variation in delivery of the feedback (Facilitator/ 
recipient personality, feedback approach, location, social interaction, 
provision of education). 
 Number and variability of outcomes (Each error, feedback session 
and so negotiated outcomes and influence on prescribing behaviour 
will be unique). 
Prescribing is a complex skill with multiple constituent parts whilst PE 
causation is equally complex.   Considering this, feedback is unlikely to have 
a linear cause and effect relationship but rather, non-linear responses with 
unexpected outcomes (Craig et al. 2008), it is an open system (Cohen et al. 
2011).  As a light source can hit a prism and refract, or a dropped stone 
creates a ripple effect across a still lake, feedback has the potential to create 
a cascade amplification of outcomes that influence the prescriber and 
prescribing process.  Any outcome could therefore depend on several 
variables including the credibility of facilitator, any variation in feedback or 
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additional training provided, the openness to receipt of feedback, 
interpretation of an error, or identifying the cause of or solutions to error. 
 
Despite provision of facilitator training in the process of constructive 
feedback and identification of error causation, feedback is a social and 
complex interaction and cannot be automated.  These heterogeneous 
variables would be difficult to control and whilst there may a cascade 
amplification of outcomes, this equally creates a cascade amplification of 
uncertainties.  Therefore, whilst feedback may be catalysing changes in 
prescribing, it is uncertain what aspect of the feedback process or what 
specific outcome is influencing prescribing the most. 
 
Individualised feedback was valued to limit potential embarrassment, but 
also allows open dialogue to question, clarify and consolidate learning from 
feedback in a safe learning environment: caveats of effective feedback 
endorsed elsewhere (Bok et al. 2012).  Such dialogue has been reported to 
complete “a full circle of shared responsibility” (Sullivan et al. 2013). 
 
The provision of written, in addition to verbal feedback, was welcomed and 
encouraged reflective practice, with prescribers using the written element for 
their training portfolios.  This augmented approach is consistent with 
empirical recommendations for effective feedback (Ivers et al. 2012) and 
supports the use of the feedback proforma. 
 
Additionally, the written feedback provided goals for prescribers to respond 
to and improve upon.  Control theory argues that individuals try to match 
their behaviour to goals and standards (Carver and Scheier 1981).  Goals 
may be learning or performance orientated (Archer 2010, Bok et al. 2013) 
and considering this, prescribers will want to learn and develop 
professionally or they will want to avoid negative experiences.  The proforma 
was used by some prescribers to benchmark their performance to peers, and 
could have created a competitiveness that further motivated prescribers to 
improve.  However, the evidence regarding benchmarking through peer 
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comparisons is conflicting (Ivers et al. 2012, Kiefe et al. 2001, Scheneider et 
al. 2008).   
 
Prescribers suggested local inductions would be useful to raise awareness of 
common errors in each clinical area.  A recent systematic review (Saedder et 
al. 2014) of serious medication incidents, revealed that seven drug classes 
account for 47% of all serious errors and ten drug classes for 73% of all fatal 
medication errors. Increased awareness of these drugs and likely errors 
could be useful and their impact explored alongside PE feedback for 
example.  This need could reflect the additional educational sessions that 
were reportedly provided by pharmacists as an outcome of feedback 
discussions. 
 
Timely feedback is important to make it actionable (Hysong et al. 2006).  
Barriers to timely feedback could include shift patterns, annual leave, or 
difficulty in identifying prescribers.  Electronic prescribing will facilitate 
prescriber identification whilst e-mailed feedback could be an alternative 
mode of communication although this has been reported as least effective 
feedback by prescribers elsewhere (Ferguson et al. 2017). 
 
Time and work pressures are obvious barriers to receipt of feedback.  
However, interviewees in this chapter reported that the feedback sessions 
were non-intrusive, typically lasting for 5 minutes for individual errors, and 15 
minutes for the initial overall feedback.  This is an important outcome for on-
going sustainability of the project.  The potential for feedback as a low-cost 
intervention has been expressed previously (Trooskin 2002) with Booth et al. 
(2012) iterating the need for cost-effective, low-technology solutions to 
reduce PEs in the current economic climate.  Prescribers were effusive that 
feedback was a worthy investment of their time and was a low-cost, high-
impact intervention.   
 
Whilst prescribers advocated the intervention was feasible for themselves, 
they did question the potential impact on pharmacist time.   This is an 
important consideration and will be explored further in chapter 8.  
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Lack of feedback may contribute to prescribers’ unawareness of PEs 
(Dornan et al. 2009) and could be considered a system failure that 
contributes to PEs (Franklin et al. 2011).  In these interviews, prescribers 
outlined the need for feedback to continue as part of routine practice.  Where 
feedback raises awareness of prescribing performance, it alters prescriber 
perceptions and they can calibrate their behaviours to achieve the desired 
prescribing standards, behaviour consistent with perceptual control theory 
(Ferguson et al. 2017). 
 
Training grade doctors prescribe more than consultants (Dornan et al. 2009, 
Seden et al. 2013) and may benefit most from feedback.  Improved, 
individualised workplace feedback has been suggested previously to support 
prescribers in the formative years of post-graduate training (Ryan et al. 
2014).  However, feedback should not be limited to a particular prescriber 
grade, but to all prescribers to support continuing professional development.  
It has been suggested (Sullivan et al. 2013) that feedback is “a vector to 
communicate and highlight vulnerabilities in medication safety that may 
change over time”. Feedback is a possible vector to raise awareness of 
these issues, and prevent similar PEs from occurring.  The results in this 
chapter present feedback as a complex intervention and therefore as a 
vector, the direction and size of effect is likely to be dependent on many 
interacting variables. 
 
6.6. Strengths and Limitations 
 
This is the first known qualitative study exploring the in-depth views of 
prescribers to receiving formalised feedback on PEs.  The results reported in 
this study support outcomes of chapter 5 that feedback can improve 
prescribing. 
 
However, the variability in delivery of PE feedback and the reported 
outcomes (enhanced teamwork, role awareness, information seeking 
behaviour, feedback seeking behaviour for example) suggest that feedback 
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is a complex intervention.  Whilst identification of potential reasons for 
improved prescribing is a strength of this chapter, there is uncertainty as to 
which variable can influence prescribing the most.  
 
It is argued that qualitative results cannot be generalised (Basit 2010).  
However, a range of prescriber grades were recruited and reflected the skill 
mix on the intervention wards, whilst data saturation (see chapter 3) was 
achieved confirming adequacy of participant numbers.  As a case study, the 
results in this chapter demonstrate that prescribers are open to and willing to 
receive feedback and engage with pharmacists more on an inter-professional 
level.  
 
The sample size was also small and it is possible that these views may not 
be shared on other wards or indeed in different hospitals where prescribing 
practices or pharmacy services for example differ.  However, in STHK, 
prescribing policies, guidelines, prescriber skill mix and ward pharmacy 
services are relatively consistent and one might expect similar views and 
opinion throughout STHK. 
 
Whilst the results provide a glimpse into potential behavioural changes of 
prescribers, the sample size was small and the topic guide designed as a 
process evaluation.  Further research specifically exploring the impact of 
feedback on prescriber behaviour will be reported in chapter 9. 
 
Participants reported discussing the process with colleagues on other wards 
and this may have contaminated the control group’s prescribing practice.  
This risk could not be avoided and any diffusion of effect could have 
influenced the results in chapter 5, although the PE rate for control group did 
not decrease, it increased.   
 
It is possible that prescriber comments did not reflect their true opinions as 
they were seeking to impress or reject the researcher.  However, the use of 
semi-structured interviews allowed clarification and probing of responses as 
described in chapter 3.  Equally, it is unknown if the positive opinions 
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reported throughout this chapter would persist or change with any longer-
term intervention. 
 
Whilst prescriber views have been reported in this chapter, the intervention 
requires pharmacists to deliver feedback.  The impact on pharmacists is 
unknown and further research is necessary to determine their views of the 
process. 
 
Finally, qualitative data analysis is a subjective process and all inferences 
may not have been identified by the author.  However, data saturation (no 
further emergent themes) was achieved whilst the research supervisors 
(SDW and SVOB), both non-pharmacists and experienced qualitative 
researchers, also independently reviewed interview transcripts, codes and 
themes.  Additionally, the results are part of a mixed methodological 
approach described in chapter 3 to support and corroborate results in other 
chapters. 
 
6.7. Implications of these interview findings 
 
PE feedback is welcomed with concerns reported by pharmacists in chapter 
4 unfounded.  The research aim has been addressed and the 
individualisation of pharmacist-led PE feedback, delivered constructively and 
timely, is valued. These outcomes underpin the rational design of the 
feedback intervention as described in chapter 2.  
 
These findings have several practical implications. 
 
 Prescribers valued the intervention, outlining that feedback should 
continue: This alone is a transferrable finding within STHK. 
 A non-punitive approach to feedback that was timely and delivered 
verbally and in writing by a ward-based pharmacist, were all 
considered important design elements. 
 These interventional model processes could be transferred to other 
areas of STHK and similar organisations.   
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 These findings can be used to reassure pharmacists of the perceived 
value of PE feedback, mitigating potential anxieties reported in 
chapter 4. 
 The model of pharmacist-led feedback should be extended to other 
ward areas in STHK and evaluated further. 
 Individualised feedback is preferred although there is an appetite for 
shared learning. 
 Process outcomes such as enhanced role awareness, teamwork, 
communication and information- and feedback-seeking behaviour 
could be evaluated individually to determine their impact on 
prescribing. 
 Further process evaluation is needed to explore the impact on 
pharmacists (chapter 8) and prescriber behaviour (chapter 9). 
 There is appetite for additional education, tailored to each ward area 
to inform context specific prescribing and the feasibility of this, and its 
impact, could be explored. 
 
6.8. Chapter Summary 
 
A key aim of this qualitative study was to explore the experiences of 
prescribers towards receiving PE feedback.  This chapter has presented 
relevant participant details, data collection and analysis techniques, and 
presentation and discussion of results.  
 
Formalisation of pharmacist-led feedback on PEs is valued and well received 
by all prescriber grades with on-going feedback welcomed to support 
professional development.  These results support the earlier positive findings 
on PE rates reported in chapter 5.  The idea of feedback as a complex 
intervention is emerging with multiple variables and outcomes. 
 
The next chapter will explore the impact of feedback on PE rates in a larger 
cohort study. 
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Chapter 7. Exploring the impact on prescribing errors 
 
7.1. Introduction 
 
This chapter will describe the impact of feedback on PEs using a larger 
controlled before and after study across sixteen hospitals wards.   
 
This will address the primary research aim to: 
 
Investigate the impact of pharmacist-led feedback on prescribing error 
rates. 
 
The results will also be used to test the research hypotheses outlined in 
chapter 3 and revisited below.  As described in chapter 2, few studies have 
explored this subject in hospital settings or for generic prescribing.  Data 
collection will be described and sample size and participant characteristics 
presented.  This will be followed by presentation of the results and 
discussion of the findings. 
 
7.1.1. Population and sample size 
   
Sixteen wards were audited, eight with doctors receiving feedback 
(intervention wards) and eight wards with normal, existing practice (control 
wards) as described in chapter 3.  A total of 78 prescribers were included, 
with 37 in the intervention group and 41 in the control group.  Prescriber and 
ward details are presented in tables 14 and 15 below.  Prescribers were not 
randomly allocated as described in chapter 3.  Prescribers were included 
where they had prescribing data at baseline and post-intervention for 
comparison.  Additionally, for the intervention arm, prescribers were included 
if they had received feedback at least once in between data collection 
periods. 
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7.1.2.  Data collection 
 
Pre-intervention data was collected over five consecutive days in September 
2015.  Hospital pharmacists collected prescribing data prospectively 
recording; ward area, prescriber name, number of items prescribed and, 
where identified, the number, type and severity of prescribing error.   Data 
was recorded on the proforma in appendix 16.  PE feedback was delivered to 
the intervention group as described in chapter 3 for overall prescribing and 
any ongoing PE that was significant or above.  This process continued for a 
period of 3 months before re-auditing prescribing over five consecutive days 
in December 2015. 
 
To limit inter-observer variability, the author independently reviewed each 
audit form and re-classified error severity and type where the PE was 
classified incorrectly.  Sixty errors were reclassified according to severity for 
pre-intervention data whilst 15 errors were reclassified for post-intervention 
data.  These were divided almost equally between over-grading (31 pre and 
9 post) and under-grading (29 pre and 6 post) of errors.  Any error that was 
reclassified was independently reviewed by another pharmacist with any 
differences in classification discussed and resolved for a consensus. 
  
One doctor, prescriber number 36, was removed from data analysis following 
review of prescribing data as they had not prescribed the same type of 
prescription (inpatient or discharge) between pre-test and post-test making 
any true inferences on the impact of feedback difficult. 
 
7.1.3. Data analysis  
 
All data from pre-test and post-test audit periods was input into SPSS v.22 
for data analysis with the prescriber and prescription the unit of analysis.  As 
described in chapter 3, PE rate was calculated by dividing total errors by total 
number of items at the prescription and prescriber level.  Results were 
calculated according to the mean PE rate and standard deviation with 95% 
confidence intervals.  Univariate analyses were performed with chi-squared 
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tests to compare error frequencies at the prescription level.  Independent t-
tests were used to determine the impact on PE rates at the prescriber level. 
 
Table 14: Number of each type of prescriber in intervention and control 
groups 
Prescriber 
grade a 
Number 
Intervention Control 
FY1 14 12 
FY2 7 12 
CT/ST 14 13 
Consultant 2 3 
NMP 0 1 
Total 37 41 
 
a See chapter 1 for an overview of prescriber grades  
 
Table 15: Prescriber and ward characteristics for intervention 
(feedback) and control (normal practice) groups 
 
Prescriber Grade a Gender Intervention 
or control 
group 
Ward Ward 
type b 
Patient 
turnover 
(per 
week) 
1 FY1 Female Intervention 1 Medical 
CoE 
40-50 
2 FY1 Female Intervention 1 Medical 
CoE 
3 FY1 Female Intervention 1 Medical 
CoE 
4 CT1 Male Intervention 1 Medical 
CoE 
5 Consultant Male Intervention 1 Medical 
CoE 
6 FY1 Male Intervention 2 Medical 30-40 
7 FY1 Female Intervention 2 Medical 
8 FY2 Male Intervention 2 Medical 
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Prescriber Grade a Gender Intervention 
or control 
group 
Ward Ward 
type b 
Patient 
turnover 
(per 
week) 
9 ST6 Male Intervention 2 Medical 
10 FY2 Female Intervention 3 Medical 
acute 
60-80 
11 CT1 Female Intervention 3 Medical 
acute 
12 ST4 Female Intervention 3 Medical 
acute 
13 FY1 Female Intervention 4 Medical 30-40 
14 FY1 Male Intervention 4 Medical 
15 FY1 Female Intervention 4 Medical 
16 CT2 Male Intervention 4 Medical 
17 FY1 Male Intervention 5 Medical 40-50 
18 FY1 Male Intervention 5 Medical 
19 FY2 Female Intervention 5 Medical 
20 CT1 Female Intervention 5 Medical 
21 ST4 Male Intervention 5 Medical 
22 Consultant Male Intervention 5 Medical 
23 FY1 Female Intervention 6 Medical 30-40 
24 FY2 Male Intervention 6 Medical 
25 CT2 Female Intervention 6 Medical 
26 FY2 Male Intervention 6 Medical 
27 CT2 Female Intervention 6 Medical 
28 FY1 Female Intervention 7 Medical 40-50 
29 CT1 Female Intervention 7 Medical 
30 CT2 Male Intervention 7 Medical 
31 ST4 Female Intervention 7 Medical 
32 ST4 Male Intervention 7 Medical 
33 FY1 Female Intervention 8 Acute 
medical / 
COE 
40-50 
34 FY1 Male Intervention 8 Acute 
medical / 
COE 
35 FY2 Female Intervention 8 Acute 
medical / 
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Prescriber Grade a Gender Intervention 
or control 
group 
Ward Ward 
type b 
Patient 
turnover 
(per 
week) 
COE 
36 FY2 Male Intervention 8 Acute 
medical / 
COE 
37 CT1 Female Intervention 8 Acute 
medical / 
COE 
38 FY1 Male Control 9 Medical 60-80 
39 FY2 Female Control 9 Medical 
40 CMT2 Female Control 9 Medical 
41 CT2 Male Control 9 Medical 
42 CT2 Male Control 9 Medical 
43 FY2 Female Control 10 Medical 
acute 
120-140 
44 FY2 Female Control 10 Medical 
acute 
45 CT1 Female Control 10 Medical 
acute 
46 CT1 Male Control 10 Medical 
acute 
47 CT1 Female Control 10 Medical 
acute 
48 Consultant Male Control 10 Medical 
acute 
49 FY1 Female Control 11 Medical 60-80 
50 FY1 Male Control 11 Medical 
51 FY1 Male Control 11 Medical 
52 FY2 Female Control 11 Medical 
53 FY1 Male Control 12 Surgical 30-40 
54 FY1 Male Control 12 Surgical 
55 FY1 Female Control 12 Surgical 
56 FY2 Female Control 12 Surgical 
57 FY1 Female Control 13 Surgical 30-40 
58 FY1 Female Control 13 Surgical 
59 FY1 Male Control 13 Surgical 
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Prescriber Grade a Gender Intervention 
or control 
group 
Ward Ward 
type b 
Patient 
turnover 
(per 
week) 
60 FY2 Male Control 13 Surgical 
61 Consultant Male Control 13 Surgical 
62 NMP Male Control 13 Surgical 
63 FY2 Male Control 14 Medical 
COE 
10-20 
64 FY2 Male Control 14 Medical 
COE 
65 FY2 Female Control 14 Medical 
COE 
66 CT1 Female Control 14 Medical 
COE 
67 FY1 Female Control 15 Medical 
COE 
10-20 
68 FY1 Female Control 15 Medical 
COE 
69 FY2 Female Control 15 Medical 
COE 
70 FY2 Female Control 16 Medical 20-30 
71 FY2 Male Control 16 Medical 
72 ST2 Male Control 16 Medical  
73 ST1 Male Control 16 Medical 
74 ST2 Female Control 16 Medical 
75 ST1 Male Control 16 Medical 
76 ST1 Female Control 16 Medical 
77 ST6 Male Control 16 Medical 
78 Consultant Male Control 16 Medical 
 
b COE = Care of Elderly 
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7.2. Results 
 
7.2.1. Impact of feedback on overall prescription errors 
 
A summary of overall prescribing data for control and intervention groups for 
both pre-test and post-test is summarised in table 16 and figures 21 and 22 
below.   
 
Table 16:  Overview of prescribing error data for overall prescribing in 
intervention and control groups  
Group Pre-
items 
Pre 
errors 
Pre-
error 
rate 
% 
Post-
items 
Post 
errors 
Post-
error 
rate 
(%) 
Difference 
in error 
rate 
Pre – post 
% 
Chi-
square 
and p-
value 
Intervention  3067 756 24.7 2985 168 5.6 -19.1 χ2(1) = 
313.8, p 
= 
<0.005, 
φ=0.212 
Control 2124 382 18.0 2137 464 21.7 3.7 χ2(1) = 
6.2, p = 
0.013, 
φ=-
0.035 
Total 5191 1138 22.0 5122 632 12.3 -9.7  
 
Pre-test 
 
A total of 950 prescriptions were audited, 475 of which were error free (50%), 
with 5191 items prescribed and 1138 PEs identified.  An overall PE rate of 
21.9%.  
 
There were 519 prescriptions in the intervention group, with 243 error free 
(46.8%).  There were 3067 prescribed items with 756 PEs, an overall PE rate 
of 24.7%. 
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There were 431 prescriptions in the control group, with 232 error free 
(53.8%). There were 2124 prescribed items with 382 PEs, an overall PE rate 
of 18.0%. 
 
Post-test 
 
A total of 913 prescriptions were audited, with 541 error free (59.3%).  There 
were 5122 prescribed items and 632 PEs identified.  An overall PE rate of 
12.3%.   
 
There were 450 prescriptions in the intervention group, with 318 error free 
(70.7%).  There were 2985 prescribed items with 168 PEs, an overall PE rate 
of 5.6%.  
 
There were 463 prescriptions in the control group, with 223 error free 
(48.2%).  There were 2137 prescribed items and 464 PEs, an overall PE rate 
of 21.7%.  
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Figure 21: Bar chart illustrating prescribed items and errors for the 
intervention group before and after the intervention period 
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Figure 22: Bar chart illustrating prescribed items and errors for the 
control group before and after the intervention period 
 
 
 
7.2.2 Analysis of overall prescription error frequency 
 
A chi-square test for association was used to determine if there were any 
statistically significant differences between and within groups for error 
frequency.  All expected cell frequencies were greater than five meeting the 
assumption of the chi-squared test as described in chapter 3.  
 
Pre-intervention, there was a statistically significant association between 
groups (intervention or control) and frequency of PEs, χ2(1) = 20.8, p = 
<0.005, φ=0.057 with error frequency dependent on the group. 
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Post-intervention, there was a statistically significant association between 
group and frequency of prescribing errors, χ2(1) = 228.2, p = <0.005, φ=-
0.199, with error frequency dependent on the group. 
 
PE frequencies were statistically significantly different between pre- and 
post-testing for both intervention (χ2(1) = 313.8, p = <0.005) and control 
groups (χ2(1) = 6.2, p = 0.014) with error frequency different for each stage of 
data collection for each group (See table 16). 
 
Whilst these results suggest that there is a difference between the two 
groups, the primary research question is concerned with determining if there 
is a difference in the mean change in PE rates.  Independent t-tests were 
used to determine this as outlined below.   
 
7.2.3. Impact of feedback on overall prescribing error rates  
 
A summary of overall prescribing data per prescriber for both control and 
intervention groups is summarised in table 17 below.  
 
Change scores were calculated by determining the difference between post-
intervention PE rates and pre-intervention PE rates. This allowed comparison 
of the mean change in PE rates. 
 
An independent t-test, as described in chapter 3, can be used to test the null 
hypothesis: 
 
H0: There is no difference in the mean change in prescribing error rates 
between the intervention and control groups following delivery of feedback to 
the intervention group. 
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7.2.3.1 Sample size and descriptive statistics 
 
Thirty-six prescribers were included in the intervention group.  There was a 
mean PE rate of 25.0% (SD 16.8, 95% CI 19.3 to 30.7) at baseline and a 
mean PE rate of 6.7% (SD 9.0, 95% CI 3.7 to 9.8) post-intervention. 
 
There was a mean reduction in PE rate in the intervention group of 18.3% 
(SD +/-14.7, 95% CI -23.2 to -13.3).   
 
Forty-one prescribers were included in the control group.   There was a 
mean PE rate of 19.7% (SD 14.5, 95% CI 15.2 to 24.3) at baseline and a 
mean PE rate of 25.1% (SD 17.0, 95% CI 19.8 to 30.6) post-intervention. 
 
There was a mean increase in PE rate in the control group of 5.4% (SD +/-
15.6, 95% CI 0.6 to 10.4).   
 
Table 17: Overall prescribing data per prescriber for control and 
intervention groups 
Prescriber Pre-
items 
Pre-
errors 
Pre-error 
rate% 
Post-
items 
Post-
errors 
Post-error 
rate (%) 
Difference 
in error 
rate 
Pre - post 
1 80 12 15 137 5 3.6 -11.4 
2 84 11 13.1 58 4 6.9 -6.2 
3 155 65 41.9 107 8 7.5 -34.4 
4 164 62 37.8 161 7 4.4 -33.4 
5 2 0 0 5 0 0 0 
6 85 21 24.7 42 2 4.8 -19.9 
7 110 34 30.9 187 16 8.6 -22.3 
8 72 24 33.3 50 5 10.0 -23.3 
9 28 11 39.3 47 3 6.4 -32.9 
10 103 24 23.3 80 5 6.3 -17.0 
11 181 83 45.9 63 13 20.6 -25.3 
12 64 29 45.3 41 8 19.5 -25.8 
13 201 30 15.0 124 3 2.4 -12.6 
14 149 30 20.1 216 9 4.2 -15.9 
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Prescriber Pre-
items 
Pre-
errors 
Pre-error 
rate% 
Post-
items 
Post-
errors 
Post-error 
rate (%) 
Difference 
in error 
rate 
Pre - post 
15 114 13 11.4 210 4 1.9 -9.5 
16 165 28 17.0 372 22 5.9 -11.1 
17 108 30 27.8 108 9 8.3 -19.5 
18 76 22 29.0 90 6 6.7 -22.3 
19 224 28 12.5 14 0 0 -12.5 
20 95 25 26.3 275 11 4.0 -22.3 
21 22 15 68.2 1 0 0 -68.2 
22 12 0 0 4 0 0 0 
23 25 6 24 101 8 7.9 -16.1 
24 208 30 14.4 57 2 3.5 -10.9 
25 23 11 47.8 2 1 50 2.2 
26 23 12 52.2 16 0 0 -52.2 
27 8 0 0 5 0 0 0 
28 129 29 22.5 101 4 4.0 -18.5 
29 53 11 20.8 24 1 4.2 -16.6 
30 61 11 18.0 37 2 5.4 -12.6 
31 19 0 0 68 1 1.5 1.5 
32 11 6 54.6 12 2 16.7 -37.9 
33 47 9 19.2 120 4 3.3 -15.9 
34 86 14 16.3 28 1 3.6 -12.7 
35 17 0 0 2 0 0 0 
36 *prescriber removed from analysis as there was no matched prescribing data 
37 63 20 31.8 20 2 10.0 -21.8 
38 15 0 0 34 7 20.6 20.6 
39 40 7 17.5 56 13 23.2 5.7 
40 39 8 20.5 61 22 36.1 15.6 
41 93 42 45.2 66 22 33.3 -11.9 
42 118 45 38.1 25 10 40.0 1.9 
43 30 8 26.7 66 21 31.8 5.1 
44 9 4 44.4 46 6 13.0 -31.4 
45 50 19 38.0 52 25 48.1 10.1 
46 27 4 14.8 17 5 29.4 14.6 
47 43 11 25.6 14 2 14.3 -11.3 
48 10 7 70 4 3 75.0 5 
49 51 3 5.9 116 11 9.5 3.6 
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Prescriber Pre-
items 
Pre-
errors 
Pre-error 
rate% 
Post-
items 
Post-
errors 
Post-error 
rate (%) 
Difference 
in error 
rate 
Pre - post 
50 95 13 13.7 133 23 17.3 3.6 
51 57 10 17.5 63 12 19.1 1.6 
52 80 16 20.0 73 14 19.2 -0.8 
53 15 5 33.3 35 13 37.1 3.8 
54 40 5 12.5 46 8 17.4 4.9 
55 65 15 23.1 27 13 48.2 25.1 
56 120 13 10.8 56 8 14.3 3.5 
57 22 2 9.1 18 5 27.8 18.7 
58 27 6 22.2 62 16 25.8 3.6 
59 64 6 9.4 95 19 20.0 10.6 
60 34 10 29.4 25 5 20.0 -9.4 
61 19 4 21.1 13 2 15.4 -5.7 
62 99 15 15.2 109 9 8.3 -6.9 
63 59 15 25.4 112 46 41.1 15.7 
64 10 4 40 49 16 32.7 -7.3 
65 82 6 7.3 124 8 6.5 -0.8 
66 113 14 12.4 33 7 21.2 8.8 
67 90 9 10 22 8 36.4 26.4 
68 54 5 9.3 91 19 20.9 11.6 
69 21 8 38.1 159 45 28.3 -9.8 
70 14 1 7.1 40 3 7.5 0.4 
71 32 6 18.8 4 3 75.0 56.2 
72 64 5 7.8 17 3 17.7 9.9 
73 68 8 11.8 57 4 7.0 -4.8 
74 66 4 6.1 29 2 6.9 0.8 
75 64 3 4.7 25 2 8.0 3.3 
76 60 5 8.3 39 0 0 -8.3 
77 63 11 17.5 20 2 10.0 -7.5 
78 2 0 0 4 2 50.0 50 
Total 5191 1138 21.9% 5122 632 12.3%  
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7.2.3.2. Assumption testing for overall prescribing error rates 
 
As outlined in chapter 3, various assumptions have to be met to determine if 
the data is suitable for independent t-tests including normality of distribution, 
absence of outliers and homogeneity of variances.  These will now be 
considered.  
 
Normality of distribution 
 
Shapiro-Wilk tests suggest non-normality of distribution with a p-value <0.05 
for the intervention group (0.03) and the control group (0.02).  However, 
inspection of the histogram (Figure 23) suggests an approximated normality 
for the control group and a mild negative skew for the intervention group. 
Additionally, inspection of the normality plots (Figures 24 and 25) suggested 
an approximated normality with a few residuals departing on both sides of 
the normal line influencing non-normality. T-tests are robust to deviations in 
normality as discussed in chapter 3, particularly with sample sizes over 30, 
whilst non-normality does not significantly affect type 1 error (false positive).   
Transforming data for a negative skew did not improve the distribution of the 
histograms (Figure 26).  Hence, a normal distribution was assumed and the 
t-test performed.   
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Figure 23:  Histogram of distribution of change scores for overall 
prescribing in control and intervention groups 
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Figure 24: Probability plot for change in overall prescribing error rates 
for the intervention group 
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Figure 25: Probability plot for change in overall prescribing error rates 
for the control group 
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Figure 26:  Histogram of distribution of transformed change scores for 
overall prescribing in control and intervention groups 
 
 
 
 
Outliers  
 
Five outliers were identified from inspection of the box plots (Figure 27).  
Whilst the t-test is robust to outliers, a sensitivity test was performed to 
compare significance with and without outliers with significance unaffected 
as reported below.   
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Figure 27: Boxplot for change in prescribing error rates for overall 
prescribing  
 
 
 
 
 
Homogeneity of variance 
 
The final assumption for independent t-tests is homogeneity of variances as 
described in chapter 3.  This was demonstrated by Levene’s tests (p>0.05 at 
0.948) and this assumption met.   
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7.2.3.3. Results for overall change in prescribing error rates 
 
PE rates were statistically significantly lower in the intervention group 
compared to the control group. Mean difference of 23.7% (SD 3.5, 95% CI, -
30.6 to -16.8), t(75) = -6.849, p<0.05, effect size (d) = 1.57 (large effect size). 
 
Removal of outliers for overall prescribing  
 
The t-test was repeated to determine the difference on the significance of the 
results without the outliers (prescribers 21, 26, 42, 69 and 76). 
 
Shapiro-Wilk scores suggested normality for the intervention group (0.593) 
and non-normality for the control group (0.004) although inspection of the 
histogram (figure 28) would suggest an approximated normal distribution for 
the control group.  There was homogeneity of variances as demonstrated by 
Levene’s score p>0.05 (0.218).  There was a statistically significant change 
in PE rates between the two groups with the intervention group (mean 
change -15.8%, SD 10.66) demonstrating a greater mean change in PE rate 
compared to the control group (+6.0%, SD 16.0).  Mean difference as 
determined by the independent t-test was -21.8% (SD 3.2, 95% CI = -28.2 to 
-15.3) t(70) = -6.707.  Results were still significant justifying inclusion of 
outliers in the initial analysis.   
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Figure 28:  Histogram of distribution of change scores for control and 
intervention groups following removal of outliers 
 
 
7.2.4.  Impact of feedback on overall error free prescription rate 
 
7.2.4.1. Sample size and descriptive statistics for EFP rate 
 
Prescribing data for error free prescriptions (EFPs) is presented in table 18 
below.   
 
There was a mean EFP rate of 48.4% (SD 27.7, 95% CI 39.1 to 57.8) at 
baseline and 72.1% (SD 27.7, 95% CI 39.1 to 57.8) post-intervention for the 
intervention group.   
 
There was a mean improvement in EFP rate of 23.7% (95% CI, 15.6 to 31.8, 
SD 24.0) in the intervention group (n=36). 
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There was a mean EFP rate of 53.7% (SD 21.4, 95% CI 46.9 to 60.4) in the 
control group at baseline and 47.9% (SD 22.5, 95% CI 40.8 to 55.0) post-
intervention.   
 
There was a mean reduction in the EFP rate of 5.8% (95% CI, -14.4 to 2.9, 
SD 27.4) in the control group (n=41). 
 
Table 18: Prescribing data for overall error free prescriptions per 
prescriber 
Prescriber Pre-
prescriptions 
Pre- 
EFP 
Pre-
EFP % 
Post-
prescriptions 
Pre- 
EFP 
Post- 
EFP 
(%) 
Difference 
in EFP % 
pre - post 
1 18 10 55.6 21 17 81.0 25.4 
2 17 9 52.9 8 5 62.5 9.6 
3 26 9 34.6 15 10 66.7 32.1 
4 22 7 31.8 21 14 66.7 34.9 
5 2 2 100.0 4 4 100.0 0 
6 16 9 56.3 6 4 66.7 10.4 
7 19 6 31.6 30 23 76.7 45.1 
8 19 7 36.8 10 5 50.0 13.2 
9 8 4 50.0 7 5 71.4 21.4 
10 21 12 57.1 11 6 54.6 -2.5 
11 41 11 26.8 14 8 57.1 30.3 
12 10 5 50.0 11 6 54.6 4.6 
13 23 10 43.5 19 16 84.2 40.7 
14 17 6 35.3 34 26 76.5 41.2 
15 16 10 62.5 31 27 87.1 24.6 
16 21 10 47.6 42 22 52.4 4.8 
17 23 13 56.5 14 6 42.9 -13.6 
18 10 4 40.0 14 9 64.3 24.3 
19 36 23 63.9 2 2 100 36.1 
20 18 11 61.1 36 28 77.8 16.7 
21 5 3 60.0 1 1 100 40.0 
22 8 8 100.0 2 2 100 0 
23 5 0 0 15 9 60 60.0 
24 22 14 63.6 11 9 81.8 18.2 
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Prescriber Pre-
prescriptions 
Pre- 
EFP 
Pre-
EFP % 
Post-
prescriptions 
Pre- 
EFP 
Post- 
EFP 
(%) 
Difference 
in EFP % 
pre - post 
25 4 0 0 1 0 0 0 
26 5 0 0 3 3 100 100 
27 1 1 100.0 1 1 100 0 
28 16 4 25.0 9 6 66.7 41.7 
29 11 4 36.4 4 3 75.0 38.6 
30 8 3 37.5 8 6 75.0 37.5 
31 9 9 100.0 12 11 91.7 -8.3 
32 2 0 0 8 6 75.0 75.0 
33 7 3 42.9 18 14 77.8 34.9 
34 16 9 56.3 3 2 66.7 10.4 
35 3 3 100.0 1 1 100 0 
36 *prescriber removed from analysis as there was no matched prescribing data 
37 14 4 28.6 3 1 33.3 4.7 
38 7 7 100.0 8 4 50.0 -50.0 
39 14 10 71.4 21 11 52.4 -19.0 
40 12 8 66.7 17 4 23.5 -43.2 
41 13 4 30.8 14 8 57.1 26.3 
42 34 18 52.9 8 3 37.5 -15.4 
43 7 3 42.9 16 3 18.8 -24.1 
44 6 3 50.0 10 6 60.0 10.0 
45 18 9 50.0 14 0 0 -50.0 
46 8 6 75.0 11 6 54.6 -20.4 
47 19 9 47.4 10 8 80.0 32.6 
48 6 3 50.0 3 0 0 -50.0 
49 7 4 57.1 16 11 68.8 11.7 
50 18 10 55.6 23 13 56.5 0.9 
51 12 4 33.3 13 5 38.5 5.2 
52 9 2 22.2 16 8 50.0 27.8 
53 10 5 50.0 15 7 46.7 -3.3 
54 8 4 50.0 14 8 57.1 7.1 
55 14 4 28.6 6 0 0 -28.6 
56 24 16 66.7 12 6 50.0 -16.7 
57 8 7 87.5 3 1 33.3 -54.2 
58 8 5 62.5 20 9 45.0 -17.5 
59 9 5 55.6 19 10 52.6 3.0 
60 4 0 0 6 4 66.7 66.7 
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Prescriber Pre-
prescriptions 
Pre- 
EFP 
Pre-
EFP % 
Post-
prescriptions 
Pre- 
EFP 
Post- 
EFP 
(%) 
Difference 
in EFP % 
pre - post 
61 4 1 25.0 5 3 60.0 35.0 
62 15 6 40.0 24 17 70.8 30.8 
63 10 4 40.0 15 4 26.7 -13.3 
64 2 1 50.0 7 2 28.6 -21.4 
65 15 9 60.0 15 12 80.0 20.0 
66 16 8 50.0 7 3 42.9 -7.1 
67 12 4 33.3 5 2 40.0 6.7 
68 8 4 50.0 12 3 25.0 -25.0 
69 3 1 33.3 21 5 23.8 -9.5 
70 6 5 83.3 8 5 62.5 -20.8 
71 4 1 25.0 4 1 25.0 0 
72 9 5 55.6 6 4 66.7 11.1 
73 14 10 71.4 8 4 50.0 -21.4 
74 8 6 75.0 6 4 66.7 -8.3 
75 10 8 80.0 8 6 75.0 -5 
76 9 7 77.8 6 6 100.0 22.2 
77 9 4 44.4 7 5 71.4 27.0 
78 2 2 100.0 4 2 50.0 -50 
 
 
7.2.4.2.  Assumption testing for overall error free prescription rate 
change  
 
Normality testing for error free prescriptions 
 
The Shapiro-Wilk test indicated non-normality for the intervention group 
(p<0.05 at 0.019) and normality for the control group (p>0.05 at 0.396).  
Inspection of the histogram (figure 29) and normality plots (figures 30 and 
31) suggest distributions that could be approximated as normal with a few 
outliers below the normality line influencing normality.  Removal of these 
outliers produced statistically significant results with normality of distribution 
as described below. 
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Figure 29:  Histogram of distribution of change scores for error free 
prescription percentage for overall prescribing  
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Figure 30: Probability plot for change in overall EFP rate in the 
intervention group 
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Figure 31: Probability plot for change in overall EFP rate in the control 
group 
 
 
 
 
Outliers 
 
Two outliers were identified from inspection of the box plots (Figure 32).  
These were considered true outliers following manual inspection of the data 
and unlikely to affect the outcome of the test. This was confirmed by 
comparing results of the t-test with and without the outlier with test 
significance unchanged. 
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Figure 32: Box plot of error free prescription % for overall prescribing 
 
 
 
 
Homogeneity of variance 
 
There was homogeneity of variance as determined by Levene’s test p>0.05 
(0.4) 
 
7.2.4.3. Results for change in overall error free prescriptions 
 
The intervention group demonstrated a mean improvement in EFPs (mean 
change 23.7%, SD 24.0) compared to the control group (mean change -
5.8%, SD 27.4), a statistically significant difference of 29.5% (SD 5.9, 95% 
CI, 17.7 to 41.2), t(75) = 4.978, p = <0.005.  Effect size (d) = 1.14 (large 
effect size). 
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Sensitivity testing  
 
Results remained significant (mean difference 27.3%, t=4.80, p<0.05) when 
performed without the above outliers (prescribers 26 and 59) with 
assumptions of normality (Shapiro-Wilk p>0.05 for both groups and see 
figure 33 below) and homogeneity of variances (Levene’s test >0.05, 
p=0.115) met. 
 
 
Figure 33: Histogram of distribution of change scores for error free 
prescription percentage for overall prescribing without outliers 
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7.2.5.1. Association between change in prescribing error rate and 
number of feedback sessions 
 
 
The number of individual feedback sessions (excluding the initial overall 
feedback session) for PEs classified as significant or greater are displayed in 
table 19 below.     
 
To determine if there is an association between number of feedback 
sessions and change in PE rate, Pearson’s correlation coefficient test was 
used.  
 
The null hypothesis for this test is as follows: 
 
H0: ρ = 0; the population correlation coefficient is equal to zero. 
 
And the alternative hypothesis is: 
 
HA: ρ ≠ 0; the population correlation coefficient is not equal to zero. 
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Table 19: Difference in overall prescribing and number of feedback 
sessions each prescriber received  
 
Prescriber Pre-error 
rate% 
Post-error 
rate (%) 
Absolute 
difference in 
error rate 
Post-pre (%) 
Number of 
individual 
feedback 
sessions 
Number of 
prescribing 
errors 
feedback 
delivered on 
1 15 3.6 -11.4 6 8 
2 13.1 6.9 -6.2 9 12 
3 41.9 7.5 -34.4 7 9 
4 37.8 4.4 -33.4 4 6 
5 0 0 0 0 0 
6 24.7 4.8 -19.9 4 7 
7 30.9 8.6 -22.3 3 5 
8 33.3 10.0 -23.3 6 9 
9 39.3 6.4 -32.9 5 12 
10 23.3 6.3 -17.0 7 10 
11 45.9 20.6 -25.3 1 3 
12 45.3 19.5 -25.8 1 2 
13 15.0 2.4 -12.6 5 12 
14 20.1 4.2 -15.9 4 6 
15 11.4 1.9 -9.5 3 3 
16 17.0 5.9 -11.1 4 7 
17 27.8 8.3 -19.5 1 1 
18 29.0 6.7 -22.3 2 6 
19 12.5 0 -12.5 3 7 
20 26.3 4.0 -22.3 4 5 
21 68.2 0 -68.2 0 0 
22 0 0 0 0 0 
23 24 7.9 -16.1 4 4 
24 14.4 3.5 -10.9 4 4 
25 47.8 50 2.2 1 2 
26 52.2 0 -52.2 1 1 
27 0 0 0 1 3 
28 22.5 4.0 -18.5 6 9 
29 20.8 4.2 -16.6 3 6 
30 18.0 5.4 -12.6 2 4 
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Prescriber Pre-error 
rate% 
Post-error 
rate (%) 
Absolute 
difference in 
error rate 
Post-pre (%) 
Number of 
individual 
feedback 
sessions 
Number of 
prescribing 
errors 
feedback 
delivered on 
31 0 1.5 1.5 1 1 
32 54.6 16.7 -37.9 1 1 
33 19.2 3.3 -15.9 3 5 
34 16.3 3.6 -12.7 2 3 
35 0 0 0 0 0 
36 *prescriber removed from analysis as there was no matched prescribing data 
37 31.8 10.0 -21.8 3 4 
38 0 20.6 20.6 0 0 
39 17.5 23.2 5.7 0 0 
40 20.5 36.1 15.6 0 0 
41 45.2 33.3 -11.9 0 0 
42 38.1 40.0 1.9 0 0 
43 26.7 31.8 5.1 0 0 
44 44.4 13.0 -31.4 0 0 
45 38.0 48.1 10.1 0 0 
46 14.8 29.4 14.6 0 0 
47 25.6 14.3 -11.3 0 0 
48 70 75.0 5 0 0 
49 5.9 9.5 3.6 0 0 
50 13.7 17.3 3.6 0 0 
51 17.5 19.1 1.6 0 0 
52 20.0 19.2 -0.8 0 0 
53 33.3 37.1 3.8 0 0 
54 12.50 17.4 4.9 0 0 
55 23.1 48.2 25.1 0 0 
56 10.8 14.3 3.5 0 0 
57 9.1 27.8 18.7 0 0 
58 22.2 25.8 3.6 0 0 
59 9.4 20.0 10.6 0 0 
60 29.4 20.0 -9.4 0 0 
61 21.1 15.4 -5.7 0 0 
62 15.2 8.3 -6.9 0 0 
63 25.4 41.1 15.7 0 0 
64 40 32.7 -7.3 0 0 
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Prescriber Pre-error 
rate% 
Post-error 
rate (%) 
Absolute 
difference in 
error rate 
Post-pre (%) 
Number of 
individual 
feedback 
sessions 
Number of 
prescribing 
errors 
feedback 
delivered on 
65 7.3 6.5 -0.8 0 0 
66 12.4 21.2 8.8 0 0 
67 10 36.4 26.4 0 0 
68 9.3 20.9 11.6 0 0 
69 38.1 28.3 -9.8 0 0 
70 7.1 7.5 0.4 0 0 
71 18.8 75.0 56.2 0 0 
72 7.8 17.7 9.9 0 0 
73 11.8 7.0 -4.8 0 0 
74 6.1 6.9 0.8 0 0 
75 4.7 8.0 3.3 0 0 
76 8.3 0 -8.3 0 0 
77 17.5 10.0 -7.5 0 0 
78 0 50.0 50 0 0 
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Figure 34: Scatterplot of absolute change in error rate and number of 
prescribing errors the prescriber received feedback on for the 
intervention group 
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Figure 35: Scatterplot of transformed absolute error rate difference data 
and number of errors the prescriber received feedback on  
 
 
 
Assumptions of Pearson’s test include linearity of response and no 
significant outliers. 
 
The relationship between number of errors the prescriber received feedback 
on and change in PE rate was considered non-linear (Figure 34) but is 
monotonic from visual inspection of figure 35.  Therefore, Spearman’s rank 
test was performed as an alternative as described in chapter 3.   
 
An increase in number of errors that prescribers received feedback on was 
associated with a non-significant improvement in change in PE rates, rs(32) 
= -0.127, p >0.05 (0.46).  Removal of outliers (prescribers 21 and 26) did not 
affect the outcome of the test. 
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7.2.5.2 Association between error free prescription rate and number of 
feedback sessions 
 
Pearson’s correlation could not be used as its assumptions of linearity was 
violated.  Therefore, a bivariate analysis using Spearman’s rank test was 
used and demonstrated a non-significant increase in absolute mean EFP 
rate (r(36)=0.038, p=0.825) and relative mean EFP rate (rs(36)=0.19, 
p=0.267) for the intervention group. 
 
7.2.6. Impact of feedback on inpatient prescription errors 
 
The impact of feedback on inpatient prescription errors will be discussed 
here. 
 
7.2.6.1. Sample size and descriptive statistics  
 
A summary of inpatient prescribing data for control and intervention groups 
at baseline and post-test is summarised in table 20 below.   
 
Pre-test 
 
A total of 620 inpatient prescriptions were audited at baseline, 330 of which 
were error free (53.2%), with 2891 items prescribed and 655 prescribing 
errors identified.  An overall prescribing error rate of 22.7%.  
 
There were 315 inpatient prescriptions in the intervention group, with 168 
error free (53.3%).  There were 1358 prescribed items with 370 prescribing 
errors, an overall prescribing error rate of 27.3%.  
 
There were 305 inpatient prescriptions in the control group, with 162 error 
free (53.1%). There were 1533 prescribed items with 285 prescribing errors, 
an overall prescribing error rate of 18.6%. 
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Post-test 
 
A total of 563 inpatient prescriptions were audited at baseline, with 349 error 
free (62.0%).  There were 2500 prescribed items and 329 prescribing errors 
identified.  An overall prescribing error rate of 13.2%.   
 
There were 265 inpatient prescriptions in the intervention group, with 192 
error free (72.5%).  There were 1191 prescribed items with 85 prescribing 
errors, an overall prescribing error rate of 7.1%. 
 
There were 298 inpatient prescriptions in the control group, with 157 error 
free (52.7%).  There were 1309 prescribed items and 244 prescribing errors, 
an overall prescribing error rate of 18.6%. 
 
Table 20:  Overview of prescribing error data for inpatient prescribing 
in intervention and control groups  
Group Pre-
items 
Pre- 
errors 
Pre-
error 
rate 
% 
Post-
items 
Post-
errors 
Post-
error 
rate 
(%) 
Difference 
in error 
rate 
Pre-post 
(%) 
Chi-
square 
and p-
value 
Intervention  1358 370 27.3 1191 85 7.1 -20.2% χ2(1) = 
124.3, p 
= 
<0.005, 
φ=0.203 
Control 1533 285 18.6 1309 244 18.6 +0.05% χ2(1) = 
0.01, p 
= 0.978 
(ns), 
φ=0 
Total 2891 655 22.7 2500 329 13.2 -9.5%  
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7.2.6.2. Analysis of inpatient prescription error frequency 
 
Using chi-squared test, there was a statistically significant change in error 
frequency in the intervention group (p<0.005) and a non-significant increase 
in error frequency in the control group (p=0.978).  Between group analysis 
suggested a statistically significant difference pre-test (χ2(1) = 19.4, p = 
<0.005, φ =0.074) and post-test (χ2(1) = 55.8 p = <0.005, φ =-0.14). 
 
7.2.6.3. Impact of feedback on inpatient prescribing error rates 
 
7.2.6.4. Sample size and descriptive statistics for inpatient PE rate 
 
A summary of inpatient prescribing data per prescriber is summarized in 
table 21 below.  Prescribers 27 and 36 were excluded from the analysis as 
they did not have any post-test inpatient prescriptions for comparison. 
 
There were 35 prescribers in the intervention group and 41 prescribers in the 
control group.  
 
There was a mean PE rate of 29.4% (SD 21.0, 95% CI 22.2 to 36.6) at 
baseline and 8.8% (SD 10.3, 95% CI 5.3 to 12.4) post-intervention for the 
intervention group.  
 
There was a mean reduction in inpatient PE rates of -20.6% (SD 20.3, 
95%CI -27.5 to -13.6) in the intervention group. 
 
There was a mean PE rate of 21.4% (SD 19.3, 95% CI 15.3 to 27.5) at 
baseline and 27.4% (SD 25.0, 95% CI  19.5 to 35.3) post-intervention for the 
control group.  
 
 
There was a mean increase in inpatient PE rates of 6.0% (SD 27.8, 95% CI -
2.7 to 14.8) in the control group. 
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Table 21: Inpatient prescribing data per prescriber 
Prescriber Pre-
items 
Pre- 
errors 
Pre-
error 
rate% 
Post-
items 
Post- 
errors 
Post-
error 
rate 
(%) 
Difference 
in error 
rate 
Pre - post 
1 34 6 17.7 52 3 5.8 -11.9 
2 36 5 13.9 16 2 12.5 -1.4 
3 31 8 25.8 62 7 11.3 -14.5 
4 41 16 39.0 17 1 5.9 -33.1 
5 2 0 0 5 0 0 0 
6 40 11 27.5 4 1 25.0 -2.5 
7 70 24 34.3 45 1 2.2 -32.1 
8 27 9 33.3 42 5 11.9 -21.4 
9 14 3 21.4 30 3 10.0 -11.4 
10 68 17 25.0 13 3 23.1 -1.9 
11 105 55 52.4 20 5 25.0 -27.4 
12 64 29 45.3 41 8 19.5 -25.8 
13 60 11 18.3 56 2 3.6 -14.7 
14 5 4 80.0 116 7 6.0 -74.0 
15 45 4 8.9 125 3 2.4 -6.5 
16 7 1 14.3 108 8 7.4 -6.9 
17 55 12 21.8 55 6 10.9 -10.9 
18 25 11 44.0 39 2 5.1 -38.9 
19 99 10 10.1 1 0 0 -10.1 
20 76 22 29.0 89 4 4.5 -24.5 
21 22 15 68.2 1 0 0 -68.2 
22 12 0 0 4 0 0 0 
23 4 3 75.0 31 4 12.9 -62.1 
24 153 27 17.7 12 0 0 -17.7 
25 23 11 47.8 2 1 50.0 2.2 
26 17 10 58.8 2 0 0 -58.8 
27 *Prescriber excluded from analysis as no matched prescribing 
data 
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Prescriber Pre-
items 
Pre- 
errors 
Pre-
error 
rate% 
Post-
items 
Post- 
errors 
Post-
error 
rate 
(%) 
Difference 
in error 
rate 
Pre - post 
28 19 6 31.6 42 1 2.4 -29.2 
29 9 3 33.3 11 1 9.1 -24.2 
30 24 4 16.7 16 2 12.5 -4.2 
31 19 0 0 68 1 1.5 1.5 
32 11 6 54.6 12 2 16.7 -37.9 
33 10 2 20.0 28 1 3.6 -16.4 
34 56 6 10.7 12 0 0 -10.7 
35 17 0 0 2 0 0 0 
36 *Prescriber excluded from analysis as no matched prescribing 
data 
37 58 19 32.8 12 1 8.3 -24.5 
38 15 0 0 34 7 20.6 20.6 
39 16 5 31.3 31 7 22.6 -8.7 
40 36 8 22.2 42 17 40.5 18.3 
41 90 42 46.7 53 19 35.9 -10.8 
42 62 25 40.3 20 8 40.0 -0.3 
43 5 1 20.0 46 13 28.3 8.3 
44 3 3 100 21 3 14.3 -85.7 
45 33 16 48.5 40 17 42.5 -6.0 
46 20 4 20.0 6 3 50.0 30.0 
47 25 10 40.0 8 1 12.5 -27.5 
48 10 7 70.0 4 3 75.0 5.0 
49 41 1 2.4 77 5 6.5 4.1 
50 54 9 16.7 73 6 8.2 -8.5 
51 49 9 18.4 53 9 17.0 -1.4 
52 56 13 23.2 65 12 18.5 -4.7 
53 6 2 33.3 5 3 60.0 26.7 
54 32 3 9.4 27 2 7.4 -2.0 
 238 
Prescriber Pre-
items 
Pre- 
errors 
Pre-
error 
rate% 
Post-
items 
Post- 
errors 
Post-
error 
rate 
(%) 
Difference 
in error 
rate 
Pre - post 
55 30 6 20.0 2 2 100.0 80.0 
56 110 12 10.9 25 5 20.0 9.1 
57 14 2 14.3 4 0 0 -14.3 
58 14 4 28.6 45 13 28.9 0.3 
59 51 4 7.8 45 9 20.0 12.2 
60 34 10 29.4 25 5 20.0 -9.4 
61 11 2 18.2 9 1 11.1 -7.07 
62 33 6 18.2 56 4 7.1 -11.1 
63 37 11 29.7 34 9 26.5 -3.2 
64 1 0 0 46 15 32.6 32.6 
65 71 4 5.6 69 3 4.4 -1.2 
66 67 11 16.4 3 3 100.0 83.6 
67 29 6 20.7 5 2 40.0 19.3 
68 40 5 12.5 41 5 12.2 -0.3 
69 5 1 20.0 60 12 20.0 0 
70 14 1 7.2 40 3 7.5 0.3 
71 32 6 18.8 4 3 75.0 56.2 
72 64 5 7.8 17 3 17.7 9.9 
73 68 8 11.8 57 4 7.0 -4.8 
74 66 4 6.1 29 2 6.9 0.8 
75 64 3 4.7 25 2 8.0 3.3 
76 60 5 8.3 39 0 0 -8.3 
77 63 11 17.5 20 2 10.0 -7.5 
78 2 0 0 4 2 50.0 50.0 
Total 2891 655  2500 329   
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7.2.6.5.  Assumption testing for inpatient prescribing error rates 
 
Assumption testing for the t-test is outlined below. 
 
Normality of distribution  
 
Shapiro-Wilk tests were <0.05 for both control and intervention groups 
indicating non-normality. Inspection of the histogram suggested the data was 
skewed (Figure 36) whilst the normality plots (figures 37 and 38) suggested a 
distribution that could be approximated as normal with several outliers above 
and below the normality lines. 
 
Figure 36: Histogram illustrating distribution of inpatient prescribing 
error rate change for intervention and control groups 
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Figure 37: Probability plot for change in inpatient prescribing error 
rates for the intervention group 
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Figure 38: Probability plot for change in inpatient prescribing error 
rates for the control group 
 
 
 
 
Although the t-test is robust to deviations from normality as described in 
chapter 3, transformation of the data was attempted before proceeding.  
Using a reflect and logarithmic transformation did not improve distribution of 
data (see figures 39-41 below) 
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Figure 39: Transformed data illustrating mean change in inpatient 
prescribing error rates for intervention and feedback groups 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 243 
Figure 40: Probability plot for transformed change in inpatient 
prescribing error rates for the intervention group 
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Figure 41: Probability plot for transformed change in inpatient 
prescribing error rates for the control group 
 
 
Considering this, the t-test was performed on the original data set, as 
although a Mann-Whitney U test could be performed, the t-test is robust to 
deviations from normality when sample sizes are greater than thirty. 
 
Outliers  
 
Seven outliers were identified from inspection of the box plots below (Figure 
42).  Manual inspection of the data suggested these were true outliers.  
Removal of the outliers produced a normal distribution for the control group 
but not for the intervention group (Shapiro-Wilk 0.055 and 0.008 respectively) 
although the normality plot was improved with a few data points above the 
normality line affecting the distribution.   The t-test was performed with and 
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without the outliers with no change in significance of results as reported 
below. 
 
Figure 42: Boxplot of mean change scores for inpatient prescribing in 
intervention and control groups 
 
 
 
Homogeneity of variances  
 
There was homogeneity of variances for mean difference in inpatient PE 
rates for the intervention and control groups, as assessed by Levene's test 
for equality of variances (p>0.05 at 0.533). 
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7.2.6.6. Results for change in inpatient prescribing error rates 
 
Mean differences in inpatient PE rates were 26.6% (95% CI, -37.9% to -15.3, 
SD = +/- 5.7) statistically, significantly lower in the intervention group 
compared to the control group t(74)=-4.70, p<0.005 (0.000012).  Effect size 
(d) = 1.09 (large effect size). 
 
Removal of outliers had no significant outcome on the statistical test (-19.3% 
mean difference, SD 3.5, 95% CI -26.3 to -12.2) t(73)=-5.462, p<0.005, 
justifying their inclusion. 
 
7.2.7. Impact of feedback on inpatient error free prescriptions  
 
7.2.7.1. Sample size and descriptive statistics for inpatient EFPs 
 
Prescribing data for EFPs per prescriber are presented in table 22 below.   
 
There was an EFP rate of 52.5% (SD 28.6, 95% CI 42.7 to 62.3) at baseline 
and 72.9% (SD 22.6, 95% CI 65.1 to 80.7) post-intervention in the 
intervention group.   
 
There was a 20.4% (95% CI, 10.6 to 30.1, SD 28.5) mean improvement in 
EFPs in the intervention group (n=35) 
 
There was an EFP rate of 53% (SD 25.2, 95% CI 45.1 to 61.0) at baseline 
and 50.1% (SD 27.7, 95% CI 41.4 to 58.9) post-intervention in the control 
group  
 
There was a reduction in EFP rate of 2.9% (95% CI, -14.5 to 8.8, SD 36.9,) 
in the control group (n=41).   
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Table 22: Prescribing data for inpatient error free prescriptions for 
intervention and control groups 
Prescriber Pre- 
prescriptions 
Pre- 
EFP 
Pre- 
EFP % 
Post- 
prescriptions 
Post- 
EFP 
Post- 
EFP 
(%) 
Difference 
in EFP % 
pre - post 
1 10 5 50.0 10 7 70.0 20.0 
2 8 5 62.5 3 2 66.7 4.2 
3 8 5 62.5 11 7 63.6 1.1 
4 6 3 50.0 5 4 80.0 30.0 
5 2 2 100 4 4 100.0 0 
6 9 5 56.0 3 2 67.0 11.0 
7 16 6 37.5 4 3 75.0 37.5 
8 11 6 54.6 9 4 44.4 -10.2 
9 5 4 0.8 5 3 60.0 -20.0 
10 14 8 57.1 5 2 40.0 -17.1 
11 31 8 25.8 11 6 54.6 28.8 
12 10 5 50.0 11 6 54.6 4.6 
13 11 6 54.6 11 9 81.8 27.2 
14 4 1 25.0 24 18 75.0 50.0 
15 8 6 75.0 22 19 86.4 11.4 
16 4 3 75.0 21 14 66.7 -8.3 
17 16 10 62.5 9 4 44.4 -18.1 
18 5 1 20 9 7 77.8 57.8 
19 26 17 65.4 1 1 100.0 34.6 
20 15 9 60.0 21 17 81.0 21.0 
21 5 3 60.0 1 1 100.0 40.0 
22 8 8 100.0 2 2 100.0 0 
23 3 0 0 8 5 62.5 62.5 
24 18 11 61.1 6 6 100.0 38.9 
25 4 0 0 1 0 0 0 
26 4 0 0 1 1 100.0 100.0 
27 *Prescriber excluded from analysis as no matched prescribing data 
28 5 1 20.0 6 5 83.3 63.3 
29 5 3 60.0 2 1 50.0 -10.0 
30 4 2 50.0 5 3 60.0 10.0 
31 9 9 100.0 12 11 91.7 -8.3 
32 2 0 0 8 6 75.0 75.0 
33 3 2 66.7 10 9 90.0 23.3 
34 11 8 72.7 1 1 100.0 27.3 
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Prescriber Pre- 
prescriptions 
Pre- 
EFP 
Pre- 
EFP % 
Post- 
prescriptions 
Post- 
EFP 
Post- 
EFP 
(%) 
Difference 
in EFP % 
pre - post 
35 3 3 100.0 1 1 100.0 0 
36 *Prescriber excluded from analysis as no matched prescribing data 
37 12 3 25.0 2 1 50.0 25.0 
38 7 7 100.0 8 4 50.0 -50.0 
39 3 1 33.3 11 6 54.6 21.3 
40 9 5 55.6 11 3 27.3 -28.3 
41 12 3 25.0 12 7 58.3 33.3 
42 18 9 50.0 5 2 40.0 -10.0 
43 3 2 66.7 10 3 30.0 -36.7 
44 2 0 0 3 2 66.7 66.7 
45 8 2 25.0 8 0 0 -25.0 
46 5 3 60.0 4 1 25.0 -35.0 
47 12 3 25.0 7 6 85.7 60.7 
48 6 3 50.0 3 0 0 -50.0 
49 5 4 80.0 8 6 75.0 -5.0 
50 12 6 50.0 14 11 78.6 28.6 
51 10 3 30.0 10 5 50.0 20.0 
52 6 1 16.7 13 7 53.9 37.2 
53 5 3 60.0 4 1 25.0 -35.0 
54 5 2 40.0 8 6 75.0 35.0 
55 10 4 40.0 2 0 0 -40.0 
56 22 15 68.2 4 0 0 -68.2 
57 4 3 75.0 1 1 100.0 25.0 
58 4 3 75.0 16 6 37.5 -37.5 
59 6 4 66.7 11 5 45.5 -21.2 
60 4 0 0 6 4 66.7 66.7 
61 2 1 50.0 4 3 75.0 25.0 
62 5 2 40.0 15 12 80 40.0 
63 8 4 50.0 7 2 28.6 -21.4 
64 1 1 100.0 6 2 33.3 -66.7 
65 13 9 69.2 8 7 87.5 18.3 
66 12 6 50.0 2 0 0 -50.0 
67 6 1 16.7 3 2 66.7 50.0 
68 7 3 42.9 7 3 42.9 0 
69 2 1 50.0 10 3 30.0 -20.0 
70 6 5 83.3 8 5 62.5 -20.8 
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Prescriber Pre- 
prescriptions 
Pre- 
EFP 
Pre- 
EFP % 
Post- 
prescriptions 
Post- 
EFP 
Post- 
EFP 
(%) 
Difference 
in EFP % 
pre - post 
71 4 1 25.0 4 1 25.0 0 
72 9 5 55.56 6 4 66.7 11.1 
73 14 10 71.4 8 4 50.0 21.4 
74 8 6 75.0 6 4 66.7 -8.3 
75 10 8 80.0 8 6 75.0 -5.0 
76 9 7 77.8 6 6 100.0 22.2 
77 9 4 44.4 7 5 71.4 27.0 
78 2 2 100.0 4 2 50.0 20.0 
Total 620 330   563 349  
 
 
7.2.7.2. Impact of feedback on inpatient error free prescription rates  
 
7.2.7.3. Assumption testing for inpatient error free prescription rates 
 
Normality of distribution   
 
There was normality of distribution as assessed by inspection of the 
histograms (Figure 43) and normality plots (figures 44 and 45) and Shapiro-
Wilk test with p values >0.05 for both intervention (0.086) and control (0.232) 
groups. 
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Figure 43: Histogram illustrating distribution of mean change in 
inpatient EFP % in both intervention and control groups  
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Figure 44: Probability plot for change in inpatient EFP % for the 
intervention group 
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Figure 45: Probability plot for change in inpatient EFP % for the control 
group 
 
 
 
 
Outliers 
 
One outlier (prescriber 26) was identified from inspection of the box plot 
below (see figure 46).  Following inspection of the data manually, the test 
was performed with the outlier and repeated for sensitivity testing without the 
outlier with no difference in the statistical significance.   
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Figure 46: Box plot of change in inpatient EFP % 
 
 
Homogeneity of variance  
 
The assumption of homogeneity of variance was violated as determined by 
Levene’s test (p<0.05 at 0.038). The independent t-test is robust to violations 
of this assumption and could be reported where the variations are not huge 
(p=0.038), hence the t-test could be reported or alternatively, Welch’s t-test 
reported. 
 
7.4.7.4. Results for change in inpatient error free prescription rates 
 
The intervention group had a statistically significantly higher mean change in 
EFP prescription rate compared to the control group with a mean difference 
of 23.23% (SD 7.7, 95% CI 8.0 to 38.5), t(74) = 3.033, p<0.005 (0.003).  
Effect size (d) = 0.70 (medium effect size). 
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Comparing the alternative Welch’s t-test for unequal variances, the results 
are still significant with a mean improvement of 23.2% (± 7.6 95% CI 8.3 to 
38.2) in EFP rates compared to the control group, t(73.313)= 3.095, p < 0.05 
(0.0033) reported. 
 
Performing the t-test without the outlier (prescriber 26) produced a mean 
difference of -20.8% (SD ± 7.5, 95% CI 6.0 to 35.7) between groups that was 
still statistically significant: t (73) = 2.8, p < 0.05 (0.007) justifying inclusion of 
the outlier. 
 
7.2.8.  Impact of feedback on discharge prescribing 
 
7.2.8.1.  Sample size and descriptive statistics  
 
A summary of discharge prescribing data for control and intervention groups 
at baseline and post-test is summarised in table 23.   
 
Table 23:  Overview of prescribing error data for discharge prescribing 
in intervention and control groups  
Group Pre-
items 
Pre- 
errors 
Pre-
error 
rate 
% 
Post-
items 
Post- 
errors 
Post-
error 
rate 
(%) 
Difference 
in error 
rate 
Pre-post 
(%) 
Chi-
square 
and p-
value 
Intervention  1709 386 22.6 1794 83 4.6 -18.0 χ2(1) 
=192, p 
= 
<0.005, 
φ=0.219 
Control 591 97 16.4 828 220 26.6 +10.2 χ2(1) 
=13.2, p 
= 
<0.005, 
φ= -
0.087 
Total 2300 483  2658 303    
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Pre-test 
 
A total of 330 discharge prescriptions were audited at baseline, 145 of which 
were error free (43.9%), with 2300 items prescribed and 483 PEs identified.  
An overall prescribing error rate of 21%. 
 
There were 204 discharge prescriptions in the intervention group, with 75 
error free (36.8%).  There were 1709 prescribed items with 386 PEs, an 
overall prescribing error rate of 22.6%. 
 
There were 126 discharge prescriptions in the control group, with 70 error 
free (55.6%). There were 591 prescribed items with 97 prescribing errors, an 
overall PE rate of 16.4%.   
 
Post-test 
 
A total of 350 discharge prescriptions were audited post-test, with 192 error 
free (54.9%).  There were 2658 prescribed items and 303 prescribing errors 
identified.  An overall PE rate of 11.4%.   
 
There were 185 discharge prescriptions in the intervention group, with 126 
error free (68.1%).  There were 1794 prescribed items with 83 PEs, an 
overall PE rate of 4.6%.  
 
There were 165 discharge prescriptions in the control group, with 66 error 
free (40%).  There were 828 prescribed items and 220 PEs, an overall PE 
rate of 26.6%.  
 
7.2.8.2. Analysis of discharge prescription error frequency 
 
Using chi squared test, there was a statistically significant reduction in error 
frequency in the intervention group (p<0.005) and a significant increase in 
error frequency in the control group (p=<0.005).   Between groups, there was 
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a statistically significant difference in error frequency at baseline  χ2(1) =6.8, 
p = 0.009, φ =0.049 and post-intervention (χ2(1) =204.4, p = <0.005, φ =-
0.263) 
 
7.2.8.3.  Impact of feedback on discharge prescriber error rates 
 
7.2.8.4. Sample size and descriptive statistics for discharge PE rates 
 
A summary of discharge prescribing data per prescriber is summarised in 
table 24 below.   
 
The intervention group included 28 prescribers.  Nine prescribers (5, 12, 21, 
22, 25, 31, 32, 35 and 36) were excluded from the analysis as they did not 
have comparative discharge prescriptions at either baseline, post-
intervention or both.   
 
The mean discharge PE rate was 22.4% (SD 12.2, 95% CI 17.7 to 27.1) at 
baseline and 4.0% (SD 4.3, 95% CI 2.4 to 5.7) post-intervention for the 
intervention group.  A mean reduction in PE rates of -18.4% (SD 12.5, 95% 
CI -23.2 to -13.6) in the intervention group. 
 
The control group consisted of 29 prescribers.   Twelve prescribers (38, 60, 
69-78) were excluded from the analysis as they did not have comparative 
discharge prescriptions at either baseline, post-intervention or both.   
 
The mean discharge PE rate was 16.1% (SD 12.6, 95% CI 11.3 to 20.9) at 
baseline and 27.3% (SD 13.0, 95% CI 22.4 to 32.3) post-intervention for the 
control group.  A mean increase in PE rates of 11.2 % (SD 15, 95% CI 5.5 to 
16.9) in the control group. 
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Table 24: Discharge prescribing data per prescriber  
Prescriber Pre-
items 
Pre- 
errors 
Pre-
error 
rate% 
Post-
items 
Post- 
errors 
Post-
error 
rate 
(%) 
Difference 
in error 
rate 
Pre-post 
1 46 6 13.0 85 2 2.4 -10.6 
2 48 6 12.5 42 2 4.8 -7.7 
3 124 57 46.0 45 1 2.2 -43.8 
4 123 46 37.4 144 6 4.2 -33.2 
5 *Prescriber excluded from analysis as no matched prescribing 
data 
6 45 10 22.2 38 1 2.6 -19.6 
7 40 10 25.0 142 15 10.6 -14.4 
8 45 15 33.3 8 0 0 -33.3 
9 14 8 57.1 17 0 0 -57.1 
10 35 7 20.0 67 2 3.0 -17.0 
11 76 28 36.8 43 8 18.6 -18.2 
12 *Prescriber excluded from analysis as no matched prescribing 
data 
13 141 19 13.5 68 1 1.5 -12.0 
14 144 26 18.1 100 2 2 -16.1 
15 69 9 13.0 85 1 1.2 -11.8 
16 158 27 17.1 264 14 5.3 -11.8 
17 53 18 34.0 53 3 5.7 -28.3 
18 51 11 21.6 51 4 7.8 -13.8 
19 125 18 14.4 13 0 0 -14.4 
20 19 3 15.8 186 7 3.8 -12.0 
21 *Prescriber excluded from analysis as no matched prescribing 
data 
22 *Prescriber excluded from analysis as no matched prescribing 
data 
23 21 3 14.3 70 4 5.7 -8.6 
24 55 3 5.5 45 2 4.4 -1.1 
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Prescriber Pre-
items 
Pre- 
errors 
Pre-
error 
rate% 
Post-
items 
Post- 
errors 
Post-
error 
rate 
(%) 
Difference 
in error 
rate 
Pre-post 
25 *Prescriber excluded from analysis as no matched prescribing 
data 
26 6 2 33.3 14 0 0 -33.3 
27 8 0 0 5 0 0 0 
28 110 23 20.9 59 3 5.1 -15.8 
29 44 8 18.2 13 0 0 -18.2 
30 37 7 18.9 21 0 0 -18.9 
31 *Prescriber excluded from analysis as no matched prescribing 
data 
32 *Prescriber excluded from analysis as no matched prescribing 
data 
33 37 7 18.9 92 3 3.3 -15.6 
34 30 8 26.7 16 1 6.3 -20.4 
35 *Prescriber excluded from analysis as no matched prescribing 
data 
36 *Prescriber excluded from analysis as no matched prescribing 
data 
37 5 1 20.0 8 1 12.5 -7.5 
38 *Prescriber excluded from analysis as no matched prescribing 
data 
39 24 2 8.3 25 6 24.0 15.7 
40 3 0 0 19 5 26.3 26.3 
41 3 0 0 13 3 23.1 23.1 
42 56 20 35.7 5 2 40.0 4.3 
43 25 7 28 20 8 40.0 12.0 
44 6 1 16.7 25 3 12.0 -4.7 
45 17 3 17.7 12 8 66.7 49.0 
46 7 0 0 11 2 18.2 18.2 
47 18 1 5.6 6 1 16.7 11.1 
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Prescriber Pre-
items 
Pre- 
errors 
Pre-
error 
rate% 
Post-
items 
Post- 
errors 
Post-
error 
rate 
(%) 
Difference 
in error 
rate 
Pre-post 
48 *Prescriber excluded from analysis as no matched prescribing 
data 
49 10 2 20.0 39 6 15.4 -4.6 
50 41 4 9.8 60 17 28.3 18.5 
51 8 1 12.5 10 3 30.0 17.5 
52 24 3 12.5 8 2 25.0 12.5 
53 9 3 33.3 30 10 33.3 0 
54 8 2 25.0 19 6 31.6 6.6 
55 35 9 25.7 25 11 44.0 18.3 
56 10 1 10.0 31 3 9.7 -0.3 
57 8 0 0 14 5 35.7 35.7 
58 13 2 15.4 17 3 17.7 2.3 
59 13 2 15.4 50 10 20.0 4.6 
60 *Prescriber excluded from analysis as no matched prescribing 
data 
61 8 2 25.0 4 1 25.0 0 
62 66 9 13.6 53 5 9.4 -4.2 
63 22 4 18.2 78 37 47.4 29.2 
64 9 4 44.4 3 1 33.3 -11.1 
65 11 2 18.2 55 5 9.1 -9.1 
66 46 3 6.5 30 4 13.3 6.8 
67 61 3 4.9 17 6 35.3 30.4 
68 14 0 0 50 14 28.0 28.0 
69 16 7 43.8 99 33 33.3 -10.5 
Total 2300 483  2658 303   
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7.2.8.5. Assumption testing for discharge prescribing PE rates 
 
Normality of distribution 
 
The Shapiro-Wilk test indicated non-normality for the intervention group 
(p=0.03) and normality for the control group (p=0.443).  Transformation of 
the data did not improve the histograms or Shapiro-Wilk test results. 
Inspection of the histogram (figure 47) and normality plots (Figures 48 and 
49) would suggest that the intervention group could be approximated to a 
normal distribution with a mild negative skew caused by a few residuals 
above the normal line.  Removal of outliers (see figure 50) normalized the 
distribution (Figures 51-53) with Shapiro-Wilk values of 0.506 and 0.426 in 
the intervention and control groups.  Considering the robustness of the 
independent t-test to outliers, the t-test was performed with the outliers and 
repeated without them as a measure of sensitivity with no difference in the 
significance of the t-test reported.  
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Figure 47: Histogram illustrating distribution of control and intervention 
group mean change in discharge prescribing error rates 
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Figure 48: Probability plot for intervention group mean change in 
discharge prescribing error rate 
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Figure 49: Probability plot for control group mean change in discharge 
prescribing error rate 
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Figure 50: Boxplot of mean change in prescribing error rates for 
discharge prescribing in intervention and control groups  
 
 
 
Six outliers were identified from visual inspection of the box plot (see figure 
50) for discharge prescribing data.  Five prescribers (prescribers 3, 4, 8, 9 
and 26) were in the intervention group and one in the control group 
(prescriber 45).  Removal of outliers produced normality of distribution as 
demonstrated by Shapiro-Wilk values (0.506 and 0.426 for intervention and 
control groups) and inspection of normality plots and histograms (figures 51-
53). 
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Figure 51: Probability plot for mean change in discharge prescribing 
error rate without outliers for the intervention group 
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Figure 52: Probability plot for mean change in discharge prescribing 
error rate without outliers for the control group 
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Figure 53: Histogram illustrating distribution of control and intervention 
group mean change in discharge prescribing error rates without 
outliers 
 
 
7.2.8.6. Results for change in discharge PE rates  
 
Homogeneity of variances was demonstrated from the Levene’s test for 
equality of variances (p= 0.131).  There was a statistically significant 
difference in mean change of PE rates in the intervention compared to the 
control group, mean difference=-29.6% (SD 3.7, 95% CI -37.0 to -22.3), t(55) 
= -8.094, p <0.005.  Effect size (d)=2.15 (large effect size). 
 
Sensitivity test 
 
The t-test was performed without the outliers.  Mean PE rates decreased by 
13.6% (SD 6.2, 95% CI -16.4 to -11.0) in the intervention group and 
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increased by 9.9% (SD 13.4, 95% CI 4.7 to 15.1) in the control group.  There 
was a statistically significant difference in the mean change in PE rate of -
23.5% (SD 3.0, 95% CI -29.6 to -17.4) t(49)=-7.765, p<0.005.  However, as 
the equality of variance was violated (P<0.05) Welch’s test should also be 
reported as a mean difference -23.3% (SD 2.8, 95% CI -29.3 to -17.8), 
t(39.801)=-8.28, p<0.005.  As the result was still significant, inclusion of the 
above outliers can be justified.   
 
7.2.9.    Impact of feedback on error free discharge prescriptions  
 
7.2.9.1 Sample size and descriptive statistics  
 
Prescribing data for discharge EFPs per prescriber are presented in table 25 
below.  A total of 57 prescribers were included in the analysis, 28 in the 
intervention group and 29 in the control group 
 
The mean discharge EFP rate was 37.2% (SD 25.0, 95% CI 27.5 to 46.9) at 
baseline and 70.6% (SD 25.5, 95% CI 60.7 to 80.5) post-intervention for the 
intervention group.  A mean improvement in EFP rates of 33.4%, SD 37.7, 
95% CI 18.7 to 48.0). 
 
The mean discharge EFP rate was 49.1% (SD 35.5, 95% CI 35.5 to 62.6) at 
baseline and 34.3% (SD 28.4, 95% CI 23.5 to 45.1) post-intervention for the 
control group.  A mean decrease in EFP rates of 14.8%, SD 43.2, 95% CI -
31.3 to 1.6).   
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Table 25: Error free discharge prescriptions for prescriber 
Prescriber Pre- 
prescriptions 
Pre- 
EFP 
Pre- 
EFP % 
Post- 
prescriptions 
Pre- 
EFP 
Post- 
EFP 
(%) 
Difference 
in EFP % 
pre-post 
1 8 5 62.5 11 10 90.9 28.4 
2 9 4 44.4 5 3 60.0 15.6 
3 18 4 22.2 4 3 75.0 52.8 
4 16 4 25.0 16 10 62.5 37.5 
5 *Prescriber excluded from analysis as no matched prescribing data 
6 7 4 57.1 3 2 66.7 9.6 
7 3 0 0 26 20 76.9 76.9 
8 8 1 12.5 1 1 100.0 87.5 
9 3 0 0 2 2 100.0 100 
10 7 4 57.1 6 4 66.7 9.6 
11 10 3 30.0 3 2 66.7 36.7 
12 *Prescriber excluded from analysis as no matched prescribing data 
13 12 4 33.3 8 7 87.5 54.17 
14 13 5 38.5 10 8 80.0 41.5 
15 8 4 50.0 9 8 88.9 38.9 
16 17 7 41.2 21 8 38.1 -3.1 
17 7 3 42.9 5 2 40.0 -2.9 
18 5 3 60.0 5 2 40.0 -20.0 
19 10 6 60.0 1 1 100.0 40.0 
20 3 2 66.7 15 11 73.3 6.6 
21 *Prescriber excluded from analysis as no matched prescribing data 
22 *Prescriber excluded from analysis as no matched prescribing data 
23 2 0 0 7 4 57.1 57.1 
24 4 3 75.0 5 3 60.0 -15.0 
25       0 
26 1 0 0 2 2 100.0 100.0 
27 1 1 100.0 1 1 100.0 0 
28 11 3 27.3 3 1 33.3 6.0 
29 6 1 16.7 2 2 100.0 83.3 
30 4 1 25.0 3 3 100.0 75.0 
31 *Prescriber excluded from analysis as no matched prescribing data 
32 *Prescriber excluded from analysis as no matched prescribing data 
33 4 1 25.0 8 5 62.5 37.5 
34 5 1 20.0 2 1 50.0 30.0 
35 *Prescriber excluded from analysis as no matched prescribing data 
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Prescriber Pre- 
prescriptions 
Pre- 
EFP 
Pre- 
EFP % 
Post- 
prescriptions 
Pre- 
EFP 
Post- 
EFP 
(%) 
Difference 
in EFP % 
pre-post 
36 *Prescriber excluded from analysis as no matched prescribing data 
37 2 1 50.0 1 0 0 -50.0 
38 *Prescriber excluded from analysis as no matched prescribing data 
39 11 9 81.8 10 5 50.0 -31.8 
40 3 3 100.0 6 1 16.7 -83.3 
41 1 1 100.0 2 1 50.0 -50.0 
42 16 9 56.3 3 1 33.3 -22.9 
43 4 1 25.0 6 0 0 -25.0 
44 4 3 75.0 7 4 57.1 -17.9 
45 10 7 70.0 6 0 0 -70.0 
46 3 3 100 7 5 71.4 -28.6 
47 7 6 85.7 3 2 66.7 -19.0 
48 *Prescriber excluded from analysis as no matched prescribing data 
49 2 0 0 8 5 62.5 62.5 
50 6 4 66.7 9 2 22.2 -44.4 
51 2 1 50.0 3 0 0 -50.0 
52 3 1 33.3 3 1 33.3 0 
53 5 2 40.0 11 6 54.6 14.6 
54 3 2 66.7 6 2 33.3 -33.34 
55 4 0 0 4 0 0 0 
56 2 1 50.0 8 6 75.0 25.0 
57 4 4 100.0 2 0 0 -100.0 
58 4 2 50.0 4 3 75.0 25.0 
59 3 1 33.3 8 5 62.5 29.2 
60 *Prescriber excluded from analysis as no matched prescribing data 
61 2 0 0 1 0 0 0 
62 10 4 40.0 9 5 55.6 15.6 
63 2 0 0 8 2 25.0 25.0 
64 1 0 0 1 0 0 0 
65 2 0 0 7 5 71.4 71.4 
66 4 2 50.0 5 3 60.0 10.0 
67 6 3 50.0 2 0 0 -50.0 
68 1 1 100 5 0 0 -100.0 
69 1 0 0 11 2 18.2 18.2 
Total 330 145 43.9% 350 192 54.9%  
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7.2.9.2. Impact of feedback on error free discharge prescription rates 
 
7.2.9.3. Assumption testing for error free discharge prescription rates  
 
Normality of distribution 
 
There was normality of distribution as demonstrated by inspection of the 
histogram (Figure 54) and normality plots (Figures 55 and 56) and the 
Shapiro-Wilk test having a p>0.05 (0.740 for intervention group and 0.661 for 
control groups). 
 
 
Figure 54: Histogram illustrating distribution of control and intervention 
group change in error free prescriptions percentage  
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Figure 55: Probability plot for intervention group mean change in EFP 
rate 
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Figure 56: Probability plot for control group mean change in discharge 
EFP rate 
 
 
Outliers 
 
No outliers were identified from inspection of the box plot below (figure 57). 
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Figure 57: Boxplot of mean change in error free prescription 
percentage per prescriber for discharge prescribing 
 
 
 
Homogeneity of variance 
 
There was homogeneity of variance as demonstrated by Levene’s test 
p>0.05 (0.441), therefore all assumptions were met for the t-test.  
 
7.2.9.4.  Results for change in error free discharge prescription rates  
 
There was an improvement in the mean percentage of EFPs in the 
intervention group compared to the control group.  This was statistically 
significant with a mean difference of 48.2% (SD+/-10.8, 95% CI, 26.6 to 
69.7), t(55)=4.478, p<0.005 (0.000038).  Effect size (d) = 1.19 (large effect 
size). 
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7.2.10. Impact on prescribing error severity 
 
The frequency and percentage of PE severities is reported in table 25, and 
figures 58 and 59 below.   
 
To explore the impact of the intervention on the distribution of PE severity, 
chi-squared tests of homogeneity were used.  Chi-squared tests were also 
used to determine the significance of any change in frequency of PE severity 
within each group. 
 
The null hypothesis is; 
 
H0: There is no difference in the distribution of error severity between groups 
 
The chi-square of homogeneity for the intervention group was reported as 
χ2(2) = 0.807 p=0.668, φ = 0.30. Therefore, the null hypothesis is accepted, 
the distribution of error severity is the same between pre- and post-testing for 
the intervention group. 
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Figure 58: Distribution of prescribing error severity for the intervention 
group at baseline and post-intervention 
 
 
 
As observed in figure 59, the distribution of error severity changed between 
pre-and post-data collection for the control group with minor errors 
predominating in the pre-intervention period and significant errors 
predominating in the post-intervention data collection period. 
 
The chi-square of homogeneity for the control group was reported as χ2(3) = 
38.313, p<0.005, φ=0.213. Therefore, the null hypothesis is rejected and the 
alternate hypothesis that the distribution of PE severity is different between 
pre- and post-testing in the control group accepted. Within group analysis 
suggested a statistically significant increase in the proportion of significant 
PEs (χ2(1)=11.9, p=0.001, φ=-0.098) and a statistically significant reduction 
in the proportion of minor PEs (χ2(1)=12.6, p<0.005, φ=0.1). 
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Figure 59: Distribution of prescribing error severity for the control 
group at baseline and post-intervention 
 
 
The frequency of each error severity is reported in table 26 below.  Where 
reported, all expected cell frequencies were greater than five. 
 
Here the null hypothesis is; 
 
H0: There is no difference in the frequency of error severity following the 
intervention period 
 
All grades of PE were reduced in the intervention group. No potentially lethal 
errors were reported. 
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In the control group, there was a significant reduction in minor errors with a 
non-significant reduction in potentially lethal errors. There was a significant 
trend towards an increase in overall prescribing errors (3.7%) with 
statistically significant increases in significant errors and non-significant 
increases in serious errors reported.  
 
Table 26: Prescribing error severity and frequency pre- and post-
intervention 
Severi
ty 
Intervention group Control Group 
Pre- rate 
(%) 
(Errors/i
tems) 
Post- 
rate (%) 
(Errors/i
tems) 
Differ
ence 
(ARR) 
χ2 and 
p-value 
Pre- rate 
(%) 
(Errors/i
tems) 
Post- 
rate (%) 
(Errors/i
tems) 
Differ
ence 
(ARR) 
p-
value 
Potent
ially 
lethal 
0/3067= 
0% 
0/2985= 
0% 
n/a N/A 2/2124= 
0.1% 
(0.5% of 
errors) 
1/2137= 
0.047% 
(0.2% of 
errors) 
-0.1% 
(-0.3% 
of 
errors) 
*Fishe
rs 
exact 
test 
p>0.0
5, 
=0.62
4 
Seriou
s 
15/3067
= 0.5% 
(2% of 
errors) 
2/2985= 
0.07% 
(1.2% of 
errors) 
-0.4% 
(-0.7% 
of 
errors) 
χ2(1)=9.
6, 
P=0.00
1981, 
φ=0.04 
15/2124
= 0.7% 
(3.9% of 
errors) 
28/2137
= 1.3% 
(6.0% of 
all 
errors) 
0.6% 
(+2.1
% of 
errors) 
χ2(1)=
3.8, 
P=0.0
51, 
φ=-
0.03 
Signifi
cant 
339/306
7= 
11.1% 
(44.8% 
of errors) 
80/2985
= 2.7% 
(47.6% 
of errors) 
-8.4% 
(+2.8
% of 
errors) 
χ2(1)=1
43.6, 
p<0.00
5, 
φ=0.14
9 
134/212
4= 6.3% 
(35.1% 
of errors) 
252/213
7= 
11.8% 
(54.3% 
of all 
errors) 
 
5.5% 
(+19.2
% of 
errors) 
χ2(1)=
32.4, 
P<0.0
5, = 
=0.00
187, 
φ=-
0.084 
Minor 402/306
7= 
13.1% 
86/2985
= 2.9% 
(51.2% 
-
10.2% 
(-2.0% 
χ2(1)=1
82.2, 
p<0.00
231/212
4= 
10.9% 
183/213
7= 8.6% 
(39.4% 
-2.3% 
(-
21.0% 
χ2(1)=
5.3, 
P<0.0
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(53.2% 
of errors) 
of errors) of 
errors) 
5, 
φ=0.16
7 
(60.5% 
of errors) 
of all 
errors) 
of 
errors) 
 
5, = 
=0.02
1, φ=-
.034 
Total 
errors 
756/306
7= 
24.7% 
168/298
5= 5.6% 
-
19.0% 
χ2(1)=3
13.8, 
P<0.05, 
φ=-
0.212 
382/212
4= 
18.0% 
464/213
7= 
(21.7% 
of all 
errors) 
+3.7% χ2(1)=
6.2, 
P<0.0
5, = 
=0.01
3, φ=-
0.035 
 
 
7.2.11. Impact on prescribing error type 
 
The frequency and percentage of each type of PE is presented in table 27 
and figures 60 and 61 below.   
 
To explore the impact of the intervention on distribution of PE type, chi-
squared tests of homogeneity were used.  In addition, chi-squared tests were 
used to determine the significance of any change in frequency of PE type 
within each group.  
 
The null hypothesis is; 
 
H0: There is no difference in the distribution of error type between groups 
 
For the intervention group, the chi-squared for homogeneity test χ2(9) = 14.3, 
p>0.05 (0.11, φ=0.124) accepts the null hypothesis and the distribution of PE 
types were the same before and after feedback. 
 
For the control group, χ2(9)=33.1, p<0.05 (0.00013, φ=0.198) and so the null 
hypothesis is rejected. The distribution of PE type differs before and after the 
intervention period for the control group.  Significant differences were 
identified for allergy status, excessive/unnecessary prescribing, omission of 
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medication, excessive prescribing, clinical safety and miscellaneous error 
types.    
 
Distribution of error type between control and intervention groups pre-test 
was significantly different, χ2(9)=41.9, p<0.05 (0.000003, φ=0.192).  
  
Distribution of error type between control and intervention groups post-test 
was significantly different, χ2(9)=12.0, p>0.05 (0.212, φ=0.138).   
 
Statistically significant reductions (p<0.05) in the frequency of all PE types 
were reported for the intervention group with writing errors and lack of clear 
directions showing the largest improvements (Table 27).  For the control 
group, significant reductions were observed for the frequency of allergy 
status and miscellaneous types of PE.  Significant increases in omission 
errors, excessive prescribing and clinical safety errors were also observed 
for the control group.  Statistically non-significant increases in writing, 
duration, drug interaction errors, and lack of clear instructions were also 
observed for the control group (Table 27).   
 
Table 27: Types and frequency of prescribing error pre- and post-
intervention 
Severity Intervention group Control Group 
Pre- 
rate 
Post- 
rate 
Differe
nce 
p-value Pre- 
rate 
Post- 
rate 
Differe
nce 
p-value 
1. Dosing error 119/30
67= 
3.9% 
32/29
85= 
1.1% 
-2.8% χ2(1)=4
6.7, p 
<0.005, 
φ=0.08
7 
58/21
24= 
2.7% 
82/213
7= 
3.8% 
+1.1 χ2(1)=3.
8, p = 
0.05, 
φ=-0.03 
2. Writing error 181/30
67= 
5.9% 
42/29
85= 
1.4% 
-4.5% χ2(1)=8
0.1, p 
<0.005, 
φ=0.11
3 
142/2
124 = 
6.7% 
143/21
37= 
6.7% 
+0.01
% 
χ2(1)=0.
00, p 
>0.05 
(0.994), 
φ=-0.00 
3. Allergy 
status 
15/306
7= 
2/298
5= 
-0.4% χ2(1)=9.
6, p 
12/21
24= 
3/2137
= 
-0.5% χ2(1)=5.
4, p 
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0.5% 0.1% <0.05 
(0.002) 
φ=0.04
0 
0.6% 0.1% <0.05 
(0.020), 
φ=-
0.036 
4. Duration of 
treatment 
81/306
7= 
2.6% 
16/29
85= 
0.5% 
-2.1% χ2(1)=4
1.2, p 
<0.05, 
φ=0.08
2 
48/21
24= 
2.3% 
42/213
7= 
2.0% 
-0.3% χ2(1)=0.
428, p 
>0.05 
(0.513), 
φ=0.01
0 
5. Drug 
Interactions 
19/306
7= 
0.6% 
3/298
5= 
0.1% 
-0.5% χ2(1)=1
1.2, p 
<0.05 
(0.001), 
φ=0.04
3 
3/212
4= 
0.1% 
10/213
7= 
0.5% 
+0.4% χ2(1)=3.
7, p 
>0.05 
(0.054), 
φ=-0.29 
6. Omission of 
medication  
109/30
67= 
3.6% 
17/29
85= 
0.6% 
-3.0% χ2(1)=6
3.4, p 
<0.05, 
φ=0.10
1 
27/21
24= 
1.3% 
52/213
7= 
2.4% 
+1.1% χ2(1)=7.
6, p 
<0.05 
(0.006), 
φ=-
0.042 
7. 
Excessive/unn
ecessary 
prescribing 
48/306
7= 
1.6% 
19/29
85= 
0.6% 
-1.0% χ2(1)=1
1.73, p 
<0.05 
(0.001), 
φ=0.04
4 
16/21
24= 
0.8% 
38/213
7= 
1.8% 
+1.0% χ2(1)=8.
7, p 
<0.05 
(0.003), 
φ=-
0.045 
8. Clinical 
safety error 
46/306
7= 
1.5% 
14/29
85= 
0.5% 
-1.0% χ2(1)=1
6.1, p 
<0.05, 
φ=0.05
1 
26/21
24= 
1.2% 
45/213
7= 
2.1% 
+0.9% χ2(1)=4.
9, p 
<0.05 
(0.027), 
φ=-
0.034 
9. Lack of clear 
directions 
114/30
67= 
3.7% 
15/29
85= 
0.5% 
-3.2% χ2(1)=7
1.8, p 
<0.05, 
φ=0.10
8 
36/21
24= 
1.7% 
44/213
7= 
2.1% 
+0.4% χ2(1)=0.
7, p 
>0.05 
(0.39), 
φ=-
0.013 
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10. 
Miscellaneous 
24/306
7= 
0.8% 
8/298
5= 
0.3% 
-0.5% χ2(1)=7.
5, p 
<0.05, 
φ=0.03
5 
14/21
24= 
0.7% 
5/2137
= 
0.2% 
-0.5% χ2(1)=4.
3, p 
<0.05 
(0.038), 
φ=0.03
2 
Total errors 756/ 
3067= 
24.7% 
168/ 
2985 
= 
5.6% 
  382/ 
2124
= 
18.0
% 
464/ 
2137 
= 
21.7% 
  
 
Figure 60: Distribution of prescribing error type for the intervention 
group pre- and post-intervention 
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Figure 61: Bar chart illustrating prescribing error type for the control 
group pre- and post-intervention 
 
 
 
7.2.12. Impact on prescriber grade 
 
The frequency and percentage of PEs for each prescriber grade is reported 
in table 28 and figures 62 and 63 below.   
 
To explore the impact of feedback on PE frequency for each prescriber 
grade, chi-squared tests were used for both groups. 
 
In the intervention group, foundation year one doctors prescribed most 
commonly pre- and post-intervention.  Consultants had the lowest PE rate 
(0%), followed by FY2s (18.2%), FY1s (22.5%) and then CT/ST grade 
doctors (32.6%).  CT/ST grade prescribers continued to have the highest PE 
rate post-intervention (6.5%), followed by FY2s (5.5%) and then FY1s (5.1%) 
and consultants (0%). 
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All prescriber grades in the intervention group demonstrated a significant 
reduction in PE frequency.  Reflecting the baseline PE rates, CT/ST grade 
doctors demonstrated the greatest reduction in PE rates (-26.1%, p<0.005), 
followed by FY1s (-17.4%, p<0.005) and FY2s (-12.7%, p<0.005).    
 
In the control group CT/ST grade doctors prescribed most commonly pre-
intervention whilst FY2 prescribed most commonly post-intervention.  
Consultants had the highest PE rate (35.5%), followed by CT/STs (20.6%), 
FY2s (18.5%) and then non-medical prescribers (15.2%) with FY1 grade 
doctors having the lowest PE rate (13.3%).  Consultants continued to have 
the highest PE rate post-intervention (33.3%) followed by CT/STs (23.3%), 
FY2s (23.2%) and then FY1 grade doctors (20.8%) with non-medical 
prescribers having the lowest PE rate (8.3%). 
 
In the control group, non-medical (-6.9%, p=0.167) and consultant grade (-
2.2%, p=0.911) prescribers demonstrated a non-significant reduction in PE 
rates.  All other grades demonstrated significant increases in PE rates. 
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Table 28: Number of prescribed items, errors and error rates for each 
prescriber grade pre- and post-intervention 
 
Prescriber 
Grade 
Intervention group Control Group 
Pre-
prescribing 
error rate 
(Items/erro
rs) 
Post-
prescribin
g error 
rate 
Differ
ence 
p-value Pre-
prescrib
ing error 
rate 
Post-
prescribing 
error rate 
Diffe
renc
e 
p-value 
FY1 326/1449= 
22.5% 
83/1629= 
5.1% 
 
-
17.4% 
χ2(1)= 
153.8, 
P=<0.0
5, φ= 
0.210 
79/595= 
13.3% 
154/742= 
20.8% 
+7.5
% 
χ2(1)= 
9.1, 
P=0.003, 
φ=     -
.076 
FY2 118/647= 
18.2% 
12/219= 
5.5% 
-
12.7% 
χ2(1)= 
16.4, 
P=<0.0
5, φ= 
0.128 
98/531= 
18.5% 
188/810= 
23.2% 
+4.7
% 
χ2(1)= 
2.8, 
P=0.093 
φ= -.042 
CT/ST 312/957= 
32.6% 
73/1128= 
6.5% 
-
26.1% 
χ2(1)= 
160.6, 
P=<0.0
5, φ= 
0.255 
179/868
= 20.6% 
106/455= 
23.3% 
+2.7
% 
χ2(1)= 
0.8, 
P=0.368, 
φ= -.022 
Consultant 0/14 = 0% 0/9= 0% 0% n/a 11/31= 
35.5% 
7/21= 
33.3% 
-
2.2% 
χ2(1)= 
0.012, 
P=0.911, 
φ= 0.013 
NMP N/A N/A n/a n/a 15/99= 
15.2% 
9/109= 
8.3% 
-
6.9% 
χ2(1)=1.9, 
P=0.167, 
φ= 0.091 
Total 756/3067= 
24.7% 
168/2985
= 5.6% 
-
19.1% 
 382/212
4= 
18.0% 
464/2137= 
21.7% 
+3.7
% 
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Figure 62: Prescribing error rate (%) by prescriber grade pre- and post-
intervention for the intervention group c 
 
 
c NB consultant grade prescribers had a 0% PE rate at baseline and post 
intervention in the intervention group 
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Figure 63: Prescribing error rate (%) by prescriber grade pre- and post-
intervention for the control group 
 
 
 
7.2.13. Summary of results 
 
 Feedback was delivered to 36 doctors over 8 wards with prescribing 
compared to 41 doctors on another eight wards who continued with normal 
practice. 
 A combination of descriptive and inferential statistics have been used to test 
the research hypotheses. 
 There was an 18.3% reduction in overall PE rate in the intervention group 
and a 5.4% increase in PE rate in the control group following the intervention 
period.  This was a statistically significant (p<0.05) change in PE rates of 
23.7%. 
 There was a 23.7% increase in overall EFP rate in the intervention group and 
a 5.9% increase in EFP rate in the control group following the intervention 
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period.  This was a statistically significant (p<0.05) change in EFP rates of 
29.5%. 
 These results were consistent for inpatient and discharge prescribing with 
significant improvements in PE rates reported.  
 No association was identified between PE rate change and number of 
feedback sessions 
 All PE types and severity were significantly reduced in the intervention group 
 All prescriber grades demonstrated an improvement in PE rate in the 
intervention group except for consultants, where no change was identified. 
 
7.3. Chapter discussion 
 
This chapter aimed to determine if the results from chapter five were 
reproducible on a larger scale.  Results in this chapter demonstrate 
statistically significant improvements in both PE and EFP rates for the 
intervention group.  Additional reductions in all PE types and severity for 
each prescriber grade have also been reported.  PE rates increased in the 
control group with reductions in EFP rates also reported.  PE rates were 
different between groups at baseline.  The higher PE rate for the intervention 
group may be an artefact of the non-randomization of wards or equally a 
‘Hawthorne effect’ of pharmacists being more motivated to collect audit data 
on the intervention wards.    
 
Baseline PE rates in this chapter are higher than the average reported in one 
large UK PE study (Dornan et al. 2009) although it is acknowledged that PE 
rate is observer dependent (Dean Franklin et al. 2005).  Furthermore, the PE 
rate is consistent with other PE studies (Bowers et al. 2009, Reynolds et al. 
2016, Ross et al. 2009) and annual audits undertaken within STHKH.  EFP 
rates were also consistent with that reported elsewhere (Seden et al. 2013). 
 
PE rates in this chapter are similar to those reported in chapter 5.  Whilst the 
PE rate improved in the intervention group, it increased by 5.4% in the 
control group.  As proposed in chapter 5, this may be due to a lack of 
feedback or “prescribing etiquette”.  It should be noted that only trainee 
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grade prescribing error rates increased in the control group with consultants 
and NMPs showing non-significant improvements.   Trainee grade 
prescribers are a transient population and it is possible that at the start of 
each rotation, perceived confidence or capability is lower than at the end of 
the rotation when prescribing was re-audited.  A lack of feedback could 
therefore contribute to any mismatch (Ryan et al. 2014) between perceived 
and actual confidence influencing the observed increase in PE rates. 
 
Studies evaluating the impact of feedback in hospital settings is limited.  
Recent studies in the hospital setting have suggested non-significant or small 
effects of feedback on PE rates (Reynolds et al. 2016,  Ajemigbitse et al. 
2016).  However, as argued in chapter 2, the feedback content, process and 
frequency were not clear whilst prescriber identification was limited 
(Reynolds et al. 2016), a key barrier to delivery of any feedback.  Large 
effect sizes of the intervention have been reported in this chapter.   This is 
consistent with the findings reported in chapter 5 and perhaps reflects the 
fact that prescribers may not have been performing well initially.  
Furthermore, the feedback intervention reflects principles of effective 
feedback which may influence its efficacy.  Additionally, where the feedback 
facilitator is ward based, they will have the advantage of recognizing 
prescriber signatures to both deliver feedback and collect relevant PE data. 
 
A greater frequency of feedback is considered to be more successful in 
improving task performance (Ivers et al. 2012).  However, no association 
was observed between change in PE rates and number of feedback 
sessions.  This suggests that intensity of feedback is not the sole driving 
factor in reducing PE rates.  The process outcomes and variations in 
feedback delivery reported in chapter 6 and as will be described in 
pharmacist interviews in chapter 8, could be masking any association. 
 
The emerging complexity of the intervention is likely to be a contributing 
factor to improvements in PE rates although the impact of each individual 
component is unknown.  McLellan et al. (2016) suggest “prescribing 
behaviour is adaptive and can be positively influenced by structured 
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feedback”.  Such adaptive processes are likely from the direct effects of 
feedback but it is also possible that prescribers may adapt their behaviour in 
anticipation of feedback as described in chapter 6.  This may be to avoid 
unfavourable comparison to peers, unfavourable feedback (Brett and Atwater 
2001), or to be viewed negatively by the ward pharmacist, a feedback ‘cost’ 
described elsewhere (Teunissen et al. 2009) or could simply be a positive 
‘Hawthorne effect’ and beneficial unintended outcome.  Further adaptive 
behaviours will be described in chapter 9.   
 
Raising awareness of PEs may change prescriber practice simply to avoid 
loss of reputation or disciplinary action if reported (Gallagher et al. 2003) with 
similar views expressed by prescribers in chapter 6.  Prescribers have 
reported being complacent about potential consequences of PEs (Ryan et al. 
2014).  Feedback can address this complacency, outlining the potential risk 
or impact on others if the PE was not intercepted; an approach consistent 
with feedback in this thesis. 
 
Prescribers have reported a reliance on pharmacists to intercept PEs 
(Dornan et al. 2009) and a culture of non-interference with senior doctors’ 
prescribing decisions (Charani et al. 2013).  Equally, pharmacists have also 
reported correcting PEs without contacting the prescriber (Bertels et al. 
2013).  Such social prescribing rules have the potential to cause patient 
harm.  Charani et al.  (2014) argue that interventions aimed at junior doctors 
may be limited where there is a dichotomy between social and organizational 
norms.  Broom et al. (2014) reported that antimicrobial prescribing decisions 
are influenced less by “bureaucratic routinisation” and more by hierarchies 
and securing of professional reputation.  This resonates with previous work 
on antimicrobial prescribing etiquette (Charani et al. 2013) and fraternal 
obligation (Björnsdóttir and Hansen 2002) with suboptimal prescribing 
considered logical, realistic and acceptable (Broom et al. 2014, Mattick et al. 
2014, McLellan et al. 2016) in workplace contexts. 
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Where these cultures exist, sub-optimal prescribing is likely to be influenced, 
especially where junior doctors prescribe the majority of items, yet the 
majority of prescribing decisions reside with a more senior prescriber (Ross 
et al. 2013a).  This may be reflected in the increase in error rates in the 
control group and the larger effect size reported for discharge over inpatient 
prescribing that is more likely to be directed by senior colleagues.  Discharge 
prescriptions in particular, have been reported as a tedious or boring task 
(Dornan et al. 2009).  Where feedback raises awareness of the potential for 
error, the impact on others and how to reduce PEs, the tedium, an error 
provoking condition itself (Dornan et al. 2009), may be mitigated. 
 
The results in this chapter suggest that feedback should be part of a new 
cultural norm with all prescriber grades receiving and expecting feedback on 
their prescribing as described in chapter 6 and reported by pharmacists in 
chapter 8.  PEs are avoidable and so error free prescriptions should be an 
expected standard, a standard encouraged and reinforced through ongoing 
feedback.  Without feedback, the risk of ward specific practices or 
“prescribing rules” that deviate from best practice could become routine and 
this is one plausible reason why PEs increased in the control group in this 
study.  Results of the interviews in chapters 6 and 8 support this suggestion 
with prescribers more engaged with the prescribing process and challenging 
accepted practice such as prescribing on ward rounds.   
 
Whilst significant reductions in PEs have been reported in this chapter, PEs 
were still occurring.  PE causation is complex and multifactorial (Dornan et 
al. 2009, Ross et al. 2013a, Tully et al 2009) and it would be naïve to 
assume that feedback can eliminate all PEs.  Equally, prescribers may be 
less motivated to prevent potentially minor errors such as not dating a 
prescription, an example of a ‘writing error’ that predominated in this study 
and resonates with both prescriber and pharmacist views in chapters 6 and 
7. 
 
Junior doctor prescribing has been described as “part of a complex adaptive 
social system” where the system and its agents co-evolve in response to 
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change” (McLellan et al. 2016).  In this setting, PE feedback has the potential 
to improve prescribing by challenging prescriber perceptions and outlining 
expected exemplary practice.  If prescribing is a social experience (McLellan 
et al. 2016), where feedback provides not only the impetus for pharmacists 
and prescribers to interact, but the catalyst for further interaction as 
described in chapters 6 and 8, the potential for feedback to influence 
prescriber actions can be seen.    
 
Additional confounding factors may have contributed to reductions in PE 
rates.  Firstly, both pharmacists and prescribers in chapters 6 and 8 reported 
enhance rapport, teamwork and communication with greater information-
seeking and feedback-seeking behaviour from prescribers.  Where inter-
professional interactions are developed following PE feedback, 
improvements in prescribing outcomes might be expected. 
 
Additionally, educational interventions, including bespoke teaching sessions 
and provision of memory aids, were reported as an outcome of delivering 
feedback.  The impact of educational outreach or pharmacist-led prescriber 
training has been reported to have small but positive impacts on prescribing 
practice (O’Brien et al.  2007). 
 
Whilst these are welcome and valued outcomes of the feedback process, 
they may have equally influenced PE rates as they were not part of routine 
ward-based pharmacist practice beforehand, making inferences on the 
impact of feedback as a single intervention, difficult to interpret.  Secondly, 
the author interviewed many of the prescribers throughout the intervention 
period on PEs they had received feedback on as described in chapter 9.   
This interview process may have encouraged further prescriber reflection 
and influenced prescriber practice.  
 
Facilitation was required by the author to support ward pharmacists in 
delivery of feedback.  This included, where requested, discussing delivery of 
feedback beforehand with the pharmacist.  Additionally, the author checked 
with pharmacists what interventions had been made, if feedback was 
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required, and had been delivered.  Whilst pharmacists will develop the 
confidence to prepare and deliver feedback autonomously, it is clear from the 
post-intervention results that the number of errors classified as significant or 
above (n=82) over one week did not reflect the number of errors that 
prescribers received feedback on over the three-month period (n=177) from 
ward pharmacists. 
 
Time constraints are an obvious potential barrier to delivering feedback 
although prescribers and pharmacists acknowledge it is a worthwhile 
investment of their time in chapters 6 and 8 respectively. It should be noted 
that despite formalizing PE feedback, it is still in its relative infancy and the 
challenge will be to ensure it becomes part of routine practice, a challenge 
that will take time. However, the results are encouraging and support 
reductions in PE rates reported in the pilot study in chapter 5.  Where PE 
rate are reduced, the intervention has potential to reduce harm and improve 
patient safety. 
 
7.4. Strengths and limitations of this chapter  
 
Evidence supporting the use of PE feedback in hospital settings is limited.  
Furthermore, such studies are typically limited to assessing an individual 
class of medications, have shown no effect, or the feedback intervention 
theoretically flawed.  To the author’s knowledge, this is the first known study 
of a PE feedback intervention reporting positive impacts on overall 
prescribing in a hospital setting, whilst detailing the content and process of 
PE feedback as described in chapter 3.  
 
A wide range of prescriber grades (Table 14) were included in the research 
in this chapter, reflecting the typical skill mix on hospital wards.  Whilst this is 
a case study, STHKH is a typical acute NHS hospital with standard ward 
pharmacy services and the results reported in this chapter are supported by 
triangulation with prescriber views in chapters 6 and 9, and pharmacist views 
in chapter 8.   
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Therefore, the author proposes that results are valid for inferences to be 
made in similar settings.  However, as discussed, the intervention is complex 
and not simplistic; the PEs discussed, feedback process and social 
interaction, and negotiated outcomes could not be standardised.  The 
ancillary outcomes on pharmacists, prescribers and pharmacist-prescriber 
relationships reported in chapters 6, 8 and 9 could well be interacting 
synergistically to produce an effect that is greater than feedback alone. 
 
The principles of timely, pharmacist-led feedback that is delivered verbally 
and in writing in the clinical environment for a defined error can be 
transferred to similar settings.  However, feedback is a dynamic process and 
the interaction between facilitator and recipient cannot be sanitized, one 
would expect variability and this flexibility reflects the nature of human 
interaction. The potential for a positive ‘Hawthorne effect’ cannot be 
discounted and may have influenced prescribing outcomes.  Additionally, the 
variability in process outcomes reported in chapters 6,8 and 9 may not be 
replicated.  However, equally, these process outcomes may resonate with 
known issues elsewhere and feedback for example, could be used to 
enhance communication and teamwork between pharmacists and 
prescribers and explored in parallel to the feedback intervention.   
 
Whilst there was a slight imbalance between intervention and control group 
participant numbers, a 1.5-fold variation would be necessary to limit use of 
the t-test analysis reported in this chapter.   Additionally, participants were 
not randomized as described in chapter 3 and any improvement could 
therefore reflect any differences between groups although statistically 
significant differences were reported.  Equally, as argued in chapter 3, 
randomization does not always isolate variables whilst it would have been 
difficult to truly randomize prescribers without risk of diffusion of effect for 
example. 
 
Ward type and turnover was not homogenous between groups.  However, 
surgical wards typically have teams that works across wards and it would 
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have been difficult to homogenize all specialties between groups.  Equally, 
two of the quickest turnover wards were in the control group and it could be 
argued that PE rate may be higher reflecting workload or environmental 
pressures.  However, the control group also had two of the slowest turnover 
wards where it could be argued that PE rates could, in contrast be lower.  
Furthermore, the variety of wards can be viewed as a strength as they are 
typical of a large NHS acute hospital.    
 
Greater numbers of prescribed items were recorded for the intervention 
group and it is possible therefore that not all prescribing data was collected 
for the control group.  This could reflect greater pharmacist motivation to 
collect data on the intervention wards.  This difference could also 
overestimate PE rate for control wards if more PEs, as opposed to correctly 
prescribed items, were recorded.  However, number of prescriptions in each 
group were similar suggesting that prescriptions in the intervention group had 
more prescribed items per prescription.  Considering a larger number of 
prescribed item numbers have been associated with an increased risk of a 
PE (Seden et al. 2013), this if anything would suggest that PE rates should 
be greater in the intervention group.   
 
7.5. Chapter Summary 
 
This chapter has presented the results of a controlled before and after study 
exploring the impact of constructive feedback on prescribing.  Significant 
reductions in PE and EFP rates have been reported for prescribers in the 
intervention group.  These benefits extended to reduction in error rates for all 
types of error, severity and prescriber grade for the intervention group.  
Potential reasons for these reductions have been discussed considering 
feedback as a complex intervention and unknown influences of unexpected 
outcomes.  The next chapter will present the experiences of pharmacists 
towards delivering the PE feedback intervention, using results from semi-
structured interviews.  
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Chapter 8. Pharmacist experiences of delivering formal prescribing 
error feedback 
 
8.1. Chapter introduction 
 
This chapter will present the results of eighteen pharmacist interviews 
exploring their experiences of delivering formal PE feedback.  These views 
and experiences are poorly understood but are important to determine the 
feasibility of the intervention and the impact on pharmacists and prescribers 
alike.  
 
The primary research aim of this chapter was to: 
 
Explore and determine pharmacists’ attitudes of, and experiences 
towards delivering formalised prescribing error feedback 
 
Seven key themes are reported from analysis of the interviews and are used 
to report pharmacist experiences of delivering prescribing error feedback. 
These results will be followed by a discussion of the findings and the 
implications for the research undertaken in this thesis. 
 
8.2. Semi-structured interviews 
 
Semi-structured interviews were used to provide the in-depth information 
required to answer the research question as described in chapter 3.  
Pharmacists involved with delivering feedback were provided with a 
participant information sheet (Appendix 7).  Standard e-mails (Appendix 6) 
were also sent to pharmacists that included participant information letters 
and consent forms.  All eligible (nineteen) pharmacists expressed an interest 
to participate.   
 
Interviews were conducted in a private interview room within the pharmacy 
department at a convenient time negotiated with each pharmacist between 
November 2015 and January 2016.  All pagers / mobile phones were turned 
off to prevent interruption.  Protected time was negotiated with the clinical 
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pharmacy services manager beforehand.  Prior to commencing the interview, 
the purpose of the study was covered again and both verbal and written 
consent obtained by the author.  A topic guide (Appendix 4) was used to 
explore key themes and ensure consistent issues were discussed. Interview 
duration varied from 28 minutes to 1 hour 29 minutes (Table 29). 
 
 Table 29: Participant information for pharmacist interviews a 
Interview 
code 
Agenda 
for 
change 
band 
Male 
or 
female 
Years 
Qualified 
at time 
of 
interview 
University Pre-
registration 
training 
Interview 
duration 
P1 7 Female  3 Medway Hospital 28 
minutes 
P2 8a Female 3 Manchester Hospital 55 
minutes 
P3 7 Female 2 Manchester  Hospital 33 
minutes 
P4 8b Female 17 Manchester  Community 45 
minutes 
P5 6 Female  2 Preston Community 33 
minutes 
P6 8a Female  7 Belfast Hospital 38 
minutes 
P7 Locum Male 8 Manchester Hospital 32 
minutes 
P8 7 Female  12 Manchester Hospital 32 
minutes 
P9 6 Female  3 months Manchester Hospital 30 
minutes 
P10 Locum Male  8 years Liverpool Hospital 48 
minutes 
P11 Locum Male  15 years Liverpool Community 1 hr 29 
minutes 
P12 7 Female  2 years Liverpool Hospital 33 
minutes 
P13 Locum Female  7 years Aston Hospital 37 
minutes 
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P14 7 Female  6 years Norwich Hospital 34 
minutes 
P15 6 Female  2 years Manchester Hospital 35 
minutes 
P16 6 Female  5 months Norwich Hospital 34 
minutes 
P17 8a Female  8 years Manchester Hospital 45 
minutes 
P18 6 Female  1 year Manchester Hospital 45 
minutes 
a see chapter 1 for an overview of each pharmacist grade 
 
8.3. Data analysis  
 
All interviews were digitally recorded and transcribed verbatim by the author, 
except for anonymising person and place names. Interviews took between 
two and six hours to transcribe.  Transcripts were read whilst simultaneously 
listening to the audio file to correct any transcription errors introduced by the 
author.  Electronic copies of the transcripts were sent to SDW and SVOB for 
independent analysis.   
 
Transcripts were coded line-by-line and analysed thematically following the 
framework approach as described in chapter 3.  An initial inductive approach 
to coding was adopted with ideas and interpretations of the data indexed in 
the margins of the transcripts.  Interpretive ideas and concepts were 
informed both a priori from research aims and the topic guide and a 
posteriori from participant views (Pope et al. 2000) that the author could not 
predict (Gale et al. 2013) such as ‘self-efficacy’, ‘job-satisfaction’ or ‘goal 
motivating behaviour’.  This abstraction and conceptualisation allows 
appreciation of the data as a ‘whole’.  
 
The research supervisors (SDW and SVOB) independently read and 
analysed transcripts for inter-coder reliability (Plummer-D'Amato 2008).  
Initial codes and themes were discussed with the research team with any 
discrepancies resolved for an analytical consensus on the initial thematic 
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framework (Appendix 24).  This was then applied to the transcripts and 
refined with further inferences and meaning identified to produce the final 
thematic framework (Table 30).  Relevant extracts of the transcripts were 
then copied and pasted under the relevant code for meaning, analysis and 
explanation.   
 
8.4. Results  
 
Eighteen pharmacists (three male and thirteen female) were recruited for 
interview out of a sample of eighteen pharmacists involved in delivering PE 
feedback.  Participant details are presented in table 29. Pharmacist grade 
ranged from band 6 to band 8b (see chapter 1 for an overview of pharmacist 
grades) reflecting the skill mix of clinical, ward-based pharmacists in the 
department.  For anonymity, pharmacists were allocated participant codes, 
P1-P18, as seen in table 29.  It was considered by the author that data 
saturation (See chapter 3) had been achieved at interview 9, although further 
interviews were conducted to provide greater richness of material and allow 
all pharmacists involved the opportunity to discuss their experiences of the 
project.   
 
Table 30: Thematic framework for pharmacist interviews 
Theme  Code 
1. Process Overview Directive vs. facilitative 
feedback 
Setting 
Feedback process 
Barriers  
Sustainability 
Proforma 
Prescriber grade 
 
2. Working relationship Rapport  
Hierarchy 
 300 
Theme  Code 
Team integration  
Trust in prescriber  
Prescriber communication 
 
3. Benefits of feedback Consistency in practice 
Role awareness 
Medicines optimisation 
Educational 
 
4. Feedback facilitator Feedback apprehension 
Facilitator training 
Job satisfaction 
Raised understanding of error 
Facilitator credibility 
Self-efficacy 
 
5. Prescriber impact Prescriber response 
Information seeking behaviour 
Feedback seeking behaviour 
Goal motivating behaviour  
Prescriber behaviour  
 
6. Prescribing error Error severity 
Timely feedback 
Supporting evidence  
Stage of prescription  
Error interpretation  
 
7. Process 
improvement 
Prescribing error procedure 
Formal vs. informal 
Shared learning 
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Theme  Code 
Protected time 
Facilitator feedback 
Incident report 
 
 
The final thematic framework is presented in table 27.  Seven key categories 
emerged from the data corpus, these were; 
 
1. Process Overview 
2. Working relationship 
3. Benefits of feedback 
4. Feedback facilitator  
5. Prescriber impact 
6. Prescribing error  
7. Process improvement 
 
Sample quotations are given under thematic headings to demonstrate 
participants views.  It is not the intention of the author to present the full body 
of data but rather a selection of quotes that articulate the themes with greater 
clarity and lucidity.  Quotes were agreed with the PhD supervisors SDW and 
SVOB. 
 
In general, all pharmacists engaged openly and freely to discuss their 
experiences of delivering PE feedback.  All pharmacists were 
overwhelmingly positive about the project discussing the impact on 
themselves and on the prescribers, with views surprisingly homogenous 
across interviews.  Importantly, despite obvious time pressures, pharmacists 
suggested that the process was sustainable and was a worthwhile 
investment of their time, echoing prescriber views reported in chapter 6. 
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8.4.1. Process overview 
 
Seven key codes were included within this category: Directive vs. facilitative 
feedback, setting, feedback process, barriers, sustainability, proforma and 
prescriber grade 
 
1a. Directive vs. facilitative feedback 
 
Pharmacists reported a shift in practice from providing directive feedback to 
a more constructive, facilitative process.  Delivery of formal, constructive 
feedback was reported as being more meaningful, creating a memorable 
encounter that prescribers were more likely to learn from.  This was 
supported by pharmacists outlining the potential impact of the error, actively 
exploring the error causation and negotiating solutions to the cause. 
 
P13. “Prior to this project then I don’t think that I have really been giving them 
feedback.  I’ve just been telling them that this is not right will you change it 
for me?  So I wouldn’t tell them the reason, this is important because… you 
know prior to this project the most of the time you would say can you change 
this for me?  This is this and it should be that.  But now, we go with a 
conscious plan to educate them and tell them why it’s important”    
 
Pharmacists reported that, because of work pressures, a directive approach 
was still used to correct PEs immediately with facilitative feedback typically 
following at a later time. 
 
P6.  “I think that it is good because that is what I was saying to you, I’d 
deliver it verbally then follow up with the written feedback and sitting down 
with them and getting them to sign it.”  
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1b. Setting 
 
Feedback appeared to be delivered in a range of areas on the ward 
depending on prescriber preference. Feedback was predominantly delivered 
in a private setting, typically a quiet room, to ensure confidentiality.   
 
P2.  “It required a flexible approach depending on the prescriber and 
workload.  It might be on the nurses’ station, the end of a day, a specific 
time, in a side room…” 
 
Some pharmacists reported that prescribers were happy to receive feedback 
in the open ward area although they strived to ensure that other colleagues 
were not around to maintain confidentiality. 
 
P15.  “It was on the ward, generally I tried to get a quiet spot with no one 
else around because no one wants to be told that they’ve made a mistake 
with other people around.  So it was just a quick five minutes, I want to talk to 
you about this and provided them with some reassurance you know like 
everyone makes mistakes and this is for your own learning type of thing.  So 
it was generally in the doctor’s office if they were on their own or on a quiet 
part of the ward with no one else around.” 
 
Pharmacists reported that taking this time to discuss the error allowed focus 
on the feedback and facilitated further dialogue that would not have 
happened with a more directive approach. 
 
P6.  “it gives them the time out to ask more questions or give the time to 
really explore the issue whereas a lot of time when you have to correct an 
error they are like yeah yeah no problem at all because they have to correct 
it in a certain time frame then get back to their jobs.  Whereas taking time 
out, you know now these ten minutes are only about this you know away 
from all of the distractions gives them a 100% focus.” 
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1c. Feedback process 
 
Most pharmacists delivered the initial overall feedback individually whilst four 
pharmacists delivered feedback to a group of prescribers, at their request.   
Three pharmacists reported that this was received very well and could allow 
benchmarking, although one pharmacist expressed that they should have 
delivered individual feedback because of prescriber embarrassment. 
 
P11. “On reflection, I think that given the choice, I wouldn’t give them the 
choice and I would just do it one on one in private because I look at how 
[core medical trainee grade doctor] reacted and I felt a bit mean on him. Now 
I’m not a mind reader and I didn’t know that his expectations were higher but 
knowing his personality I should have realised that.”   
 
Pharmacists reported demonstrating empathy when talking to prescribers 
and following a structured approach, providing balanced feedback on good 
and poor aspects of prescribing.  This included outlining the potential impact 
of the error, identifying the error causation and finally negotiating solutions to 
reduce the risk of error recurrence.  
 
P6.  “You’re not just saying to them you are doing this error you’re actually 
sitting back with them and sympathising with them and going I know what it 
is like.  You know it’s crazy out there, and they say can see oh you don’t 
want me to be a machine and write these TTOs and they see that you are 
being more sympathetic and understanding of workload, and their response 
has been better then too.” 
 
1d. Barriers 
 
Pharmacists reported that workload and time pressures made delivering 
feedback difficult at times, although they reported adopting a flexible 
approach to find the time to deliver feedback. 
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P1.  “Some days it was difficult especially when they were throwing out TTOs 
[to take out or discharge prescription] but those were the days when the 
mistakes were happening so you’d have those days when they made loads 
of mistakes and significant errors were produced.  The following day you’d 
be battling to see the new patients but once you had won that battle you 
could sit down with them and say I know that yesterday was busy but this, 
that and the other.” 
 
Several pharmacists stated that timely feedback was not always possible 
where the prescriber was on leave or working a night shift, making memory 
recall of the situation and prescription difficult.  
 
P13. “Sometimes it was the time, sometimes it was the doctor.  You know, 
you would identify the error but sometimes the doctor mightn’t be in for three 
or four days because they are on nights or off on leave and then when you… 
especially if you don’t have a copy of the chart then you are trying to 
remember and they are trying to remember but…” 
 
1e. Sustainability 
 
Pharmacists unanimously agreed that delivering formal feedback was 
worthwhile and sustainable, with one pharmacist arguing it should be a 
routine role of all hospital pharmacists. 
 
P11. “This shouldn’t just be part of our practice but part of our job.  Every 
single pharmacist in this department is going to encounter mistakes in this 
hospital every single day and so they are always going to need to deliver 
feedback and the minimum standard and nature of that feedback needs 
defining and this, this what we are doing is the framework in which we can 
define it.”  
 
Despite time pressures, feedback was considered sustainable and a valid 
use of pharmacist time with the prescribing feedback taking approximately 
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10-15 minutes for the initial overall feedback, and 5-10 minutes for each 
individual error.   
 
P6.  “Yeah I think it is sustainable I know that is more work but at the same 
time you have to think about the impact on the errors that you are correcting 
and that’s why I’m saying that we have to roll it out.”   
 
Pharmacists agreed that the most demanding aspect of the process was 
data collection and analysis for the initial audit.  Two pharmacists suggested 
that audit and feedback on all prescribing was unnecessary and that 
feedback on significant errors was only required.  However, the majority of 
pharmacists felt that a baseline audit was necessary to discuss all aspects of 
prescribing and establish early working relationships.   
 
P3.  “It doesn’t have to be a week [to audit prescribing] it can be a couple of 
days to get some numbers then deliver feedback and that creates that 
relationship then.”   
 
1f. Proforma  
 
Pharmacists reported that the feedback proforma was a useful tool to 
support the process and provide a consistency and structure to the feedback, 
although two pharmacists felt it was distracting for the prescriber and only 
provided it after delivering the PE feedback. 
 
P9. “Yeah and like I said the sheets I think really helped because it was sort 
of a focus point on these are the errors, these are the risks and you know 
what can go wrong and this is how you can improve it and I think that that 
was really, really useful.” 
 
Five pharmacists reported that prescribers requested copies of the proforma 
to use as reflective pieces of evidence in their training portfolios, whilst two 
pharmacists reported they kept copies as part of their own portfolios. 
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P1. “I found it useful and kept a copy for my records and the doctors kept a 
copy for their records for their portfolio so they were asking me for a copy 
and I know one of the doctors who has included all of them in their training 
portfolio.” 
 
Three pharmacists suggested that the proforma itself contributed to a change 
in prescribing practice, as it contributed to it being a more formal process and 
they had to sign the feedback form. 
 
P10. “So it becomes very real for the doctor when you tell them about the 
error, this is how significant it was and this is where you sign.” 
 
1g. Prescriber Grade 
 
Pharmacists reported that they delivered feedback mostly to junior doctors, 
reflecting their volume of prescribing, but that all grades would benefit where 
they have made a PE. 
 
P1.  “I think it is across the board [what grade of prescriber will benefit].  I 
was talking to the consultants less and delivering less feedback but that’s 
because they were prescribing less and so making less errors.” 
 
8.4.2. Working relationship 
 
Five key codes were included within this category: Rapport, hierarchy, team 
integration, trust in prescriber and prescriber communication 
 
2a. Rapport 
 
Pharmacists were consistent in outlining the importance of rapport in 
facilitating delivery of PE feedback, reporting that established prescriber 
rapport reduced apprehensions in both the delivery and receipt of feedback 
from prescribers.  
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P7. “I felt quite comfortable and confident because I knew the doctors and 
you have to build that rapport with your doctors.” 
 
In addition, pharmacists consistently proposed that the feedback process 
accelerated rapport building to establish new working relationships with 
prescribers. This was because the formalised process encouraged greater 
communication and interaction between pharmacists and doctors.   
 
P6.  “I think it is establishing it [working relationship] quicker whereas there 
probably wouldn’t be any need for you to have as much interaction [without 
feedback] whereas you are having interaction from word go so that is your 
rapport going from word go” 
 
Three pharmacists who covered additional wards compared the two 
processes of feedback, noting positive differences in how pharmacists were 
perceived and utilised as a result of delivering constructive feedback. 
 
P13. “Because you tend to communicate more then it improves your rapport 
and communication and I think they have more respect… maybe that isn’t 
the right word but they think oh she knows much more than I thought.  Or at 
least that is what I think, because they tend to ask more questions.  I think 
that the pilot wards [feedback intervention wards] tend to ask more questions 
than the other wards and they are aware of the presence of the pharmacist 
than on other wards.” 
 
2b. Hierarchy  
 
There appeared to be an inter-professional hierarchy with pharmacists 
initially concerned that their feedback would be dismissed by prescribers. 
Hierarchical influences with prescriber grades were also noted with 
pharmacists reporting greater apprehension when approaching consultants 
with feedback as opposed to junior doctors.  
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P1. “It was more intimidating with the senior grades than it was with the basic 
grades because I was a basic grade pharmacist or had just moved up to a 
band 7 and I was never really doing anything like this as such.” 
 
One pharmacist suggested this was less about their status but more about 
having a more fragmented working relationship.  
 
P4. “There is a bit of that yeah and I mean there is a way in that consultants 
tend to behave and there’s almost a sort of a professional barrier, there are 
no… they don’t really laugh and joke and let you into their personal space 
whereas with some of the juniors you see some of their human side.” 
 
Two pharmacists reported that they felt only junior doctors made mistakes 
and were embarrassed to be highlighting errors to the head of the team. 
 
P14. “I was a bit apprehensive about doing it to the consultant because they 
tend to… the junior doctors then you tend to expect them to make an error 
whereas with the consultants then you feel a bit silly saying do you know that 
you have made this error and they are okay about it but not that many of my 
consultants prescribe either.” 
 
However, four pharmacists reported that consultants were happy to receive 
feedback in front of their juniors and this acceptance of the pharmacist and 
the feedback raised the profile of the pharmacist on the ward further. 
 
P4. “[Consultant name] had the group session so the esteem for the 
pharmacist after that would have gone up massively from the junior doctors 
and it’s the same when you are on the ward round and you make a 
suggestion and the consultant agrees with you and they action it then it 
raises your credibility.”   
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2c. Team integration 
 
The majority of pharmacists reported feeling more integrated in the team as 
a result of the feedback process.   
 
P11. “I think that the immediate impact for me is that I feel immediately more 
integrated into the healthcare world at ward level and… just reflecting on it 
afterwards as you are more integrated just the position of pharmacy and how 
it has changed so it has changed massively.” 
 
Various reasons for this were proposed including increased communication 
and shared decision making, self-confidence of the pharmacist, raised 
credibility of the pharmacists and information seeking behaviours.   
 
P12. “I find as well, especially when on [intervention ward] that it was easier 
to integrate yourself into the team really and they were involving me in their 
decisions and asking me for my opinion.” 
 
2d. Trust in prescriber 
 
Three pharmacists reported that they didn’t need to worry about PEs for their 
doctors because they knew they had improved and were discussing the 
prescribing decision  with them beforehand.    
 
P7. “I don’t have to worry about the doctors’ prescribing errors because they 
have already discussed it with me.” 
 
2e. Prescriber communication 
 
There was a clear uplift in communication between pharmacists and 
prescribers both directly from the feedback sessions, but also indirectly as a 
result of increased confidence of both pharmacists and prescribers to ask 
questions of each other. 
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P10. “I think it has helped with approaching them, it does help, and even the 
other way the doctors come up to you as well and I think that that is another 
main change in that the doctors recognise you as a source of information.” 
 
Several pharmacists reported that some prescribers were anticipating 
questions on new or unusual prescribing decisions and involving them in the 
prescribing decision from the start.  
 
P1.  “They’d [consultant] be like oh [pharmacist’s name] have you heard of 
this rare regimen or have you read this paper or spoken to this rep [drug 
representative].  Like one of the consultant’s printed out a paper and said I’d 
like to use this on here.” 
 
8.4.3. Benefits of feedback 
 
Four key codes were included within this category: Consistency in practice, 
role awareness, medicines optimisation, educational 
 
3a. Consistency in practice  
 
Pharmacists acknowledged that they encountered PEs daily and agreed that 
the process provided a consistent approach to feedback.  Several 
pharmacists reported that this consistency raised expectations of prescribers 
to receive feedback where it became routine practice.   Three pharmacists 
also suggested that this standardisation can improve the quality of 
communication of pharmacists with prescribers. 
 
P11. “Well first and foremost the biggest stand out thing for me is that it 
standardises pharmacist behaviour or attempts to provide some consistency. 
I think this formal process will help the people who have struggled previously 
you know who are too timid and you know what I am getting at it will bring 
them up to a level where we will have a baseline to work from.” 
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3b. Role awareness 
 
Pharmacists consistently reported that delivering PE feedback was raising 
awareness of the role of hospital pharmacists with prescribers.   Pharmacists 
felt their knowledge and skills were recognised more, raising their identity at 
ward level and facilitating information seeking behaviour. 
 
P12. “I also think that sometimes people sort of overlook you and are just like 
oh all they do is the drug histories and they don’t know anything about drugs 
and specific conditions so you kind of… not that you are trying to get what 
you do noticed as such, but it is sort of noted that actually the pharmacist 
knows about those conditions so let’s sort of ask them and get their opinion 
as well.” 
 
Some pharmacists suggested this raised awareness of their role and team 
integration and was shifting their role from a peripheral, to a more integrated 
member of the team, which was helping to establish the professional role 
and identity of pharmacists. 
 
P11. “This is another opportunity to establish yourself professionally… 
because this defines the relationship. With Pharmacy, I think that it has been 
slightly kind of nebulous and no one is really sure of what pharmacy does.  
But now as part of their education, and ongoing professional development 
then, they have got this interaction, this formalised interaction with 
pharmacists.” 
 
Other pharmacists suggested it was the formal interaction which contributed 
to acknowledging the role of the pharmacist. 
 
P15. “I think that it gives you a sort of a contribution to a team as opposed to 
someone who goes around and checks all of the kardexes and then just 
walks off the ward.” 
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3c. Medicines optimisation  
 
Pharmacists were unanimously effusive that delivering constructive feedback 
was an improvement on previous practice.  They reported that prescribers 
were not repeating the same errors and were getting it right the first time, 
although different errors were still being observed.   
 
P12. “I have found that up on [medical ward] when I had delivered feedback 
that they were still making mistakes but not on the area that I had fed back 
so it does teach them the way of prescribing one thing…obviously the main 
outcome of that is that we are improving patient care and patient safety so I 
do think that it is really, really useful.” 
 
This was reported to have several benefits including increased patient safety 
and efficient use of pharmacist’s time as they could focus more time on 
patient care and not correcting PEs. 
 
P1. “I don’t have to correct every drug interaction or Seretide [inhaler device] 
or reducing dose [of steroids], the antibiotic is coming through with the 
duration and indication and they are reviewed after twenty four hours.  I know 
that they are minor things but it takes so much workload off of you because 
you don’t have to check if they are using an accuhaler or evohaler [inhaler 
devices] for example because the doctor has done it already.” 
 
3d. Educational 
 
Pharmacists reported that the process was educational for prescribers, 
encouraging reflection and personal development.  This was facilitated by 
them having time to ask questions and clarify key points.  Pharmacists also 
reported delivering ad hoc teaching where knowledge gaps were identified 
during the feedback session. 
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P7. “It also allows me to gather information like with that [doctor name] and 
inhalers like not only deliver feedback but give her training then I was able to 
train her on different inhalers and devices and stuff.” 
 
Furthermore, some pharmacists developed additional prescribing aids for 
repetitive PEs or educational sessions at the request of prescribers and 
delivered at a later time. 
 
P1. “Well a lot of them weren’t doing reducing regimens of steroids and 
things like that so I just made a little hand-out for them which they carried 
around.” 
 
The potential for learning was reciprocal with several pharmacists reporting 
that they were developing and learning from delivering feedback.  
Pharmacists reported they were spending more time researching and 
preparing for the feedback in comparison to a more directive approach which 
helped their own professional development.   
 
P3. “Well I’m learning obviously as well. Like with errors when we identify 
something on the drug chart then we have to go away and research it and 
look it up even more to try and give them the feedback do you get what I’m 
saying?” 
 
Several pharmacists suggested this also placed them at a vantage point as 
they had time to prepare for the session and anticipate potential questions.  
 
P12. “We’re also in a really good position as pharmacists because we are 
not under pressure to give them an answer there and then so you can kind of 
look something up and then take it to the doctor and it looks like you know it 
all and you’re like yeah we know all about this.” 
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8.4.4. Feedback facilitator  
 
Six key codes were identified within this category: Feedback apprehension, 
facilitator training, job satisfaction, raised understanding of error, facilitator 
credibility and self-efficacy 
 
4a. Feedback apprehension  
 
All pharmacists reported an initial apprehension towards the process as it 
was a new role and they lacked self-confidence in their own knowledge or 
abilities as a facilitator.   
 
P15. “I had to psyche myself up a bit initially because that just comes down 
to self-confidence in delivering feedback because it was a new thing 
[expected of pharmacist to do].” 
 
Pharmacists also reported an anxiety towards potentially upsetting a 
prescriber, or compromising their working relationship if it was perceived 
punitively or poorly.  However, any initial apprehension subsided following 
delivery of their first feedback session and they realised the positive 
outcomes of feedback. 
 
P6.  “I think initial anxiety because normally there is a good dynamic on the 
ward and we had a good relationship and I didn’t want to change that 
dynamic with them thinking oh here’s [pharmacist] again… and you going to 
tell me that I have done something else wrong and then your dynamic could 
change but if anything it just got better and they are two things that … that’s 
what I’m saying that surprised me a wee bit.” 
 
4b. Facilitator training  
 
Pharmacists reported that facilitator training provided them with the 
confidence to deliver the feedback.  Role play scenarios were cited as being 
particularly useful whilst an understanding of prescriber views on receiving 
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feedback also helped.  Pharmacists agreed that the training and use of a 
feedback proforma, provided a structure and consistency to the process.  
 
P4. “Just you know, your power point presentation and just having a few 
simple suggestions laid out for you that just helps you shape how you are 
gonna…it just shapes how you… and it gives a confidence boost you know 
you go oh okay that makes sense you know I go in with this then I talk about 
that subject and it just gives you structure to follow.  And you know it’s a bit 
rusty to start with and you’re like oh what do I do now but then that eventually 
becomes second nature as with most things so no definitely.” 
 
Several junior pharmacists also reported finding it useful to use a second 
person as a soundboard before delivering the feedback. 
 
P15. “I felt prepared, the training helps and I particularly liked that if I sort of 
came to you for advice on how to deliver it then I liked the way that you 
delivered it, you would set the context and provide background and set 
reflective questions to ask and obviously suggest some ideas to prevent it 
from happening again so I preferred it coming from you first before I gave the 
feedback.  Like I knew what the problem was but needed a little bit of 
guidance on how to deliver it.” 
 
4c. Job satisfaction 
 
Pharmacists reported feeling a greater sense of job satisfaction from 
delivering PE feedback.   
 
P10. “Job satisfaction is much higher than if you are working individually in 
the corner and phoning doctors or paging them or asking them to just change 
stuff or just changing stuff yourself like minor errors.  But once you get that 
whole picture with the doctors and the impact on the patient then you do feel 
more part of the team and I do think that that is biggest change for me.” 
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There appeared to be a number of reasons for this with pharmacists saying 
they felt more valued and part of the team where their contributions were 
recognised.   They also reported feeling more confident and useful as a 
result of increased communication with prescribers. 
 
P14. “Well it makes you feel really valued as a pharmacist and you go ‘do 
you know what I am making a difference’.  Maybe it’s not to the patients 
directly but indirectly by improving their prescribing that we are making a 
difference and I think that pharmacists get overlooked most of the time and 
on the ward it would be the doctors, nurses, physios [physiotherapists] who 
get the thanks but pharmacy don’t.” 
 
4d. Raised understanding of error 
 
Pharmacists reported an increased awareness and understanding of error 
causation, with some expressing surprise at the number of errors that were 
not knowledge based.  This in turn influenced pharmacists approach to PEs 
with a shift from needing to correct the error, to wanting to understand the 
error and prevent it recurring. 
 
P6. “We are too focused on knowledge based errors and that has really 
opened my eyes up a bit more you know so if it is a knowledge based error is 
fair enough that a knowledge deficiency and that’s what pharmacists are 
used to dealing with but I think the one that I did most delivery about this time 
was thinking about your human factors you know so thinking about your 
ways we do TTOs on the ward and thinking about your prescribing and then 
taking more time with it in a quiet environment.  So I thought that that was a 
really good angle this time that I wouldn’t have thought about delivering 
feedback on that before.” 
 
Pharmacists reported that this awareness supported a solution focused 
approach to the feedback including identifying solutions to error provoking 
conditions that may be contributing to the PE. 
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P1.  “Definitely so, [foundation doctor] knew she was dyslexic so always sat 
on the pharmacy computer [quiet side room] because she was always 
selecting the wrong drugs because I kept saying you’ve picked this drug 
instead of this drug on the TTO [to take our or discharge prescription] so she 
kicked me off my computer and I used to go somewhere else when she was 
writing her TTOs.  That was a sacrifice I made because the TTOs always 
came out right.” 
 
4e. Facilitator credibility 
 
Pharmacists agreed that they were credible facilitators as they intercepted 
the PEs, had established working relationships with the prescribers and were 
perceived as experts in medication use by prescribers.   
 
P12. “I think that we are in a good position to be doing it really especially if 
we are the ones picking up the errors which is what our job is really isn’t it?  
So I think that we are in a good position to deliver feedback really.  You could 
say that we should be feeding back to the consultants and then they have to 
feed it down to their juniors but that could be quite intimidating for the juniors 
and so maybe that’s why it’s better coming from us.  Some people describe 
us as the experts in medicine so maybe we could do a little teaching session 
as well while we are there.”  
 
Pharmacists advanced that by delivering feedback, their credibility as experts 
in medicines use was raised at a local level, raising the awareness of the 
pharmacist’s role as reported earlier.  However, two pharmacists also 
reported that feedback was a dynamic process with the prescriber asking 
many additional questions and where the facilitator could not answer these, 
their credibility was diminished. 
 
P3. “Well the way that I have seen it they have asked other pharmacists on 
the ward and they come back and say oh well I don’t want to ask them again 
because they don’t know so they are going to stop asking them.” 
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4f. Self-efficacy  
 
Pharmacists reported a raised awareness of, and confidence in their own 
skills from delivering feedback. 
 
P12. “You don’t know how much you know until you have to start telling other 
people.  So, you probably do start becoming self-confident and are like wow I 
do actually know my stuff and I should start trusting myself.” 
 
Some pharmacists reported surprise at how little prescribers appeared to 
know about medications which appeared to influence their self-efficacy, 
raising their awareness of their potential role as educators at the prescribing 
level and providing the confidence to engage more with the medical teams. 
 
8.4.5. Prescriber impact 
 
Five key codes were identified within this category: Prescriber response, 
information seeking behaviour, feedback seeking behaviour, goal motivating 
behaviour and prescribing behaviour.  
 
5a. Prescriber response  
 
Pharmacists reported that prescribers were overwhelmingly open to 
feedback, showing a genuine interest in their performance, asking further 
questions and seeking further feedback which surprised some pharmacists. 
 
P6.  “Great, I mean I think that it is brilliant one of my biggest shocks well not 
shocks actually is that the prescribers liked it they actually loved it.” 
 
Pharmacists acknowledged that their apprehensions regarding negative 
impacts on their working relationships where misplaced. 
 
P9. “I think that I had a preconception that it would deteriorate our 
relationship but no they took it really well and I think that they were really 
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pleased to hear about it as well.  Like [doctor] was absolutely fine with it and I 
went through the sheet with him and he was absolutely fine.” 
 
Pharmacists noted an initial anxiety from prescribers who were new to the 
process but equally acknowledged that those who had received feedback 
previously in the pilot study were expecting it as part of routine practice. 
 
P7. “The doctors that have already done it in previous years they will be 
expecting it and will be used to it like… you started it last year didn’t you and 
so the senior doctors were already expecting that and even the junior doctors 
when you approach them they have already been told oh this is what we do 
so it’s nothing new.” 
 
Several pharmacists suggested that this prescriber response, and increased 
self-efficacy as reported earlier, motivated them to deliver further feedback 
and invest more time in their preparation. 
 
P1: “I don’t think that I would have given it as much love because I would feel 
like I was wasting my time.  But I was able to give it my love because I would 
go away and research it and answer as many questions as I did with them.” 
 
5b. Information seeking behaviour  
 
A prominent theme throughout was an increase in information seeking 
behaviour from prescribers.  Pharmacists reported that feedback was 
interactive with prescribers seeking further information and clarification. 
 
P1. “When they saw me they would be like ok but why and why … it wasn’t 
just feedback, I was hit with about twenty questions.” 
 
Several pharmacists suggested this was because the feedback was often 
delivered in a setting away from clinical areas, allowing time to ask 
questions. 
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P6.  “They were like oh I didn’t know about this so can you tell me some 
more and they used it as an opportunity to maybe ask all of those questions 
that maybe they wouldn’t.” 
 
Advancing on this, most pharmacists noted a change in prescriber behaviour 
at the point of prescribing with a notable increase in use of medicines 
information resources such as the BNF, prescribing guidelines or the 
pharmacists themselves. 
 
P15. “Yeah definitely what I noticed, especially with the junior doctors on my 
last ward then I was being asked what to prescribe and how to prescribe and 
that’s been consistent with the last two sets [who have had feedback] so 
yeah they would be standing there with their pen ready to prescribe and 
asking you for advice.” 
 
5c. Feedback seeking behaviour 
 
Ten pharmacists reported that prescribers were seeking further feedback 
verbally on their prescribing.  This appeared to be both directly: 
 
P1.  “Like, [core trainee] came around and was like ok what feedback have 
you got for me? What have I done wrong this week?” 
 
Or indirectly when seeking clarification and confirmation that their 
prescription was correct. 
 
P6. “They done their TTOs beside me and they were saying can I double 
check this with you and double check this here as they were going through it 
and therefore asking and they said to me when they had done their TTOs 
can you check for any errors and I said no and they went there you go happy 
days.” 
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5d. Goal motivating behaviour  
 
Pharmacists advocated that they felt prescribers were improving and making 
less PEs following feedback.    They suggested that this may have been 
because of reasons already reported, improved knowledge, awareness of 
error provoking conditions and information seeking behaviour.  However, five 
pharmacists also suggested that improvements in prescribing may have 
been because prescribers were acutely aware that their prescribing was 
being monitored with the potential for feedback on any PE. 
 
P13.  “I think they are more aware of what they are prescribing.  So far, for 
the doctors that I have given feedback to they are aware that whatever they 
have written then someone else is looking at it and monitoring it and that 
makes them more conscious of what they are writing.” 
 
5e. Prescribing behaviour 
 
Pharmacists consistently described a change in prescribing behaviour and 
attitude with prescriptions given a greater priority by prescribers.  As 
reported, there was a notable increase in information and feedback seeking 
behaviour but pharmacists also noted a more considered approach to 
prescribing as opposed to a routine task.  This included challenging senior 
doctors on prescribing decisions, reviewing the medication chart before 
prescribing and checking their prescription afterwards. 
 
P7. “The main thing that has changed has been attitude like I say… attitude 
towards prescribing is the main thing they won’t just recklessly prescribe, I 
don’t think that they do that now.” 
 
Several pharmacists noted prescribers changing location for their prescribing 
to limit error provoking conditions, solutions that had been negotiated during 
the feedback session. 
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P6. “One prescriber has said to me oh do you know how bad my prescribing 
error rate was and then when they were doing TTOs they said they weren’t 
doing TTOs on the ward round and then they waited and done the TTOs at 
the end to the nursing staff which didn’t go down too well [laughter] but that’s 
what they said they were doing.” 
 
8.4.6.  Prescribing error  
 
Five key codes were identified within this category: Error severity, timely 
feedback, supporting evidence, stage of prescription and error interpretation 
 
6a. Error severity 
 
Pharmacists agreed that all PEs required feedback and could be captured as 
an initial audit and feedback process.  For on-going feedback, pharmacists 
agreed that feedback should be for significant errors only to limit diluting the 
message or being perceived as pedantic as one pharmacist suggested. 
 
P11. “I think that you have got the right level to go in at the right level for 
significant errors, if you go in with minor errors too then they will just switch 
off.  It’s the impact of the error so it’s the severity.  It has to register.  I think 
that you become a bit… If you start delivering feedback on every single error 
then you become a bit of a… of a… if you go back to the punitive nature then 
they’ll just be like oh here we go here is [pharmacist] with another mistake 
and no matter how much he dresses it up its just another mistake and the 
message is lost.”  
 
The majority of pharmacists felt the training helped them to classify the errors 
appropriately although some felt it was still subjective and could lead to 
inconsistencies in what feedback is delivered.  Two pharmacists 
acknowledged they had probably been under-rating errors because they 
misinterpreted what a significant error was.  Some pharmacists reported that 
prescribers did not always appear to agree with the severity rating and 
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suggested the severity rating was distracting for prescribers and that 
prescribers needed education on the error rating process. 
 
P17. “It is interesting because they don’t think lansoprazole od [once daily] 
instead of bd [twice daily] is the same severity as the wrong drug.  I mean I 
could write that one down but I know what I’ll get with [registrar name] Ohhhh 
yes I know, I know yes yes and then he’s all too helpful to get the pen off you 
and change it quick.” 
 
6b. Timely feedback 
 
Pharmacists agreed that timely feedback was essential to recollect the event 
and optimise the learning.  Timely feedback appeared to be delivered in the 
majority of cases although pharmacists acknowledged that it was difficult at 
times when the prescriber had gone on nights or was on leave. 
 
P8. “If I had the forms it would be that day or the next day but sometimes it 
could be later if I just missed them before going on nights.” 
 
6c. Supporting evidence  
 
Where the PE was identified by a different pharmacist, in the dispensary for 
example, and they asked the ward based pharmacist to deliver the feedback, 
pharmacists reported that evidence of the PE was needed to contextualise 
the feedback and facilitate memory recall of the prescriber. 
 
P2. “Yeah definitely sometimes when you are trying to explain to somebody 
about an error that has been made and its complicated, they haven’t written 
it in the right place or something then it is easier to see it even if you just get 
a photocopy before you get the feedback sheet so you say what do you think 
is wrong with that and see if you match up.” 
 
 
 
 325 
6d. Stage of prescription 
 
Pharmacists reported that there was a noticeable improvement in the quality 
of prescribing especially discharge prescriptions and rewritten medication 
charts with doctors changing where they undertook these tasks on the ward 
as described earlier. 
 
8.4.7.  Process improvement 
 
Four codes were identified within this category: Formal vs. informal, shared 
learning, protected time and facilitator feedback 
 
Pharmacists were supportive of the process with the majority suggesting no 
improvements were necessary although some plausible initiatives to be 
explored were identified from the data.   
 
7a. Formal vs. informal 
 
Pharmacists were consistent in advocating that the formalised process 
created consistency in both delivery and expectation of receipt of feedback 
on PEs.  However, some pharmacists suggested that the term ‘formalised’ 
created apprehension and that it should just be described as feedback and 
delivered informally. 
 
P4. “It doesn’t really have to be very formal.  I think that when we say 
formalised then you get this impression of you know we’re going to take you 
into this dark room and it’s going to be very serious but it doesn’t need to be 
like that.” 
 
Equally, three pharmacists recognised the need to have a robust system in 
place where concerns could be escalated where prescribers were not 
improving. 
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P2.  “If you have got a doctor with a lot of errors coming through and have 
received feedback and they are not improving then you do need to go to their 
consultant and say look this is happening and you maybe need to step in 
now and have a word.  I hate getting people into trouble.  I wouldn’t want to 
feel that I was grassing anybody up.  But if it’s not being sorted in the first 
instance then I’m going to go someone else.” 
 
Some pharmacists questioned whether incident reports should be completed 
for any errors that require feedback but others suggested such a system was 
not designed for these purposes and could be perceived punitively.   
 
P10. “I have been doing datixes [incident reports] on patients coming in from 
MAU [Medical Assessment Unit] if they have missed any critical meds.  But 
the problem there is that it doesn’t really tell you who done it and it asks you 
about pressure sores and was it a slip or a fall.” 
 
Other pharmacists suggested a more centralised process was required with 
a database for auditing what errors had been identified and what feedback 
had been given.  
 
7b. Shared learning 
 
There was clear potential for shared learning where PEs were discussed in 
general to a group of prescribers although some pharmacists felt this was not 
specific enough and could be dismissed as irrelevant by individual 
prescribers.  Several pharmacists suggested however that serious, 
prominent, or recurrent errors could be highlighted to all prescriber grades 
periodically at team meetings or via e-mail. 
 
P17. “What you could do is every Monday talk to them [doctors] in the 
meeting and I could say that the error of the month is…”  
 
Other pharmacist’s recognised that they were delivering feedback on the 
same PEs, suggesting local inductions could be created and delivered to 
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prescribers when they rotate into each ward area to raise awareness of area 
specific PEs. 
 
P15. “I think a ward based induction including common errors to that ward 
would be useful particularly coming off endocrinology then you see problems 
with GKI, insulin infusion, different insulin’s so I think that that would be 
useful and show them what you know and how useful you can be from the 
start.”   
 
7c. Protected time 
 
Some pharmacists suggested that having protected time to deliver feedback 
would be useful to limit the impact on their workload.  However, the majority 
of pharmacists felt that whilst this would be ideal, it was unlikely to work as 
you would not be delivering timely feedback.  Others suggested that the 
feedback may not be constructive where multiple messages on multiple PEs 
had to be delivered.  
 
P12. “The only problem I can see with that is that you are saving up 
everything until one specific time and I don’t know if that would bombard 
them with too much information and whether or not they would be able to 
remember everything that they did on say Monday if you did it on Friday.  
Especially with the patient moving then you wouldn’t have the drug charts to 
show them and prompt their memory it would just be a case of oh do you 
remember Mr. Bloggs who came in with an AKI [Acute Kidney Injury] and 
sepsis but then that’s what everyone comes in with.”  
 
7d. Facilitator feedback 
 
Some pharmacists reported that they would like feedback on the process to 
allow them to deliver feedback more effectively.  Others argued that there 
was a lack of feedback within pharmacy but that pharmacy staff would all 
benefit from receiving similar feedback on their performance. 
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P2.  “I think as well though that there should be a 360 feedback about how I 
approached them on the ward.  I’d like feedback about how they would like to 
be approached.  Do they want a list of jobs to do at the end of the day? Do 
they want me to come to them after I’ve seen every patient? In the doctor’s 
jobs book? [a list of tasks to complete].” 
 
8.5. Chapter discussion 
 
The aim of this chapter was to explore and determine the experiences of 
hospital pharmacists of delivering PE feedback.  The interviews used have 
provided the rich qualitative data to illuminate this aim and will be discussed 
below. 
 
8.5.1. The process 
 
The initiative was welcomed from all participants allowing consistent delivery 
of PE feedback echoing the findings of Bertels et al. (2013), where 
pharmacists agreed that individualised feedback on PEs was “both 
acceptable and desirable”.  Pharmacists are considered experts in medicines 
use (Ojeleye et al. 2014) and information providers (Elvey et al. 2013) with a 
key role considered that of a ‘teacher’ (Wiedenmayer 2006).  Considering 
this, it is perhaps no surprise that participants felt they were credible 
feedback facilitators, echoing prescriber views in chapter 6.   
 
Pharmacists reported a shift from a process of corrective, or directive 
feedback to one of facilitative feedback.  This was often supported by 
delivery of confidential feedback away from the clinical area. This “safe 
climate” allowed open dialogue for prescribers to question and clarify any 
feedback points, important considerations for the process to be successful 
(Bok et al. 2013).  Pharmacists also reported keeping the feedback ‘informal’ 
to mitigate potential anxieties.  Where such feedback is seen as supportive 
with clear benefits to the prescriber, they are more likely to seek further 
feedback (Teunissen et al. 2009), an outcome reported in these interviews 
and in chapter 6.   
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Difficulties in delivering timely feedback were reported by pharmacists with 
similar prescriber views in chapter 6, because of working patterns or annual 
leave.  Untimely feedback limits memory recall (Hysong et al. 2006), whilst 
no feedback is a missed learning opportunity.  Further feedback modalities 
such as e-mailed feedback could be explored, although they do not reflect 
the principles of effective feedback which should be delivered verbally and in 
writing (Ivers et al. 2012).  The NHS has proposed seven day working for 
consistent working practices, patient care and improved quality (NHS 2014).  
Such consistency in service provision could extend to the provision of 
consistent ancillary ward-based education and response to PEs, with 
feedback delivered consistently 7-days a week.  
 
8.5.2. Impact on prescribing  
 
Participants observed improvements in prescribing, corroborating the 
consistent reductions in PE rates reported in chapters 5 and 7, and views of 
prescribers in chapter 6.  Elsewhere, 11.7% of pharmacist time wastages 
have been attributed to correcting PEs (Green et al. 2015).  Where the 
average time to correct a PE has been reported to be fifteen minutes 
(Sullivan et al. 2013), the time pharmacists, nurses and doctors spend 
correcting PEs is considerable.  If pharmacists spend less time correcting 
PEs, their skills and resources can be focused on other patient centred tasks 
to improve the quality of care.  The Carter report (DOH 2016) advocates 
more effective use of hospital pharmacists, recommending that hospital 
trusts ensure that more than 80% of pharmacist resources are utilised for 
direct medicines optimisation activities.  Where feedback has the potential to 
improve prescribing and patient safety, then delivery of constructive 
feedback as part of a clinical pharmacy service should become routine 
practice. 
 
Improvements in prescribing could be directly related to the feedback where 
knowledge based gaps were identified.  However, knowledge based 
mistakes do not always predominate as described in chapter 1.  
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Furthermore, pharmacists interviewed in this chapter expressed surprise at 
how many PEs were not knowledge based.  Prescribers of all grades make 
PEs (Ashcroft et al. 2015), suggesting knowledge or at least prescribing 
education is only part of the problem (Maxwell et al. 2007).     
 
Pharmacists noted a change in prescriber behaviour with prescribers seeking 
more information and feedback to inform prescribing.  Similar outcomes were 
reported by prescribers suggesting feedback is influencing skills beyond a 
cognitive level.  Feedback can raise self-awareness, reducing the gap 
between perceived and actual prescribing performance (Randolph et al. 
2009).  For learning goal-oriented individuals, this may be motivation enough 
to learn, engage with solution focused activities (Brett and Atwater 2001) and 
become exemplary prescribers with further feedback inquiry (Teunissen et al. 
2009).  For others, the primary driving goal may be to avoid receiving 
unfavourable feedback (Brett and Atwater 2001) or their performance 
perceived in a negative light, an outcome described as a feedback ‘cost’ in 
performance oriented individuals (Teunissen et al. 2009).  The use of 
credible feedback facilitators who have observed prescribing practice may 
also be influencing prescriber motivation (Bok et al. 2013), underpinning the 
use of ward based pharmacists as feedback facilitators. 
 
It has been reported that much of a trainee doctors learning occurs in 
practice in an apprenticeship model (Dornan et al. 2009, Brazil et al. 2002) 
with Garbutt et al. (2005) reporting junior doctors learn about safe prescribing 
by “copying orders written by other physicians”.  Such a model is prone to 
error where the prescriber does not prescribe in context for the next patient’s 
renal function, co-morbidities or medications for example, or when the 
original prescription is erroneous to begin with.  The conscious competence 
learning model suggests that learners may progress through four stages of 
competence from unconsciously incompetent, to unconsciously competent 
(Figure 64). 
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Figure 64: Conscious competence learning model 
 
Delivery of constructive feedback has been described as optimizing learning 
by junior doctors (Kroll et al. 2008).  Considering this, prescribers’ learning 
and development will be limited or they may assume their performance is 
satisfactory, unless a significant event occurs or they receive feedback; that 
is, they are “unconsciously incompetent”.  Feedback can raise self-
awareness and highlight the importance and value of prescribing accurately 
and safely; the prescriber becomes “consciously incompetent”.  Constructive 
feedback provides solutions and ideas to improve practice, where 
prescribers implement these, it is likely to require greater focus or 
concentration; that is, they are “consciously competent”; a more considered 
approach reported in this chapter or raised discretionary effort reported in 
chapter 6.  For prescribers to reach the final stage of competence, it is likely 
to take further time than has been allowed in this project but can be 
facilitated with a commitment to lifelong learning and ongoing feedback to 
encourage permanent changes in prescribing behaviours.  Considering this 
and given the benefits on PEs reported in this thesis, where PE feedback is 
not delivered, are pharmacists derelict in their duties? 
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8.5.3. Impact on pharmacists 
 
A prominent theme reported in these interviews was increased self-efficacy 
and self-worth, influencing the perceived value and job satisfaction of 
pharmacists. 
 
Self-efficacy is a core component of social cognitive theory (Bandura 1997).  
Individuals are capable of altering their behaviour and environment through 
their perceived self-efficacy, and ability to achieve results with their tasks or 
roles (Bandura 1977).  People have a tendency to engage in activities in 
which they feel confident and competent in, and avoid those in which they do 
not (Pajares 1996).  In chapter 4, pharmacists described apprehensions in 
communicating with prescribers and delivering feedback.  Following 
formalisation of PE feedback, pharmacists reported improved prescriber 
rapport and communication, actively attending ward rounds, seeking out 
feedback opportunities, delivering bespoke training sessions and being 
utilised more as an information source.  Here, they altered their own 
behaviour and environment.  Considering this, the greater their sense of self-
efficacy, the more effort pharmacists invested into delivering feedback and 
becoming involved in other ward-based activities.  As one pharmacist 
described, they gave it more of their ‘love’, resonating with social cognitive 
theory where individuals are more likely to commit to action where they 
believe they can solve a problem (Bandura 1997).  These outcomes contrast 
with the apprehensions reported by pharmacists in chapter 4 with the 
intervention increasing their self-confidence to engage with prescribers and 
influence prescribing further. 
 
Pharmacist motivation also resonates with the five-stage hierarchy of needs 
(Maslow 1943) where people are motivated to achieve certain needs (Figure 
65).  Before progressing to higher level growth needs, lower level needs 
must be fulfilled or as a pharmacist fulfils one need, they seek to fulfil the 
next one.  Where pharmacists feel more integrated in the clinical team there 
will be a greater sense of ‘belonging’.  Where they have improved ‘esteem’ 
and confidence from professional achievements, and recognition and respect 
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from prescribers as reported in chapter 6, they can climb the hierarchy to 
realize their potential and develop as a professional.  In both the pharmacist 
interviews in this chapter and prescriber interviews in chapter 6, additional 
educational interventions and prescribing support tools were reported as 
outcomes of feedback: pharmacists were innovating practice. If hospital 
pharmacist skills are to be utilized to optimize medicines use as outlined in 
the Carter report (DOH 2016), raising their self-efficacy to empower 
interaction and integration with clinical teams can only help.  
 
Figure 65: Maslow’s hierarchy of needs (Maslow 1943) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Constructive feedback is a dynamic, interactive conversation to facilitate 
learning (Lloyd et al. 2016a).  The focus should be on the task and individual 
receiving feedback.  It should not be a passive process (Archer 2010, Lloyd 
2016) to encourage “a full circle of shared responsibility” (Sullivan et al. 
2013) through active participation and dialogue.  Within the socio-
constructivist paradigm, feedback enables learners to gain fresh insight and 
understanding, emphasising that the facilitator does not dictate the process 
(Evans 2013, Archer 2010).  A co-constructivist approach advances this 
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further suggesting that the dynamic nature of delivering feedback creates a 
reciprocal learning process where both facilitator, and learner, learn from 
each other (Carless et al.  2011).  More recently, Telio et al. (2015) proposed 
an “educational alliance” framework for feedback delivery.  In chapter 6 
prescribers reported the educational outcomes of feedback and in these 
interviews, pharmacists have similarly reported delivering PE feedback 
supports their own personal development. 
 
Such interactions could be considered as part of a “community of practice” 
(Lave and Wenger 1991).  Here, prescribers and pharmacists are interacting 
to enhance a collective understanding of each other, prescribing issues and 
their meaning in the context of the clinical environment.  This context will 
include the social, cultural and environmental factors that all interact to 
influence prescribing.   
 
8.5.4. Impact on pharmacist-prescriber relationships 
 
A dominant theme in these interviews was improved rapport with prescribers 
and greater team integration, comments echoed by prescribers interviewed 
in chapter 6.  Appreciating the reasons for PEs and the pressures that 
prescribers are under increased pharmacist empathy with prescribers, 
informing a less critical approach to PEs, with similar views reported 
elsewhere (McGuire et al. 2015).   
 
Pharmacists consistently advocated that they were more integrated in the 
clinical team which was accelerating rapport building with prescribers: an 
important consideration for teamwork when junior doctors typically rotate 
every four months.  Directly, feedback opens dialogue with prescribers, 
creating a community of learning that can foster rapport and establish 
working relationships.  Indirectly, where this increases self-confidence and 
self-efficacy of pharmacists, they would be more likely to engage with the 
clinical team.  Another plausible consideration is that by acting as facilitators 
of PE feedback, an educational teacher-student (pharmacist-prescriber) 
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hierarchy is created providing pharmacists with the confidence to challenge 
prescribing more. 
 
These process outcomes for pharmacists are all plausible positive 
influencers on prescribing.  This resonates with the variable outcomes 
reported by prescribers in chapter 6 and underscores the complexity of the 
feedback intervention.  An unintended negative consequence was reported, 
with the credibility of one pharmacist questioned where they were unable to 
answer relevant questions.  A similar minority view was expressed by 
prescribers in chapter 6 and here, the knowledge, skills, experience and 
confidence of individual pharmacists would be an additional variable. 
 
In complexity theory, the system is connected (Cohen et al. 2011). 
Pharmacists, prescribers, nurses, patients, resources, equipment and the 
environment are all key components of a complex ecology.  The prescribing 
process, and learning to prescribe, is part of a “complex adaptive social 
system” (McLellan et al. 2015).  If an element of these components changes, 
a ‘butterfly effect’ occurs and the system changes.  These components co-
evolve in response to change, and are auto-catalytic with any resultant new 
order a result of internal self-organization.  Each component in the system 
interacts and in this research, feedback has altered that interaction and 
amplified pharmacist and prescriber behaviours.  For “self-organized 
criticality” (Bak 1996, Cohen et al. 2011), a single, seemingly simple 
intervention, in this case PE feedback, can create a large effect from 
interactivity and non-linear connections. 
 
The variables that influence a prescribing decision are complex (Aronson 
2009a) and PE interpretation can be subjective (Dean franklin et al. 2005).  
Where or if the decision to provide feedback is initiated, how the pharmacist 
and prescriber engage and interact will vary, with dialogue and discourse 
non-linear.  What solutions are negotiated and how these affect prescriber or 
pharmacist practice or interaction with the clinical environment, is unknown.  
The potential for a cascade amplification of these variables is illustrated in 
figure 66.  
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Figure 66: Variability of process outcomes from prescribing error 
feedback 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Therefore, the true affecters of change on prescribing are elusive, and could 
be any number or combination of variables reported here or in chapters 6 or 
9 interacting synergistically, creating a cascade of uncertainty of the true 
effect of prescribing error feedback. 
 
Where a complex system has “connectedness”, changes to this 
connectedness through increased teamwork will produce changes in 
prescribing.  Where pharmacists are more integrated or involved in 
prescribing decisions, the system will self-organize.  Where feedback, either 
positive or negative is provided, the interaction between the prescriber, 
senior colleagues, patients, the prescription chart and pharmacist will 
change.  Where prescribers seek further feedback, the system will continue 
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or could simply be a perturbation that pushes the system beyond a ‘tipping 
point’ for seismic change. 
 
For example, where feedback raises role awareness or usefulness of a 
pharmacist, this is likely to influence teamwork and information-seeking 
behaviour at point of prescribing.  Where this raises the confidence of 
pharmacists, they are more likely to engage with prescribers and innovate 
practice which will influence prescribing outcomes.  Equally, the social 
process of feedback can create motivation for prescribers to improve and the 
support to do so.  The setting and environment are components of the 
system and the role of the ward-based pharmacist will influence motivation of 
prescribers to learn, and the pharmacist to deliver any bespoke education. 
 
Which of these multiple outcomes manifests or has the greatest influence on 
prescribing would be supposition, but offers possibilities for further research 
and avenues of enquiry.  However, the author proposes that several process 
outcomes are more likely to influence prescribing.  Firstly, good teamwork 
alone can improve patient safety (Firth-Cozens 1998) and where 
pharmacists deliver prescribing education as part of any feedback process, 
teamwork could be improved (Lewis and Tully 2009).  Teamwork includes 
information and feedback-seeking behaviour as reported in this research.  
Secondly, feedback can raise self-awareness of prescribing competence with 
enhanced situational awareness informing self-regulation of prescribing.  
Finally, the importance of self-checking to identify slips and lapses is 
reported and is a simple intervention to identify skill-based errors.   
 
These behaviours could support the prescribing process both before, during 
and after completion and suggest possibilities for prescribing education.  
They also tell us that the feedback can influence multiple components of a 
complex social prescribing system, and that the outcomes are potentially 
greater than its individual component parts. 
 
Considering these variances, where the feedback intervention is applied 
uncritically in other settings, similar outcomes may not be obtained.  For 
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example if the feedback process differs or the conditions of the system vary 
(for example pharmacist and prescriber relationships are already optimised 
or there are more non-medical prescribers who may respond differently to 
feedback) then similar prescribing outcomes may not be observed.  
 
Some pharmacists suggested information seeking from prescribers was 
excessive and created an overreliance on them in some cases.  Here it could 
be argued that prescribers are sharing responsibility with the pharmacist for 
the prescribing decision if they perceive it to be risky (Di Caccavo et al. 1995) 
or likely to result in feedback.  A similar phenomenon has been reported in 
primary care where GPs pass responsibility to hospital consultants 
(Armstrong and Ogden 2006), a term coined ‘defensive avoidance’ (Di 
Caccavo et al. 1995) where prescribing decisions are ‘deferred’.  However, 
equally, seeking accurate medicines information at the point of prescribing is 
a core element of effective prescribing (Maxwell and Walley 2003).  Where 
senior prescribers are unavailable for advice, such lack of supervision has 
been associated with PEs (Dean et al. 2002).  Pharmacists recognise 
themselves as information providers (Elvey et al. 2013) as reported in these 
interviews and the focus groups in chapter 4, and where this role is 
recognised by prescribers, their potential to both inform and negotiate 
prescribing should be utilised.   
 
Inter-professional ward-based interactions have been described elsewhere 
as ad-hoc, task-oriented and terse (Lewin and Reeves 2011).  Doctor-nurse 
relationships in particular have been described as ‘parallel’ with limited 
information sharing or effective collaborative working (Lewin and Reeves 
2011).  There appears potential for feedback to influence teamwork, 
changing from a process of parallel working where pharmacists feel like they 
are anonymous and working on the periphery of clinical teams, to a more 
centralised and co-operative process with shared decision making.  In “To 
Err Is Human: Building a safer health system” (Institute of Medicine 1999), as 
part of a triangulated approach to PEs, it was recommended that 
pharmacists should be part of the ‘rounding’ (ward round) process.  Such a 
team approach can allow prescribers to prescribe correctly every time where 
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the pharmacist informs prescribing choice, dose, frequency and monitoring 
with clear benefits for patient care.  Such an approach can provide a culture 
where the prescriber and pharmacist act as counter balances and checks, 
improving the prescribing safety net and driving development of each others’ 
practice. 
 
Being an effective communicator has been proposed as an essential role of 
pharmacists (Wiedenmayer 2006). However, it has been suggested that 
pharmacists are often anonymous characters, or perceived negatively in the 
media (Elvey et al. 2013, Poirier et al 1987), views that do not support the 
status of the profession.  Patients have reported a lack of understanding of 
the role of hospital pharmacists in their care (Morecroft et al. 2015), views 
expressed by other healthcare professionals (Healthcare commission 2007).  
Such professional ambiguity and anonymity could be exacerbated by the 
communication apprehensions and limited communication with prescribers 
reported in chapter 4.  Concerns over pharmacist’s social skills have been 
reported previously with hospital pharmacists described as ‘aloof’ (Elvey et 
al. 2013).  This echoes the views of student healthcare professionals 
elsewhere with pharmacists receiving low ratings for perceived social skills 
(Hean et al.  2006).  Considering the multi-professional approach to patient 
care, the implications of such findings have ramifications for teamwork and 
patient care.  Delivery of PE feedback creates a platform for pharmacists and 
prescribers to interact and catalyse further communication.  Hospital 
pharmacists have been striving for professional recognition and in these 
interviews, pharmacists described an increased awareness of their roles by 
and communication with prescribers.  These outcomes are consistent with 
prescriber views reported in chapter 6 and can contribute to developing the 
professional identity and professional recognition that pharmacists strive for. 
 
8.5.5. Sustainability 
 
Pharmacists agreed that PE feedback was gauged correctly for significant 
errors, with a risk of diluting the message and making the interaction less 
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memorable for minor errors.  This is consistent with prescriber views 
reported in chapter 6 and findings published elsewhere (Bertels et al. 2013).  
 
The initiative was considered sustainable with little demand on pharmacist 
time.  Individual PE feedback typically took less than five minute, with overall 
PE feedback lasting less than fifteen minutes although this required little 
investment of pharmacist’s time, echoing findings elsewhere (Sullivan et al. 
2013, Gordon and Bose-Haider 2012).  Furthermore, it was considered that 
the potential benefits of feedback warranted investment of pharmacist time, 
with some pharmacists suggested it was more relevant than other 
responsibilities. 
 
The process of auditing prescribing and drafting feedback reports was 
considered more time consuming, consistent with limitations of audit and 
feedback reported elsewhere (Montesi and Lechi 2009).  However, 
pharmacists did advocate that audit and feedback at the start of prescriber 
rotations facilitated rapport building and was essential.  Reducing the audit 
period from five to two days could allow collection of some prescribing data 
that would be less labour intensive, minimising the risk of data collection 
fatigue (Ashcroft et al. 2015) whilst still supporting PE feedback. 
 
8.5.6. Improving feedback  
 
The potential for shared learning was reported echoing findings in chapters 4 
and 6 and could facilitate group discussion, a feedback approach considered 
likely to influence future prescribing (Ferguson et al. 2017).  Group 
discussion could allow benchmarking to other prescribers, creating further 
goal-oriented behaviour to modify practice (Jamtvedt et al. 2006).  However, 
an individualised approach is considered more effective as described in 
chapter 2. 
 
Lewis et al. (2014) suggested that prescribers need to be aware of the 
support that pharmacy can offer at hospital induction.  Advancing on this, 
each clinical area will have unique prescribing problems and a more 
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proactive approach to ‘feedback’ could be local ward-based inductions for 
prescribers.  This could support initial rapport building, highlight prescribing 
problems and how to avoid them, and the role and support that pharmacy 
provide.  This approach could be considered as feeding-forward where 
certain PEs are anticipated and solutions to avoid them negotiated.  It has 
been proposed previously that regular formal and informal communication 
can encourage good team working (Firth-Cozens 1998) with Lewis and Tully 
(2009) suggesting that pharmacist-led training on medications could improve 
teamwork at a local level.  
 
8.6. Strengths and limitations of these interviews 
 
This is the first qualitative study exploring the in-depth views of pharmacists 
to delivering formalised PE feedback.  The semi-structured interviews have 
provided the qualitative depth needed to illuminate the research aims.   
 
This study has confirmed reports of improvements and changes in prescriber 
behaviour from chapter 6.  However, building on the reported themes from 
chapter 6, there are multiple variables that could be influencing prescribing 
outcomes.   
 
These unintended positive outcomes make inferences on the true effect of 
what is a complex intervention difficult to interpret.  Feedback can provide 
information for the system to change and grow but equally it may be no more 
than a perturbance (Cohen et al. 2011) that catalyses a chain of events in 
what is a complex and adaptive system.  Therefore, the same outcomes may 
not be obtained with this intervention in other settings where pharmacist,  
prescriber or other service provision differs. 
 
Whilst there was a limited number of interviewees, data saturation was 
achieved with redundancy of themes, confirming adequacy of the recruited 
sample (Guest 2006).  Equally, not all pharmacist grades were interviewed 
although participant views are likely representative of the wider department.  
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Qualitative data analysis is open to interpretation, and this limitation was 
mitigated by independent second coding by the supervisory team (SDW and 
SVOB). 
 
Whilst the author knew the pharmacists in a professional capacity, the risks 
of halo or Hawthorne effects (Basit 2010) were limited by clarification of 
responses.  Furthermore, as described in chapter 3, having rapport with 
interviewees and understanding the background and context of the research 
is a potential strength and not weakness. 
 
8.7. Implications of these interview findings 
 
Pharmacists value the PE feedback intervention and consider it sustainable.  
Echoing prescriber views in chapter 6, the concerns reported by pharmacists 
in chapter 4 appear unfounded.  In contrast, delivering PE feedback has 
positive impacts on pharmacist-prescriber relationships and pharmacists 
themselves, supporting the need for routine practice of pharmacist-led PE 
feedback in STHKH.  These outcomes may also be having unanticipated 
positive effects on prescribing practice and, whilst feedback can be the 
accelerator to amplify change, the true effect of the intervention as a single 
process cannot be determined with any certainty. 
 
8.8. Chapter Summary 
 
A key aim of these interviews was to understand the experiences of hospital 
pharmacists of delivering formalised PE feedback.  This chapter has 
presented relevant participant details, data collection and analysis 
techniques, and an overview and discussion of the results. 
 
Pharmacists value and welcome the feedback intervention considering it 
worthwhile and sustainable.  Benefits extend beyond improved prescribing 
with enhanced prescriber rapport and communication, team integration and 
shared decision making for prescribing reported.  These outcomes appear to 
positively influence the self-efficacy, confidence and job satisfaction of 
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pharmacists.  It is possible that these process outcomes are contributing to 
the reported changes in prescribing error rates and underlines the complexity 
of the intervention.  Chapter 9 will now explore the impact of feedback on 
prescribing behaviour. 
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Chapter 9. Exploring the impact of feedback on prescribing behaviour 
 
 
9.1. Chapter Introduction 
 
This penultimate chapter will explore the impact of PE feedback on 
prescribing behaviour. 
 
The primary research aim of this chapter was to: 
 
Explore the impact of feedback on prescribing behaviour 
 
An overview of the interview process will be described initially followed by 
presentation of the results with relevant interview quotes.  These results will 
then be discussed, compared and contrasted to the wider literature and other 
findings in this thesis, outlining the impact of pharmacist-led feedback on 
prescribing practice.  The chapter will then conclude with a summary of these 
findings. 
 
It has been proposed that future research into prescribing education needs to 
“enhance our understanding of what underpins observed behaviour changes” 
(Brennan and Mattick 2013, Craig et al. 2008) by including a qualitative 
process evaluation within quantitative study designs.  The results of chapters 
5 and 7 reported significant impacts on PE rates whilst the experiences of 
receiving and delivering feedback have been described in chapters 6 and 8.  
However, whilst changes in prescribing behaviour were reported, these 
changes were not explored in detail.  An understanding of these changes will 
highlight why the intervention is having an effect, and could support both the 
feedback process and PE reduction interventions further. 
 
9.2 Semi-structured interviews 
 
Semi-structured interviews were used to provide the in-depth information 
required as described in chapter 3.   
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9.2.1 Eligibility for interview 
 
Forty-seven prescribers worked on the intervention wards.  Of these, thirty-
seven received feedback on overall prescribing as reported in chapter 7.  
Prescribers were eligible to be interviewed if they received feedback on an 
individual significant PE in the previous week.  This was to ensure they had 
sufficient memory recall to discuss the PE.  Receipt of feedback on overall 
prescribing was not a pre-requisite.  Pharmacists were trained in delivery of 
PE feedback as discussed in chapter 4. 
 
9.2.2. Prescriber recruitment 
 
Prescribers were recruited by ward pharmacists who provided participant 
information sheets (Appendix 10) following delivery of feedback to the 
prescribers.  Where prescribers expressed an interest to participate, the 
author followed up with a face-to-face discussion at ward level before 
arranging a mutually convenient time to conduct the interview.   All 
prescribers who were approached during recruitment expressed an interest 
to participate.   Twenty-four prescribers expressed an interest to participate 
following PE feedback.  A total of 23 prescribers were interviewed (Table 31) 
and 65 errors discussed over 38 interviews between September and 
December 2015.  One prescriber (Grade CT1) could not be interviewed 
during the recruitment phase as the error had occurred more than a week 
ago.  Similarly, three prescribers (R1, R6 and R10) were illegible for further 
interviews but were not approached as the PE had occurred over a week 
previously.  The reasons for the time delay were typically the prescriber 
being on annual leave or working night shifts.  Additionally, two prescribers 
(prescriber R6 and R16) refused further interviews as they had already 
participated at least once in the interviews in this chapter.  Once it was 
considered that data saturation was achieved as described in chapter 3, no 
further prescribers were recruited. 
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Table 31: Participant information for semi-structured interviews a 
Prescriber 
code 
Prescriber 
grade 
Male 
or 
female 
Years 
Qualified 
at time 
of 
interview 
University Number 
of 
interviews 
Number 
of errors 
discussed 
R1 FY1 Female 1 Liverpool 4 9 
R2 FY1 Female 1 Norwich 2 3 
R3 FY1 Female 1 Keele 3 3 
R4 FY2 Male 2 Liverpool 3 3 
R5 FY1 Female  1 Liverpool 1 1 
R6 FY2 Female 2 Liverpool 2 3 
R7 CT2 Female 4 Liverpool 2 2 
R8 CT2 Male 5 Leicester  1 2 
R9 FY1 Male 1 St. 
George’s 
3 3 
R10 ST6 Male 8 Liverpool 1 3 
R11 ST4 Male 6 Liverpool 1 1 
R12 FY1 Male 1 Liverpool 1 2 
R13 CT1 Male 3 Liverpool 1 3 
R14 FY1 Female 1 Czech 
Republic 
1 3 
R15 FY1 Female 1 King’s 
College 
1 1 
R16 FY1 Male 1 Ireland 1 3 
R17 FY1 Female 1 Liverpool 1 2 
R18 FY1 Female 1 Liverpool 2 5 
R19 FY1 Female 1 Liverpool 1 3 
R20 FY2 Female 2 Warwick 1 1 
R21 CT1 Female 3 London 1 4 
R22 CT1 Male 3 Liverpool 2 2 
R23 FY1 Female 1 Liverpool 2 3 
 Total 38 65 
a An overview of each prescriber grade is provided in chapter 1 
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9.2.3. Interview process 
 
Interview duration varied between 8 and 33 minutes (Table 32).  Interviews 
were conducted in a private interview room, typically on the ward although 
several interviews were also conducted in an interview room in the pharmacy 
department at the discretion of the prescriber. Ward staff were informed of 
the interview in an attempt to limit disruptions.  Prior to commencing the 
interview, the purpose of the study was covered again and both verbal and 
written consent obtained by the author.  A topic guide (Appendix 5) was used 
to explore key themes and ensure consistent issues were discussed.  
 
Table 32: Overview of prescriber interviews 
Interview Duration 
(mins) 
Prescriber Prescriber 
grade 
Error Stage of 
prescription 
(InP = 
inpatient, 
TTO = 
discharge) 
Active 
failure 
1 11:45 R1 FY1 1. Rivaroxaban renal 
dose 
InP KBM 
2 11:22 R1 FY1 2. Amlodipine 10mg vs 
5mg  
3. Seretide 500 2 bd vs 
250/25 2 bd  
TTO 
TTO 
Slip 
 
Violation 
3 22:53 R2 FY1 4. Latanoprost omitted 
5. Amlodipine 20mg 
prescribed 
TTO 
TTO 
Slip 
Slip 
4 16:12 R3 FY1 6. Omeprazole od vs 
bd 
TTO RBM 
5 18:27 R3 FY1 7. Enoxaparin omitted 
on re-write 
InP Slip 
6 12:38 R4 FY2 8. Amiodarone and 
simvastatin 40mg 
(IP) 
InP KBM 
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Interview Duration 
(mins) 
Prescriber Prescriber 
grade 
Error Stage of 
prescription 
(InP = 
inpatient, 
TTO = 
discharge) 
Active 
failure 
7 14:08 R5 FY1 9. Losartan/HCTZ Rxd 
vs losartan (TTO) 
TTO Lapse 
8 15:26 R6 FY2 10. Amlodipine and 
simvastatin 40mg  
TTO Lapse 
9 18:42 R7 CT2 11. Doxycycline in 1st tri 
pregnancy  
InP RBM 
10 14:52 R8 CT1 12. Olanzapine instead 
of osalazine  
13. Kayceel but K+ >4  
TTO 
TTO 
Slip 
 
Lapse 
11 17:04 R9 FY1 14. Ramipril on TTO but 
stopped on kardex  
TTO Slip 
12 15:30 R10 CT6 15. Nine items Rxd for 
Incorrect patient 
(TTO) 
16. Pregabalin 75mg od 
vs bd 
17. Atorvastatin omitted 
TTO 
 
TTO 
TTO 
Slip 
 
 
Slip 
 
Slip 
13 13:32 R6 FY2 18. Mirtazepine 45mg 
po bd vs od  
19. Omeprazole 20mg 
po od vs 40mg 
TTO 
TTO 
Slip 
 
Slip 
14 19:01 R7 CT2 20. Tramadol Rxd wrong 
patient  
InP Slip 
15 12:38 R4 FY2 21. Rivaroxaban and 
enoxaparin  
InP Lapse 
16 21:31 R11 ST4 22. Humalog bd vs 
Humalog mix  
InP RBM 
17 19:02 R12 FY1 23. Fluvoxamine bd TTO Slip 
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Interview Duration 
(mins) 
Prescriber Prescriber 
grade 
Error Stage of 
prescription 
(InP = 
inpatient, 
TTO = 
discharge) 
Active 
failure 
instead of od  
24. Quetiapine omitted 
TTO  
Slip 
18 13:04 R1 FY1 25. Bisacodyl 10mg bd 
vs od 
26. Adcal D3 tds vs bd 
27. Dorzolamide vs 
dorzolamide/timolol  
TTO 
TTO 
TTO 
Slip 
 
Slip 
Slip 
19 17:37 R13 CT1 28. Metoclopramide no 
duration  
29. Amitriptyline 50mg 
on vs 100mg  
30. Modafanil 100mg on 
vs om and 100mg 
pm 
TTO 
TTO 
 
TTO 
KBM 
 
Slip 
 
Slip 
20 18:27 R14 FY1 31. Tramadol 
transcribed 50mg po 
tds instead of qds 
32. Gaviscon Advance 
transcribed 10mL po 
tds instead of qds 
33. Flucloxacillin 
prescribed as 
500mg po tds 
TTO 
 
TTO 
 
TTO 
Slip 
 
 
 
Slip 
 
 
KBM 
21 19:40 R15 FY1 34. Incorrect insulin 
dose for 
hyperkalaemia  
InP KBM 
22 18:56 R16 FY1 35. Meropenem 1g IV 
tds. should have 
been 1g IV bd (GFR) 
36. Prednisolone 30mg 
po od prescribed.  
InP 
 
TTO 
 
 
KBM 
 
 
 
Slip 
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Interview Duration 
(mins) 
Prescriber Prescriber 
grade 
Error Stage of 
prescription 
(InP = 
inpatient, 
TTO = 
discharge) 
Active 
failure 
No reducing course 
prescribed but 
needed in this 
patient. 
37. Amoxicillin 500mg 
po tds for five days 
but course was 
complete 
 
TTO 
 
 
 
 
 
Slip 
23 11:42 R1 FY1 38. Metformin 1g bd vs 
500mg bd  
39. Doxycyline and iron  
40. Cephalexin on TTO 
but C&S = R  
TTO 
InP 
TTO 
Slip 
 
KBM 
Slip 
24 19:49 R3 FY1 41. Nicorandil 150mg od 
vs 10mg bd (TTO) 
TTO Slip 
25 14:47 R9 FY1 42. Digoxin on TTO but 
stopped as inpatient 
(TTO) 
TTO RBM 
26 23:20 R17 FY1 43. Clexane Tx dose 
with fondaparinux 
44. Spiriva 2puffs bd vs I 
od 
InP 
 
InP 
Lapse 
 
KBM 
27 23:28 R18 FY1 45. Sulfadiazine vs 
sulfasalazine 
46. Lansoprazole 
omitted from TTO  
TTO 
TTO 
Slip 
 
Slip 
28 19:10 R18 FY1 47. Metoclopramide 
prescribed regularly 
no duration 
48. Incorrect  Lithium 
TTO 
 
TTO 
TTO 
KBM 
 
 
Slip 
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Interview Duration 
(mins) 
Prescriber Prescriber 
grade 
Error Stage of 
prescription 
(InP = 
inpatient, 
TTO = 
discharge) 
Active 
failure 
dose on TTO  
49. Lansoprazole 
prescribed on TTO 
but discontinued 
 
Slip 
29 14:21 R19 FY1 50. Seretide device 
incorrect 
51. Midazolam Rx 
duplicated  
52. Latanoprost / timolol 
transcribed as 
latanoprost only.   
TTO 
TTO 
InP 
Slip 
 
Slip 
 
Slip 
30 20:22 R20 FY2 53. Madopar CR 125 po 
qds vs madopar 
(TTO) 
 Slip 
31 21:04 R21 CT1 54. Insulin infusion 
1mL/kg/hr  
55. Levetiracetam 
multiple doses 
prescribed on one 
medication chart 
entry.  
56. Sodium Valprotae 
multiple doses 
prescribed on one 
medication chart 
entry. 
57. Novorapid [short 
acting insulin] 
prescribed with an 
insulin infusion 
InP 
InP 
 
 
InP 
 
 
InP 
KBM 
 
RBM 
 
 
 
 
RBM 
 
 
 
 
KBM 
32 33:26 R2 FY1 58. Dabigatran Rxd TTO Slip 
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Interview Duration 
(mins) 
Prescriber Prescriber 
grade 
Error Stage of 
prescription 
(InP = 
inpatient, 
TTO = 
discharge) 
Active 
failure 
instead of 
darifenacin 
33 18:07 R9 FY1 59. Novomix 30 instead 
of Novorapid 
TTO Slip 
34 08:27 R4 FY1 60. Humalog instead on 
Humalog Mix25 
InP RBM 
35 17:11 R22 CT1 61. Prednisolone 
reduced to zero.  
Should be 10mg 
maintenance 
TTO RBM 
36 12:20 R22 CT1 62. Stalevo no strength TTO Slip 
37 14:09 R23 FY1 63. Thiamine od vs tds TTO Slip 
38 12:11 R23 FY1 64. Latanoprost vs 
latanoprost/timolol 
65. Amoxicillin bd vs tds 
TTO 
 
TTO 
Slip 
 
Slip 
       
 
 
9.2.4. Data analysis  
 
All interviews were digitally recorded and transcribed verbatim by the author, 
with the exception of anonymising person and place names. Interviews took 
between one and two hours to transcribe.  Transcripts were read whilst 
simultaneously listening to the audio file to correct any transcription errors. 
 
All transcripts were independently read by the supervisory team, SDW and 
SVOB.   
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Transcripts were coded line-by-line and analysed thematically by the author 
as described in chapter 3.  This included open coding of transcripts for 
relevant data with codes identified both deductively from the topic guide and 
results from chapters 6 and 8, and inductively, for codes that could not be 
predicated beforehand.  
 
An initial inductive approach to coding was adopted with ideas and 
interpretations of the data indexed in the margins of the transcripts.  
Interpretive ideas and concepts were informed both a priori from research 
aims and a posteriori from participant views (Pope et al. 2000) that the 
researcher could not predict (Gale et al. 2013) such as ‘assertive behaviour’, 
‘task-prioritisation’, ‘mindful prescribing’, ‘self-regulation’ or ‘self-detection of 
errors’. Codes were then amalgamated into larger categories to produce an 
initial thematic framework (Appendix 25). 
 
Categories and codes were discussed with the PhD supervisors at regular 
team meetings.   Inter-coder discrepancies were resolved for an analytical 
consensus.  The framework was then applied to transcripts to measure the 
fit, with further inferences and refinements typical of the framework 
approach.  Relevant transcript extracts were then copied and pasted under 
the relevant code in the final thematic framework for further analysis and 
meaning in relation to the research question.   
 
9.2.4.1. Prescribing error classification 
 
Errors were initially categorised by the author following descriptions outlined 
in chapter 1.  Where the prescriber described situations reflecting more than 
one type of error (for example a KBM and a slip), the error was classified 
according to the most prevalent typology described by the prescriber.  Error 
classification was also undertaken independently by SDW and SVOB with 
any discrepancies resolved through discussion.  An overview of PEs 
discussed is presented in tables 32 and 33. 
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Table 33: Overview of active failures discussed during prescriber 
interviews 
 
Prescriber 
grade 
Error 
type 
Prescriber Grade 
FY1 (n=13) FY2 
(n=3) 
CT/ST 
(n=7) 
Total 
(n=23) 
Mistake KBM 7 (16.3%) 1 (16.7%) 3 (18.8%) 11 (16.9%) 
RBM 4 (9.3%)  4 (25.0%) 8 (12.3%) 
Skill 
bases 
error 
Slip 29 (67.4%) 3 (50.0%) 8 (50.0%) 40 (61.5%) 
Lapse 2 (4.7%) 2 (33.3%) 1 (6.3%) 5 (7.7%) 
Violation 1 (2.3%) 0 0 1 (1.5%) 
Total 43 6 16 65 
 
 
9.3. Results  
 
Twenty-three prescribers were recruited with a range of prescriber grades 
from FY1 to CT6 (Tables 32 and 33).  Prescribers were allocated codes for 
anonymity (Table 32).  It was considered by the author and PhD supervisors 
that data saturation had been achieved by interview 20, although further 
interviews were conducted to provide greater richness of material for each 
active failure.  Relevant qualitative extracts are referred to by transcript 
number T1-T38. 
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Table 34: Thematic framework for prescriber interviews 
Category Code Code occurrence (and number of 
interviewees) 
KBM RBM Slip Lapse Violation 
1. Affective 
behaviour 
Assertive 
behaviour 
2(2)  5(4) 7(4) 0 
Reflective 
practice 
4(4) 3(5) 7(5) 7(5) 0 
Self-
awareness 
5(5) 4(5) 27(18) 4(4) 1(1) 
Self-regulation 1(1) 6(5) 7(6) 3(2) 0 
Emotional 
impact 
6(6) 13(6) 29(16) 10(5) 0 
Task 
prioritisation 
0 2(2) 9(7) 3(2) 0 
 
2. Learning 
outcome 
Prescribing 
knowledge  
13(6) 3(3) 2(2) 0 0 
Self-detection 
of errors 
0 3(3) 7(6) 2(2) 1(1) 
Raised 
situational 
awareness 
0 0 6(6) 3(2) 0 
Prescribing 
practice 
Separate category see below 
 
3. Prescribing 
practice 
Information 
seeking 
behaviour 
9(8) 3(2) 12(9) 0 0 
Mindful 
prescribing  
0 10(7) 25(16) 8(4) 1(1) 
Systematic 
approach to 
0 5(3) 20(15) 3(2) 0 
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Category Code Code occurrence (and number of 
interviewees) 
KBM RBM Slip Lapse Violation 
prescribing  
Prescribing 
location 
0 0 10(6) 4(4) 0 
 
4. Error recurrence Specific vs. 
general 
learning  
19(11) 20(9) 38(18) 11(6) 1(1) 
Facilitator 
variability 
3(2) 2(2) 4(4) 0 0 
 
 
 
The complete thematic framework with themes and secondary codes can be 
seen in table 34. Four key categories emerged from the data corpus, these 
were: 
 
1. Affective behaviour 
2. Learning outcome 
3. Prescribing practice 
4. Error recurrence 
 
Sample quotations are given under thematic headings to demonstrate the 
experiences and views of participants.  These quotes were agreed with the 
research team SDW and SVOB and will be reported below in the context of 
mistakes and skill-based errors.  
 
In general, prescribers discussed their PEs openly and candidly 
acknowledging the error as their own and the need to learn and improve their 
prescribing practice.  One prescriber (R15) was somewhat defensive when 
discussing their PE although they had also had a formal conversation with 
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their senior over a particular PE that may have influenced their attitude.  All 
prescribers were overwhelmingly positive about the project, echoing findings 
of chapter 6, and openly discussed the potential impact that feedback was 
having on their prescribing practice. 
 
9.3.1. Affective behaviour 
 
Six codes were included in this category: assertive behaviour, reflective 
practice, self-awareness, self-regulation, emotional impact and task 
prioritisation.  
 
1a. Assertive behaviour  
 
For mistakes, prescribers reported being more assertive in challenging 
hierarchy and prescriber etiquette: avoiding assumptions that more senior 
prescribers are always correct or in seeking further information to inform their 
prescribing as discussed later. 
  
T22: “If they say oh go with 1g tds [three times a day] then I would usually go 
with what they say like if they said go with this, they are the experts… that 
[feedback] would be like a prompt now I guess for me to say and by the way 
they have a reduced creatinine clearance what dose would you go for?” 
[KBM] 
 
For skill-based errors such as slips and lapses, prescribers reported being 
more assertive in managing disruptions and communicating such issues with 
team members for example. 
 
T26: “After [ward pharmacist] pointed that out then I have…like when I am 
doing a kardex re-write or something and someone interrupts me I’ll say no! 
[puts hand up] and I did that to [consultant] the other day… he had a group of 
medical students and I was writing this complicated digoxin loading dose and 
I just said “I’m sorry, but I’m doing this otherwise I’ll make a mistake” 
[laughter].” [Lapse] 
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It was acknowledged however that distractions were always likely and that in 
some cases it can be difficult to challenge the status quo as a junior doctor. 
 
T15: “I think maybe only in terms of being more forceful now and saying give 
me a list and I’ll sort it later but sometimes especially on [acute medical ward] 
it can be difficult with the environment and it’s a very nurse led environment 
and so as the doctor or the junior doctor especially, then you are just 
following the line rather than challenging the status quo.” [Lapse] 
 
1b. Reflective practice 
 
For all error types, prescribers reported reflecting on action to determine the 
error causation and for action required, to ascertain how they need to 
perform differently next time to minimise error recurrence. 
 
T32: “It’s good because really this is the kind of thing that you should be 
talking … about isn’t it and you know what are you doing wrong, what can 
you do to address it?” [Slip] 
 
Advancing on this, where prescribers reported prescribing a similar drug or 
being in a similar situation, they were reflecting-in-action to become more 
mindful and inform their decisions with the feedback session functioning like 
a flag or cue to further focus them on their prescribing. 
 
T34: “I was thinking about what [ward pharmacist name] said and checking 
the dose, frequency and stuff and writing fifteen minutes before their meal.” 
[KBM] 
 
1c. Self-awareness 
 
For all error types, prescribers consistently reported a raised awareness of 
PEs for both their own practice and in general, understanding the risk of, and 
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ease at which PEs can occur.  For mistakes, it was clear that feedback was 
informing practice and highlighting what they didn’t know. 
 
T16: “Yeah I thought it was useful I’ve had the learning point from it and it 
just reminds you how easy it is to make errors because with the law of 
averages you must go through an average year making x amount of 
mistakes and no one ever tells you about it and until you get an intervention 
such as this you don’t learn.” [RBM] 
 
Feedback equally highlighted “blind spots” for skill-based errors.  Several 
prescribers reported that discharge prescriptions or rewriting of medication 
charts was a routine and monotonous task but equally one they did not 
realise had the potential for error. 
 
T20: “TTOs, I think that it is just… a robotic task that you have to do and you 
don’t really have to use your brain and that was how I was thinking about it 
when I first started and when I watched other doctors do it I just thought oh 
okay it’s very easy and you don’t really have to think about it and you just 
copy it and that was my first impression! [Laughter] But it is easy to make a 
mistake and you do have to think.” [Slip] 
 
This self-awareness highlighted prescribing competence, limitations in 
practice and areas for improvement as one prescriber articulated. 
 
T26: “I hope that the feedback continues because without it you are 
unconsciously incompetent and with it you are consciously incompetent and 
you can change! [Laughter]  And you can’t learn without feedback!” [KBM] 
 
1d) Self-regulation 
 
By raising self-awareness, it was consistently advocated that feedback 
informed prescribing, allowing prescribers to regulate their prescribing 
practice and adapt their prescribing behaviours, facilitated by the solution 
focused outcome of feedback.  
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T28: “I do also think that it is useful to get feedback and pull out specific 
things because it’s quite difficult to make a change unless you have that 
feedback and know what you have done and what you need to do.” [Slip] 
 
For mistakes, prescribers acknowledged the need for greater information 
seeking behaviour whilst for skill-based errors, the need for more mindful 
prescribing was acknowledged although there was a general sense amongst 
prescribers that prescribing can become a mindless task. 
 
T14: “I always thought that I was a dead good prescriber but I have perhaps 
become a little more lax.” [RBM] 
 
Considering this, prescribers advanced that feedback needed to be on-going, 
routine and consistent to continually self-regulate prescribing and prevent 
bad habits from resurfacing or creeping back into practice, especially for skill-
based errors. 
 
T24: “We haven’t had that many TTO errors recently so we’re improving… I 
have been checking more again although I don’t know if that is just a 
rebound effect of getting criticised and then you go a wee while and you’re 
like oh that’s okay I’m alright now.”  [Slip]  
 
1e) Emotional impact 
 
Constructive feedback was unanimously welcomed and valued for all error 
types. For mistakes, there was a sense of embarrassment, disappointment 
and self-criticism for deficits in their own prescribing knowledge. 
 
T6: “I was glad to have got the feedback because there are going to be lots 
of people on simvastatin and amiodarone here [cardiology ward] potentially.  
I was disappointed perhaps that I hadn’t known it in the first place but that 
was purely a knowledge base but you can’t know everything and learning 
from it is the most important thing.” [KBM] 
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T9: “I was really, really upset.  I pride myself on usually being a good 
prescriber and it was a lapse and I’m not overly confident in pregnancy so I 
should just check everything that I prescribe in pregnancy because I know 
that it is not something that I confident in and I don’t know why I didn’t to be 
fair.” [RBM] 
 
For slips and lapses there was a sense of guilt and frustration at making an 
avoidable error. 
 
T13: “I think… this is just a slip really so it is just a bit frustrating really that I 
didn’t identify it and I think that the feedback is a positive thing rather than a 
negative thing.” [Slip] 
 
T8: “I was a bit annoyed that I didn’t identify it myself.” [Lapse] 
 
This frustration was accelerated where the prescriber, through feedback, 
identified error provoking conditions as key causative factors. 
 
T27: “I got upset when I saw this because I knew that was just a ticking time 
bomb and it was just a matter of time before something like this was going to 
happen” [Slip] 
 
1f) Task prioritisation 
 
It was acknowledged that prescribing was sometimes considered a lower 
priority task than other responsibilities.  For slips, prescribers reported 
greater prioritisation of the prescribing task to limit PEs.  Several prescribers 
reported commencing discharge prescriptions in advance of discharge to 
ease pressures on their workload later and avoidance of multi-tasking.  This 
appeared to be in countenance to previous practice where prescribing was 
routinely undertaken at the same time as another task or during a busy ward 
round for example. 
 
 362 
T12: “I think that it can definitely help them I think that errors will always 
occur but I do think that it helps you to prioritise your TTO’s, don’t bunch 
them and be more errr… thorough, to save any further embarrassment.” 
[Slip] 
 
For lapses, prescribers reported acting on prescribing jobs immediately 
instead of leaving them to a later time and risking forgetting to change a 
prescription or commence a new medication for example. 
 
T3: “I should have written it down and prescribed it there and then and then 
at least it would have been prescribed instead of saying oh I must do that.” 
[Lapse]  
 
For skill-based errors, the need to prioritise prescribing created conflict at 
times with junior doctors in particular struggling to prioritise tasks. 
 
T5: “You know so in this case this patient in this bed needs their TTOs done 
or just a letter from me because I’ve just spent twenty minutes with the 
discharge facilitator now trying to work out what they want me to do now 
when they had ten things and I was like well what do you want me to do first?  
That’s quite difficult to prioritise then because they just want you to do 
everything which obviously you can’t.” [Slip] 
 
9.3.2. Learning outcome 
 
Three codes were included within this category: prescribing knowledge, self-
detection of errors and raised situational awareness.  A fourth code, 
prescribing practice was moved into its own category (3a-d) as there were 
several tertiary codes associated with it upon analysis as described below.   
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2a) Prescribing knowledge 
 
Whilst prescribers acknowledged they could learn from any error, it was 
largely mistakes that were reported to improve their drug related knowledge 
with education making the process more meaningful and memorable. 
 
T6: “Well you get the form and the contextualisation in terms of the 
interaction and what it is makes it helpful and you then remember it because 
you can’t just remember a list of numbers oh this dose with this and this dose 
with this.  So knowing the pharmacology behind it helps you to remember 
and so you can then apply it to other situations and it reminds you about the 
inducers and inhibitors [of enzymes] situations.” [KBM] 
 
This was not restricted to specific medications but also to specific situations 
such as dosing in pregnancy, renal impairment or checking for drug 
interactions. 
 
T1. “Especially being on a care of elderly ward I know now that I should be 
checking renal function more often.” [KBM] 
 
For slips, it was clear that feedback improved specific drug related 
knowledge when the incorrect dose or frequency was chosen for example.  
Some prescribers suggested that it would be difficult to look up the dose of 
every single medication they had to prescribe or transcribe from one chart to 
another, although it was acknowledged that this should be best practice. 
 
T24: “It was useful and the fact that it was bd [twice daily] and also it 
reminded me to look up what drugs are in general yeah because I know the 
common ones but I wouldn’t have known something like that to be honest.” 
[Slip] 
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2b) Self-detection of errors 
 
Prescribers reported identifying more of their own errors after receiving 
feedback especially on skill-based errors, although prescribers who received 
feedback on mistakes also reported self-detection of errors from being more 
careful and mindful with their prescribing. 
 
T4: “And I have actually found a couple of times when I have made mistakes 
and like when a dose was ten but actually it was forty and stuff like that so I 
have picked up some of my own errors from rechecking it.  So, that is 
worthwhile doing.” [RBM] 
 
For mistakes, it was acknowledged that it can be difficult to identify an error 
where you are confident it is correct. 
 
T21: “So when you are sure of something then you don’t look it up for 
example you don’t look up every dose of every drug that you prescribe.  For 
example you prescribe Tazocin and you know the dose is 4.5g so you don’t 
look it up.  You prescribe paracetamol you know the dose is 1g so you don’t 
look it up, you know if you are sure of something then you don’t look it up.” 
[KBM] 
 
Through raising awareness of their own PEs and prescribing knowledge, 
some junior doctors reported challenging senior prescribers and seeking 
further information from them to inform their prescribing. 
 
T22: “I have to admit with regards to the amoxicillin and reducing regimen 
that was a mistake that I was making when I first started and now I have 
realised that then when I am prescribing it I am looking through the drug 
chart and speaking to the consultant and saying what are we doing with this? 
How many days do you want?” [Slip] 
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2c) Raised situational awareness 
 
For skill-based errors, prescribers reported having a raised awareness of the 
situation when they are prescribing, such as distractions and other error 
provoking conditions, and the need to be vigilant to manage these causative 
factors. 
 
T26: “Distraction wise, I have an increased awareness now and perhaps 
better communication with the nursing staff too just please don’t interrupt me 
when I am prescribing.” [Lapse] 
 
This was not limited to external factors with several prescribers reporting 
taking forced breaks following feedback discussions when tired, hungry or 
stressed to limit the impact on their prescribing.  
 
2d) Prescribing practice 
 
Prescribing practice appeared to be influenced at many levels by feedback 
with improved knowledge informing future prescribing decisions.  Equally, 
prescribers reported refining their prescribing skills at a non-technical level.  
This latter outcome was considered a more prominent learning outcome 
theme and will be discussed separately below. 
 
9.3.3. Prescribing practice 
 
Four codes were included within this category: information seeking 
behaviour, mindful prescribing, systematic prescribing and prescribing 
location.  
 
Overall, feedback was considered a positive intervention that would facilitate 
prescribing improvements at the knowledge and technical level.  One 
prescriber articulated the impact on their prescribing quite adroitly. 
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T4: “With [ward pharmacist] I feel like at the end of my four-month rotation I 
will be a better prescriber.” [RBM]  
 
3a) Information seeking behaviour 
 
For mistakes, prescribers were consistent in advocating that they were 
seeking information at the point of prescribing to guide and inform their 
decisions.  This included communicating with pharmacists more and where 
they were guided by a more senior prescriber to initiate a medication, 
prescribers reported seeking more information on the dose and duration.  
This extended beyond drug specific medicines information, to seeking 
technical information on renal function and reviewing the medication chart for 
potential drug interactions or duplication for example. 
 
T9: “I think as well now that I will be extra cautious and if I can’t find the 
information or get on toxbase then I’ll just call the on-call pharmacist for 
advice.  You don’t want to bother them but it is very easy to make mistakes 
especially when I’m not confident in a specific area.” [RBM] 
 
Prescribers reported asking pharmacists to check their prescribing prior to 
submitting discharge prescriptions in particular.  Prescribers also reported 
proactively seeking and acting on written pharmacy communication in the 
medical notes or on the medication chart, information that they may have 
previously not paid attention to. 
 
T28: “Today when I was looking at the kardexes I was making sure that I 
was super-duper doubly looking through them and I saw that there were 
pharmacy comments and I do find that I now look for green pen whereas I 
perhaps wouldn’t have been… not interested as… not disinterested but I 
wouldn’t have really thought to look.” [Slip] 
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3b) Mindful prescribing 
 
For KBMs, prescribers reported greater information seeking behaviour as 
reported.  However, there was also a clear sense of more careful, considered 
or ‘mindful’ prescribing for RBMs. 
 
Prescribers reported being more conscious of their prescribing instead of it 
being a routine task and the need for second opinions.  This was informed by 
a raised awareness of errors and the potential emotional impact from making 
the error. 
 
T4: “I think that I’m more aware that it is being looked at and for example I’m 
paying more attention than if you wasn’t doing it.  Now I’m like if this is wrong 
it costs time for somebody else and if it isn’t it gets done quicker and you 
don’t end up in that position because I’m thinking well if I can get it right the 
first time then I don’t have to get it fixed later and I don’t have to have it as a 
black mark as such… I knew that she would spot the error and come and tell 
me off so I would put a bit more effort in.” [RBM] 
 
As reported, prescribers were prioritising their prescribing more to maintain 
required standards and not multi-tasking at the expense of PEs.  This 
extended to taking more time and care with the task.  For skill-based errors 
in particular, prescribers reported investing more time and not rushing the 
task to ensure their prescription was correct first time.  
 
T27: “I try to be a lot more careful and I try to slow down with them.” [Slip] 
 
Again, this practice appeared to be motivated by not only the potential 
emotional impact of the PE: 
 
T3: “I mean that [prescribing error] freaked me out massively and I know that 
you think it’s not that significant, but to me it was because if I done that with 
something else and killed someone then that is a massive problem and I 
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wouldn’t like to be in that kind of position so there are benefits for taking a bit 
of extra time and care then actually you can avoid that can’t you?” [Slip] 
 
But the potential embarrassment of receiving feedback on avoidable errors: 
 
T22: “I’ve been discussing this with [another FY1] and we’ve been saying 
that because we know that [ward pharmacist] is watching then we do take 
that little bit of extra time and you know now I’ll double check my 
prescriptions whereas before I wouldn’t and I was making these silly little 
errors because I knew that pharmacy would come and check it after me.” 
[Slip] 
 
3c) Systematic prescribing  
 
In addition to being more mindful and investing more time in prescribing, 
prescribers also reported adapting their prescribing behaviour, adopting a 
more systematic approach and introducing safeguards to minimise error.  As 
one prescriber reported, it was about going back to basics with each 
prescription to maintain standards. 
 
T14: “I think that it is just about being methodical so even if you are busy you 
keep going through those basics and making sure that you are not missing 
anything and double checking so I think that it is transferrable across the 
board.” [RBM] 
 
Another prescriber suggested that feedback is a prompt to continue with 
these basic principles that may be missed over time. 
 
T8: “I need to get a little bit better …. I mean I was perhaps a little bit better 
at this when I first started and now I’m a little bit more…. I need to get back 
to reviewing my medications more after I have done the TTO.  You know 
when you try and do it as quick as you can and submit whereas now I need 
to go through it and review them [the medications] and go back and look at 
the kardex [medication chart].” [Lapse]  
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For KBMs, this approach reinforced the need to seek appropriate information 
to inform prescribing as reported.  For RBMs, prescribers reported reviewing 
others’ prescribing and not assuming it was correct.  For example, on 
discharge prescriptions that other prescribers have been involved with and 
not just items that they have prescribed. 
 
T25: “I guess the solution is just not to assume that the TTO is fine and I 
need to look through every single time that I use then before I submit it and 
that’s all …and I mean even from today, this morning with a TTO I made sure 
that it was right, I corrected myself… when I had a patient that needed 
discharging today, then I printed off both lists and went through and 
compared and made sure that I had everything on that TTO because that 
TTO was done a couple of weeks ago when that patient was ready to go 
home so I made sure that I didn’t make this again.” [RBM] 
 
Prescribers reported that skill-based errors would be difficult to eliminate 
entirely.  However, a raised self-awareness of their own errors appeared to 
re-iterate the need for safeguards in their own prescribing practice.  In 
particular, prescribers reported introducing a second check of their 
prescriptions once completed to identify avoidable errors: errors they have 
reported detecting more following feedback as discussed earlier. 
 
T13: “I think that this has just reinforced the need to re-check my TTOs 
which I do now after the last one [previous interview] and it doesn’t take that 
long to just take a quick glance to make sure it’s okay and it just makes 
sense in my head as well because it is so easy isn’t it to make a simple slip 
when you haven’t read it and then you read it again and think why the hell 
have I prescribe it like that you know why have I done it twice when I know 
that it is once a day” [Slip] 
 
Specific changes to prescribing processes included printing off the discharge 
summary to check their prescribing as opposed to previously checking it on 
the computer screen.  Other changes in practice included typing in the full 
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drug name as opposed to a few letters to avoid choosing the incorrect item 
from drop boxes on electronic prescribing systems.  Several prescribers 
reported performing a particular aspect of their prescribing first to make sure 
they didn’t repeat a particular slip, such as the transcribing of enoxaparin for 
venous thromboembolism prophylaxis, or not ticking boxes for frequencies of 
medications. These changes appeared to be coping mechanisms to avoid 
specific types of errors.  Building on this, feedback for skill-based errors 
appeared to refine prescribing with subtle but important changes in their 
prescribing practice as proposed by one prescriber. 
 
T11: “Well I think that the feedback is definitely improving the way that I 
prescribe you know it’s just like little things here and there” [Slip] 
 
3d) Prescribing location 
 
Echoing earlier results where the ease of error was recognised and the need 
to afford greater priority to prescribing, the suitability of the working 
environment for prescribing was questioned.  Prescribing was considered 
ubiquitous with prescribers acknowledging that they would often prescribe 
mid-ward round or on busy clinical stations.   
 
T15: “It was on ward round and I was going through patients.  It’s not an 
ideal environment it’s a busy ward round and you’re not remembering to 
check back on things.  I think that at the time there were a few instances 
where nurses were coming up to you and saying can you do the TTO for this 
one and at the same time can you write them up for some laxatives so it was 
a very busy ward round with lots of interference” [Lapse] 
 
Whilst this did not appear to influence mistakes, the impact on skill-based 
errors was telling.  Prescribers described increased assertive behaviour in 
response to distractions as already reported with some refusing to complete 
discharges or re-write discharge prescriptions mid ward-round. 
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T26: “I won’t re-write a kardex on the ward round now, I’ll put it on my list and 
I’ll do that later because I can’t multi-task.” [Lapse] 
 
Several prescribers reported changing locations where distractions could not 
be mitigated. 
 
T7: “I’ve changed computers or I’ll use this room more [a quiet doctor’s 
office] and I’ll read through them again, even read through the TTO aloud 
when I’m doing the TTOs so very much so.” [Lapse] 
 
9.3.4. Error recurrence 
 
Two sub-categories were included in this category: Specific vs. general 
learning and facilitator variability 
 
4a) Specific vs. generic learning 
 
Prescribers reported that they were unlikely to repeat the same mistake twice 
and that they would be actively looking for that specific issue in future when 
prescribing the same medication.  This was informed by improved knowledge 
for mistakes and also reflection-in-action for specific errors and situations as 
reported earlier.  
 
T6: “It is certainly something that I will look for and have a glance to see if 
they are on simvastatin.  I’m certainly looking for it now. Yeah I mean I’m 
more aware now and so will look for it [the interaction]…. But it was drug 
specific.” [KBM] 
 
However, despite outlining the importance of seeking appropriate medicines 
information to reduce mistakes, prescribers acknowledged that any error 
reduction was likely to be limited to specific situations discussed during 
feedback such as dosing in renal failure or pregnancy for example. 
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T9: “I think that this particular case and the tools that I have been given 
would really just stick with the pregnancy because I do know that there are 
renal formularies and stuff but I still don’t know how to get hold of them!”  
[RBM] 
 
For skill-based errors, prescribers reported that the learning outcomes 
should be generic and would not be limited to the specific error or 
medication.  By taking more time, prioritising prescriptions and adopting a 
more systematic approach to their prescribing, all skill-based errors could be 
reduced. 
  
T17: “With these it’s not a mistake or a knowledge issue, it’s about the skill of 
prescribing” [Slip] 
 
Equally, for skill-based errors in particular, there was a sense of futility 
regarding feedback amongst some prescribers where PEs were always likely 
to occur, unless the system was changed to support prescribing and 
eliminate the error provoking conditions. 
 
T15: “The previous error that we discussed last time was more of a 
knowledge thing so that was why whereas this one was just a distraction... a 
work-based or workload one so risk will be reduced but risk will always be 
there.” [Lapse] 
 
4b) Facilitator variability  
 
Variations in facilitator approach to feedback were reported. For mistakes, it 
was reported that some pharmacists discussed the detail behind a specific 
drug interaction, choice of dose or contraindication for example.  Others 
appeared to take this further by delivering bespoke educational sessions or 
provide further examples to contextualise the learning. 
 
T34: “The feedback was very good and I was glad to have the feedback, you 
need to know about your errors so you can correct them.  We discussed the 
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differences and why it happened and she talked through the insulin 
education aid although I had had that last year as well.” [RBM] 
 
For skill-based errors with some pharmacists appeared to advise prescribers 
of the need to ‘be more careful’. This echoes findings from interviews with 
pharmacists in chapter 8 with some pharmacists reporting they had nothing 
‘juicy’ to work with.  Other pharmacists appeared to be far more constructive 
with their feedback, identifying specific solutions to mitigate further problems, 
provided other examples or education for example. 
 
T29: “For the Seretide [an inhaler] device, [ward pharmacist] also brought up 
some inhalers to show me the difference. It does just remind you that they 
are different and what one patient can use isn’t always the same as what 
another patient can use.” [Slip] 
 
Prescribers acknowledged that the latter style of feedback would be more 
constructive and meaningful. 
 
T33: “We had a small talk about it, nothing specifically on differences or 
timings… I think some [education] would just sort of drill it into you really.”  
[Slip] 
 
Two prescribers suggested that where feedback was not particularly 
constructive, the potential impact went beyond the learning outcome and 
influenced the rapport and working relationship with the pharmacist, key 
ancillary outcomes of the feedback process reported in chapters 8 and 4. 
 
T4: “When the new pharmacist was there I didn’t feel under as much 
pressure because I wasn’t very intimidated by her because she was quite 
junior and quite nervous and it was quite hard to get that professional 
relationship with her whereas when [ward pharmacist] was there I knew that 
she would spot the error and come and tell me off so I would put a bit more 
effort in.  Whereas with my newly qualified pharmacist she would be like oh 
well you’ve done this wrong but it’s okay I’ll just fix it for you so there was 
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less pressure on me to get it right the first time.  Whereas… I’m not intimated 
by [ward pharmacist] you know but she is clearly very good at her job and 
you want to emulate that yourself.”  [RBM] 
 
9.4. Chapter discussion 
 
These interviews were undertaken to understand and determine the impact 
of feedback on prescribing behaviour and to help explain the quantitative 
results reported in chapters 5 and 7.  The results suggest that whilst 
feedback is influencing prescribing practice and skill development at a 
knowledge and technical level, delivery of feedback is having a greater 
influence on development of non-technical skills (NTS). 
 
Echoing results of prescriber interviews in chapter 6, feedback provides a 
formal intervention for prescribers to reflect on the situation, identify 
causative factors and plan adaptive strategies to prevent the error from 
recurring: an agenda-led, outcome based approach to feedback advocated 
for teaching of prescribing competencies (Lum et al. 2013).  As part of their 
commitment to professional development, prescribers should reflect on their 
practice and identify learning outcomes empirically and iteratively.  Feedback 
reduces the gap between perceived and actual performance (Randolph et al. 
2009) and can catalyse progression around the experiential learning cycle 
(Hill 2007) to accelerate development of prescribing competency (Figure 67). 
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Figure 67: Experiential learning cycle (from Lloyd et al. 2016b) 
 
 
 
Prescribers in these interviews reported amending their prescribing 
behaviour with a range of adaptive behaviours.  Some of these behaviours 
are reported in table 32 below and highlight some of the NTS required to 
prescribe appropriately and limit mistakes and skill-based errors. 
 
The majority of PEs were classified by the author as skill-based errors and 
not mistakes, findings consistent with previous publications (Dean et al. 
2002, Lewis et al. 2009).  In these cases, a lack of knowledge is not the sole 
underpinning reason behind the error (Tully et al. 2009, McLellan et al. 
2012).  This is perhaps not surprising considering current medical education 
for undergraduates and foundation grade doctors, is reported to focus on 
technical and knowledge based aspects of prescribing (Kirkham et al. 2015). 
 
As articulated recently (Gordon et al. 2013b): “A technically perfect 
prescriber can and will still persistently carry out aberrant prescribing”.  
Building on this, education or improved knowledge, as argued elsewhere 
(Ross, Patey and Flin 2013), is not the panacea of PE reduction strategies.  
This is perhaps why the prescribing safety assessment is so curious:- in 
2014 there was a 94% pass rate (Sayburn 2015) suggesting that prescriber 
knowledge in general is to be commended.  However, the assessment 
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gauges the lowest form of competence, ‘knows’, whereas in clinical practice 
we are more concerned with the doing, a level of competence that is 
influenced by far more than the knowledge and technical aspects of 
prescribing.   
 
That said, where education is required, the feedback facilitator can help to 
educate and improve a prescriber’s knowledge.  Indeed, educational 
outcomes of feedback have been reported in this chapter and also prescriber 
interviews in chapter 6.  As discussed in chapter 8, this can be a co-
constructed event or “educational alliance” with the feedback facilitator also 
learning.   
 
However, many of the adaptive behaviours and skills reported in this chapter 
resonate with the nontechnical skills (NTS) required to prescribe safely and 
accurately.  Perhaps in this regard, education should be considered as part 
of a wider skills acquisition, of which NTS will be one facet of prescribing 
competence.  NTS include the social skills of communication, team working 
and leadership and the cognitive skills of situational awareness and decision 
making (Ross et al. 2013). These skills also include error awareness and 
professional responsibility and are increasingly recognised as integral to safe 
prescribing (Gordon et al. 2013a, Kirkham et al. 2015).  In other high-risk 
industries such as aviation, the need to address NTS of individuals, as well 
as technical expertise and system-wide issues to reduce error, has been 
reported (Lerner et al. 2009). 
 
Several prescribers reported that they just needed to return to ‘basics’ and 
arguably each individual component of prescribing could be considered a 
‘basic’ skill.  However, as a whole, prescribing is a complex skill (Aronson 
2006) with multiple steps and processes.  This complexity makes the 
prescribing process littered with opportunities for PEs, making it a high-risk 
task (Coombes et al. 2007, Gordon et al. 2013a).  The EQUIP study reported 
that learning to prescribe is a social experience (Dornan et al. 2009), one 
that is part of the clinical environment in which prescribers learn.  Therefore, 
it is inappropriate to teach prescribing exclusively in isolated silos away from 
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clinical areas.  Recently, McClellan et al. (2012) have articulated this 
eloquently (Figure 68) illustrating prescribing as an integrated set of complex 
skills involved in the expert performance of it.  The model illustrates how 
knowledge, skills and attitudes interact with the environment (social context) 
in which they are applied.  These skills are self-regulated to enable the 
prescriber to adapt to the changing demands of their environment and 
clinical situations.  Such self-regulation requires self-reflection, with feedback 
a potential catalyst to accelerate development as described at the beginning 
of this discussion.  
 
Figure 68: Theoretical model based on theories of expertise 
development and instructional design theory for complex skills (from 
McLellan et al. 2012) 
 
This theoretical model proposed by McLellan et al. (2012) advocates that the 
skill of prescribing is greater than the sum of its parts but it should be 
highlighted that it does not explicitly include NTS as a ‘part’ that can 
influence unsuccessful execution of the prescribing task.  NTS reported as 
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contributing to PEs include poor communication, managing workload, poor 
teamwork and supervision, and impaired prescriber well-being (Dornan et al. 
2009, Ross et al. 2013b).  A taxonomy of NTS required to prescribe safely 
has been proposed (Dearden et al. 2015) and includes: 
 
 Situational Awareness 
 Decision making 
 Communication and team working 
 Task management 
 
This taxonomy resonates with the findings reported in this chapter with NTS 
reported mapped against relevant active failures in table 35 below.  The 
diversity of outcomes builds on findings from chapters 6 and 8 that the 
feedback intervention is complex with multiple process outcomes.   
 
Table 35: Reported prescriber behaviours following feedback on 
specific error types  
Error type Non-technical skill Reported NTS outcome of feedback 
Mistakes (KBMs 
and RBMs) 
Situational Awareness  Raised awareness of own limitations  
 Information seeking behaviour 
 Access pharmacist more 
 Request second opinion on 
prescribing 
Decision making  Information seeking at point of 
prescribing to inform decisions 
 Access relevant guidelines and 
information resources 
Communication and 
team working 
 Documenting course duration for 
antibiotics or steroids for example 
 Clarifying prescribing decisions with 
senior colleagues 
 Feedback seeking behaviour to 
inform practice 
Task management  Prescribe in context i.e. review all 
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Error type Non-technical skill Reported NTS outcome of feedback 
medications not just what you 
prescribe 
 Check allergy status, renal function, 
co-morbidities before prescribing 
 Adhere to best prescribing practice 
Skill based errors 
(slips and lapses) 
Situational Awareness  Raised awareness of error provoking 
conditions 
 Raised self-awareness of own errors 
 Be ‘mindful’ of prescribing task 
(especially when on-call) 
 Check relevant bloods and 
observations routinely 
 Aware of impact on patient safety and 
team members 
 Prescribing mindfully and treating 
prescribing as a high-risk task 
 Introduce safeguarding practices 
such as accuracy check of own work 
 Control emotions when under stress 
or remove self from area until calmed 
down 
 Force self to take a break when tired / 
hungry / thirsty 
 Avoid completing discharges 
immediately after a long / busy ward 
round 
 Prescribing in a quiet location 
 Slow down when aware that they are 
rushing 
Decision making 
 
 Information seeking at point of 
prescribing to inform decision more 
 Access relevant guidelines 
 Change location if cannot manage 
distractions 
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Error type Non-technical skill Reported NTS outcome of feedback 
Communication and 
team working 
 
 Asking for second checks before 
completing / submitting discharge 
prescriptions 
 Communicating risks of distractions 
with colleagues 
 Challenge distracting / disruptive 
behaviour 
 Refining working practices (i.e. jobs 
lists) to limit distractions 
 Communicate workload demands 
with seniors 
 Ask for jobs to be documented to 
prevent lapses in memory 
 Seek more information when 
prescribing unfamiliar medications 
 
Task management 
 
 Changing routine of prescribing to 
limit previous mistakes (i.e. check 
allergy status first) 
 Change location if cannot manage 
distractions 
 Develop a more systematic routine 
for own prescribing 
 Try and commence discharges in 
anticipation of discharge to limit 
impact on workload 
 Utilise other non-medical prescribing 
staff when workload high 
 Avoid multi-tasking 
 Avoid completing discharges or re-
writing medication charts on a ward 
round 
 Prioritise workload to minimise risk of 
rushing 
 Slow down when aware that they are 
rushing 
 Print off electronic prescriptions to 
check on paper before submitting to 
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Error type Non-technical skill Reported NTS outcome of feedback 
pharmacy 
 Do not assume pharmacists will 
correct errors for you 
 
Duncan et al. (2012) identified nine domains that could be targeted in 
interventions to improve prescribing: 
 social/professional role and identity 
 social influences 
 knowledge 
 skills 
 environmental context and resources 
 memory, attention and decision process 
 behavioural regulation 
 beliefs about capabilities and; 
 beliefs about consequences. 
 
The authors acknowledged that the domains were interrelated and provided 
example behaviour change techniques with feedback suggested to raise 
awareness of capabilities.  However, as the domains are related, the results 
of this thesis suggest that PE feedback can influence each of these domains. 
 
Chapters 6 and 8 established that feedback was a social process with 
enhanced teamwork and communication reported (social role and social 
influences).  Feedback raised awareness of PEs and their risks and 
outcomes (beliefs about consequences), whilst the process and provision of 
bespoke education by facilitators enhanced prescribing knowledge.   
Feedback raised awareness of deficits in prescriber performance (beliefs 
about capabilities) whilst identifying any relevant error causation 
(environmental context).  This allowed prescribers to reflect and regulate 
their own practice (memory, attention, decision process) with action plans 
allowing refinement of skills.  
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There was a clear change in reported prescriber behaviour with consistent 
reference to a raised situational and self-awareness informing greater 
information seeking behaviour at the point of prescribing.   
 
A raised awareness of PEs may influence the conscious effort of prescribers 
with an enhanced professional responsibility to avoid harm, views reported 
elsewhere as a result of negative prescribing (Gordon et al. 2013a).  This 
motivation can improve the appropriateness of prescribing and compliance 
with relevant standards.   Considering the application of NTS as a feedback 
outcome to the prescribing improvement domains, the complexity of the 
intervention can be seen. These feedback outcomes may have all resulted in 
changes to prescribing behaviour.  Which one has the greatest or least effect 
is unknown, and would require further investigation with emphasis on each 
behaviour enhanced or reduced and outcomes measured accordingly. 
 
McLellan et al. (2012) propose that the prescribing task interacts with the 
system and the author agrees with this unreservedly.  However, the results 
of these interviews suggest that it is the NTS that are dynamically engaged 
with the system to influence other tenets of prescribing and prescribing 
outcomes. Irrespective of cognitive and technical prescribing abilities, errors 
are likely to occur where NTS are deficient.  In figure 69 below the author 
proposes a revised relationship and reflexivity between the working 
environment, application of both technical and nontechnical prescribing skills 
and the prescribing outcome.  The NTS are separate from other prescribing 
skills as they are latent and interact with the clinical environment, guided by 
situational awareness, and could be considered a hidden skill set for safe 
prescribing.  This echoes the sentiments of McLellan et al. (2012) who 
propose that the level of prescribing effort or ‘cognitive engagement’ for a 
successful prescribing outcome will vary depending on the situation, 
mirroring the proposal that the level of skill required for a successful 
prescribing outcome will vary depending on the working environment, social 
context and error provoking conditions. 
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Figure 69: Model of prescribing illustrating integration of technical and 
nontechnical skills with the working environment and in response to 
feedback 
 
There was a clear sense in these interviews that prescribing was a more 
conscious and mindful process, and was no longer a routine, automatic task.  
Through feedback, prescribers were putting more effort into their prescribing: 
they were more “cognitively engaged” (McLellan et al. 2012).  Feedback was 
encouraging reflection on, for and in-action for prescribing with prescribers 
taking a step back to pause for thought.  This reflection informs self-
regulation of prescribers to control their cognitive processes as illustrated in 
figure 68 above.  Such meta-cognitive processes have been reported to 
minimise cognitive error and invoke the “conscious mind” (Graber 2009), with 
reflection facilitating recall of previous problems and limitations in practice 
(Croskerry 2003): outcomes reported in this chapter.  Prescribers reported 
changes in communication with team members including clarification of 
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prescribing information with senior prescribers and greater teamwork.  This 
echoes reports from interviews with pharmacists in chapter 8 who reported 
improved teamwork following delivery of feedback.  Prescribers also reported 
improved time management and prescribing prioritisation following feedback, 
all NTS that are integral to safe prescribing. 
 
Gordon et al. (2013a) suggest that “there might be value in structured 
education to ensure uniform safety and nontechnical skill acquisition”.  The 
results of these interviews would support this argument.  However, given the 
isolation of NTS from other prescribing skills proposed here and their 
interplay with the clinical environment, the difficulties in teaching prescribing 
in context to undergraduates can be seen.   That said, such skill acquisition 
could commence through simulated scenario training, inter-professional 
learning, or ‘pre-prescribing’ (Smith et al. 2012) for example.  This could 
raise role awareness of team members and facilitate communication and 
teamwork.  However, equally, they are likely to be labour intensive whilst 
lacking the fidelity of the clinical environment.  Any NTS intervention and 
evaluation should consider their complex interactions with the prescribing 
system and ideally measure the effectiveness of each group of NTS to inform 
future prescribing pedagogy. 
 
There is unlikely to be a single intervention to solve what is a challenging 
problem but feedback is one adjunctive intervention that can support 
acquisition and mastery of the NTS essential for safe prescribing.  Indeed, it 
is advocated that agenda-led, outcome based feedback, such as that used 
throughout this project, should be used to facilitate achievement of prescriber 
competence (Lum et al. 2013) via a mentor who, in the case of this research, 
is a ward-based pharmacist.   This feedback should ideally commence at 
undergraduate level.  It should form part of an integrated prescribing 
curriculum with immediate feedback following contextualised learning.  This 
should persist into their formative prescribing years as they serve their 
prescribing apprenticeship and beyond, to develop the NTS required to 
prescribe safely.  The logistics of such a programme of course would be 
challenging. 
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PEs reflect a complex interplay of active failures, latent conditions, system 
failures and error provoking conditions (Tully et al. 2009).  It has been 
suggested that training in the understanding of cognitive errors and factors 
contributing to human error is a plausible intervention to target PEs (Lewis et 
al. 2014).  In these interviews, when asked about distractions and error 
causation, prescribers expressed that they should have a raised situational 
awareness and understanding of error provoking conditions because of their 
training in advanced life support for example.  However, this training is out of 
context for a different skill and situation, and the transfer to prescribing 
scenarios may well be limited.  Equally, it is reported that feedback may 
support performance in a given task but not the transfer of knowledge to 
other tasks (Archer 2010).   
 
With guidance on human factors in development to promote patient safety 
(MHRA 2015), the potential for greater integration of human factors into 
prescribing curricula could be realized in the future.  The EQUIP study 
reported that “a “safety culture” was conspicuous by its absence from 
respondents’ discourses of their prescribing errors”. (Dornan et al. 2009) 
Such a culture needs to be embedded within undergraduate curricula and 
postgraduate prescribing guidance and norms.  Training in the understanding 
of cognitive errors in relation to prescribing can support the knowledge based 
and technical aspects of prescribing as defined elsewhere (British 
Pharmacological Society 2016, de Vries et al. 1994).  As discussed, 
immediate feedback can be used to contextualize any underpinning 
knowledge and allow application and grounding in each prescriber’s practice.  
Indeed, the need for prescribers to seek and act upon constructive feedback, 
outcomes reported in interviews in chapters 6 and 8, has been described as 
an underpinning element of prescribing competencies elsewhere (Lum et al. 
2013).  
 
In chapter 4, pharmacists expressed initial anxieties in interviews that 
delivery of formal feedback could be destructive to their inter-professional 
working relationships with prescribers.  This fear could be influenced by a 
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perception that pharmacists may ‘police’ prescribing, a role that hospital 
pharmacists elsewhere have reported being keen to avoid (Williams et al. 
2013, Weiss 1994).  A ‘policing’ role is undoubtedly necessary to be vigilant 
of potentially fraudulent behaviour for example, but clearly isn’t the focus of 
what hospital pharmacists can, and should be doing, in clinical areas.  They 
are also safeguards: defences in the error chain to identify and intercept 
errors. In chapters 6 and 8, there was a clear sense from both prescriber and 
pharmacist interviews that the role of the pharmacist was increasingly 
recognised by prescribers with greater team integration and communication 
reported, and perhaps iterating the need for greater inter-professional 
learning at undergraduate level.   
 
The modern pharmacist performs multiple roles as outlined in figure 70 
below.  As a feedback facilitator, they draw on all of these roles to enhance 
delivery of feedback.  Their role as caregivers and leaders in medicines use 
raises their credibility.  Their role as a teacher and communicator informs 
effective delivery of feedback.  However, it is their role as a manager that 
perhaps warrants further consideration given prescribers were more 
motivated and engaged with the prescribing process following feedback. 
 
An effective manager will set direction and communicate clear targets and 
expectations.  They will also provide recognition for good performance and 
commit to developing individuals through effective feedback.  In doing so, 
employees (prescribers) are more engaged, take more pride in their work 
and will be more productive.  These principles and outcomes resonate with 
the ethos of effective constructive feedback delivered throughout this project, 
and the results reported in this chapter.  Pharmacists are no longer simply 
safeguards, information providers or the prescribing ‘police’, they are 
managing the prescribing process to engage and motivate prescribers, raise 
their discretionary efforts and improve their prescribing performance, 
outcomes reported in the interviews in chapters 6 and 8. 
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Figure 70: The roles of the eight-star pharmacist (Adapted from the 
Wiedenmayer et al. 2006) 
 
 
 
 
 
 
The results of this chapter suggested some inconsistencies in facilitator 
approach, particularly with skill-based errors where vague feedback such as 
“just be more careful” was reported.  It is possible that pharmacists lacked 
the tacit understanding of human factors to deconstruct the subtleties of the 
error and negotiate creative solutions to minimize error recurrence.  Equally, 
prescribers reported that errors were always likely to recur where the 
conditions or system failures do not change.  Considering this, it would seem 
prudent that PE feedback facilitators are also trained in human factors so 
that prescribing safety is understood and continually integrated and 
reinforced. The results from interviews in chapter 8 would support this 
argument with pharmacists expressing surprise at the number of non-
knowledge based errors and the influence of human factors.   
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9.5. implications of these findings 
 
Throughout this thesis there has been an ever-emerging picture of a complex 
intervention.  Prescribers, pharmacists, clinical teams and the clinical 
environment and structures that they work within are all connected.  How 
prescribers interact within the system is influenced by their NTS with 
feedback influencing the application and development of these skills.  This 
raises the complexity of the feedback intervention further whilst casting 
further uncertainty as to what part of the process or outcome is having an 
impact on PE rates.  Given the breadth of NTS, training in and evaluation of 
the effectiveness of each domain (Situational awareness, decision making, 
communication and team working) on prescribing outcomes would be useful. 
 
Additionally, considering the influence of the environment on NTS and 
prescribing outcomes, prescribing education should be taught in context and 
not in isolation.  Whilst this can be difficult to achieve at undergraduate level, 
pharmacists, through prescribing error feedback could provide the 
appropriate ‘scaffolding’ (Cohen et al. 2011) to develop prescriber skills and 
competence. 
 
Facilitator training should include contextualising prescribing education in 
human factors.  This could enhance the feedback process further whilst 
empowering pharmacists to address environmental issues that could be 
contributing to suboptimal prescribing.  Similar training could be explored for 
prescribers at undergraduate and postgraduate level to facilitate awareness 
of error, error provoking conditions and how to respond to them.  
 
9.6. Strengths and limitations 
 
This is the first known qualitative study exploring the impact of feedback on 
different active failures. The semi-structured approach to the interviews 
provided the qualitative depth needed to answer the research aims.  
Importantly, the qualitative results supports understanding of any 
underpinning reason for change in PE rates reported in chapters 5 and 7. 
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Qualitative data analysis is open to interpretation, a limitation the author was 
cognisant of and one mitigated by independent second coding by the 
supervisory team (SDW and SVOB).  Additionally, data saturation was 
achieved with redundancy of themes as reported, confirming adequacy of the 
recruited sample of participants (Guest 2006).  Equally, classification of 
active failures was open to interpretation where the prescriber references 
different failures but this potential limitation was mitigated by the PhD 
supervisors also reviewing the PE classification.  
 
Prescribers were required to recall specifics of an individual error to inform 
classification.  This may have been hindered by memory failure and recall 
but equally mitigated by only interviewing prescribers who had both made a 
PE, and received feedback in the previous week.   
 
The risks of halo or Hawthorne effects (Basit 2010) were limited by 
clarification of responses to limit potential bias.  This was facilitated by the 
semi-structured topic guide allowing further probing and clarification of 
responses.  In addition, use of critical incident theory in the opening stages of 
the interview facilitated exploration of the error causation in detail.  This may 
have been supported by pharmacists trained in and using similar techniques 
as part of their facilitator training.   
 
A potential limitation of the study is that the active failures reported were not 
evenly distributed, especially for violations with only one case reported.  
However, the distribution was comparable to that of previous studies (Dean 
et al. 2002, Lewis et al. 2009) on error causation whilst the research team 
was satisfied that data saturation was achieved with further recruitment 
unlikely to illuminate further inferences from the data.  Equally, it should be 
acknowledged that only PEs classified as significant or above required 
individualised feedback and the motivators to change practice may not be as 
powerful for minor errors, despite these being the most frequent error 
severity reported. 
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Not all prescriber grades, for example consultants, were interviewed.  
However, a range of foundation, core and specialty training grade doctors 
were and it is this cohort that prescribe the majority of medications.  It should 
also be noted that most error causation research has focused on foundation 
doctors so inclusion of more experienced prescribers provides added depth 
and quality. 
 
A further strength of this study is that the results can be triangulated with 
quantitative findings in chapters 5 and 7.  In this regard, the mixed 
methodology supports and corroborates findings with these results “mutually 
illuminating” (Bryman 2007) what the impact on prescribing is and why it has 
occurred.   
 
Finally, as this is a case study, and participants were recruited from one NHS 
hospital only, the results cannot be generalised to other settings.  However, 
the purpose of the research was always to understand the impact of PE 
feedback in STHKH and this has been achieved whilst triangulation with 
other quantitative and qualitative results in this thesis provide greater 
inferences for similar settings.   
 
9.7. Chapter summary 
 
This chapter has reported the impact of feedback on prescribing behaviour 
from semi-structured interviews.  PE feedback supports prescriber 
development at a knowledge level and facilitates utilisation and development 
of the NTS required for safe and appropriate prescribing.   
 
The following and concluding chapter, will summarise the findings of this 
thesis, outlining the overall strengths and limitations of the research, 
personal reflections of the author, and concluding with a consideration of the 
implications for practice and further research.  
 
 391 
Chapter 10. Overall conclusions, implications for practice and further 
research 
 
 
10.1. Chapter introduction 
 
This concluding chapter will summarize the overall results and implications of 
the research in this thesis for practice.  The strengths and limitations of the 
research will also be summarized and reflections of the author and their role 
in the research presented.  Finally, further programmes of enquiry to 
advance understanding of this field of study will be presented. 
 
10.2. Overall discussion 
 
This thesis has explored the impact and effectiveness of pharmacist-led PE 
feedback in a hospital setting.  The results from this thesis have contributed 
to what little is known on this subject. 
 
The intervention is valued, welcomed and importantly, considered 
sustainable with the intervention now part of routine practice at STHKH.  The 
intervention has had positive influences on prescribing.  The pilot study 
demonstrated a mean reduction in overall PE rates of 11.5% in the 
intervention group and an increase of 5.9% in the control group, a significant 
change in PE rates of 17.4% (SD 4.7, 95% CI, -27.3 to –7.6, p<0.05, d=1.6) 
between groups.  For the larger cohort in chapter 7, there was a mean 
reduction in overall PE rates of 18.3% in the intervention group and an 
increase of 5.4% in the control group, a significant change in PE rates of 
23.7% (SD 3.5, 95% CI, -30.6 to -16.8, p<0.05, d=1.57) between groups.  
Qualitative results illuminated the potential reasons for improvements in 
prescribing and that PE feedback is a complex intervention.  Prescribers 
were using the NTS of prescribing more.  Feedback raised self-awareness of 
prescribing performance and encouraged reflection to modify prescribing 
behaviour.  Both prescribers and pharmacists reported ancillary interventions 
from the feedback process, with bespoke educational sessions for example 
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delivered by ward pharmacists to support prescribing further and enhanced 
teamwork. 
 
There was a paradigmatic shift from a system of directed feedback to one of 
facilitative feedback.  This underpins the considered design of the feedback 
intervention and choice of feedback facilitator to resonate with principles of 
effective feedback. 
 
Feedback has been identified as a priority for developing diagnostic decision 
making (Elstein 2009) and considered transferrable to prescribing (Mattick et 
al. 2014).  The results presented in this thesis support this hypothesis with 
prescribers and pharmacists advocating that the benefits of PE feedback 
demanded their time and that the process should continue. 
 
Opportunities to refine the art of prescribing have been described as “patchy” 
at ward level (Mattick et al. 2014).  Where formal dialogue on prescribing is 
non-existent, the risk of prescribers copying what others do increases, with 
such processes becoming an important way to learn prescribing in the 
clinical area (Garbutt et al. 2006).  However, given known PE rates, this 
method is less favourable to learn the principles of safe prescribing, and 
underpins the need for on-going feedback on prescribing from credible 
facilitators such as pharmacists. 
 
Hafferty (1998) describes a formal, informal and hidden curriculum that apply 
to doctors’ workplace learning.  The formal curriculum is what is taught away 
from the clinical area, such as weekly teaching.  The informal curriculum is 
often opportunistic, delivered at ward level whilst the hidden curriculum is 
that of the healthcare culture, unique to each clinical setting and where a 
great deal of what is taught and most of what is learned takes place (Hafferty 
1998).  Each organization and clinical area will have its own identity and local 
practices that perhaps cannot be taught or learnt from a textbook and echoes 
the sentiment that effective feedback is the “cornerstone of clinical teaching” 
(Cantillon and Sargeant 2008).  Hafferty (1998) suggest that we should 
“create structures that allow individuals to reflect upon the larger structural 
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picture of which they are a part”.  When delivered constructively, PE 
feedback has potential to create this structure, providing a platform to 
achieve the prescribing standards demanded in healthcare. 
 
Advancing this argument, prescribing competency frameworks (RPS 2016, 
Lum et al. 2013) outline that prescribers should seek and act upon feedback 
to improve prescribing.  This should be delivered in a blame free 
environment with protected time allocated (Likic and Maxwell 2009).  The 
results in this thesis support these recommendations with pharmacists and 
prescribers advocating a non-punitive approach was necessary and that 
feedback should focus on developmental needs.  Whilst not “protected”, 
delivery of feedback away from routine clinical tasks allows prescribers time 
to reflect and engage openly with the pharmacist.   
 
For prescribers to receive or seek feedback on their prescribing, appropriate 
facilitators are required for the process to be effective (Ivers et al. 2012) with 
pharmacists considered credible PE feedback facilitators.  They have expert 
drug-related knowledge whilst prescribers interviewed in this thesis consider 
feedback an extension of their role.  Effective feedback is influenced by 
whether the facilitator is a colleague (Ivers et al. 2012), has observed 
practice and if it is delivered as part of everyday practice (Cantillon and 
Sargeant 2008).  Therefore, ward pharmacists have the additional advantage 
of working with the prescriber and observing their prescribing practice whilst 
being able to deliver timely and frequent feedback. 
 
Pharmacists have been described as ‘change agents’ previously (Cresswell 
et al. 2012, Avery et al. 2012) to influence safe prescribing decisions in a 
desirable direction.  In this research, pharmacists can be considered change 
agents to improve the quality and safety of prescribing, with their role in 
affecting change accepted as credible facilitators of PE feedback.   
 
Initial apprehensions of pharmacists surrounding the intervention were 
unfounded.  Pharmacists reported greater self-confidence, self-worth and job 
satisfaction with enhanced prescriber communication and teamwork 
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reported.  Good teamwork alone is considered to improve patient care and 
safety (Firth-Cozens and Moss 1998, Baker et al. 2006) and the results in 
this thesis outline the need for good rapport, and communication, for 
effective delivery of PE feedback.  Furthermore, the additional educational 
interventions developed following PE feedback can only help with 
educational outreach for example (O’Brien et al. 2007), having positive 
effects on prescribing.  Where pharmacists innovate ward-based activities 
and deliver further prescribing education as an outcome of PE feedback, this 
can only help to harness the skills of pharmacists more effectively and 
improve prescribing safety.   
 
The need to understand what underpins “observed behaviour changes” has 
been reported (Brennan and Mattick 2013, Craig et al. 2008) and the 
qualitative results of this thesis have informed the potential prescribing 
behaviours that underpin changes in PE rates. 
 
The process outcomes reported for pharmacists, prescribing and prescribing 
behaviour highlight the complexity of the feedback intervention.  Whilst 
significant improvements in PE rates were observed, it is not a simple closed 
loop system with a clearly defined cause and effect relationship, and perhaps 
feedback is simply a catalyst to accelerate change.  All of the reported 
process outcomes are “connected” and will influence each other as the 
system self-organizes.  The positive outcomes reported are welcome 
outcomes but equally they provide uncertainty as to whether it is the 
feedback or another one of these outcomes that is improving prescribing. 
 
PE feedback is educational and can support professional development and 
this may be enough motivation to change prescribing behaviour for learning 
goal oriented prescribers.  For other performance oriented prescribers, it was 
clear that avoiding feedback or being perceived in a negative light by a 
colleague was a motivating behaviour. 
 
The educational outcomes of feedback extended beyond knowledge of the 
medication or clinical condition, with reported changes in prescribing 
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behaviour resonating with the NTS of prescribing.  PE feedback allowed 
identification of PE causation through reflection, and this in turn increased 
self-awareness and situational awareness of prescribers.    Prescribers were 
more engaged in prescribing tasks with greater communication, teamwork, 
information and feedback seeking behaviour, decision making, and task 
prioritisation reported to optimise prescribing outcomes.  
 
These skills are increasingly recognised as integral to safe prescribing 
(Gordon et al. 2013a, Kirkham et al. 2015) and the results of this thesis 
outline the importance of acquiring these skills in more formative years.  
 
Non-technical skill acquisition should form part of a wider prescribing 
pedagogy to complement the cognitive and technical aspects of prescribing.  
Whilst such training will be challenging, the benefits could be substantial and 
potentially developed though enhanced simulation based training, inter-
professional learning and feedback on any pre-prescribing.  Such feedback 
should continue into professional practice where it is both expected and 
delivered as part of routine clinical practice in hospital settings. 
 
10.3. Implications for practice 
 
Audit and feedback on PEs can provide the framework for a proactive 
approach to prescribing safety.  Prescribers have previously reported that ‘no 
news is good news’ (Mattick et al. 2014) although arguably ‘no news is no 
news’ and prescribers cannot change prescribing practice if they do not know 
what to change.  Formalising PE feedback can provide a consistency to 
feedback to reduce the gap between perceived and actual performance 
(Randolph et al. 2009).  Where this happens, prescribers have the potential 
to improve and regulate their prescribing behaviour, but the process requires 
investment, commitment and diligence of participants and facilitators of 
feedback to affect change.  As a complex, non-linear system, each time 
feedback is delivered, the system or clinical environment will evolve or “self-
organize” with a culture of feedback facilitating a culture of safety. 
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Process outcomes reported in this thesis raise important considerations for 
prescribing education.  Developing prescribing skills at the cognitive, 
technical and non-technical level are all important curriculum components.  
Training in human factors to raise awareness of how prescribers interact with 
their environment could also be useful.  Some of the reported outcomes in 
this thesis pose more significant questions for the context of any prescribing 
pedagogy.  
 
Prescribing education has recently been conceptualised as a complex 
system encompassing both individualistic cognitive, and socio-cultural 
learning theories (McLellan et al. 2015).  In clinical practice, a prescriber will 
engage and interact with the system, patients and other healthcare 
professionals.  These interactions are complex and varied, as are the 
behaviours required to successfully navigate them, resonating with the varied 
outcomes reported in this thesis. 
 
Prescribing is a complex skill and social experience (Dornan et al. 2009), and 
prescribing should not be taught in isolated silos.  Where prescribing is 
taught out of context, the task will be reduced to individual constituent parts 
that may not be transferrable to the clinical environment.  The whole task is 
far more than the sum of its parts (McLellan et al. 2012) and prescribing 
should be learnt in context to accommodate the variances and nuances of 
real-life prescribing.  Key themes reported in this thesis have included 
improved teamwork and rapport, communication, information-seeking and 
feedback-seeking behaviour and role awareness.  This iterates the 
importance of contextualised learning as an undergraduate through exposure 
to inter-professional learning and pre-prescribing either in the clinical 
environment or high fidelity simulated scenarios.  Here, PE feedback could 
act as “scaffolding” (Coehn et al. 2011) to encourage reflection and provide 
the support and infrastructure for prescribers to develop. 
 
Delivery of constructive pharmacist-led PE feedback is now part of routine 
clinical practice in STHKH where prescribers receive frequent feedback from 
ward-based pharmacists.  A similar model of feedback could be adopted in 
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similar settings with ward-based pharmacists used as facilitators of PE 
feedback.  Feedback facilitators require training in delivery of PE feedback 
and this should include an understanding of human factors to inform 
negotiation of potential solutions to PEs.  Given the role of pharmacists to 
intercept and correct PEs, such training should begin at undergraduate level. 
 
Where pharmacist-led PE feedback is adopted, this will optimally include 
funded support to facilitate this, and other ward based educational 
interventions to develop a triangulated, multi-faceted approach to targeting 
PEs.   
 
10.4. Strengths and limitations  
 
As with any research, the research undertaken in this thesis has strengths 
and limitations.  These have been discussed individually in each results 
chapter but will be summarised here. 
 
10.4.1. Study strengths  
 
This is a mixed methods study and this approach is a key strength of this 
research.  The quantitative results have been triangulated with the results 
from pharmacist and prescriber interviews in chapters 6, 8 and 9.  For 
example, both prescribers and pharmacists reported improvements in 
prescribing following feedback, comments substantiated with the quantitative 
results.  Additionally, the qualitative results have illuminated why prescribing 
has changed and that it is a complex intervention.  Enhanced use of NTS 
was reported by prescribers, echoing reports of increased teamwork and 
information seeking behaviour by pharmacists in chapter 8 for example.  This 
provides the richness of data to inform what behaviours underpin the 
changes in PE rates reported in chapters 5 and 7, whilst understanding the 
impact of the intervention on prescribers and pharmacists.  Additionally, the 
model of prescribing (figure 69) presented in chapter 9 and non-technical 
prescribing behaviours (table 35) provides a framework to inform further 
prescribing education to enhance these skills and evaluate any impact on 
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prescribing performance.  This triangulation of research methods has 
afforded a comprehensive understanding of the PE feedback intervention in 
STHKH. 
 
The intervention has been implemented in a large acute hospital with clinical 
pharmacy services on most wards.  This intervention should be transferrable 
to similar settings although variations in outcomes might be expected given 
the complexity of the intervention described throughout this thesis. 
 
10.4.2. Study limitations 
 
The qualitative sample sizes in chapters 6, 8 and 9 could be considered 
small, although the research was explorative and the sample size adequate 
to answer the research questions, with data saturation achieved as 
described in chapter 3 and each relevant results chapter. 
 
The issue of transferability has been discussed in relevant chapters.  Briefly 
the complexity of the intervention and variability in outcomes may limit 
transferability to other settings.  Where the system, participants, principles of 
feedback, facilitator training or staff engagement vary, the outcomes may not 
be replicable.  For example, where pharmacists and prescribers already work 
to a high degree of collegiality, would the same benefits be realised?  Where 
pharmacists already attend ward rounds or deliver educational outreach at 
ward level, would the same effect size be observed?  However, equally, the 
qualitative results provide rich data for others to decide if the intervention and 
its unintended outcomes, could be transferrable elsewhere. 
 
The author interviewed all prescribers and pharmacists.  Whilst this limits 
potential inter-interviewer variability, it is possible that the author has not 
identified all relevant codes and themes, or that they are biased by their 
experiences and understanding of the literature.  This limitation was 
mitigated by the PhD supervisors, who are experienced qualitative 
researchers, reading all transcripts independently and initial codes and 
themes discussed with the author for an analytical consensus. 
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Results of the qualitative studies are limited to STHKH and may not be 
generalized to other settings.  However, this was not the purpose of the 
research with participants recruited to understand the context of the PE 
intervention in the organisation.  Any inferences that others can take from 
research publications will be an added bonus.  Equally, triangulation with the 
quantitative results provides a platform for others to understand the process 
and effect of pharmacist-led individualised PE feedback. 
 
As described in chapters 3, 5 and 7, prescribers were non-randomized and it 
is possible that improvements have occurred because of differences 
between groups.  Whilst this is a potential limitation, randomization of 
participants to an educational intervention does not always eliminate 
potential bias.  Equally, a similar range of prescribers were involved across 
control and intervention wards, whilst it should be noted that PE rate in the 
control group increased, whilst PE rate in the intervention group improved. 
 
Finally, whilst a mixed ecology of medical, care of elderly and acute wards 
were involved in the research, the impact of feedback in all settings was not 
assessed for example on surgical wards.  However, the wards do reflect the 
mixed ecology of a typical acute hospital and surgical wards have similar 
ward-based pharmacy services so it is likely that the intervention will have 
similar outcomes in these settings. 
 
10.5. Personal reflections 
 
Researchers are part of the social world that they are researching (Cohen et 
al. 2011:225).  Experiences define who we are and researchers have their 
own world views that can influence their role in any research.  As outlined in 
chapter 3, the epistemological view of the author depends on the research 
question, a view that reflects the mixed methods approach in this thesis.   
 
The author is a clinical pharmacist and medical educator and these roles 
have had inextricable influences on this thesis.  Firstly, the concept for this 
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thesis was kindled from the author’s role as a clinical pharmacist with 
significant experience of PE interception and resolution, and as a medical 
educator with a keen interest in prescribing education. 
 
Secondly, as described in chapter 3, the author was aware of potential power 
asymmetry in interviews that could impede the depth and authenticity of 
interviewee responses.  Additionally, as a pharmacist and medical educator, 
the author was cognisant of the risk of a Hawthorne effect (Basit 2010), with 
interviewees attempting to avoid, impress or reject the researcher questions.  
To counter these issues, a topic guide was used for consistency whilst a 
semi-structured approach allowed clarification of participant responses.  
Additionally, the author attempted to build rapport with interviewees and used 
a conversational approach throughout to engage participants.  This was 
facilitated by the semi-structured approach allowing deviation from the topic 
guide and put interviewees at ease, allowing more introspective information 
to be obtained from them.  Furthermore, the author’s role as a pharmacist 
and medical educator facilitated this conversational tone and candour and is 
considered a potential strength in this context and not a weakness. 
 
Finally, in analysing the qualitative data, the author’s experience as a clinical 
pharmacist and knowledge of the subject area may bias interpretations.  To 
this end, the author remained as objective as possible with independent 
review of the transcripts, codes and themes by the PhD supervisors, who are 
not pharmacists, adding additional validity to the results. 
 
On a personal level, the journey towards completion of this PhD has been 
exhilarating and demanding in equal measures.  On reflection, it has been a 
steep learning curve and one that has stretched my intellect and catalysed 
my development.  The journey has served as an apprenticeship in research 
and this thesis demonstrates some of the skills that have been developed 
and refined over the past three years.  These skills have been transformative 
in developing as an independent researcher and most importantly, provided 
the self-confidence and belief to continue as a clinical researcher.  As a 
pharmacist and educationalist, the motivations to undertake this PhD were 
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described in chapter 1. The skills and abilities developed throughout this 
research have kindled further desire and motivation to lead on research into 
prescribing errors and optimise prescribing, and patient safety.   
 
10.6. Future research 
 
The research presented in this thesis has produced important results to 
address the research questions.  However equally, they have raised further 
research questions and avenues of enquiry. 
 
Both the prescribers and pharmacists interviewed in this thesis outlined the 
potential for shared learning on PEs.  Whilst this does not reflect the 
principles of effective feedback, its comparison as an alternative or in 
combination to individualised PE feedback should be explored.  Given the 
complexity and uncertainty of the process outcomes, variations in emphasis 
on teamwork, reflection, situational awareness or self-checking for example 
could be carefully incorporated into future feedback research or investigated 
individually to evaluate their impact on prescribing practice. 
 
Future research should aim to increase the intensity of PE feedback from 
pharmacists whilst the impact and effectiveness on NMPs is unknown. 
 
PE feedback is now delivered routinely at STHKH and a further study using a 
questionnaire would be useful to elicit the views of a wider range of 
prescribers in a wider range of clinical areas towards receiving formalised PE 
feedback. 
 
The potential for PE feedback in undergraduate prescribing education should 
be explored perhaps as part of inter-professional or simulation-based 
teaching. 
 
PEs were not eliminated by feedback in this research and the optimal 
combination of feedback with other PE reduction initiatives should be 
explored. 
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This research is limited to STHKH, it would be useful to determine what PE 
feedback is delivered, how, when and by whom across the North-West 
deanery and the impact if any on their prescribing practices. 
 
Finally, this study was limited to the hospital setting and the potential of 
individualised PE feedback in other settings such as primary care could be 
explored. 
 
10.7. Overall conclusion  
 
The research aims outlined in this thesis have been addressed with the 
impact of PE feedback on prescribing, prescribers and the facilitators of 
feedback, pharmacists, described.   
 
Feedback has positive influences on prescribing with statistically significant 
reductions in PE rates reported.  Where PEs are reduced, patient safety and 
outcomes can be improved and optimised.  Feedback has encouraged 
greater interaction between pharmacists and prescribers through enhanced 
teamwork and prescribing support.   Feedback supports the professional 
development of both prescribers and pharmacists at a knowledge based 
level with potential for PE feedback to also increase the self-efficacy and 
confidence of pharmacists.  Feedback also supports development of non-
technical prescribing skills, with potential for further context specific training 
in these skills to enhance prescribing education further. 
 
By designing the feedback intervention to reflect principles of effective 
feedback, a pragmatic educational framework is provided to support 
development of prescribing skills through feedback in the clinical 
environment that is timely, frequent, delivered verbally and in writing by a 
credible facilitator.  However, PE feedback is a complex intervention with 
variations and unexpected positive outcomes and these variations and 
outcomes may be influencing prescribing outcomes. 
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Finally, the intervention is unanimously valued and welcomed by prescribers 
and pharmacists and considered sustainable, with the intervention now part 
of routine clinical practice at STHKH.  This intervention is transferrable to 
similar settings with ward based clinical pharmacy services to support 
prescribing, reduce PEs and improve patient safety across secondary care 
settings. 
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12. Appendices 
 
Appendix 1: Overall prescribing feedback proforma 
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Appendix 2: Individual prescribing error feedback proforma 
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Appendix 3: Interview topic guide for prescriber views of receiving 
feedback 
 
Venue: On site in Hospital at convenient time for Foundation doctor 
Ensure undisturbed i.e. pagers, phones etc turned off 
Likely Duration: 20-30 minutes.   Follow up interviews may be required to 
clarify discrepancies in the interviews 
 
Preliminary: Greet, establish rapport and candour.  Summarise study 
purpose again, including need for consent.  Obtain written consent and allow 
opportunity to ask any questions before commencing the interview. 
 
Advise that as all questions must be asked.  Hence, it may seem that some 
are repeated as we progress through the interview where you have provided 
an answer earlier. 
 
Themes are in bold.  Follow up prompting questions are denoted by P) 
 
Perceptions of formalised Prescribing Error Feedback 
 
Q) Is the formalised process an improvement on the current system? 
Q) What have been the main advantages and disadvantages of the 
formalised process? 
Q) How important is receiving prescribing error feedback to you? 
 P) What are the main benefits? 
 P) Who benefits? 
Q) What do you think are the benefits of receiving feedback on 
prescribing errors? 
Q) Have there been any practical barriers to receiving feedback on 
prescribing errors? 
 Q) Have you been able to find the time to receive feedback? 
 Q) has there been adequate support at ward level? 
Q) Has feedback been timely? 
Q) Do you think that timely feedback is important? 
Q) Was the delivery of feedback on overall prescribing useful? 
 P) Did it allow you to consider positive aspects of your prescribing 
too? 
 P) is this important for learning too? 
Q) Do you think that feedback should continue to be formalised? 
Q) Was provision of the feedback proforma useful in any way? 
 
 
Perceptions of impact of receiving feedback on themselves 
 
Q) What has been the impact, if any, of feedback on your own 
prescribing? 
 P) Can you think of any specific examples, positive or negative, on 
your own prescribing? 
 442 
P) Do you think that you may make less prescribing errors as a result 
of feedback? 
Q) Are you more aware of risks of prescribing errors as a result of 
feedback? 
 P) For example error causation or root cause analysis? 
Q) How has this informed your practice? 
Q) Have you used any examples of feedback for your training portfolio? 
 P) If yes has this made you prescribe any differently? 
 P) If No, then why not?  Could you? 
_____________________________________________________________
______ 
Perceptions on receiving feedback from Pharmacists? 
 
Q) Is feedback delivered consistently? 
Q) What are your views on receiving feedback on prescribing errors 
from Pharmacists? 
 P) Are they suitable? 
P) Did you find it useful / not useful? 
Q) How was feedback delivered by your Pharmacist? 
 P) i.e. was it constructive / educational ? 
Q) Do you receive feedback on the quality of your prescribing from any 
other colleagues? 
 If yes, P) Does this differ at all from feedback delivered by 
Pharmacists? 
Q)  Has formalised feedback changed had any impact on your working 
relationship with your Pharmacist? 
P) Has the process of feedback changed how you seek advice from 
your Pharmacist? 
P) Has it affected your rapport? 
Future Delivery of error feedback 
Q) Should a formalized feedback process be rolled out trustwide? 
 P) Why is that? 
Q) Could prescribing error feedback be delivered any differently? 
Q) How would you prefer to receive feedback on your prescribing? 
 P) Face to face? 
 P) e-mail? 
 P) Letter? 
Q) Can the system of formalised feedback be improved at all? 
 
General second / probing questions 
Silence…. 
You said earlier… 
Can you provide an example / clarify what you mean… 
Can you elaborate on that…. 
Could you expand on that…. 
Ask if any questions at end and thank them for their time 
Finish interview.  Turn off audiotape.  Advise thankyou letter will be 
circulated. 
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Appendix 4: Interview topic guide for pharmacist experiences of 
delivering feedback 
 
Version 1.1: June 2015 
Pharmacist focus group schedule  
 
Venue: Any pharmacy seminar room at a convenient time for the participant 
pharmacist 
Ensure undisturbed i.e. pagers, phones etc. turned off 
Likely Duration: 20-30 minutes. 
 
Preliminary: Greet, establish rapport and candour.  Summarise study 
purpose again, including need for consent.  Obtain written consent and allow 
opportunity to ask any questions before commencing the interview. 
Study Purpose 
Prescription errors account for the majority of all Medication errors and are 
considered more likely to cause patient harm.  Formalised feedback on 
prescription errors is one proposal suggested to mitigate prescribing errors.  
Pharmacists are often advocated as the most appropriate individual to both 
intercept and deliver feedback on prescribing errors.  Little is currently known 
on the attitudes of Pharmacists to delivering formal feedback on prescribing 
errors. 
 
This study is concerned with exploring your attitudes and views to delivering 
feedback in a more structured and formal manner. 
 
Advise that as all questions must be asked.  Hence, it may seem that some 
are repeated as we progress through the schedule where you have provided 
an answer earlier. 
 
 
 
Themes are in bold.  Follow up prompting questions are denoted by P) and 
will be used to clarify responses and gain more detailed responses (as 
opposed to yes/no responses for example) 
 
Turn digital recorder on and start recording. 
 
Background information 
Q)  Can you state your current band and number of years you have been 
qualified? 
 
General views of the process 
Q)  How did you find the process of delivering individualised formal feedback 
on prescribing errors? 
 P) Did you feel adequately prepared? 
Q)  Is the process an improvement on the current system? 
 P) How does it differ? 
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Q) What do you think are the key benefits of providing formal feedback on 
prescribing errors? 
Q) Was it clear what you had to deliver feedback on? 
 P) Overall? 
 P) For each significant error? 
Q) How did you find completing and delivering feedback using the proforma? 
 P) Overall? 
 P) Each error? 
 P) Confident? Useful? Supportive or distracting? 
Q)  How do you think that doctors took / received the feedback? 
 P) Relaxed? Open? Anxious or afraid? 
Q) Did you encounter any barriers to the process? 
 
Specific process themes 
Q) Were you able to find the time to deliver feedback as part of your ward 
visits? 
Q) How did you negotiate time with the doctor to deliver feedback? 
Q) Where did you deliver feedback?  How did you decide on this? 
 P) Ward / seminar room / office etc 
Q) Did you provide feedback on every significant error that you identified?  
 P) If no, then why not? 
Q) How soon after identifying an error did you provide feedback to the docto
  
Q) Do you think doctors changed their prescribing behaviour in response to 
your feedback? 
Impact on individual Pharmacists 
Q) How did you feel about delivering formal feedback on prescribing errors? 
 P) Comfortable? Confident? Relaxed? Anxious? Afraid? 
Q) Do you think any other staff group could / should deliver prescribing error 
feedback? 
 P) Should all Pharmacists be doing this? 
Q)  What has been the impact on you? 
 P) Any positive impacts? 
 P) Any negative impacts? 
 P) Impact of workload? 
 
Q) Has the process of feedback changed how you work in any way? 
 P) How you review prescriptions or communicate with doctors for 
example? 
Q) Has there been any impact on your working relationship with your 
doctors? 
Q) Is the process sustainable?  
P) Could you continue to audit prescribing every rotation? 
P) Could you continue to deliver feedback on prescribing errors to all 
doctors? 
 
------------------------------------------------------------------------------------------------------
- 
Ending Questions 
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Q)  Should doctors continue to receive feedback on their prescribing? 
Q)  Should it continue in the current format or could it be delivered any 
differently or improved? 
 
We wanted you to help review and evaluate systems of feedback on PE’s in 
the hospital.  We’ve covered various issues including…..   Is there anything 
that we have not discussed or would you like to revisit a particular question 
to add anything? 
 
Thank them for their time.  Turn off audio tape. 
 
Advise participants that a thankyou letter will be sent out in the post. 
 
General second / probing questions 
Silence…. 
You said earlier… 
Can you provide an example / clarify what you mean… 
Can you elaborate on that…. 
Could you expand on that…. 
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Appendix 5: Interview topic guide for impact of feedback on prescribing 
behaviour  
 
Version 1.1: June 2015 
Prescriber interview schedule 
 
Venue: Any private room on site at STHKH at a convenient time for the 
participant Prescriber 
Ensure undisturbed i.e. pagers, phones etc. turned off 
Likely Duration: 20-30 minutes. 
 
Preliminary: Greet, establish rapport and candour.  Summarise study 
purpose again, including need for consent.  Obtain written consent and allow 
opportunity to ask any questions before commencing the interview. 
Study Purpose 
Prescription errors account for the majority of all Medication errors and are 
considered more likely to cause patient harm.  Feedback on prescription 
errors is one solution proposed to reduce prescribing errors with doctors 
welcoming and valuing feedback to support professional development.   
However, little is known on the impact of feedback on prescribing errors 
specifically, the impact on different types of error. 
 
This study is concerned with exploring the causes of prescribing error and 
the perceived impact of receiving feedback from Pharmacists on your 
prescribing. 
 
Advise that all questions must be asked.  Hence, it may seem that some are 
repeated as we progress through the schedule where you have provided an 
answer earlier. 
 
 
 
Themes are in bold.  Follow up prompting questions are denoted by P) and 
will be used to clarify responses and gain more detailed responses (as 
opposed to yes/no responses for example) 
 
Turn digital recorder on and start recording. 
 
------------------------------------------------------------------------------------------------------
-------------------- 
 
Background information 
Q)  Can you state your current grade, number of years qualified, University 
you trained in and how long you have worked at the hospital 
Q) What education and training have you had to prepare you for prescribing? 
 P) Do you feel it was adequate / prepared you for practice? 
 
------------------------------------------------------------------------------------------------------
-------------------- 
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The Prescription error 
Q) Error details: 
P) Medication details (dose, route, frequency etc) 
P) The type of prescribing error.  (i.e. why was it an error e.g. dose, 
GFR, interaction, omission, allergy, course duration etc) 
P) Stage of prescription i.e. admission, during stay, transcription, 
discharge 
Q) Did you prescribe it yourself or was it transcribed from another chart, 
clinical notes or were you verbally asked to prescribe it by someone else for 
example? 
Q) Was or could there have been any impact on the patient / other staff or 
the organisation? 
------------------------------------------------------------------------------------------------------
-------------------- 
 
 
Situational factors 
Q) Can you describe the situation for me when you wrote the prescription?  
 P) Patient factors 
P) Location (Ward but also exact location on ward) 
 P) Usual ward or other area? 
 P) Day /  time 
 P) Workload / supervision / number of doctors in on that day 
 P) Distractions?  Who else was around? Supervision 
 
Q) Did you have adequate access to relevant information resources? 
 P) BNF / Guidelines / policies etc 
P) Maxims / EDMS 
P) Pharmacist available? 
P) Senior doctor available for advice? 
 
Q) How was you feeling at the time? 
 P) i.e. physically and mentally 
 P) Tired? 
 P) Hungry? 
 P) Angry  / upset / frustrated? 
 P) Stressed? 
P) Ill or unwell? 
 
 
Q) What do you think was the cause of the prescription error? 
 P) Knowledge, communication, resources, environment, slip or lapse? 
------------------------------------------------------------------------------------------------------
-------------------- 
The feedback 
 Q) Who delivered the feedback and how was it delivered? 
 Q) How did you feel about making the error? 
Q)  How did you feel after receiving the feedback? 
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Q) Has the feedback had any impact on your prescribing practice? 
 P) Had the error happened before? 
 P) Has it happened since? 
 P) Are you aware of any other prescribers who have made this 
error? 
Q) Will feedback prevent this specific error happening again? 
Q) Will it prevent similar errors from happening? 
Q) Can anything else be done to prevent the error from happening? 
 
 
Closing 
We’ve covered various issues including the prescription error, possible error 
causation and potential impact of feedback on you as a prescriber.  Is there 
anything else that we have not discussed or do you have any suggestions or 
would you like to revisit a particular question to add anything? 
 
Thank them for their time.  Turn off audio tape. 
Advise participants that a thankyou letter will be sent out in the post. 
 
General second / probing questions 
Silence…. 
What are you thinking right now… 
You said earlier… 
Can you provide an example / clarify what you mean… 
Can you elaborate on that…. 
Could you expand on that… 
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Appendix 6: e-mail for pharmacist interviews 
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Appendix 7: Participant information letter for pharmacist interviews 
 
Exploring experiences on delivering formal prescribing error feedback 
 
Version Number: 1.1  1st June 2015 
1. Introduction 
You are being invited to participate in a research study. Before you decide 
whether to participate, it is important for you to understand why the research 
is being done and what it will involve. Please take time to read the following 
information carefully and feel free to ask us if you would like more 
information or if there is anything that you do not understand. Please also 
feel free to discuss this with others if you wish.   We would like to stress that 
you do not have to accept this invitation and should only agree to take part if 
you want to. 
 
Thank you for reading this. 
  
2. What is the purpose of the study? 
Feedback is one intervention proposed to reduce prescribing errors with 
pharmacists advocated as best placed to facilitate and deliver feedback to 
doctors.  We know that doctors welcome and value formalised feedback from 
pharmacists with both direct and indirect benefits reported.  However, little is 
known on pharmacists’ attitudes and opinions to delivering feedback in a 
formal and structured way. 
 
This study is concerned with exploring the attitudes and opinions of 
pharmacists to delivering formal feedback on prescription errors to hospital 
doctors. 
  
3. Why have I been chosen to take part? 
You are a pharmacist based at the host organisation and have been involved 
in delivering formal feedback to your ward based doctors. 
 
4. Do I have to take part? 
It is entirely up to you to decide whether or not to join the study and be 
interviewed by the researcher.  If you agree to participate, the researcher will 
talk to you about the research and will go through this information sheet with 
you. You will be asked to sign a consent form.  You are free to withdraw from 
the study at any time. 
 
5. What will happen if I take part? 
If you would like to participate in this study: 
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• You will be asked to take part in an interview that will last for 
approximately 20-30 minutes.    
• In this interview, we will ask you about your experiences of delivering 
formal feedback on prescribing errors 
• The interview will be carried out on the hospital premises at a time 
convenient for yourself.  Michael Lloyd will facilitate the interview.  
• The interview will be recorded on a digital recorder, and will be 
transcribed verbatim so that we have a written account of what you have said 
for subsequent analysis. 
 
 
6. Expenses and / or payments 
No expenses or payments will be available 
 
7. Are there any risks in taking part? 
There are no anticipated risks involved.  However, it is possible that you may 
discuss medication errors that have occurred which may cause some 
distress.  No harm is wished upon you and you may refuse to answer 
questions or discuss issues at any time, and without giving a reason.  Any 
Pharmacist that is distressed will be allowed to the leave the study and will 
be referred to their supervisor for support in accordance with trust 
procedures. 
 
8. Are there any benefits in taking part? 
By participating in this research, you will be actively contributing to 
knowledge in this field. You will be helping us to improve our understanding 
and delivery of feedback on prescribing errors.  Specifically, the impact of 
delivering formal feedback on pharmacists and doctor-pharmacists 
relationships.  This may lead to improvements in patient safety and the 
delivery of feedback on prescribing errors.   
 
9. What if I am unhappy or if there is a problem? 
You can contact the researcher Michael Lloyd at Michael.lloyd@sthk.nhs.uk  
or Dr Simon Watmough at efcsw@liv.ac.uk  or Professor Sarah O’Brien at 
Sarah.OBrien@sthelensccg.nhs.uk and we will try to help.   If you remain 
unhappy or have a complaint which you feel you cannot come to us with then 
you should contact the Research Governance Officer at ethics@liv.ac.uk.  
When contacting the Research Governance Officer, please provide details of 
the name or description of the study (so that it can be identified), the 
researcher(s) involved, and the details of the complaint you wish to make. 
 
10. Will my participation be kept confidential? 
• Only the researchers involved in the study will listen to the recording 
of your interview, or read the transcript   
• The information that you provide will be kept anonymous – it will not 
be linked with you personally. 
• After the study has been completed, the recording of your interview 
will be erased. 
• Your details will not be disclosed to any third party. 
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• The information that you provide will be treated in the strictest 
confidence, in accordance with the Data Protection Act 1998. 
• Confidentiality will be assured to all participants throughout the 
entirety of the study. The sole exception being when intentional malpractice 
or unsafe practice is identified.  In these situations, details will be referred to 
your educational supervisor for further review. 
 
11. What will happen to the results of the study? 
• Our aim is that the results of the research will contribute to our 
understanding on the feedback of prescribing errors to prescribers.  
Specifically, the impact of delivering formalised feedback.  
• We plan to publish our results in a peer reviewed journal or 
educational conference. 
• All information will be anonymised to prevent identification of 
individual research participants. 
• Results will also be presented locally at relevant meetings 
 
12. What will happen if I want to stop taking part? 
Participants can withdraw at anytime, without explanation. Results up to the 
period of withdrawal may be used, if you are happy for this to be done. 
Otherwise you may request that they are destroyed and no further use is 
made of them.  If results are anonymised you should make clear that results 
may only be withdrawn prior to anonymisation. 
 
13. Who can I contact if I have further questions? 
Please contact Michael Lloyd between 8:30 am and 5pm, Mon-Fri, on either 
extension 4323, or pager 7437.  Alternatively, Michael can be contacted at 
Michael.lloyd@sthk.nhs.uk.    Alternatively you can contact Dr. Simon 
Watmough at efcsw@liv.ac.uk  
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Appendix 8: Consent form 
 
 
 
 
	
Participant	Consent	Form	
Exploring	prescribing	error	feedback	
	
1. I	confirm	that	I	have	read	and	have	understood	the	information	sheet	version	number	1.1	dated	19th	
July	2014	for	the	above	study.	I	have	had	the	opportunity	to	consider	the	information,	ask	questions	
and	have	had	these	answered	satisfactorily.	
	
2. I	understand	that	my	participation	is	voluntary	and	that	I	am	free	to	withdraw	at	any	time	without	
giving	any	reason,	without	my	rights	being	affected.		In	addition,	should	I	not	wish	to	answer	any	
particular	question	or	questions,	I	am	free	to	decline.			
	
3. I	understand	that,	under	the	Data	Protection	Act,		I	can	at	any	time	ask	for	access	to	the	information	I	
provide	and	I	can	also	request	the	destruction	of	that	information	if	I	wish.		
	
4. I	understand	that	the	interview	will	be	recorded	and	transcribed,	and	that	the	interview	recording	will	
be	erased	on	completion	of	the	study.	
	
5. I	understand	that	my	contribution	will	be	anonymised.		I	understand	that	extracts	from	my	interview	
may	be	quoted	anonymously	in	print	and	online	when	the	findings	of	the	study	are	published.	
	
6. I	agree	to	take	part	in	the	above	study.				
	
	
____________________________________	 	 ____________________	
Participant	Name		 	 	 	 	 Date	
	
	
____________________________________	 	 ____________________	
Participant	signature	 	 	 	 	 	 Date	
	
	
Principal	Investigator:	 	 	 	 	 Student	Researcher:	
Dr.	Simon	Watmough	 	 	 	 	 Michael	Lloyd	
Dept.	of	Medical	education	 	 	 	 Pharmacy	Department	
University	of	Liverpool	 	 	 	 	 0151-430-1565	
efcsw@liv.ac.uk			 	 	 	 	 Michael.lloyd@sthk.nhs.uk	
	
Version	Number:		1.1	19th	July	2014	
Please	initial	
in	the	box	
below	
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Appendix 9: Participant information sheets for prescriber interviews in 
chapter 6 
 
Exploring Prescribing Error Feedback 
 
Version Number: 1.1 19th July 2014 
 
 
Invitation Paragraph 
 
You are being invited to participate in part of a research study involving 
an interview.  This is part of a larger research project involving audits, 
other interviews and focus groups. Before you decide whether to 
participate, it is important for you to understand why the research is 
being done and what it will involve. Please take time to read the 
following information carefully and feel free to ask us if you would like 
more information or if there is anything that you do not understand. 
Please also feel free to discuss this with others if you wish.   We would 
like to stress that you do not have to accept this invitation and should 
only agree to take part if you want to. 
 
Thank you for reading this. 
  
What is the purpose of the study? 
Prescription errors account for the majority of all Medication errors and are 
considered more likely to cause patient harm.  Various solutions have been 
advocated to reduce prescribing errors including electronic prescribing, 
greater reporting of errors and a focus on education and training. However, 
trainees have expressed concerns over their preparedness to prescribe and 
report that they would welcome feedback on their prescribing. 
 
Formalised feedback is one proposal to mitigate prescribing errors with 
prescribers suggesting errors would not be repeated if they knew about 
them.  Little is known on the attitudes and experiences of Prescribers to 
receiving feedback on prescribing errors.  
 
This study is concerned with exploring the impact of formalized 
prescribing errors feedback on prescribers. 
  
Why have I been chosen to take part? 
You are one of the current prescribers on the pilot ward. 
 
Do I have to take part? 
It is entirely up to you to decide whether or not to join the study and be 
interviewed by the researcher. If you agree to participate, the researcher will 
talk to you about the research and will go through this information sheet with 
you. You will be asked to sign a consent form.  You are free to withdraw from 
the study at any time. 
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What will happen if I take part? 
If you would like to participate in this study: 
 You will be asked to take part in a short interview with the 
researcher which will last approximately 20 to 30 minutes.  
 In this interview, the researcher will ask you about your 
experiences of receiving feedback on prescribing errors 
 The interview will be carried out on the hospital premises at a time 
convenient to you. 
 The interview will be recorded on a digital recorder, so that we can 
analyse what you have said. The recording will be transcribed 
verbatim so that we have a written account of what you have said 
for analysis. 
 
Expenses and / or payments 
No expenses or payments will are available 
 
Are there any risks in taking part? 
No harm is intended to you.  Whilst the study is focused on attitudes to 
receiving feedback, it is possible that you may discuss prescribing errors 
affecting real patients.  You do not have to discuss any issues that you do 
not want to, and without explanation.  You should also be aware that the 
researcher will be operating within their codes of professional practice and so 
confidentiality cannot be assured at all times.  Where intentional malpractice 
or unsafe practice is identified this will be referred to your clinical / 
educational supervisor for further review. 
 
Are there any benefits in taking part? 
By participating in this research, you will be contributing to knowledge in this 
field. You will be helping us to improve our understanding of and delivery of 
feedback on prescribing errors.  This may lead to improvements in patient 
safety and the delivery of feedback on prescribing errors. 
 
What if I am unhappy or if there is a problem? 
You can contact the researcher Michael Lloyd at Michael.lloyd@sthk.nhs.uk 
or Dr Simon Watmough at efcsw@liv.ac.uk or professor Sarah O’Brien at 
sarah.o’brien@sthk.nhs.uk and we will try to help.   If you remain unhappy or 
have a complaint which you feel you cannot come to us with then you should 
contact the Research Governance Officer at ethics@liv.ac.uk. When 
contacting the Research Governance Officer, please provide details of the 
name or description of the study (so that it can be identified), the 
researcher(s) involved, and the details of the complaint you wish to make. 
 
Will my participation be kept confidential? 
 Only the researchers involved in the study will listen to the 
recording of your interview, or read the transcript   
 The information that you provide will be kept anonymous – it will 
not be linked with you personally. 
 After the study has been completed, the recording of your interview 
will be erased. 
 Your details will not be disclosed to any third party. 
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 The information that you provide will be treated in the strictest 
confidence, in accordance with the Data Protection Act 1998. 
 Confidentiality will be assured to all participants throughout the 
entirety of the study. The sole exception being when intentional 
malpractice or unsafe practice is identified.  In these situations, 
details will be referred to your educational supervisor for further 
review. 
 
What will happen to the results of the study? 
• Our aim is that the results of the research will contribute to our 
understanding on the feedback of prescribing errors to prescribers.  
Specifically, the impact of receiving formalised feedback.  
• We plan to publish our results in a peer reviewed journal or 
educational conference. 
• All information will be anonymised to prevent identification of 
individual research participants. 
• Results will also be presented locally at relevant meetings 
 
What will happen if I want to stop taking part? 
 
Participants can withdraw at anytime, without explanation. Results up to the 
period of withdrawal may be used, if you are happy for this to be done. 
Otherwise you may request that they are destroyed and no further use is 
made of them. .If results are anonymised you should make clear that results 
may only be withdrawn prior to anonymisation. 
 
Who can I contact if I have further questions? 
Please contact Michael Lloyd between 8:30 am and 5pm, Mon-Fri, on either 
extension 4323, or pager 7437.  Alternatively, Michael can be contacted at 
Michael.lloyd@sthk.nhs.uk.   Alternatively you can contact Dr. Simon 
Watmough at efcsw@liv.ac.uk 
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Appendix 10: Participant information sheets for prescriber interviews in 
chapter 9 
 
 
 
 
Exploring the impact of prescribing error feedback on specific 
prescription error types 
 
Version Number: 1.1  1st June 2015 
Introduction 
You are being invited to participate in a research study. Before you decide 
whether to participate, it is important for you to understand why the research 
is being done and what it will involve. Please take time to read the following 
information carefully and feel free to ask us if you would like more 
information or if there is anything that you do not understand. Please also 
feel free to discuss this with others if you wish.   We would like to stress that 
you do not have to accept this invitation and should only agree to take part if 
you want to. 
 
Thank you for reading this. 
  
What is the purpose of the study? 
Prescribing errors account for the majority of all medication errors and are 
considered more likely to cause patient harm.  Feedback on errors has been 
proposed to improve prescribing whist it is also valued and welcomed by 
prescribers to inform their professional development.   
 
However, little is known on the impact of feedback on prescriber behaviour 
and specifically, if feedback changes prescribing practice or if its influence is 
dependent on the error causation.  Understanding these problems further will 
help to support design and delivery of more robust and tailored feedback 
processes.  
 
 
Hence, this study is concerned with exploring the impact of feedback on 
specific types of prescription errors.    
  
Why have I been chosen to take part? 
You are a doctor based at the host organisation and have been involved in 
receiving individualised, formal feedback on a prescription error from your 
ward based pharmacist. 
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Do I have to take part? 
It is entirely up to you to decide whether or not to join the study and be 
interviewed by the researcher.  If you agree to participate, the researcher will 
talk to you about the research and will go through this information sheet with 
you. You will be asked to sign a consent form.  You are free to withdraw from 
the study at any time. 
 
What will happen if I take part? 
If you would like to participate in this study: 
 
• You will be asked to take part in an interview that will last for 
approximately 20-30 minutes.    
• In this interview, we will ask you about the causes of a specific 
prescription error that you have received feedback on in the past 96 hours 
and the impact if any, that the feedback has had on your prescribing.  
• The interview will be carried out on the hospital premises at a time 
and venue convenient for yourself.  Michael Lloyd will facilitate the interview.  
• The interview will be recorded on a digital recorder, and will be 
transcribed verbatim so that we have a written account of what you have said 
for subsequent analysis. 
 
 
Expenses and / or payments 
No expenses or payments will be available 
 
Are there any risks in taking part? 
There are no anticipated risks involved, all data will be anonymised and 
confidentiality maintained (see point 10 below).  However, you will be 
discussing a prescription error that has occurred which may cause some 
distress.  No harm is wished upon you and you may refuse to answer 
questions or discuss issues at any time, and without giving a reason.  Any 
doctor that appears distressed will be allowed to the leave the study and will 
be referred to relevant support in accordance with trust procedures. 
 
Are there any benefits in taking part? 
By participating in this research, you will be actively contributing to 
knowledge in this field. You will be helping us to improve our understanding 
and delivery of feedback on prescribing errors.  Specifically, the impact of 
prescribing error feedback on certain types of errors.  This may lead to 
improvements in patient safety and the delivery of feedback on prescribing 
errors.   
 
What if I am unhappy or if there is a problem? 
You can contact the researcher Michael Lloyd at Michael.lloyd@sthk.nhs.uk  
or Dr Simon Watmough at efcsw@liv.ac.uk  or Professor Sarah O’Brien at 
Sarah.OBrien@sthelensccg.nhs.uk and we will try to help.   If you remain 
unhappy or have a complaint which you feel you cannot come to us with then 
you should contact the Research Governance Officer at ethics@liv.ac.uk.  
When contacting the Research Governance Officer, please provide details of 
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the name or description of the study (so that it can be identified), the 
researcher(s) involved, and the details of the complaint you wish to make. 
 
Will my participation be kept confidential? 
• Only the researchers involved in the study will listen to the recording 
of your interview, or read the transcript   
• The information that you provide will be kept anonymous – it will not 
be linked with you personally. 
• After the study has been completed, the recording of your interview 
will be erased. 
• Your details will not be disclosed to any third party. 
• The information that you provide will be treated in the strictest 
confidence, in accordance with the Data Protection Act 1998. 
• Confidentiality will be assured to all participants throughout the 
entirety of the study. The sole exception being when intentional malpractice 
or unsafe practice is identified.  In these situations, details will be referred to 
your educational supervisor for further review. 
 
What will happen to the results of the study? 
• Our aim is that the results of the research will contribute to our 
understanding on the feedback of prescribing errors to prescribers.  
Specifically, the influence of feedback on certain types of error causation.  
• We plan to publish our results in a peer reviewed journal or 
educational conference. 
• All information will be anonymised to prevent identification of 
individual research participants. 
• Results will also be presented locally at relevant meetings 
 
What will happen if I want to stop taking part? 
Participants can withdraw at anytime, without explanation. Results up to the 
period of withdrawal may be used, if you are happy for this to be done. 
Otherwise you may request that they are destroyed and no further use is 
made of them. Results may only be withdrawn prior to anonymisation of the 
data. 
 
Who can I contact if I have further questions? 
Please contact Michael Lloyd between 8:30 am and 5pm, Mon-Fri, on either 
extension 4323, or pager 7437.  Alternatively, Michael can be contacted at 
Michael.lloyd@sthk.nhs.uk.    Alternatively you can contact Dr. Simon 
Watmough at efcsw@liv.ac.uk  
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Appendix 11: e-mail for prescriber interviews in chapter 6 
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Appendix 12: e-mail for prescriber interviews in chapter 9 
 
Subject line: Research study assessing impact of feedback on prescribing  
 
Email content: 
 
Dear ‘Dr. Name’, 
 
 
Please find attached a participant information sheet providing an overview of 
a research study exploring the impact of feedback on prescribing behaviour. 
 
As you have recently received feedback on your prescribing you are eligible 
to participate.    
 
This study is being undertaken by Michael Lloyd as part of an PhD, 
supervised by Dr. Simon Watmough at the University of Liverpool. 
 
 
Please read the attached participant information sheet about the study and 
then decide if you would or would not like to participate in the research. 
 
If you wish to participate in the study, please contact Michael Lloyd at 
Michael.lloyd@sthk.nhs.uk who will then be in contact to arrange a 
convenient date for the interview. 
 
If you have any questions at all regarding the study please do not hesitate to 
contact Michael for further information. 
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Appendix 13: Invitational e-mail for focus group participation  
 
Subject line: Research study exploring attitudes of pharmacists towards 
delivering prescribing error feedback 
 
Email content: 
 
Dear Pharmacist, 
 
 
Please find attached a participant information sheet providing an overview of 
a research study.   Briefly, the study is concerned in exploring your attitudes, 
views and opinions towards delivering prescribing error feedback. 
 
This study is being undertaken by Michael Lloyd as part of an MPhil, 
supervised by Dr. Simon Watmough at the University of Liverpool. 
 
Please read the attached participant information sheet about the study and 
then decide if you would or would not like to participate in the research. 
 
If you wish to participate in the study, please contact Michael Lloyd at 
Michael.lloyd@sthk.nhs.uk who will then be in contact to arrange a 
convenient date for the focus group. 
 
If you have any questions at all regarding the study please do not hesitate to 
contact Michael for further information. 
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Appendix 14: Participant information letter for pharmacists focus 
groups 
 
Version Number: 1.1 19th July 2014 
 
Introduction 
 
You are being invited to participate in part of a research study involving 
focus groups. This is part of a larger research project involving audits, 
interviews and other focus groups. Before you decide whether to 
participate, it is important for you to understand why the research is 
being done and what it will involve. Please take time to read the 
following information carefully and feel free to ask us if you would like 
more information or if there is anything that you do not understand. 
Please also feel free to discuss this with others if you wish.   We would 
like to stress that you do not have to accept this invitation and should 
only agree to take part if you want to. 
 
Thank you for reading this. 
  
What is the purpose of the study? 
 
Prescription errors account for the majority of all Medication errors and are 
considered more likely to cause patient harm.  Various solutions have been 
advocated to reduce prescribing errors including electronic prescribing, 
greater reporting of errors and a focus on education and training although 
prescription errors still occur. 
 
Formalised feedback is one proposal to mitigate prescribing errors with 
prescribers suggesting errors would not be repeated if they knew about 
them.  Pharmacists are often considered best placed to deliver prescribing 
error feedback. Little is known on the attitudes of Pharmacists to delivering 
prescribing error feedback. 
 
This study is concerned with exploring the attitudes and opinions of 
Pharmacists to delivering feedback on Prescription errors. 
  
Why have I been chosen to take part? 
 
You are a Pharmacist based at the host organisation. 
 
Do I have to take part? 
 
It is entirely up to you to decide whether or not to join the study and be 
interviewed by the researcher. If you agree to participate, the researcher will 
talk to you about the research and will go through this information sheet with 
you. You will be asked to sign a consent form.  You are free to withdraw from 
the study at any time. 
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What will happen if I take part? 
 
If you would like to participate in this study: 
 
 You will be asked to take part in a focus group with 6-8 other 
Pharmacists and the researcher which will last approximately 60 
minutes.  
 In this interview, we will ask you about your experiences of 
delivering feedback on prescribing errors 
 The focus group will be carried out on the hospital premises at a 
time convenient for the group and facilitated by the researcher 
Michael Lloyd. 
 The focus group discussion will be recorded on a digital recorder, 
so that we can analyse what you have said. The recording will be 
transcribed verbatim so that we have a written account of what you 
have said for analysis. 
 
 
 
Expenses and / or payments 
 
No expenses or payments will be available 
 
Are there any risks in taking part? 
 
There are no anticipated risks involved.  However, it is possible that you may 
discuss medication errors that have occurred.  These may causes some 
discomfort and embarrassment in front of your colleagues.  No harm is 
wished upon you and you may refuse to answer questions or discuss issues 
at any time, and without giving a reason.  Any Pharmacist that appears 
distressed will be allowed to the leave the study and will be referred to their 
supervisor for support in accordance with trust procedures. 
 
Are there any benefits in taking part? 
 
By participating in this research, you will be actively contributing to 
knowledge in this field. You will be helping us to improve our understanding 
and delivery of feedback on prescribing errors.  Specifically, the impact of 
delivering any feedback on the Pharmacists. This may lead to improvements 
in patient safety and the delivery of feedback on prescribing errors.   
 
What if I am unhappy or if there is a problem? 
 
You can contact the researcher Michael Lloyd at Michael.lloyd@sthk.nhs.uk 
or Dr Simon Watmough at efcsw@liv.ac.uk or professor Sarah O’Brien at 
sarah.o’brien@sthk.nhs.uk and we will try to help.   If you remain unhappy or 
have a complaint which you feel you cannot come to us with then you should 
contact the Research Governance Officer at ethics@liv.ac.uk. When 
contacting the Research Governance Officer, please provide details of the 
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name or description of the study (so that it can be identified), the 
researcher(s) involved, and the details of the complaint you wish to make. 
 
Will my participation be kept confidential? 
 
 Only the researchers involved in the study will listen to the 
recording of your interview, or read the transcript   
 The information that you provide will be kept anonymous – it will 
not be linked with you personally. 
 After the study has been completed, the recording of your interview 
will be erased. 
 Your details will not be disclosed to any third party. 
 The information that you provide will be treated in the strictest 
confidence, in accordance with the Data Protection Act 1998. 
 Confidentiality will be assured to all participants throughout the 
entirety of the study. The sole exception being when intentional 
malpractice or unsafe practice is identified.  In these situations, 
details will be referred to your educational supervisor for further 
review. 
 
What will happen to the results of the study? 
 
 Our aim is that the results of the research will contribute to our 
understanding on the feedback of prescribing errors to prescribers.  
Specifically, the impact of delivering formalised feedback.  
 We plan to publish our results in a peer reviewed journal or 
educational conference. 
 All information will be anonymised to prevent identification of 
individual research participants. 
 Results will also be presented locally at relevant meetings 
 
What will happen if I want to stop taking part? 
 
Participants can withdraw at anytime, without explanation. Results up 
to the period of withdrawal may be used, if you are happy for this to be 
done. Otherwise you may request that they are destroyed and no 
further use is made of them. .If results are anonymised you should 
make clear that results may only be withdrawn prior to anonymisation. 
 
Who can I contact if I have further questions? 
 
Please contact Michael Lloyd between 8:30 am and 5pm, Mon-Fri, on 
either extension 4323, or pager 7437.  Alternatively, Michael can be 
contacted at Michael.lloyd@sthk.nhs.uk.   Alternatively you can 
contact Dr. Simon Watmough at efcsw@liv.ac.uk 
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Appendix 15: Focus group topic guide 
 
Venue: Pharmacy seminar room at a convenient time for pharmacists 
Ensure undisturbed i.e. pagers, phones etc. turned off 
Likely Duration: 30-60 minutes. 
 
Preliminary: Greet, establish rapport and candour.  Summarise study 
purpose again, including need for consent.  Obtain written consent and allow 
opportunity to ask any questions before commencing the interview. 
Study Purpose 
Prescription errors account for the majority of all medication errors and are 
considered more likely to cause patient harm.  Various solutions have been 
advocated to reduce prescribing errors including electronic prescribing, 
greater reporting of errors and a focus on education and training.  Formalised 
feedback on prescription errors is one proposal to mitigate prescribing errors.  
Pharmacists are often advocated as the most appropriate individual to both 
intercept and deliver feedback on prescribing errors.  Little is currently known 
on the attitudes of Pharmacists to delivering feedback on prescribing errors. 
 
This study is concerned with exploring the attitudes, views and opinions of 
Hospital Pharmacist on delivering feedback on prescribing errors. 
 
Advise that as all questions must be asked.  Hence, it may seem that some 
are repeated as we progress through the schedule where you have provided 
an answer earlier. 
 
Themes are in bold.  Follow up prompting questions are denoted by P) and 
will be used to clarify responses and gain more detailed responses (as 
opposed to yes/no responses for example) 
 
Background information 
Can you state your current band and number of years you have been 
qualified 
 
Theme: Perceptions of delivering Prescribing Error Feedback 
 
Introduction 
Do you think that prescribers should receive feedback on PE’s? 
 P: Why? 
What system currently exists in the Hospital for identifying prescription 
errors? 
P: Does it work well?  Who identifies PE’s? 
Are there any problems with the current system? 
How often do you identify PE’s? 
 P: i.e. daily? weekly? 
Do you provide feedback on PE’s? 
P: How often? 
Do you record PE’s that you identify in the clinical notes? 
 P: If not then why? 
Do you complete DATIX reports for PE’s? 
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P: Are you expected to complete DATIX reports for PE’s? 
Do you think that DATIX reports should be completed for PE’s? 
 P: Does this happen now? 
Does the severity of the PE influence how you deal with it? 
 P: In what way? 
Why do you think delivery of PE feedback might be inconsistent? 
 
------------------------------------------------------------------------------------------------------
- 
Transition 
What do you think are the benefits of delivering feedback on PE’s? 
Who do you think is the best person to provide feedback on PE’s? 
P: i.e. Pharmacist, doctor, nurse or someone else 
Is it the role of a Pharmacist to deliver feedback on PE’s? 
Is the speed of feedback important? 
 P: Is timely feedback needed? 
Can you provide any examples where you have delivered PE feedback? 
 P: How was it delivered? How did you feel about it? 
When you identify a PE, what do you do? 
 P: Do you feedback to the prescriber? Amend the error yourself? 
How do you deliver feedback, if any, on prescribing errors? 
P: i.e. face to face, written, e-mail etc 
What factors make you decide whether you feedback or not on a PE? 
 P: i.e. PE severity, rapport with prescriber, time pressures? 
Can you think of any barriers to delivering feedback on PE’s? 
Do you feel comfortable delivering feedback on PE’s? 
 P: Do you feel confident? Prepared? If unsure / afraid then why? 
What impact if any does providing feedback have on you? 
 P: Workload? Commitments? Rapport with prescriber? 
What impact if any does providing feedback have on your working 
relationship with the prescriber? 
------------------------------------------------------------------------------------------------------
- 
Ending Questions 
In an ideal world, how do you feel that PE feedback should be 
delivered?  
What can be done to improve the current system? 
We wanted you to help review and evaluate systems of feedback on 
PE’s in the hospital.  We’ve covered various issues including…..   Is 
there anything that we have missed or anyone would like to add before 
we conclude the meeting? 
 
Thank them for their time.  Turn off audio tape. 
Advise participants that a thankyou letter will be sent out in the post. 
General second / probing questions 
Silence…. 
You said earlier… 
Can you provide an example / clarify what you mean… 
Can you elaborate on that…. 
Could you expand on that…. 
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Appendix 16: Prescribing error data collection tool 
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Appendix 17: Prescribing error severity  
Potentially lethal 
error 
An error is defined as potentially lethal if it could have 
one or more of the following consequences: 
 The serum level resulting from such a dose is 
likely to be in the severe toxicity range based on 
common dosage guidelines, e.g. serum 
theophylline concentrations greater than 30 
micrograms per ml. More than 10 times the 
dose of chemotherapy agent for example 
 The drug being administered has a high 
potential to cause cardiopulmonary arrest in the 
dose ordered. 
 The drug being administered has a high 
potential to cause a life threatening adverse 
reaction, such as anaphylaxis, in light of the 
patient’s medical history. 
 The dose of a potentially life saving drug is too 
low for a patient having the disease being 
treated 
 The dose of a drug with a very low therapeutic 
index such as digoxin is too high (ten times the 
normal dose) 
Serious Error An error is defined as serious if it could have one or 
more of the following results: 
 The route of drug administration ordered is 
inappropriate, with the potential of causing the 
patient to suffer a severe toxic reaction. 
 The dose of the drug prescribed is too low for a 
patient with serious disease who is in acute 
distress 
  The dose of a drug with a low therapeutic index 
is too high (four to ten times the normal dose) 
 The dose of the drug would result in serum drug 
levels in the toxic range, e.g. theophylline levels 
20-30 micrograms per mL. 
 The drug orders could exacerbate the patient’s 
condition, e.g. drug-drug interaction or drug-
disease interaction. 
 The name of the drug is misspelled or illegible 
creating a risk that the wrong drug might be 
dispensed (i.e. amiloride instead of amlodipine) 
including errors in decimal points or units if the 
error could lead to the dose being given 
  High dosage (ten times) normal of a drug 
without a low therapeutic index 
Significant error An error is defined as significant if it could have one or 
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more of the following results: 
 The dose of the drug with low therapeutic index 
is too high (half – four times the normal dose) 
 The dose of the drug is too low for a patient with 
the condition being treated 
 The wrong laboratory studies to monitor a 
specific side effect of a drug are ordered e.g. 
CBC and reticulocyte counts are ordered to 
monitor gentamicin toxicity 
 The wrong route of administration for the 
condition being treated is ordered e.g. the 
inadvertent change from IV to oral therapy for 
the treatment of meningitis 
 Errors ordering fluids are made e.g. specific 
additives needed for complete therapy are 
omitted or incompatible fluids are ordered 
 Errors of omission whereby patient’s regular 
medication is not prescribed either on 
admission, during a rewrite and on discharge 
Minor error An error is defined as minor if it could have one or 
more of the following results: 
 Duplicate therapy was prescribed without 
potential for increased adverse effects 
 The wrong route was ordered without potential 
for toxic reactions or therapeutic failure 
 The order lacked specific drug, dose, dosage 
strength, frequency, route or frequency 
information 
  Illegible, ambiguous or non-standard 
abbreviations 
 An errant order was written that was unlikely to 
be carried out given the nature of the drug, 
dosage forms, route ordered, missing 
 information etc 
Examples include, simvastatin prescribed in the 
morning rather than at night. Bisoprolol – two puffs four 
times a day. 
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Appendix 18: Prescribing error types 
Error category Includes Excludes 
1. Dosing 
errors 
Overdose, underdose, dose 
rate/mismatch  
Excludes overdoses 
caused by duplication 
eg, 
Paracetamol with co-
codamol 
2. Writing Strength/dose missing  
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errors Product/ formulation not 
specified, Incorrect 
formulation, No signature, 
Start date incorrect/missing, 
CD requirements 
incorrect/missing, dose units 
missing 
3. Allergy 
status 
Significant allergy, Includes 
allergy status not completed, 
or where a drug has been 
prescribed despite an allergy 
to that 
drug/class 
 
4. Duration of 
treatment  
Continuation for longer than 
needed, Includes no 
stop/review 
date for antibiotics, steroids 
etc, Premature 
discontinuation, Includes 
drugs stopped without 
appropriate reducing course 
 
5. Drug 
Interactions 
 Excludes 2 items 
prescribed from same 
class eg, omeprazole 
with 
lansoprazole 
(duplication) 
6. Omissions  Omission on admission, 
Omission on Discharge, Drug 
not prescribed but indicated 
 
7. Excessive / 
unnecessary 
prescribing  
Duplication: Includes a 
second agent prescribed 
which contains an ingredient 
already being taken; 2 drugs 
prescribed 
from the same class/with 
same clinical effect eg, 
Lansoprazole + Omeprazole.   
Unintentional Rx: Drug 
prescribed was not that 
desired. 
Includes prescription of a 
discontinued drug, excluding 
discontinuation due to ADR, 
or course is too long 
 
8. Clinical 
safety 
No max dose. 
Clinical Contraindication. 
Continuation after ADR. 
No dosage alteration after 
levels out of range 
Excludes prescriptions 
with 
no frequency 
(administration times 
missing/incorrect) 
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9. Lack of clear 
directions  
Administration times 
incorrect/ missing 
Incorrect route 
Intravenous instructions 
incorrect/missing 
Route missing 
Daily dose divided incorrectly 
 
10. Miscellaneou
s 
No indication: Includes PRN 
medications, where lack of 
indication on prescription 
could prevent administration. 
Excludes 
failure to write an indication 
when prescribing antibiotic. 
Illegible drug details, non-
standard abbreviations, 
patient details 
incorrect/missing, 
warfarin fixed dose 
prescribed 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix 19: Prescribing scenarios for pharmacist training  
1. Inpatient Prescription: 
Patient admitted with a mild LRTI, CURB65 = 1, commenced on amoxicillin. 
Also commenced on amlodipine for hypertension. On simvastatin 40mg po 
on. 
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2. Inpatient Prescription: 
Epileptic patient (stable) on valproate.  Admitted with confusion, UTI 
diagnosed resistant to trimethoprim, sensitive to ciprofloxacin and cephalexin 
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3. Inpatient prescription 
Diabetic patient admitted. 
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4. Inpatient prescription  
Patient prescribed treatment dose Clexane for suspected PE. Reduced GFR 
(25mL/min). 
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5. Discharge prescription  
No items omitted 
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6. Discharge prescription 
Exacerbation of COPD. Multiple recent courses of steroids, no maintenance 
dose (but needs reducing regimen).  NKDA 
Drug Chart: 
 479 
Tiotropium 18mcg inh od 
Furosemide 40mg po om 
Salbutamol evo 100mcg 2puffs inh prn 
Seretide 250/25 evohaler 2 puffs inh bd 
Amoxicillin 500mg po tds 7/7 (3/7 remaining) 
Prednisolone 30mg poo m 7/7 (3/7 remaining then reduce by 5mg every 
three days to zero) 
Aminophylline MR 225mg po bd 
 
 
 
 
 
 
 
 
 
7. Inpatient prescription 
Diabetic patient admitted with a LRTI CURB65=4.  Treated empirically as per 
local policy. 
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8. Inpatient prescription 
Parkinson’s patient, admitted with a fall.  eVTE completed, needs clexane. 
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9. Inpatient Prescription 
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Admitted with mild LRTI.  Known MRSA positive. Nil DHx. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
10. Inpatient Prescription 
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NIDDM patient admitted, has own medications with them.  U&E’s and BMs 
NAD. 
 
DHx (patient has PODs and repeat list): Simvastatin 40mg po on, 
Levothyroxine 50mcg po od, sodium valproate EC 500mg po bd, Metformin 
500mg po om, 
 
 
 
 
 
 
 
 
 
 
Appendix 20: University of Liverpool ethical approval letter 
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Appendix 21: STHKH research approval letter 
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Appendix 22: Initial thematic framework for pharmacist focus groups 
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Delivery of Feedback 
 
 
Inconsistent 
Formal vs. Informal 
Communication of error 
Incident Reporting 
Correction vs. Feedback 
 
Impact of Feedback Patient Safety 
Time saving 
Information seeking behaviour 
Feedback Seeking behaviour 
 
Prescription Error Error Severity 
Error repetition 
Timely Feedback 
 
Work environment 
 
  
Time pressures 
Location 
Contacting prescriber 
Blame vs. No-blame culture 
Pharmacy Service 
Out of hours 
Prescription stage 
 
Feedback Facilitator Staff Group 
Confidence  
Job Satisfaction 
Expert Knowledge 
Emotional Intelligence 
Interpretation of error 
 
Working relationships Rapport 
Team integration 
Hierarchy 
Fear / anxiety 
 
Education and Training Independent Learning 
Constructive feedback 
Reflective Practice  
Positive vs. Negative 
 
Future Recommendations Electronic prescribing 
Prescriber Training (induction, shared 
learning) 
Clinical Governance 
Ward based 
Shared vs. individual learning 
Facilitator Training 
 
 
Appendix 23: Initial thematic framework for prescriber interviews 
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Theme Code 
Feedback process  Importance of feedback 
Formal vs Informal 
Error Severity 
Prescriber Grade 
Correction vs Feedback 
Proforma 
Timely 
Non-intrusive 
 
Work environment  Time pressures 
Location 
Pharmacy Service / Cover 
Open Culture 
Prescriber Identification 
 
Feedback 
facilitator  
Recognised Role / Objective 
Rapport 
Social Context 
Patient context 
Difference of opinion 
Hierarchy 
 
Education and 
Training  
Educational Process 
Positive vs. Negative 
Constructive feedback (/ memory 
recall) 
Personal Development / 
Independent Learning 
Reflection 
Portfolio 
Educational Process 
Positive vs. Negative 
 
Prescriber impact Error Awareness 
Discretionary Effort 
Information Seeking Behaviour 
Feedback Seeking Behaviour 
Emotional  Impact 
Job Satisfaction 
Time saving  
Error Awareness 
 
System 
improvement 
Shared Learning 
Trust-wide process 
Evidence of error 
Learning Aids 
Induction 
 
Appendix 24: Initial thematic framework for pharmacist interviews 
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Theme  Code 
1. Process Overview Directive vs. facilitative 
feedback 
Setting 
Feedback content 
Barriers 
Sustainability 
 
2. Working relationship Rapport 
Hierarchy 
Team integration 
Trust in prescriber 
 
3. Benefits of feedback Consistency in practice 
Role awareness 
Medicine optimisation  
Working relationship 
Educational 
Reciprocal learning  
 
4. Feedback facilitator Feedback apprehension 
Facilitator training 
Job satisfaction 
Facilitator credibility 
Raised understanding of error 
 
5. Prescriber impact Prescriber response 
Information seeking behaviour 
Feedback seeking behaviour  
Goal motivating behaviour 
Prescriber apprehension 
Prescribing behaviour 
 
6. Prescribing error Error severity 
Timely feedback 
Supporting evidence 
Stage of prescription 
Error type 
Error interpretation 
 
7. Process improvement Prescribing error procedure 
Formal vs informal 
Shared learning 
Incident report 
Facilitator feedback 
Protected time 
 
Appendix 25: Initial thematic framework for prescriber error interviews 
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Theme / primary 
code 
Code / secondary code 
1. Affective 
behaviour 
Assertive behaviour 
Reflective practice 
Self-awareness 
Self-regulation 
Emotional impact 
Task prioritisation 
 
2. Learning 
outcome 
Improved knowledge  
Error awareness 
Self-detection of errors 
Raised situational 
awareness 
Prescribing practice 
 
3. Prescribing 
process / 
behaviour 
Information seeking 
behaviour 
Careful prescribing  
Systematic prescribing  
Prescribing location 
 
4. Error 
recurrence 
Transferrable learning 
Cognitive anchor 
Facilitator variability 
 
5. Further 
learning 
needs 
Local induction 
Prescribing education 
 
 
